Nothing Special   »   [go: up one dir, main page]

US8285354B2 - System and methods for processing analyte sensor data - Google Patents

System and methods for processing analyte sensor data Download PDF

Info

Publication number
US8285354B2
US8285354B2 US12/730,077 US73007710A US8285354B2 US 8285354 B2 US8285354 B2 US 8285354B2 US 73007710 A US73007710 A US 73007710A US 8285354 B2 US8285354 B2 US 8285354B2
Authority
US
United States
Prior art keywords
data
sensor
sensor data
stability
analyte
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime, expires
Application number
US12/730,077
Other versions
US20100174168A1 (en
Inventor
Paul V. Goode
James Brauker
Apurv U. Kamath
Victoria E. Carr-Brendel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dexcom Inc
Original Assignee
Dexcom Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/633,367 external-priority patent/US7778680B2/en
Application filed by Dexcom Inc filed Critical Dexcom Inc
Priority to US12/730,077 priority Critical patent/US8285354B2/en
Assigned to DEXCOM, INC. reassignment DEXCOM, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BRAUKER, JAMES H., CARR-BRENDEL, VICTORIA, GOODE, PAUL V. JR., KAMATH, APURV U.
Publication of US20100174168A1 publication Critical patent/US20100174168A1/en
Application granted granted Critical
Publication of US8285354B2 publication Critical patent/US8285354B2/en
Adjusted expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/145Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/1495Calibrating or testing of in-vivo probes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/145Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14532Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/145Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/1486Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using enzyme electrodes, e.g. with immobilised oxidase
    • A61B5/14865Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using enzyme electrodes, e.g. with immobilised oxidase invasive, e.g. introduced into the body by a catheter or needle or using implanted sensors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B2560/00Constructional details of operational features of apparatus; Accessories for medical measuring apparatus
    • A61B2560/02Operational features
    • A61B2560/0223Operational features of calibration, e.g. protocols for calibrating sensors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/145Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14542Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring blood gases

Definitions

  • the present invention relates generally to systems and methods for analyte sensor data processing. Particularly, the present invention relates to retrospectively and/or prospectively initiating a calibration, converting sensor data, updating the calibration, evaluating received reference and sensor data, and evaluating the calibration for the analyte sensor.
  • Diabetes mellitus is a disorder in which the pancreas cannot create sufficient insulin (Type I or insulin dependent) and/or in which insulin is not effective (Type 2 or noninsulin dependent).
  • Type I or insulin dependent in which the pancreas cannot create sufficient insulin
  • Type 2 or noninsulin dependent in which insulin is not effective
  • a hypoglycemic reaction low blood sugar
  • SMBG self-monitoring blood glucose
  • systems and methods are needed that accurately provide substantially continuous estimated analyte measurements for a variety of known analytes (e.g., oxygen, salts, protein, and vitamins) to provide prospective and/or retrospective data analysis and output to a user.
  • analytes e.g., oxygen, salts, protein, and vitamins
  • systems and methods are provided for retrospectively and/or prospectively calibrating a sensor, initializing a sensor, converting sensor data into calibrated data, updating and maintaining a calibration over time, evaluating received reference and sensor data for clinical acceptability, and evaluating the calibration statistical acceptability, to ensure accurate and safe data output to a patient and/or doctor.
  • a method for initializing a substantially continuous analyte sensor including: receiving a data stream from an analyte sensor, including one or more sensor data points; receiving reference data from a reference analyte monitor, including two or more reference data points; providing at least two matched data pairs by matching reference analyte data to substantially time corresponding sensor data; forming a calibration set including the at least two matching data pairs; and determining a stability of the continuous analyte sensor.
  • the step of determining the stability of the substantially continuous analyte sensor includes waiting a predetermined time period between about one minute and about six weeks.
  • the step of determining the stability of the substantially continuous analyte sensor includes evaluating at least two matched data pairs.
  • the step of determining the stability of the substantially continuous analyte sensor includes evaluating one of pH, oxygen, hypochlorite, interfering species, correlation of matched pairs, R-value, baseline drift, baseline offset, and amplitude.
  • the method further includes providing one of an audible, visual, or tactile output to a user based on the stability of the sensor.
  • the step of providing output based on the stability of the sensor includes indicating at least one of a numeric estimated analyte value, a directional trend of analyte concentration, and a graphical representation of an estimated analyte value.
  • the step of receiving sensor data includes receiving sensor data from a substantially continuous glucose sensor.
  • the step of receiving sensor data includes receiving sensor data from an implantable glucose sensor.
  • the step of receiving sensor data includes receiving sensor data from subcutaneously implantable glucose sensor.
  • the step of receiving reference data includes receiving reference data from a self-monitoring blood glucose test.
  • the step of receiving reference data includes downloading reference data via a cabled connection.
  • the step of receiving reference data includes downloading reference data via a wireless connection.
  • the step of receiving reference data from a reference analyte monitor includes receiving within a receiver internal communication from a reference analyte monitor integral with the receiver.
  • the step of forming a calibration set includes evaluating at least one matched data pair using inclusion criteria.
  • the step of receiving sensor data includes receiving sensor data that has been algorithmically smoothed.
  • the step of receiving sensor data includes algorithmically smoothing the received sensor data.
  • the step of forming a calibration set includes including in the calibration set between one and six matched data pairs.
  • the step of forming a calibration set includes including six matched data pairs.
  • the step of forming a calibration set further includes determining a value for n, where n is greater than one and represents the number of matched data pairs in the calibration set.
  • the step of determining a value for n is determined as a function of the frequency of the received reference data points and signal strength over time.
  • a system for initializing a continuous analyte sensor, including: a sensor data module operatively connected to a continuous analyte sensor that receives a data stream including a plurality of time spaced sensor data points from the analyte sensor; a reference input module adapted to obtain reference data from a reference analyte monitor, including one or more reference data points; a processor module that forms one or more matched data pairs by matching reference data to substantially time corresponding sensor data and subsequently forms a calibration set including the one or more matched data pairs; and a start-up module associated with the processor module programmed to determine the stability of the continuous analyte sensor.
  • the sensor data module is adapted to wirelessly receive sensor data points from the sensor.
  • the start-up module is programmed to wait a predetermined time period between six hours and six weeks.
  • the start-up module is programmed to evaluate at least two matched data pairs.
  • the start-up module is programmed to evaluate one of pH, oxygen, hypochlorite, interfering species, correlation of matched pairs, R-value, baseline drift, baseline offset, and amplitude.
  • system further includes an output control module associated with the processor module and programmed to control output of sensor data.
  • the output control module indicates at least one of a numeric estimated analyte value, a directional trend of analyte concentration, and a graphical representation of an estimated analyte value.
  • the sensor data module is configured to receive sensor data from substantially the continuous glucose sensor.
  • the sensor data module is configured to receive sensor data from an implantable glucose sensor.
  • the sensor data module is configured to receive sensor data from subcutaneously implantable glucose sensor.
  • the reference input module is configured to receive reference data from a self-monitoring blood glucose test.
  • the reference input module is configured to download reference data via a cabled connection.
  • the reference input module is configured to download reference data via a wireless connection.
  • system further includes a reference analyte monitor integral with the system and wherein the reference input module is configured to receive an internal communication from the reference analyte monitor.
  • the processor module includes programming to evaluate at least one matched data pair using inclusion criteria.
  • the reference input module is configured to receive sensor data that has been algorithmically smoothed.
  • the reference input module is configured to algorithmically smooth the received sensor data.
  • the calibration set includes between one and six matched data pairs.
  • the calibration set includes six matched data pairs.
  • the calibration set includes n matched data pairs, where n is greater than one.
  • n is a function of the frequency of the received reference data points and signal strength over time.
  • a computer system for initializing a continuous analyte sensor, the computer system including: a sensor data receiving module that receives sensor data from the substantially continuous analyte sensor via a receiver, including one or more sensor data points; a reference data receiving module that receives reference data from a reference analyte monitor, including one or more reference data points; a data matching module that forms one or more matched data pairs by matching reference data to substantially time corresponding sensor data; a calibration set module that forms a calibration set including at least one matched data pair; and a stability determination module that determines the stability of the continuous analyte sensor.
  • the stability determination module includes a system for waiting a predetermined time period.
  • the stability determination module evaluates at least two matched data pairs.
  • the stability determination module evaluates one of pH, oxygen, hypochlorite, interfering species, correlation of matched pairs, R-value, baseline drift, baseline offset, and amplitude.
  • the computer system further includes an interface control module that provides output to the user based on the stability of the sensor.
  • the output from the interface control module includes at least one of a numeric estimated analyte value, an indication of directional trend of analyte concentration, and a graphical representation of an estimated analyte value.
  • the reference data receiving module is adapted to receive sensor data from a substantially continuous glucose sensor.
  • the reference data receiving module is adapted to receive sensor data from an implantable glucose sensor.
  • the reference data receiving module is adapted to receive sensor data from a subcutaneously implantable glucose sensor.
  • the reference data receiving module is adapted to receive sensor data from a self-monitoring blood glucose test.
  • the reference data receiving module is adapted to receive sensor data from a cabled connection.
  • the reference data receiving module is adapted to download reference data via a wireless connection.
  • the reference data receiving module is adapted to receive reference data from an internal reference analyte monitor that is housed integrally the computer system.
  • the calibration set module evaluates at least one matched data pair using inclusion criteria.
  • the sensor data receiving module is adapted to receive sensor data that has been algorithmically smoothed.
  • the computer system further includes a data smoothing module that smoothes the received sensor data.
  • the calibration set module includes between one and six matched data pairs.
  • the calibration set module includes six matched data pairs.
  • the calibration set includes n number of matched data pairs, where n is greater than one.
  • n is a function of the frequency of the received reference data points and signal strength over time.
  • method for initializing a substantially continuous analyte sensor, the method including: receiving sensor data from a substantially continuous analyte sensor, including one or more sensor data points; receiving reference data from a reference analyte monitor, including one or more reference data points; forming one or more matched data pairs by matching reference data to substantially time corresponding sensor data; forming a calibration set including at least one matched data pair; determining stability of continuous analyte sensor; and outputting information reflective of the sensor data once a predetermined level of stability has been determined.
  • a system for initializing a continuous analyte sensor, including: a sensor data module operatively linked to a continuous analyte sensor and configured to receive one or more sensor data points from the sensor; a reference input module adapted to obtain one or more reference data points; and a processor module associated with the sensor data module and the input module and programmed to match reference data points with time-matched sensor data points to form a calibration set including at least one matched data pair; and a start-up module associated with the processor module programmed to determine the stability of the continuous analyte sensor and output information reflective of the sensor data once a predetermined level of stability has been determined.
  • a computer system for initializing a continuous analyte sensor, the system including: a sensor data receiving module that receives sensor data including one or more sensor data points from the substantially continuous analyte sensor via a receiver; a reference data receiving module for receiving reference data from a reference analyte monitor, including one or more reference data points; a data matching module for forming one or more matched data pairs by matching reference data to substantially time corresponding sensor data; a calibration set module for forming a calibration set including at least one matched data pair; a stability determination module for evaluating the stability of the continuous analyte sensor; and an interface control module that outputs information reflective of the sensor data once a predetermined level of stability has been determined.
  • a method for initializing a glucose sensor including: receiving sensor data from the glucose sensor, including one or more sensor data points; receiving reference data from a reference glucose monitor, including one or more reference data points; forming one or more matched data pairs by matching reference data to substantially time corresponding sensor data; determining whether the glucose sensor has reached a predetermined level of stability.
  • a system for initializing a continuous analyte sensor, including: a sensor data module operatively linked to a continuous analyte sensor and configured to receive one or more sensor data points from the sensor; a reference input module adapted to obtain one or more reference data points; and a processor module associated with the sensor data module and the input module and programmed to match reference data points with time-matched sensor data points to form a calibration set including at least one matched data pair; and a stability module associated with the processor module programmed to determine the stability of the continuous analyte sensor.
  • a method for evaluating clinical acceptability of at least one of reference and sensor analyte data, the method including: receiving a data stream from an analyte sensor, including one or more sensor data points; receiving reference data from a reference analyte monitor, including one or more reference data points; and evaluating the clinical acceptability at least one of the reference and sensor analyte data using substantially time corresponding reference or sensor data, wherein the at least one of the reference and sensor analyte data is evaluated for deviation from its substantially time corresponding reference or sensor data and clinical risk associated with that deviation based on the glucose value indicated by at least one of the sensor and reference data.
  • the method further includes providing an output through a user interface responsive to the clinical acceptability evaluation.
  • the step of providing an output includes alerting the user based on the clinical acceptability evaluation.
  • the step of providing an output includes altering the user interface based on the clinical acceptability evaluation.
  • the step of altering the user interface includes at least one of providing color-coded information, trend information, directional information (e.g., arrows or angled lines), and/or fail-safe information.
  • the step of evaluating the clinical acceptability includes using one of a Clarke Error Grid, a mean absolute difference calculation, a rate of change calculation, a consensus grid, and a standard clinical acceptance test.
  • the method further includes requesting additional reference data if the clinical acceptability evaluation determines clinical unacceptability.
  • the method further includes repeating the clinical acceptability evaluation step for the additional reference data.
  • the method further includes a step of matching reference data to substantially time corresponding sensor data to form a matched pair after the clinical acceptability evaluation step.
  • a system for evaluating clinical acceptability of at least one of reference and sensor analyte data, the method including: means for receiving a data stream from an analyte sensor, a plurality of time-spaced sensor data points; means for receiving reference data from a reference analyte monitor, including one or more reference data points; and means for evaluating the clinical acceptability of at least one of the reference and sensor analyte data using substantially time corresponding reference and sensor data, wherein the at least one of the reference and sensor analyte data is evaluated for deviation from its substantially time corresponding reference or sensor data and clinical risk associated with that deviation based on the glucose value indicated by at least one of the sensor and reference data.
  • system further includes means for providing an output based through a user interface responsive to the clinical acceptability evaluation.
  • the means for providing an output includes means for alerting the user based on the clinical acceptability evaluation.
  • the means for providing an output includes means for altering the user interface based on the clinical acceptability evaluation.
  • the means for altering the user interface includes at least one of providing color-coded information, trend information, directional information (e.g., arrows or angled lines), and/or fail-safe information.
  • the means for evaluating the clinical acceptability includes using one of a Clarke Error Grid, a mean absolute difference calculation, a rate of change calculation, a consensus grid, and a standard clinical acceptance test.
  • system further includes means for requesting additional reference data if the clinical acceptability evaluation determines clinical unacceptability.
  • system further includes means for repeated the clinical acceptability evaluation for the additional reference data.
  • system further includes means for matching reference data to substantially time corresponding sensor data to form a matched data pair after the clinical acceptability evaluation.
  • a computer system for evaluating clinical acceptability of at least one of reference and sensor analyte data
  • the computer system including: a sensor data receiving module that receives a data stream including a plurality of time spaced sensor data points from a substantially continuous analyte sensor; a reference data receiving module that receives reference data from a reference analyte monitor, including one or more reference data points; and a clinical acceptability evaluation module that evaluates at least one of the reference and sensor analyte data using substantially time corresponding reference and sensor data, wherein the at least one of the reference and sensor analyte data is evaluated for deviation from its substantially time corresponding reference or sensor data and clinical risk associated with that deviation based on the glucose value indicated by at least one of the sensor and reference data.
  • the computer system further includes an interface control module that controls the user interface based on the clinical acceptability evaluation.
  • the interface control module alerts the user based on the clinical acceptability evaluation.
  • the interface control module alters the user interface based on the clinical acceptability evaluation.
  • the interface control module alters the user interface by providing at least one of providing color-coded information, trend information, directional information (e.g., arrows or angled lines), and/or fail-safe information.
  • the clinical acceptability evaluation module uses one of a Clarke Error Grid, a mean absolute difference calculation, a rate of change calculation, a consensus grid, and a standard clinical acceptance test to evaluate clinical acceptability.
  • the interface control module that requests additional reference data if the clinical acceptability evaluation determines clinical unacceptability.
  • the interface control module evaluates the additional reference data using clinical acceptability evaluation module.
  • the computer system further includes a data matching module that matches clinically acceptable reference data to substantially time corresponding clinically acceptable sensor data to form a matched pair.
  • a method for evaluating clinical acceptability of at least one of reference and sensor analyte data, the method including: receiving a data stream from an analyte sensor, including one or more sensor data points; receiving reference data from a reference analyte monitor, including one or more reference data points; evaluating the clinical acceptability at least one of the reference and sensor analyte data using substantially time corresponding reference and sensor data, wherein the at least one of the reference and sensor analyte data is evaluated for deviation from its substantially time corresponding reference or sensor data and clinical risk associated with that deviation based on the glucose value indicated by at least one of the sensor and reference data; and providing an output through a user interface responsive to the clinical acceptability evaluation.
  • a method for evaluating clinical acceptability of at least one of reference and sensor analyte data, the method including: receiving a data stream from an analyte sensor, including one or more sensor data points; receiving reference data from a reference analyte monitor, including one or more reference data points; and evaluating the clinical acceptability at least one of the reference and sensor analyte data using substantially time corresponding reference and sensor data, including using one of a Clarke Error Grid, a mean absolute difference calculation, a rate of change calculation, and a consensus grid.
  • a computer system for evaluating clinical acceptability of at least one of reference and sensor analyte data
  • the computer system including: a sensor data module that receives a data stream including a plurality of time spaced sensor data points from a substantially continuous analyte sensor; a reference input module that receives reference data from a reference analyte monitor, including one or more reference data points; a clinical module that evaluates at least one of the reference and sensor analyte data using substantially time corresponding reference and sensor data, wherein the at least one of the reference and sensor analyte data is evaluated for deviation from its substantially time corresponding reference or sensor data and clinical risk associated with that deviation based on the glucose value indicated by at least one of the sensor and reference data; and an interface control module that controls the user interface based on the clinical acceptability evaluation.
  • a computer system for evaluating clinical acceptability of at least one of reference and sensor analyte data
  • the computer system including: a sensor data module that receives a data stream including a plurality of time spaced sensor data points from a substantially continuous analyte sensor; a reference input module that receives reference data from a reference analyte monitor, including one or more reference data points; and a clinical module that evaluates at least one of the reference and sensor analyte data with substantially time corresponding reference and sensor data, wherein the clinical module uses one of a Clarke Error Grid, a mean absolute difference calculation, a rate of change calculation, a consensus grid, and a standard clinical acceptance test to evaluate clinical acceptability.
  • a computer system for evaluating clinical acceptability of at least one of reference and sensor analyte data
  • the computer system including: a sensor data module that receives a data stream including a plurality of time spaced sensor data points from a substantially continuous analyte sensor via a receiver; a reference input module that receives reference data from a reference analyte monitor, including one or more reference data points; and a clinical module that uses a Clarke Error Grid to evaluate the clinical acceptability at least one of the reference and sensor analyte data using substantially time corresponding reference and sensor data; and a fail-safe module that controls the user interface responsive to the clinical module evaluating clinical unacceptability.
  • a method for evaluating clinical acceptability of at least one of reference and sensor glucose data including: receiving a data stream from an analyte sensor, including one or more sensor data points; receiving reference data from a reference glucose monitor, including one or more reference data points; evaluating the clinical acceptability at least one of the reference and sensor glucose data using substantially time corresponding reference and sensor data, wherein the at least one of the reference and sensor analyte data is evaluated for deviation from its substantially time corresponding reference or sensor data and clinical risk associated with that deviation based on the glucose value indicated by at least one of the sensor and reference data; and a fail-safe module that controls the user interface responsive to the clinical module evaluating clinical unacceptability.
  • a method for maintaining calibration of a substantially continuous analyte sensor including: receiving a data stream from an analyte sensor, including one or more sensor data points; receiving reference data from a reference analyte monitor, including two or more reference data points; providing at least two matched data pairs by matching reference analyte data to substantially time corresponding sensor data; forming a calibration set including the at least two matching data pairs; creating a conversion function based on the calibration set; converting sensor data into calibrated data using the conversion function; subsequently obtaining one or more additional reference data points and creating one or more new matched data pairs; evaluating the calibration set when the new matched data pair is created, wherein evaluating the calibration set includes at least one of 1) ensuring matched data pairs in the calibration set span a predetermined time range, 2) ensuring matched data pairs in the calibration set are no older than a predetermined value, 3) ensuring the calibration set has substantially distributed high and low matched data pairs over the predetermined time range, and
  • the step of evaluating the calibration set further includes at least one of evaluating a rate of change of the analyte concentration, evaluating a congruence of respective sensor and reference data in the matched data pairs, and evaluating physiological changes.
  • the step of evaluating the calibration set includes evaluating only the new matched data pair.
  • the step of evaluating the calibration set includes evaluating all of the matched data pairs in the calibration set and the new matched data pair.
  • the step of evaluating the calibration set includes evaluating combinations of matched data pairs from the calibration set and the new matched data pair.
  • the step of receiving sensor data includes receiving a data stream from a long-term implantable analyte sensor.
  • the step of receiving sensor data includes receiving a data stream that has been algorithmically smoothed.
  • the step of receiving sensor data stream includes algorithmically smoothing the data stream.
  • the step of receiving reference data includes downloading reference data via a cabled connection.
  • the step of receiving reference data includes downloading reference data via a wireless connection.
  • the step of receiving reference data from a reference analyte monitor includes receiving within a receiver internal communication from a reference analyte monitor integral with the receiver.
  • the reference analyte monitor includes self-monitoring of blood analyte.
  • the step of creating a conversion function includes linear regression.
  • the step of creating a conversion function includes non-linear regression.
  • the step of forming a calibration set includes including in the calibration set between one and six matched data pairs.
  • the step of forming a calibration set includes including six matched data pairs.
  • the step of forming a calibration set further includes determining a value for n, where n is greater than one and represents the number of matched data pairs in the calibration set.
  • the step of determining a value for n is determined as a function of the frequency of the received reference data points and signal strength over time.
  • the method further includes determining a set of matching data pairs from the evaluation of the calibration set and re-forming a calibration set.
  • the method further includes repeating the step of re-creating the conversion function using the re-formed calibration set.
  • the method further includes converting sensor data into calibrated data using the re-created conversion function.
  • a system for maintaining calibration of a substantially continuous analyte sensor, the system including: means for receiving a data stream from an analyte sensor, a plurality of time-spaced sensor data points; means for receiving reference data from a reference analyte monitor, including two or more reference data points; means for providing two or more matched data pairs by matching reference analyte data to substantially time corresponding sensor data; means for forming a calibration set including at least two matched data pair; means for creating a conversion function based on the calibration set; means for converting sensor data into calibrated data using the conversion function; subsequently obtaining one or more additional reference data points and creating one or more new matched data pairs; means for evaluating the calibration set when the new matched data pair is created, wherein evaluating the calibration set includes at least one of 1) ensuring matched data pairs in the calibration set span a predetermined time range, 2) ensuring matched data pairs in the calibration set are no older than a predetermined value, 3) ensuring the calibration set has
  • the means for evaluating the calibration set further includes at least one of means for evaluating a rate of change of the analyte concentration, means for evaluating a congruence of respective sensor and reference data in matched data pairs; and means for evaluating physiological changes.
  • the means for evaluating the calibration set includes means for evaluating only the one or more new matched data pairs.
  • the means for evaluating the calibration set includes means for evaluating all of the matched data pairs in the calibration set and the one or more new matched data pairs.
  • the means for evaluating the calibration set includes means for evaluating combinations of matched data pairs from the calibration set and the one or more new matched data pair.
  • the means for receiving sensor data includes means for receiving sensor data from a long-term implantable analyte sensor.
  • the means for receiving sensor data includes means for receiving sensor data that has been algorithmically smoothed.
  • the means for receiving sensor data includes means for algorithmically smoothing the receiving sensor data.
  • the means for receiving reference data includes means for downloading reference data via a cabled connection.
  • the means for receiving reference data includes means for downloading reference data via a wireless connection.
  • the means for receiving reference data from a reference analyte monitor includes means for receiving within a receiver internal communication from a reference analyte monitor integral with the receiver.
  • the means for receiving reference data includes means for receiving from a self-monitoring of blood analyte.
  • the means for creating a conversion function includes means for performing linear regression.
  • the means for creating a conversion function includes means for performing non-linear regression.
  • the means for forming a calibration set includes including in the calibration set between one and six matched data pairs.
  • the means for forming a calibration set includes including in the calibration set six matched data pairs.
  • the means for forming a calibration set further includes determining a value for n, where n is greater than one and represents the number of matched data pairs in the calibration set.
  • the means for determining a value for n is determined as a function of the frequency of the received reference data points and signal strength over time.
  • the system further includes means for determining a set of matching data pairs from the evaluation of the calibration set and re-forming a calibration set.
  • system further includes the means for repeating the set of creating the conversion function using the re-formed calibration set.
  • system further includes means for converting sensor data into calibrated data using the re-created conversion function.
  • a computer system for maintaining calibration of a substantially continuous analyte sensor, the computer system including: a sensor data receiving module that receives a data stream including a plurality of time spaced sensor data points from a substantially continuous analyte sensor; a reference data receiving module that receives reference data from a reference analyte monitor, including two or more reference data points; a data matching module that forms two or more matched data pairs by matching reference data to substantially time corresponding sensor data; a calibration set module that forms a calibration set including at least two matched data pairs; a conversion function module that creates a conversion function using the calibration set; a sensor data transformation module that converts sensor data into calibrated data using the conversion function; and a calibration evaluation module that evaluates the calibration set when the new matched data pair is provided, wherein evaluating the calibration set includes at least one of 1) ensuring matched data pairs in the calibration set span a predetermined time period, 2) ensuring matched data pairs in the calibration set are no older than a predetermined value
  • the evaluation calibration module further evaluates at least one of a rate of change of the analyte concentration, a congruence of respective sensor and reference data in matched data pairs; and physiological changes.
  • the evaluation calibration module evaluates only the new matched data pair.
  • the evaluation calibration module evaluates all of the matched data pairs in the calibration set and the new matched data pair.
  • the evaluation calibration module evaluates combinations of matched data pairs from the calibration set and the new matched data pair.
  • the sensor data receiving module receives the data stream from a long-term implantable analyte sensor.
  • the sensor data receiving module receives an algorithmically smoothed data stream.
  • the sensor data receiving module includes programming to smooth the data stream.
  • the reference data receiving module downloads reference data via a cabled connection.
  • the reference data receiving module downloads reference data via a wireless connection.
  • the reference data receiving module receives within a receiver internal communication from a reference analyte monitor integral with the receiver.
  • the reference data receiving module receives reference data from a self-monitoring of blood analyte.
  • the conversion function module includes programming that performs linear regression.
  • the conversion function module includes programming that performs non-linear regression.
  • the calibration set module includes in the calibration set between one and six matched data pairs.
  • the calibration set module includes in the calibration set six matched data pairs.
  • the calibration set module further includes programming for determining a value for n, where n is greater than one and represents the number of matched data pairs in the calibration set.
  • the programming for determining a value for n determines n as a function of the frequency of the received reference data points and signal strength over time.
  • data matching module further includes programming to re-form the calibration set based on the calibration evaluation.
  • the conversion function module further includes programming to re-create the conversion function based on the re-formed calibration set.
  • the sensor data transformation module further including programming for converting sensor data into calibrated using the re-created conversion function.
  • a method for maintaining calibration of a glucose sensor including: receiving a data stream from an analyte sensor, including one or more sensor data points; receiving reference data from a reference analyte monitor, including two or more reference data points; providing at least two matched data pairs by matching reference analyte data to substantially time corresponding sensor data; forming a calibration set including the at least two matching data pairs; creating a conversion function based on the calibration set; subsequently obtaining one or more additional reference data points and creating one or more new matched data pairs; and evaluating the calibration set when the new matched data pair is created, wherein evaluating the calibration set includes at least one of 1) ensuring matched data pairs in the calibration set span a predetermined time range, 2) ensuring matched data pairs in the calibration set are no older than a predetermined value, 3) ensuring the calibration set has substantially distributed high and low matched data pairs over the predetermined time range, and 4) allowing matched data pairs only within a predetermined range of ana
  • a computer system for maintaining calibration of a glucose sensor, the computer system including: a sensor data module that receives a data stream including a plurality of time spaced sensor data points from a substantially continuous analyte sensor; a reference input module that receives reference data from a reference analyte monitor, including two or more reference data points; a processor module that forms two or more matched data pairs by matching reference data to substantially time corresponding sensor data and subsequently forms a calibration set including the two or more matched data pairs; and a calibration evaluation module that evaluates the calibration set when the new matched data pair is provided, wherein evaluating the calibration set includes at least one of 1) ensuring matched data pairs in the calibration set span a predetermined time period, 2) ensuring matched data pairs in the calibration set are no older than a predetermined value, 3) ensuring the calibration set has substantially distributed high and low matched data pairs over a predetermined time range, and 4) allowing matched data pairs only within a predetermined range of analyt
  • a method for evaluating the quality of a calibration of an analyte sensor, the method including: receiving a data stream from an analyte sensor, including one or more sensor data points; receiving reference data from a reference analyte monitor, including two or more reference data points; providing at least two matched data pairs by matching reference analyte data to substantially time corresponding sensor data; forming a calibration set including the at least two matching data pairs; creating a conversion function based on the calibration set; receiving additional sensor data from the analyte sensor; converting sensor data into calibrated data using the conversion function; and evaluating the quality of the calibration set using a data association function.
  • the step of receiving sensor data includes receiving a data stream that has been algorithmically smoothed.
  • the step of receiving sensor data includes algorithmically smoothing the data stream.
  • the step of receiving sensor data includes receiving sensor data from a substantially continuous glucose sensor.
  • the step of receiving sensor data includes receiving sensor data from an implantable glucose sensor.
  • the step of receiving sensor data includes receiving sensor data from a subcutaneously implantable glucose sensor.
  • the step of receiving reference data includes receiving reference data from a self-monitoring blood glucose test.
  • the step of receiving reference data includes downloading reference data via a cabled connection.
  • the step of receiving reference data includes downloading reference data via a wireless connection.
  • the step of receiving reference data from a reference analyte monitor includes receiving within a receiver internal communication from a reference analyte monitor integral with the receiver.
  • the step of evaluating the quality of the calibration set based on a data association function includes performing one of linear regression, non-linear regression, rank correlation, least mean square fit, mean absolute deviation, and mean absolute relative difference.
  • the step of evaluating the quality of the calibration set based on a data association function includes performing linear least squares regression.
  • the step of evaluating the quality of the calibration set based on a data association function includes setting a threshold of data association.
  • the step of evaluating the quality of the calibration set based on data association includes performing linear least squares regression and wherein the step of setting a threshold hold includes an R-value threshold of 0.79.
  • the method further includes providing an output to a user interface responsive to the quality of the calibration set.
  • the step of providing an output includes displaying analyte values to a user dependent upon the quality of the calibration.
  • the step of providing an output includes alerting the dependent upon the quality of the calibration.
  • the step of providing an output includes altering the user interface dependent upon the quality of the calibration.
  • the step of providing an output includes at least one of providing color-coded information, trend information, directional information (e.g., arrows or angled lines), and/or fail-safe information.
  • a system for evaluating the quality of a calibration of an analyte sensor, the system including: means for receiving a data stream from an analyte sensor, a plurality of time-spaced sensor data points; means for receiving reference data from a reference analyte monitor, including two or more reference data points; means for providing two or more matched data pairs by matching reference analyte data to substantially time corresponding sensor data; means for forming a calibration set including at least two matched data pair; means for creating a conversion function based on the calibration set; means for converting sensor data into calibrated data using the conversion function; means for evaluating the quality of the calibration set based on a data association function.
  • the means for receiving sensor data includes means for receiving sensor data that has been algorithmically smoothed.
  • the means for receiving sensor data includes means for algorithmically smoothing the receiving sensor data.
  • the means for receiving sensor data includes means for receiving sensor data from substantially continuous glucose sensor.
  • the means for receiving sensor data includes means for receiving sensor data from an implantable glucose sensor.
  • the means for receiving sensor data includes means for receiving sensor data from subcutaneously implantable glucose sensor.
  • the means for receiving reference data includes means for receiving reference data from a self-monitoring blood glucose test.
  • the means for receiving reference data includes means for downloading reference data via a cabled connection.
  • the means for receiving reference data includes means for downloading reference data via a wireless connection.
  • the means for receiving reference data from a reference analyte monitor includes means for receiving within a receiver internal communication from a reference analyte monitor integral with the receiver.
  • the means for evaluating the quality of the calibration set includes means for performing one of linear regression, non-linear regression, rank correlation, least mean square fit, mean absolute deviation, and mean absolute relative difference.
  • the means for evaluating the quality of the calibration set includes means for performing linear least squares regression.
  • the means for evaluating the quality of the calibration set includes means for setting a threshold of data association.
  • the means for evaluating the quality of the calibration set includes means for performing linear least squares regression and wherein the means for setting a threshold hold includes an R-value threshold of 0.71.
  • system further includes means for providing an output to a user interface responsive to the quality of the calibration set.
  • the means for providing an output includes means for displaying analyte values to a user dependent upon the quality of the calibration.
  • the means for providing an output includes means for alerting the dependent upon the quality of the calibration.
  • the means for providing an output includes means for altering the user interface dependent upon the quality of the calibration.
  • the means for providing an output includes at least one of providing color-coded information, trend information, directional information (e.g., arrows or angled lines), and/or fail-safe information.
  • a computer system for evaluating the quality of a calibration of an analyte sensor, the computer system including: a sensor data receiving module that receives a data stream including a plurality of time spaced sensor data points from a substantially continuous analyte sensor; a reference data receiving module that receives reference data from a reference analyte monitor, including two or more reference data points; a data matching module that forms two or more matched data pairs by matching reference data to substantially time corresponding sensor data; a calibration set module that forms a calibration set including at least two matched data pairs; a conversion function module that creates a conversion function using the calibration set; a sensor data transformation module that converts sensor data into calibrated data using the conversion function; and a quality evaluation module that evaluates the quality of the calibration set based on a data association function.
  • the sensor data receiving module receives sensor data that has been algorithmically smoothed.
  • the computer system further includes a data smoothing module that algorithmically smoothes sensor data received from the sensor data receiving module.
  • the sensor data receiving module is adapted to receive sensor data from substantially continuous glucose sensor.
  • the sensor data receiving module is adapted to receive sensor data from an implantable glucose sensor.
  • the sensor data receiving module is adapted to receive sensor data from subcutaneously implantable glucose sensor.
  • the reference data receiving module is adapted to receive reference data from a self-monitoring blood glucose test.
  • the reference data receiving module is adapted to download reference data via a cabled connection.
  • the reference data receiving module is adapted to download reference data via a wireless connection.
  • the reference data receiving module is adapted to receive reference data from a reference analyte monitor integral with the receiver.
  • the quality evaluation module performs one of linear regression, non-linear regression, rank correlation, least mean square fit, mean absolute deviation, and mean absolute relative difference to evaluate calibration set quality.
  • the quality evaluation module performs linear least squares regression.
  • the quality evaluation module sets a threshold for the data association function.
  • the quality evaluation module performs linear least squares regression and wherein the threshold of the data association function includes an R-value threshold of at least 0.79.
  • the computer system further includes an interface control module that controls the user interface based on the quality of the calibration set.
  • the interface control module displays analyte values to a user dependent upon the quality of the calibration set.
  • the interface control module alerts the user based upon the quality of the calibration set.
  • the interface control module alters the user interface based upon the quality of the calibration set.
  • the interface control module provides at least one of color-coded information, trend information, directional information (e.g., arrows or angled lines), and/or fail-safe information.
  • a method for evaluating the quality of a calibration of an analyte sensor, the method including: receiving a data stream from an analyte sensor, including one or more sensor data points; receiving reference data from a reference analyte monitor, including two or more reference data points; providing at least two matched data pairs by matching reference analyte data to substantially time corresponding sensor data; forming a calibration set including the at least two matching data pairs; creating a conversion function based on the calibration set; receiving additional sensor data from the analyte sensor; converting sensor data into calibrated data using the conversion function; and evaluating the quality of the calibration set based on a data association function selected from the group consisting of linear regression, non-linear regression, rank correlation, least mean square fit, mean absolute deviation, and mean absolute relative difference.
  • a method for evaluating the quality of a calibration of an analyte sensor, the method including: receiving a data stream from an analyte sensor, including one or more sensor data points; receiving reference data from a reference analyte monitor, including two or more reference data points; providing at least two matched data pairs by matching reference analyte data to substantially time corresponding sensor data; forming a calibration set including the at least two matching data pairs; creating a conversion function based on the calibration set; receiving additional sensor data from the analyte sensor; converting sensor data into calibrated data using the conversion function; evaluating the quality of the calibration set using a data association function; and providing an output to a user interface responsive to the quality of the calibration set.
  • a computer system for evaluating the quality of a calibration of an analyte sensor, the computer system including: a sensor data module that receives a data stream including a plurality of time spaced sensor data points from a substantially continuous analyte sensor; a reference input module that receives reference data from a reference analyte monitor, including two or more reference data points; a processor module that forms two or more matched data pairs by matching reference data to substantially time corresponding sensor data and subsequently forms a calibration set including the two or more matched data pairs; and a conversion function module that creates a conversion function using the calibration set; a sensor data transformation module that converts sensor data into calibrated data using the conversion function; a quality evaluation module that evaluates the quality of the calibration set based on a data association selected from the group consisting of linear regression, non-linear regression, rank correlation, least mean square fit, mean absolute deviation, and mean absolute relative difference.
  • a computer system for evaluating the quality of a calibration of an analyte sensor, the computer system including: a sensor data module that receives a data stream including a plurality of time spaced sensor data points from a substantially continuous analyte sensor; a reference input module that receives reference data from a reference analyte monitor, including two or more reference data points; a processor module that forms two or more matched data pairs by matching reference data to substantially time corresponding sensor data and subsequently forms a calibration set including the two or more matched data pairs; and a conversion function module that creates a conversion function using the calibration set; a sensor data transformation module that converts sensor data into calibrated data using the conversion function; a quality evaluation module that evaluates the quality of the calibration set based on data association; and a fail-safe module that controls the user interface based on the quality of the calibration set.
  • a method for evaluating the quality of a calibration of a glucose sensor including: receiving sensor data from a glucose sensor, including one or more sensor data points; receiving reference data from a reference glucose monitor, including one or more reference data points; providing one or more matched data pairs by matched reference glucose data to substantially time corresponding sensor data; forming a calibration set including at least one matched data pair; and evaluating the quality of the calibration set based on data association.
  • FIG. 1 is an exploded perspective view of a glucose sensor in one embodiment.
  • FIG. 2 is a block diagram that illustrates the sensor electronics in one embodiment.
  • FIG. 3 is a graph that illustrates data smoothing of a raw data signal in one embodiment.
  • FIGS. 4A to 4D are schematic views of a receiver in first, second, third, and fourth embodiments, respectively.
  • FIG. 5 is a block diagram of the receiver electronics in one embodiment.
  • FIG. 6 is a flow chart that illustrates the initial calibration and data output of the sensor data in one embodiment.
  • FIG. 7 is a graph that illustrates a regression performed on a calibration set to obtain a conversion function in one exemplary embodiment.
  • FIG. 8 is a flow chart that illustrates the process of evaluating the clinical acceptability of reference and sensor data in one embodiment.
  • FIG. 9 is a graph of two data pairs on a Clarke Error Grid to illustrate the evaluation of clinical acceptability in one exemplary embodiment.
  • FIG. 10 is a flow chart that illustrates the process of evaluation of calibration data for best calibration based on inclusion criteria of matched data pairs in one embodiment.
  • FIG. 11 is a flow chart that illustrates the process of evaluating the quality of the calibration in one embodiment.
  • FIGS. 12A and 12B are graphs that illustrate an evaluation of the quality of calibration based on data association in one exemplary embodiment using a correlation coefficient.
  • analyte is a broad term and is used in its ordinary sense, including, without limitation, to refer to a substance or chemical constituent in a biological fluid (for example, blood, interstitial fluid, cerebral spinal fluid, lymph fluid or urine) that can be analyzed. Analytes may include naturally occurring substances, artificial substances, metabolites, and/or reaction products. In some embodiments, the analyte for measurement by the sensor heads, devices, and methods is analyte.
  • analytes are contemplated as well, including but not limited to acarboxyprothrombin; acylcarnitine; adenine phosphoribosyl transferase; adenosine deaminase; albumin; alpha-fetoprotein; amino acid profiles (arginine (Krebs cycle), histidine/urocanic acid, homocysteine, phenylalanine/tyrosine, tryptophan); andrenostenedione; antipyrine; arabinitol enantiomers; arginase; benzoylecgonine (cocaine); biotinidase; biopterin; c-reactive protein; carnitine; carnosinase; CD4; ceruloplasmin; chenodeoxycholic acid; chloroquine; cholesterol; cholinesterase; conjugated 1- ⁇ hydroxy-cholic acid; cortisol; creatine kinase; creatine kinase
  • Salts, sugar, protein, fat, vitamins and hormones naturally occurring in blood or interstitial fluids may also constitute analytes in certain embodiments.
  • the analyte may be naturally present in the biological fluid, for example, a metabolic product, a hormone, an antigen, an antibody, and the like.
  • the analyte may be introduced into the body, for example, a contrast agent for imaging, a radioisotope, a chemical agent, a fluorocarbon-based synthetic blood, or a drug or pharmaceutical composition, including but not limited to insulin; ethanol; cannabis (marijuana, tetrahydrocannabinol, hashish); inhalants (nitrous oxide, amyl nitrite, butyl nitrite, chlorohydrocarbons, hydrocarbons); cocaine (crack cocaine); stimulants (amphetamines, methamphetamines, Ritalin, Cylert, Preludin, Didrex, PreState, Voranil, Sandrex, Plegine); depressants (barbituates, methaqualone, tranquilizers such as Valium, Librium, Miltown, Serax, Equanil, Tranxene); hallucinogens (phencyclidine, lysergic acid, mescaline, peyote, p
  • Analytes such as neurochemicals and other chemicals generated within the body may also be analyzed, such as, for example, ascorbic acid, uric acid, dopamine, noradrenaline, 3-methoxytyramine (a3MT), 3,4-Dihydroxyphenylacetic acid (DOPAC), Homovanillic acid (HVA), 5-Hydroxytryptamine (5HT), and 5-Hydroxyindoleacetic acid (FHIAA).
  • ascorbic acid uric acid
  • dopamine dopamine
  • noradrenaline 3-methoxytyramine (a3MT), 3,4-Dihydroxyphenylacetic acid (DOPAC), Homovanillic acid (HVA), 5-Hydroxytryptamine (5HT), and 5-Hydroxyindoleacetic acid (FHIAA).
  • HVA Homovanillic acid
  • 5HT 5-Hydroxytryptamine
  • FHIAA 5-Hydroxyindoleacetic acid
  • operably connected and “operably linked,” as used herein, are broad terms and are used in their ordinary sense, including, without limitation, one or more components being linked to another component(s) in a manner that allows transmission of signals between the components, e.g., wired or wirelessly.
  • one or more electrodes may be used to detect the amount of analyte in a sample and convert that information into a signal; the signal may then be transmitted to an electronic circuit means.
  • the electrode is “operably linked” to the electronic circuitry.
  • EEPROM electrically erasable programmable read-only memory, which is user-modifiable read-only memory (ROM) that can be erased and reprogrammed (e.g., written to) repeatedly through the application of higher than normal electrical voltage.
  • SRAM static random access memory
  • A/D Converter is a broad term and is used in its ordinary sense, including, without limitation, hardware that converts analog signals into digital signals.
  • microprocessor is a broad term and is used in its ordinary sense, including, without limitation a computer system or processor designed to perform arithmetic and logic operations using logic circuitry that responds to and processes the basic instructions that drive a computer.
  • RF transceiver is a broad term and is used in its ordinary sense, including, without limitation, a radio frequency transmitter and/or receiver for transmitting and/or receiving signals.
  • jitter is a broad term and is used in its ordinary sense, including, without limitation, uncertainty or variability of waveform timing, which may be cause by ubiquitous noise caused by a circuit and/or environmental effects; jitter can be seen in amplitude, phase timing, or the width of the signal pulse.
  • raw data signal is a broad term and is used in its ordinary sense, including, without limitation, an analog or digital signal directly related to the measured analyte from the analyte sensor.
  • the raw data signal is digital data in “counts” converted by an A/D converter from an analog signal (e.g., voltage or amps) representative of an analyte concentration.
  • counts is a broad term and is used in its ordinary sense, including, without limitation, a unit of measurement of a digital signal.
  • a raw data signal measured in counts is directly related to a voltage (converted by an A/D converter), which is directly related to current.
  • analyte sensor is a broad term and is used in its ordinary sense, including, without limitation, any mechanism (e.g., enzymatic or non-enzymatic) by which analyte can be quantified.
  • some embodiments utilize a membrane that contains glucose oxidase that catalyzes the conversion of oxygen and glucose to hydrogen peroxide and gluconate: Glucose+O 2 ⁇ Gluconate+H 2 O 2
  • host is a broad term and is used in its ordinary sense, including, without limitation, mammals, particularly humans.
  • matched data pairs is a broad term and is used in its ordinary sense, including, without limitation, reference data (e.g., one or more reference analyte data points) matched with substantially time corresponding sensor data (e.g., one or more sensor data points).
  • Clarke Error Grid is a broad term and is used in its ordinary sense, including, without limitation, an error grid analysis, which evaluates the clinical significance of the difference between a reference glucose value and a sensor generated glucose value, taking into account 1) the value of the reference glucose measurement, 2) the value of the sensor glucose measurement, 3) the relative difference between the two values, and 4) the clinical significance of this difference. See Clarke et al., “Evaluating Clinical Accuracy of Systems for Self-Monitoring of Blood Glucose”, Diabetes Care, Volume 10, Number 5, September-October 1987, which is incorporated by reference herein in its entirety.
  • Consensus Error Grid is a broad term and is used in its ordinary sense, including, without limitation, an error grid analysis that assigns a specific level of clinical risk to any possible error between two time corresponding glucose measurements.
  • the Consensus Error Grid is divided into zones signifying the degree of risk posed by the deviation. See Parkes et al., “A New Consensus Error Grid to Evaluate the Clinical Significance of Inaccuracies in the Measurement of Blood Glucose”, Diabetes Care, Volume 23, Number 8, August 2000, which is incorporated by reference herein in its entirety.
  • Clinical acceptability is a broad term and is used in its ordinary sense, including, without limitation, determination of the risk of inaccuracies to a patient.
  • Clinical acceptability considers a deviation between time corresponding glucose measurements (e.g., data from a glucose sensor and data from a reference glucose monitor) and the risk (e.g., to the decision making of a diabetic patient) associated with that deviation based on the glucose value indicated by the sensor and/or reference data.
  • One example of clinical acceptability may be 85% of a given set of measured analyte values within the “A” and “B” region of a standard Clarke Error Grid when the sensor measurements are compared to a standard reference measurement.
  • R-value is a broad term and is used in its ordinary sense, including, without limitation, one conventional way of summarizing the correlation of data; that is, a statement of what residuals (e.g., root mean square deviations) are to be expected if the data are fitted to a straight line by the a regression.
  • data association and data association function are a broad terms and are used in their ordinary sense, including, without limitation, a statistical analysis of data and particularly its correlation to, or deviation from, from a particular curve.
  • a data association function is used to show data association.
  • the data that forms that calibration set as described herein may be analyzed mathematically to determine its correlation to, or deviation from, a curve (e.g., line or set of lines) that defines the conversion function; this correlation or deviation is the data association.
  • a data association function is used to determine data association.
  • data association functions include, but are not limited to, linear regression, non-linear mapping/regression, rank (e.g., non-parametric) correlation, least mean square fit, mean absolute deviation (MAD), mean absolute relative difference.
  • rank e.g., non-parametric correlation
  • MAD mean absolute deviation
  • the correlation coefficient of linear regression is indicative of the amount of data association of the calibration set that forms the conversion function, and thus the quality of the calibration.
  • quality of calibration is a broad term and is used in its ordinary sense, including, without limitation, the statistical association of matched data pairs in the calibration set used to create the conversion function.
  • an R-value may be calculated for a calibration set to determine its statistical data association, wherein an R-value greater than 0.79 determines a statistically acceptable calibration quality, while an R-value less than 0.79 determines statistically unacceptable calibration quality.
  • congruence is a broad term and is used in its ordinary sense, including, without limitation, the quality or state of agreeing, coinciding, or being concordant. In one example, congruence may be determined using rank correlation.
  • cordant as used herein, is a broad term and is used in its ordinary sense, including, without limitation, being in agreement or harmony, and/or free from discord.
  • continuous (or continual) analyte sensing is a broad term and is used in its ordinary sense, including, without limitation, the period in which monitoring of analyte concentration is continuously, continually, and or intermittently (but regularly) performed, for example, about every 5 to 10 minutes.
  • a sensor head is a broad term and is used in its ordinary sense, including, without limitation, the region of a monitoring device responsible for the detection of a particular analyte.
  • a sensor head comprises a non-conductive body, a working electrode (anode), a reference electrode and a counter electrode (cathode) passing through and secured within the body forming an electrochemically reactive surface at one location on the body and an electronic connective means at another location on the body, and a sensing membrane affixed to the body and covering the electrochemically reactive surface.
  • the counter electrode has a greater electrochemically reactive surface area than the working electrode.
  • the sensing membrane further comprises an enzyme domain (e.g., and enzyme layer), and an electrolyte phase (e.g., a free-flowing liquid phase comprising an electrolyte-containing fluid described further below).
  • an enzyme e.g., glucose oxidase
  • the reaction of the biological sample (or portion thereof) results in the formation of reaction products that allow a determination of the analyte (e.g., glucose) level in the biological sample.
  • the sensing membrane further comprises an enzyme domain (e.g., and enzyme layer), and an electrolyte phase (e.g., a free-flowing liquid phase comprising an electrolyte-containing fluid described further below).
  • electrochemically reactive surface is a broad term and is used in its ordinary sense, including, without limitation, the surface of an electrode where an electrochemical reaction takes place.
  • the hydrogen peroxide produced by the enzyme catalyzed reaction of the analyte being detected creates a measurable electronic current (e.g., detection of analyte utilizing analyte oxidase produces H 2 O 2 peroxide as a by product, H 2 O 2 reacts with the surface of the working electrode producing two protons (2H + ), two electrons (2e ⁇ ) and one molecule of oxygen (O 2 ) which produces the electronic current being detected).
  • a reducible species e.g., O 2 is reduced at the electrode surface in order to balance the current being generated by the working electrode.
  • electronic connection is a broad term and is used in its ordinary sense, including, without limitation, any electronic connection known to those in the art that may be utilized to interface the sensor head electrodes with the electronic circuitry of a device such as mechanical (e.g., pin and socket) or soldered.
  • sensing membrane is a broad term and is used in its ordinary sense, including, without limitation, a permeable or semi-permeable membrane that may be comprised of two or more domains and constructed of materials of a few microns thickness or more, which are permeable to oxygen and may or may not be permeable to an analyte of interest.
  • the sensing membrane comprises an immobilized glucose oxidase enzyme, which enables an electrochemical reaction to occur to measure a concentration of glucose.
  • biointerface membrane is a broad term and is used in its ordinary sense, including, without limitation, a permeable membrane that may be comprised of two or more domains and constructed of materials of a few microns thickness or more, which may be placed over the sensor body to keep host cells (e.g., macrophages) from gaining proximity to, and thereby damaging, the sensing membrane or forming a barrier cell layer and interfering with the transport of analyte across the tissue-device interface.
  • host cells e.g., macrophages
  • Eq and Eqs (equivalents); mEq (milliequivalents); M (molar); mM (millimolar) ⁇ M (micromolar); N (Normal); mol (moles); mmol (millimoles); ⁇ mol (micromoles); nmol (nanomoles); g (grams); mg (milligrams); ⁇ g (micrograms); Kg (kilograms); L (liters); mL (milliliters); dL (deciliters); ⁇ L (microliters); cm (centimeters); mm (millimeters); ⁇ m (micrometers); nm (nanometers); h and hr (hours); min. (minutes); s and sec. (seconds); ° C. (degrees Centigrade).
  • the preferred embodiments relate to the use of an analyte sensor that measures a concentration of analyte of interest or a substance indicative of the concentration or presence of the analyte.
  • the sensor is a continuous device, for example a subcutaneous, transdermal, or intravascular device.
  • the device may analyze a plurality of intermittent blood samples.
  • the analyte sensor may use any method of analyte-sensing, including enzymatic, chemical, physical, electrochemical, spectrophotometric, polarimetric, calorimetric, radiometric, or the like.
  • the analyte sensor uses any known method, including invasive, minimally invasive, and non-invasive sensing techniques, to provide an output signal indicative of the concentration of the analyte of interest.
  • the output signal is typically a raw signal that is used to provide a useful value of the analyte of interest to a user, such as a patient or physician, who may be using the device. Accordingly, appropriate smoothing, calibration, and evaluation methods may be applied to the raw signal and/or system as a whole to provide relevant and acceptable estimated analyte data to the user.
  • the analyte sensor useful with the preferred embodiments may be any device capable of measuring the concentration of an analyte of interest.
  • One exemplary embodiment is described below, which utilizes an implantable glucose sensor.
  • the devices and methods described herein may be applied to any device capable of detecting a concentration of analyte of and providing an output signal that represents the concentration of the analyte.
  • FIG. 1 is an exploded perspective view of a glucose sensor in one embodiment.
  • the implantable glucose sensor 10 utilizes amperometric electrochemical sensor technology to measure glucose.
  • a body 12 and a head 14 house electrodes 16 and sensor electronics, which are described in more detail with reference to FIG. 2 .
  • Three electrodes 16 are operably connected to the sensor electronics ( FIG. 2 ) and are covered by a sensing membrane 17 and a biointerface membrane 18 , which are attached by a clip 19 .
  • the number of electrodes may be less than or greater than three.
  • the three electrodes 16 which protrude through the head 14 , including a platinum working electrode, a platinum counter electrode, and a silver/silver chloride reference electrode.
  • the top ends of the electrodes are in contact with an electrolyte phase (not shown), which is a free-flowing fluid phase disposed between the sensing membrane and the electrodes.
  • the sensing membrane 17 includes an enzyme, e.g., glucose oxidase, which covers the electrolyte phase.
  • the biointerface membrane 18 covers the sensing membrane 17 and serves, at least in part, to protect the sensor from external forces that may result in environmental stress cracking of the sensing membrane 17 .
  • the counter electrode is provided to balance the current generated by the species being measured at the working electrode.
  • the species being measured at the working electrode is H 2 O 2 .
  • Glucose oxidase catalyzes the conversion of oxygen and glucose to hydrogen peroxide and gluconate according to the following reaction: Glucose+O 2 ⁇ Gluconate+H 2 O 2
  • the change in H 2 O 2 can be monitored to determine glucose concentration because for each glucose molecule metabolized, there is a proportional change in the product H 2 O 2 .
  • Oxidation of H 2 O 2 by the working electrode is balanced by reduction of ambient oxygen, enzyme generated H 2 O 2 , or other reducible species at the counter electrode.
  • the H 2 O 2 produced from the glucose oxidase reaction further reacts at the surface of working electrode and produces two protons (2H + ), two electrons (2e ⁇ )and one oxygen molecule (O 2 ) (See, e.g., Fraser, D. M. “An Introduction to In vivo Biosensing: Progress and problems.” In “Biosensors and the Body,” D. M. Fraser, ed., 1997, pp. 1-56 John Wiley and Sons, New York.)
  • a potentiostat is used to measure the electrochemical reaction(s) at the electrode(s) (see FIG. 2 ).
  • the potentiostat applies a constant potential between the working and reference electrodes to produce a current value.
  • the current that is produced at the working electrode (and flows through the circuitry to the counter electrode) is proportional to the diffusional flux of H 2 O 2 . Accordingly, a raw signal may be produced that is representative of the concentration of glucose in the users body, and therefore may be utilized to estimate a meaningful glucose value, such as described elsewhere herein.
  • FIG. 2 is a block diagram that illustrates the sensor electronics in one embodiment.
  • the potentiostat 20 is shown, which is operatively connected to electrodes 16 ( FIG. 1 ) to obtain a current value, and includes a resistor (not shown) that translates the current into voltage.
  • An A/D converter 21 digitizes the analog signal into counts for processing. Accordingly, the resulting raw data signal in counts is directly related to the current measured by the potentiostat 20 .
  • a microprocessor 22 is the central control unit that houses EEPROM 23 and SRAM 24 , and controls the processing of the sensor electronics. It may be noted that alternative embodiments utilize a computer system other than a microprocessor to process data as described herein. In some alternative embodiments, an application-specific integrated circuit (ASIC) may be used for some or all the sensor's central processing.
  • the EEPROM 23 provides semi-permanent storage of data, storing data such as sensor ID and necessary programming to process data signals (e.g., programming for data smoothing such as described below).
  • the SRAM 24 is used for the system's cache memory, for example for temporarily storing recent sensor data.
  • a battery 25 is operatively connected to the microprocessor 22 and provides the necessary power for the sensor.
  • the battery is a Lithium Manganese Dioxide battery, however any appropriately sized and powered battery may be used (e.g., AAA, Nickel-cadmium, Zinc-carbon, Alkaline, Lithium, Nickel-metal hydride, Lithium-ion, Zinc-air, Zinc-mercury oxide, Silver-zinc, or hermetically-sealed).
  • a plurality of batteries may be used to power the system.
  • a Quartz Crystal 26 is operatively connected to the microprocessor 22 and maintains system time for the computer system as a whole.
  • An RF Transceiver 27 is operably connected to the microprocessor 22 and transmits the sensor data from the sensor to a receiver (see FIGS. 4 and 5 ). Although an RF transceiver is shown here, other embodiments include a wired rather than wireless connection to the receiver. In yet other embodiments, the receiver is transcutaneously powered via an inductive coupling, for example. A quartz crystal 28 provides the system time for synchronizing the data transmissions from the RF transceiver. It may be noted that the transceiver 27 may be substituted for a transmitter in one embodiment.
  • an analyte sensor produces a raw data signal that is indicative of the analyte concentration of a user, such as described in more detail with reference to FIGS. 1 and 2 , above.
  • the above described glucose sensor is only one example of an abundance of analyte sensors that are able to provide a raw data signal output indicative of the concentration of the analyte of interest.
  • the devices and methods of the preferred embodiments including data smoothing, calibration, evaluation, and other data processing, may be applied to raw data obtained from any analyte sensor capable of producing a output signal.
  • raw data signals received from an analyte sensor include signal noise, which degrades the quality of the data.
  • smoothing algorithms help improve the signal-to-noise ratio in the sensor by reducing signal jitter, for example.
  • One example of a conventional data smoothing algorithms include finite impulse response filter (FIR), which is particularly suited for reducing high-frequency noise (see Steil et al. U.S. Pat. No. 6,558,351).
  • FIR finite impulse response filter
  • Other analyte sensors have utilized heuristic and moving average type algorithms to accomplish data smoothing of signal jitter in data signals, for example.
  • transient, low frequency, non-analyte related signal fluctuations e.g., transient ischemia and/or long transient periods of postural effects that interfere with sensor function due to lack of oxygen and/or other physiological effects.
  • this attenuation of transient low frequency non-analyte related signal noise is accomplished using a recursive filter.
  • a recursive filter is an equation that uses moving averages as inputs; that is, a recursive filter includes previous averages as part of the next filtered output. Recursive filters are advantageous at least in part due to their computational efficiency.
  • FIG. 3 is a graph that illustrates data smoothing of a raw data signal in one embodiment.
  • the recursive filter is implemented as a digital infinite impulse response filter (IIR) filter, wherein the output is computed using 6 additions and 7 multiplies as shown in the following equation:
  • IIR digital infinite impulse response filter
  • y ⁇ ( n ) a 0 * x ⁇ ( n ) + a 1 * x ⁇ ( n - 1 ) + a 2 * x ⁇ ( n - 2 ) + a 3 * x ⁇ ( n - 3 ) - b 1 * y ⁇ ( n - 1 ) - b 2 * y ⁇ ( n - 2 ) - b 3 * y ⁇ ( n - 3 ) b 0
  • This polynomial equation includes coefficients that are dependent on sample rate and frequency behavior of the filter. In this exemplary embodiment, frequency behavior passes low frequencies up to cycle lengths of 40 minutes, and is based on a 30 second sample rate.
  • data smoothing may be implemented in the sensor and the smoothed data transmitted to a receiver for additional processing.
  • raw data may be sent from the sensor to a receiver for data smoothing and additional processing therein.
  • the sensor is integral with the receiver and therefore no transmission of data is required.
  • data smoothing is performed in the sensor to ensure a continuous stream of data.
  • data smoothing may be transmitted from the sensor to the receiver, and the data smoothing performed at the receiver; it may be noted however that there may be a risk of transmit-loss in the radio transmission from the sensor to the receiver when the transmission is wireless.
  • the raw sensor signal may be more consistent within the sensor (in vivo) than the raw signal transmitted to a source (e.g., receiver) outside the body (e.g., if a patient were to take the receiver off to shower, communication between the sensor and receiver may be lost and data smoothing in the receiver would halt accordingly.) Consequently, it may be noted that a multiple point data loss in the filter may take, for example, anywhere from 25 to 40 minutes for the smoothed data to recover to where it would have been had there been no data loss.
  • FIGS. 4A to 4D are schematic views of a receiver in first, second, third, and fourth embodiments, respectively.
  • a receiver 40 comprises systems necessary to receive, process, and display sensor data from an analyte sensor, such as described elsewhere herein.
  • the receiver 40 may be a pager-sized device, for example, and comprise a user interface that has a plurality of buttons 42 and a liquid crystal display (LCD) screen 44 , and which may include a backlight.
  • the user interface may also include a keyboard, a speaker, and a vibrator such as described with reference to FIG. 5 .
  • FIG. 4A illustrates a first embodiment wherein the receiver shows a numeric representation of the estimated analyte value on its user interface, which is described in more detail elsewhere herein.
  • FIG. 4B illustrates a second embodiment wherein the receiver shows an estimated glucose value and one hour of historical trend data on its user interface, which is described in more detail elsewhere herein.
  • FIG. 4C illustrates a third embodiment wherein the receiver shows an estimated glucose value and three hours of historical trend data on its user interface, which is described in more detail elsewhere herein.
  • FIG. 4D illustrates a fourth embodiment wherein the receiver shows an estimated glucose value and nine hours of historical trend data on its user interface, which is described in more detail elsewhere herein.
  • a user is able to toggle through some or all of the screens shown in FIGS. 4A to 4D using a toggle button on the receiver.
  • the user is able to interactively select the type of output displayed on their user interface.
  • the sensor output may have alternative configurations, such as is described with reference to FIG. 6 , block 69 , for example.
  • FIG. 5 is a block diagram of the receiver electronics in one embodiment.
  • the receiver may comprise a configuration such as described with reference to FIGS. 4A to 4D , above.
  • the receiver may comprise any configuration, including a desktop computer, laptop computer, a personal digital assistant (PDA), a server (local or remote to the receiver), or the like.
  • a receiver may be adapted to connect (via wired or wireless connection) to a desktop computer, laptop computer, a PDA, a server (local or remote to the receiver), or the like in order to download data from the receiver.
  • the receiver is housed within or directly connected to the sensor in a manner that allows sensor and receiver electronics to work directly together and/or share data processing resources. Accordingly, the receiver, including its electronics, may be generally described as a “computer system.”
  • a quartz crystal 50 is operatively connected to an RF transceiver 51 that together function to receive and synchronize data signals (e.g., raw data signals transmitted from the RF transceiver). Once received, the microprocessor 52 processes the signals, such as described below.
  • data signals e.g., raw data signals transmitted from the RF transceiver.
  • the microprocessor 52 is the central control unit that provides the necessary processing, such as calibration algorithms stored within an EEPROM 53 .
  • the EEPROM 53 is operatively connected to the microprocessor 52 and provides semi-permanent storage of data, storing data such as receiver ID and necessary programming to process data signals (e.g., programming for performing calibration and other algorithms described elsewhere herein).
  • an application-specific integrated circuit ASIC may be used for some or all the receiver's central processing.
  • An SRAM 54 is used for the system's cache memory and is helpful in data processing.
  • the microprocessor 52 which is operatively connected to EEPROM 53 and SRAM 54 , controls the processing of the receiver electronics including, but not limited to, a sensor data receiving module, a reference data receiving module, a data matching module, a calibration set module, a conversion function module, a sensor data transformation module, a quality evaluation module, a interface control module, and a stability determination module, which are described in more detail below. It may be noted that any of the above processing may be programmed into and performed in the sensor electronics ( FIG. 2 ) in place of, or in complement with, the receiver electronics ( FIG. 5 ).
  • a battery 55 is operatively connected to the microprocessor 52 and provides the necessary power for the receiver.
  • the battery is a AAA battery, however any appropriately sized and powered battery may be used.
  • a plurality of batteries may be used to power the system.
  • a quartz crystal 56 is operatively connected to the microprocessor 52 and maintains system time for the computer system as a whole.
  • a user interface 57 comprises a keyboard, speaker, vibrator, backlight, LCD, and a plurality of buttons.
  • the components that comprise the user interface 57 provide the necessary controls to interact with the user.
  • a keyboard may allow, for example, input of user information about himself/herself, such as mealtime, exercise, insulin administration, and reference analyte values.
  • a speaker may provide, for example, audible signals or alerts for conditions such as present and/or predicted hyper- and hypoglycemic conditions.
  • a vibrator may provide, for example, tactile signals or alerts for reasons such as described with reference to the speaker, above.
  • a backlight may be provided, for example, to aid the user in reading the LCD in low light conditions.
  • An LCD may be provided, for example, to provide the user with visual data output such as described in more detail with reference to FIGS. 4A to 4D and FIG. 6 . Buttons may provide toggle, menu selection, option selection, mode selection, and reset, for example.
  • Communication ports including a personal computer (PC) com port 58 and a reference analyte monitor com port 59 may be provided to enable communication with systems that are separate from, or integral with, the receiver.
  • the PC com port 58 comprises means for communicating with another computer system (e.g., PC, PDA, server, or the like).
  • the receiver is able to download historic data to a physician's PC for retrospective analysis by the physician.
  • the reference analyte monitor com port 59 comprises means for communicating with a reference analyte monitor so that reference analyte values may be automatically downloaded into the receiver.
  • the reference analyte monitor is integral with the receiver, and the reference analyte com port 59 allows internal communication between the two integral systems.
  • the reference analyte monitor com port 59 allows a wireless or wired connection to the reference analyte monitor such as a self-monitoring blood glucose monitor (e.g., for measuring finger stick blood samples).
  • FIG. 6 is a flow chart that illustrates the initial calibration and data output of the sensor data in one embodiment.
  • Calibration of an analyte sensor comprises data processing that converts sensor data signal into an estimated analyte measurement that is meaningful to a user. Accordingly, a reference analyte value is used to calibrate the data signal from the analyte sensor.
  • a sensor data receiving module receives sensor data (e.g., a data stream), including one or more time-spaced sensor data points, from a sensor via the receiver, which may be in wired or wireless communication with the sensor.
  • the sensor data point(s) may be smoothed, such as described with reference to FIG. 3 , above. It may be noted that during the initialization of the sensor, prior to initial calibration, the receiver (e.g., computer system) receives and stores the sensor data, however may not display any data to the user until initial calibration and possibly stabilization of the sensor has been determined.
  • a reference data receiving module receives reference data from a reference analyte monitor, including one or more reference data points.
  • the reference analyte points may comprise results from a self-monitored blood analyte test (e.g., from a finger stick test).
  • the user may administer a self-monitored blood analyte test to obtain an analyte value (e.g., point) using any known analyte sensor, and then enter the numeric analyte value into the computer system.
  • a self-monitored blood analyte test comprises a wired or wireless connection to the receiver (e.g.
  • the self-monitored analyte test is integral with the receiver so that the user simply provides a blood sample to the receiver, and the receiver runs the analyte test to determine a reference analyte value.
  • acceptability parameters may be set for reference values received from the user.
  • the receiver may only accept reference analyte values between about 40 and about 400 mg/dL.
  • Other examples of determining valid reference analyte values are described in more detail with reference to FIG. 8 .
  • a data matching module also referred to as the processor module, matches reference data (e.g., one or more reference analyte data points) with substantially time corresponding sensor data (e.g., one or more sensor data points) to provide one or more matched data pairs.
  • reference data e.g., one or more reference analyte data points
  • sensor data e.g., one or more sensor data points
  • one reference data point is matched to one time corresponding sensor data point to form a matched data pair.
  • a plurality of reference data points are averaged (e.g., equally or non-equally weighted average, mean-value, median, or the like) and matched to one time corresponding sensor data point to form a matched data pair.
  • one reference data point is matched to a plurality of time corresponding sensor data points averaged to form a matched data pair.
  • a plurality of reference data points are averaged and matched to a plurality of time corresponding sensor data points averaged to form a matched data pair.
  • a time corresponding sensor data comprises one or more sensor data points that occur 15 ⁇ 5 min after the reference analyte data timestamp (e.g., the time that the reference analyte data is obtained).
  • the 15 minute time delay has been chosen to account for an approximately 10 minute delay introduced by the filter used in data smoothing and an approximately 5 minute physiological time-lag (e.g., the time necessary for the analyte to diffusion through a membrane(s) of an analyte sensor).
  • the time corresponding sensor value may be more or less than the above-described embodiment, for example ⁇ 60 minutes. Variability in time correspondence of sensor and reference data may be attributed to, for example a longer or shorter time delay introduced by the data smoothing filter, or if the configuration of the analyte sensor incurs a greater or lesser physiological time lag.
  • the reference analyte data may be obtained at a time that is different from the time that the data is input into the receiver. Accordingly, it should be noted that the “time stamp” of the reference analyte (e.g., the time at which the reference analyte value was obtained) is not the same as the time at which the reference analyte data was obtained by receiver. Therefore, some embodiments include a time stamp requirement that ensures that the receiver stores the accurate time stamp for each reference analyte value, that is, the time at which the reference value was actually obtained from the user.
  • tests are used to evaluate the best matched pair using a reference data point against individual sensor values over a predetermined time period (e.g., about 30 minutes).
  • the reference data point is matched with sensor data points at 5-minute intervals and each matched pair is evaluated.
  • the matched pair with the best correlation may be selected as the matched pair for data processing.
  • matching a reference data point with an average of a plurality of sensor data points over a predetermined time period may be used to form a matched pair.
  • a calibration set module also referred to as the processor module, forms an initial calibration set from a set of one or more matched data pairs, which are used to determine the relationship between the reference analyte data and the sensor analyte data, such as will be described in more detail with reference to block 67 , below.
  • the matched data pairs, which make up the initial calibration set may be selected according to predetermined criteria. It may be noted that the criteria for the initial calibration set may be the same as, or different from, the criteria for the update calibration set, which is described in more detail with reference to FIG. 10 .
  • the number (n) of data pair(s) selected for the initial calibration set is one. In other embodiments, n data pairs are selected for the initial calibration set wherein n is a function of the frequency of the received reference data points. In one exemplary embodiment, six data pairs make up the initial calibration set.
  • the data pairs are selected only within a certain analyte value threshold, for example wherein the reference analyte value is between about 40 and about 400 mg/dL.
  • the data pairs that form the initial calibration set are selected according to their time stamp.
  • the calibration set is selected such as described with reference to FIG. 10
  • a stability determination module determines the stability of the analyte sensor over a period of time.
  • some analyte sensors may have an initial instability time period during which the analyte sensor is unstable for environmental, physiological, or other reasons.
  • initial sensor instability is an embodiment wherein the analyte sensor is implanted subcutaneously; in this example embodiment, stabilization of the analyte sensor may be dependent upon the maturity of the tissue ingrowth around and within the sensor.
  • Another example of initial sensor instability is in an embodiment wherein the analyte sensor is implemented transdermally; in this example embodiment, stabilization of the analyte sensor may be dependent upon electrode stabilization and/or sweat, for example.
  • determination of sensor stability may include waiting a predetermined time period (e.g., an implantable sensor is known to require a time period for tissue, and a transdermal sensor is known to require time to equilibrate the sensor with the user's skin); in some embodiments, this predetermined waiting period is between about one minute and about six weeks.
  • the sensitivity e.g., sensor signal strength with respect to analyte concentration
  • the stability of the sensor may be used to determine the stability of the sensor; for example, amplitude and/or variability of sensor sensitivity may be evaluated to determine the stability of the sensor.
  • detection of pH levels, oxygen, hypochlorite, interfering species e.g., ascorbate, urea, and acetaminophen
  • correlation between sensor and reference values e.g., R-value
  • baseline drift and/or offset e.g., baseline drift and/or offset, and the like
  • the sensor is a glucose sensor
  • it is known to provide a signal that is associated with interfering species e.g., ascorbate, urea, acetaminophen
  • the counter electrode can be monitored for oxygen deprivation, which may be used to evaluate sensor stability or functionality.
  • the system determines whether the analyte sensor is sufficiently stable according to certain criteria, such as described above.
  • the system waits a predetermined time period believed necessary for sufficient tissue ingrowth and evaluates the sensor sensitivity (e.g., between about one minute and six weeks).
  • the receiver determines sufficient stability based on oxygen concentration near the sensor head.
  • the sensor determines sufficient stability based on a reassessment of baseline drift and/or offset.
  • the system evaluates stability by monitoring the frequency content of the sensor data stream over a predetermined amount of time (e.g., 24 hours); in this alternative embodiment, a template (or templates) are provided that reflect acceptable levels of glucose physiology and are compared with the actual sensor data, wherein a predetermined amount of agreement between the template and the actual sensor data is indicative of sensor stability. It may be noted that a few examples of determining sufficient stability are given here, however a variety of known tests and parameters may be used to determine sensor stability without departing from the spirit and scope of the preferred embodiments.
  • the processing returns to block 61 , wherein the receiver receives sensor data such as described in more detail above. The above-described steps are repeated until sufficient stability is determined.
  • processing continues to block 67 and the calibration set is used to calibrate the sensor.
  • the conversion function module uses the calibration set to create a conversion function.
  • the conversion function substantially defines the relationship between the reference analyte data and the analyte sensor data.
  • a variety of known methods may be used with the preferred embodiments to create the conversion function from the calibration set.
  • a linear least squares regression is performed on the initial calibration set such as described with reference to FIG. 7 .
  • FIG. 7 is a graph that illustrates a regression performed on a calibration set to create a conversion function in one exemplary embodiment.
  • a linear least squares regression is performed on the initial calibration set.
  • the x-axis represents reference analyte data; the y-axis represents sensor data.
  • the conversion function may comprise two or more different optimal conversions because an optimal conversion at any time is dependent on one or more parameters, such as time of day, calories consumed, exercise, or analyte concentration above or below a set threshold, for example.
  • the conversion function is adapted for the estimated glucose concentration (e.g., high vs. low). For example in an implantable glucose sensor it has been observed that the cells surrounding the implant will consume at least a small amount of glucose as it diffuses toward the glucose sensor. Assuming the cells consume substantially the same amount of glucose whether the glucose concentration is low or high, this phenomenon will have a greater effect on the concentration of glucose during low blood sugar episodes than the effect on the concentration of glucose during relatively higher blood sugar episodes.
  • the conversion function is adapted to compensate for the sensitivity differences in blood sugar level.
  • the conversion function comprises two different regression lines wherein a first regression line is applied when the estimated blood glucose concentration is at or below a certain threshold (e.g., 150 mg/dL) and a second regression line is applied when the estimated blood glucose concentration is at or above a certain threshold (e.g., 150 mg/dL).
  • a predetermined pivot of the regression line that forms the conversion function may be applied when the estimated blood is above or below a set threshold (e.g., 150 mg/dL), wherein the pivot and threshold are determined from a retrospective analysis of the performance of a conversion function and its performance at a range of glucose concentrations.
  • the regression line that forms the conversion function is pivoted about a point in order to comply with clinical acceptability standards (e.g., Clarke Error Grid, Consensus Grid, mean absolute relative difference, or other clinical cost function).
  • clinical acceptability standards e.g., Clarke Error Grid, Consensus Grid, mean absolute relative difference, or other clinical cost function.
  • a sensor data transformation module uses the conversion function to transform sensor data into substantially real-time analyte value estimates, also referred to as calibrated data, as sensor data is continuously (or intermittently) received from the sensor.
  • the sensor data which may be provided to the receiver in “counts”, is translated in to estimate analyte value(s) in mg/dL.
  • the offset value at any given point in time may be subtracted from the raw value (e.g., in counts) and divided by the slope to obtain the estimate analyte value:
  • the senor and/or reference analyte values are stored in a database for retrospective analysis.
  • an output module provides output to the user via the user interface.
  • the output is representative of the estimated analyte value, which is determined by converting the sensor data into a meaningful analyte value such as described in more detail with reference to block 68 , above.
  • User output may be in the form of a numeric estimated analyte value, an indication of directional trend of analyte concentration, and/or a graphical representation of the estimated analyte data over a period of time, for example.
  • Other representations of the estimated analyte values are also possible, for example audio and tactile.
  • the estimated analyte value is represented by a numeric value.
  • the user interface graphically represents the estimated analyte data trend over predetermined a time period (e.g., one, three, and nine hours, respectively). In alternative embodiments, other time periods may be represented.
  • the user interface begins displaying data to the user after the sensor's stability has been affirmed. In some alternative embodiments however, the user interface displays data that is somewhat unstable (e.g., does not have sufficient stability at block 66 ); in these embodiments, the receiver may also include an indication of instability of the sensor data (e.g., flashing, faded, or another indication of sensor instability displayed on the user interface). In some embodiments, the user interface informs the user of the status of the stability of the sensor data.
  • real-time continuous analyte information may be displayed on the user interface so that the user may regularly and proactively care for his/her diabetic condition within the bounds set by his/her physician.
  • the conversion function is used to predict analyte values at future points in time. These predicted values may be used to alert the user of upcoming hypoglycemic or hyperglycemic events. Additionally, predicted values may be used to compensate for the time lag (e.g., 15 minute time lag such as described elsewhere herein), so that an estimate analyte value displayed to the user represents the instant time, rather than a time delayed estimated value.
  • time lag e.g. 15 minute time lag such as described elsewhere herein
  • the substantially real time estimated analyte value, a predicted future estimate analyte value, a rate of change, and/or a directional trend of the analyte concentration is used to control the administration of a constituent to the user, including an appropriate amount and time, in order to control an aspect of the user's biological system.
  • a constituent to the user including an appropriate amount and time
  • the analyte data e.g., estimated glucose value, rate of change, and/or directional trend
  • the glucose sensor e.g., glucose value, rate of change, and/or directional trend
  • FIG. 8 is a flow chart that illustrates the process of evaluating the clinical acceptability of reference and sensor data in one embodiment. Although some clinical acceptability tests are disclosed here, any known clinical standards and methodologies may be applied to evaluate the clinical acceptability of reference and analyte data herein.
  • the conventional analyte meters e.g., self-monitored blood analyte tests
  • the conventional analyte meters are known to have a + ⁇ 20% error in analyte values.
  • gross errors in analyte readings are known to occur due to patient error in self-administration of the blood analyte test.
  • self-monitored analyte tests e.g., test strips
  • self-monitored analyte tests are occasionally subject to manufacturing error.
  • Another cause for error includes infrequency and time delay that may occur if a user does not self-test regularly, or if a user self-tests regularly but does not enter the reference value at the appropriate time or with the appropriate time stamp. Therefore, it may be advantageous to validate the acceptability of reference analyte values prior to accepting them as valid entries. Accordingly, the receiver evaluates the clinical acceptability of received reference analyte data prior to their acceptance as a valid reference value.
  • the reference analyte data (and/or sensor analyte data) is evaluated with respect to substantially time corresponding sensor data (and/or substantially time corresponding reference analyte data) to determine the clinical acceptability of the reference analyte and/or sensor analyte data.
  • Clinical acceptability considers a deviation between time corresponding glucose measurements (e.g., data from a glucose sensor and data from a reference glucose monitor) and the risk (e.g., to the decision making of a diabetic patient) associated with that deviation based on the glucose value indicated by the sensor and/or reference data. Evaluating the clinical acceptability of reference and sensor analyte data, and controlling the user interface dependent thereon, may minimize clinical risk.
  • the receiver evaluates clinical acceptability each time reference data is obtained. In another embodiment, the receiver evaluates clinical acceptability after the initial calibration and stabilization of the sensor, such as described with reference to FIG. 6 , above. In some embodiments, the receiver evaluates clinical acceptability as an initial pre-screen of reference analyte data, for example after determining if the reference glucose measurement is between about 40 and 400 mg/dL. In other embodiments, other methods of pre-screening data may be used, for example by determining if a reference analyte data value is physiologically feasible based on previous reference analyte data values (e.g., below a maximum rate of change).
  • the sensor data receiving module 61 receives substantially continuous sensor data (e.g., a data stream) via a receiver and converts that data into estimated analyte values.
  • substantially continuous is broad enough to include a data stream of individual measurements taken at time intervals (e.g., time-spaced) ranging from fractions of a second up to, e.g., 1, 2, or 5 minutes.
  • time intervals e.g., time-spaced
  • sensor data is continuously converted, it may be occasionally recalibrated such as described in more detail with reference FIG. 10 .
  • Initial calibration and re-calibration of the sensor requires a reference analyte value.
  • the receiver may receive reference analyte data at any time for appropriate processing. These reference analyte values may be evaluated for clinical acceptability such as described below as a fail-safe against reference analyte test errors.
  • the reference data receiving module also referred to as the reference input module, receives reference analyte data from a reference analyte monitor.
  • the reference data comprises one analyte value obtained from a reference monitor.
  • the reference data includes a set of analyte values entered by a user into the interface and averaged by known methods such as described elsewhere herein.
  • the reference data is pre-screened according to environmental and physiological issues, such as time of day, oxygen concentration, postural effects, and patient-entered environmental data.
  • the sensor comprises an implantable glucose sensor
  • an oxygen sensor within the glucose sensor is used to determine if sufficient oxygen is being provided to successfully complete the necessary enzyme and electrochemical reactions for glucose sensing.
  • the counter electrode could be monitored for a “rail-effect”, that is, when insufficient oxygen is provided at the counter electrode causing the counter electrode to reach operational (e.g., circuitry) limits.
  • the patient is prompted to enter data into the user interface, such as meal times and/or amount of exercise, which could be used to determine likelihood of acceptable reference data.
  • evaluation data such as described in the paragraph above, may be used to evaluate an optimum time for reference analyte measurement.
  • the user interface may then prompt the user to provide a reference data point for calibration within a given time period. Consequently, because the receiver proactively prompts the user during optimum calibration times, the likelihood of error due to environmental and physiological limitations may decrease and consistency and acceptability of the calibration may increase.
  • the clinical acceptability evaluation module also referred to as clinical module, evaluates the clinical acceptability of newly received reference data and/or time corresponding sensor data.
  • the rate of change of the reference data as compared to previous data is assessed for clinical acceptability. That is, the rate of change and acceleration (or deceleration) of many analytes has certain physiological limits within the body. Accordingly, a limit may be set to determine if the new matched pair is within a physiologically feasible range, indicated by a rate of change from the previous data that is within known physiological and/or statistical limits.
  • any algorithm that predicts a future value of an analyte may be used to predict and then compare an actual value to a time corresponding predicted value to determine if the actual value falls within a clinically acceptable range based on the predictive algorithm, for example.
  • the clinical acceptability evaluation module 82 matches the reference data with a substantially time corresponding converted sensor value such as described with reference to FIG. 6 above, and plots the matched data on a Clarke Error Grid such as described in more detail with reference to FIG. 9 .
  • FIG. 9 is a graph of two data pairs on a Clarke Error Grid to illustrate the evaluation of clinical acceptability in one exemplary embodiment.
  • the Clarke Error Grid may be used by the clinical acceptability evaluation module to evaluate the clinical acceptability of the disparity between a reference glucose value and a sensor glucose (e.g., estimated glucose) value, if any, in an embodiment wherein the sensor is a glucose sensor.
  • the x-axis represents glucose reference glucose data and the y-axis represents estimated glucose sensor data. Matched data pairs are plotted accordingly to their reference and sensor values, respectively.
  • matched pairs that fall within the A and B regions of the Clarke Error Grid are considered clinically acceptable, while matched pairs that fall within the C, D, and E regions of the Clarke Error Grid are not considered clinically acceptable.
  • FIG. 9 shows a first matched pair 92 is shown which falls within the A region of the Clarke Error Grid, therefore is it considered clinically acceptable.
  • a second matched pair 94 is shown which falls within the C region of the Clarke Error Grid, therefore it is not considered clinically acceptable.
  • the Consensus Grid is used to evaluate the clinical acceptability of reference and sensor data.
  • a mean absolute difference calculation may be used to evaluate the clinical acceptability of the reference data.
  • the clinical acceptability may be evaluated using any relevant clinical acceptability test, such as a known grid (e.g., Clarke Error or Consensus), and including additional parameters such as time of day and/or the increase or decreasing trend of the analyte concentration.
  • a rate of change calculation may be used to evaluate clinical acceptability.
  • the conversion function could be used to predict an estimated glucose value at a time corresponding to the time stamp of the reference analyte value (this may be required due to a time lag of the sensor data such as described elsewhere herein). Accordingly, a threshold may be set for the predicted estimated glucose value and the reference analyte value disparity, if any.
  • the results of the clinical acceptability evaluation are assessed. If clinical acceptability is determined with the received reference data, then processing continues to block 84 to optionally recalculate the conversion function using the received reference data in the calibration set. If, however, clinical acceptability is not determined, then the processing progresses to block 86 to control the user interface, such as will be described with reference to block 86 below.
  • the conversion function module optionally recreates the conversion function using the received reference data.
  • the conversion function module adds the newly received reference data (e.g., including the matched sensor data) into the calibration set, displaces the oldest, and/or least concordant matched data pair from the calibration set, and recalculates the conversion function accordingly.
  • the conversion function module evaluates the calibration set for best calibration based on inclusion criteria, such as described in more detail with reference to FIG. 10 .
  • the sensor data transformation module uses the conversion function to continually (or intermittently) convert sensor data into estimated analyte values, also referred to as calibrated data, such as described in more detail with reference to FIG. 6 , block 68 .
  • the interface control module also referred to as the fail-safe module, controls the user interface based upon the clinical acceptability of the reference data received. If the evaluation (block 82 ) deems clinical acceptability, then the user interface may function as normal; that is, providing output for the user such as described in more detail with reference to FIG. 6 , block 69 .
  • the fail-safe module begins the initial stages of fail-safe mode.
  • the initial stages of fail-safe mode include altering the user interface so that estimated sensor data is not displayed to the user.
  • the initial stages of fail-safe mode include prompting the user to repeat the reference analyte test and provide another reference analyte value. The repeated analyte value is then evaluated for clinical acceptability such as described with reference to blocks 81 to 83 , above.
  • fail-safe module may alter the user interface to reflect full fail-safe mode.
  • full fail-safe mode includes discontinuing sensor analyte display output on the user interface.
  • color-coded information, trend information, directional information (e.g., arrows or angled lines), gauges, and/or fail-safe information may be displayed, for example.
  • the first analyte value is discarded, and the repeated analyte value is accepted.
  • the process returns to block 84 to optionally recalculate the conversion function, such as described in more detail with reference to block 84 , above.
  • FIG. 10 is a flow chart that illustrates the process of evaluation of calibration data for best calibration based on inclusion criteria of matched data pairs in one embodiment.
  • calibration of analyte sensors may be variable over time; that is, the conversion function suitable for one point in time may not be suitable for another point in time (e.g., hours, days, weeks, or months later).
  • the maturation of tissue ingrowth over time may cause variability in the calibration of the analyte sensor.
  • physiological changes in the user e.g., metabolism, interfering blood constituents, lifestyle changes
  • a continuously updating calibration algorithm includes reforming the calibration set, and thus recalculating the conversion function, over time according to a set of inclusion criteria.
  • the reference data receiving module also referred to as the reference input module, receives a new reference analyte value (e.g., data point) from the reference analyte monitor.
  • a new reference analyte value e.g., data point
  • the reference analyte value may be pre-screened according to criteria such as described in more detail with reference to FIG. 6 , block 62 .
  • the reference analyte value may be evaluated for clinical acceptability such as described in more detail with reference to FIG. 8 .
  • the data matching module also referred to as the processor module, forms one or more updated matched data pairs by matching new reference data to substantially time corresponding sensor data, such as described in more detail with reference to FIG. 6 , block 63 .
  • a calibration evaluation module evaluates the new matched pair(s) inclusion into the calibration set.
  • the receiver simply adds the updated matched data pair into the calibration set, displaces the oldest and/or least concordant matched pair from the calibration set, and proceeds to recalculate the conversion function accordingly (block 105 ).
  • the calibration evaluation includes evaluating only the new matched data pair. In some embodiments, the calibration evaluation includes evaluating all of the matched data pairs in the existing calibration set and including the new matched data pair; in such embodiments not only is the new matched data pair evaluated for inclusion (or exclusion), but additionally each of the data pairs in the calibration set are individually evaluated for inclusion (or exclusion). In some alternative embodiments, the calibration evaluation includes evaluating all possible combinations of matched data pairs from the existing calibration set and including the new matched data pair to determine which combination best meets the inclusion criteria. In some additional alternative embodiments, the calibration evaluation includes a combination of at least two of the above-described embodiments.
  • Inclusion criteria comprise one or more criteria that define a set of matched data pairs that form a substantially optimal calibration set.
  • One inclusion criterion comprises ensuring the time stamp of the matched data pairs (that make up the calibration set) span at least a set time period (e.g., three hours).
  • Another inclusion criterion comprises ensuring that the time stamps of the matched data pairs are not more than a set age (e.g., one week old).
  • Another inclusion criterion ensures that the matched pairs of the calibration set have a substantially distributed amount of high and low raw sensor data, estimated sensor analyte values, and/or reference analyte values.
  • Another criterion comprises ensuring all raw sensor data, estimated sensor analyte values, and/or reference analyte values are within a predetermined range (e.g., 40 to 400 mg/dL for glucose values).
  • Another criterion comprises evaluating the rate of change of the analyte concentration (e.g., from sensor data) during the time stamp of the matched pair(s). For example, sensor and reference data obtained during the time when the analyte concentration is undergoing a slow rate of change may be less susceptible inaccuracies caused by time lag and other physiological and non-physiological effects.
  • Another criterion comprises evaluating the congruence of respective sensor and reference data in each matched data pair; the matched pairs with the most congruence may be chosen.
  • Another criterion comprises evaluating physiological changes (e.g., low oxygen due to a user's posture that may effect the function of a subcutaneously implantable analyte sensor, or other effects such as described with reference to FIG. 6 ) to ascertain a likelihood of error in the sensor value.
  • evaluation of calibration set criteria may comprise evaluating one, some, or all of the above described inclusion criteria. It is contemplated that additional embodiments may comprise additional inclusion criteria not explicitly described herein.
  • the evaluation of the calibration set determines whether to maintain the previously established calibration set, or if the calibration set should be updated (e.g., modified) with the new matched data pair.
  • the oldest matched data pair is simply displaced when a new matched data pair is included. It may be noted however that a new calibration set may include not only the determination to include the new matched data pair, but in some embodiments, may also determine which of the previously matched data pairs should be displaced from the calibration set.
  • the conversion function module recreates the conversion function using the modified calibration set. The calculation of the conversion function is described in more detail with reference to FIG. 6 .
  • the sensor data transformation module converts sensor data to calibrated data using the updated conversion function. Conversion of raw sensor data into estimated analyte values is described in more detail with reference to FIG. 6 .
  • FIG. 11 is a flow chart that illustrates the process of evaluating the quality of the calibration in one embodiment.
  • the calibration quality may be evaluated by determining the statistical association of data that forms the calibration set, which determines the confidence associated with the conversion function used in calibration and conversion of raw sensor data into estimated analyte values.
  • calibration quality may be evaluated after initial or updated calculation of the conversion function such as described elsewhere herein. However it may be noted that calibration quality may be performed at any time during the data processing.
  • a sensor data receiving module also referred to as the sensor data module, receives the sensor data from the sensor such as described in more detail with reference to FIG. 6 .
  • a reference data receiving module also referred to as the reference input module, receives reference data from a reference analyte monitor, such as described in more detail with reference to FIG. 6 .
  • the data matching module also referred to as the processor module, matches received reference data with substantially time corresponding sensor data to provide one or more matched data pairs, such as described in more detail with reference to FIG. 6 .
  • the calibration set module also referred to as the processor module, forms a calibration set from one or more matched data pairs such as described in more detail with reference to FIGS. 6 , 8 , and 10 .
  • the conversion function module calculates a conversion function using the calibration set, such as described in more detail with reference to FIGS. 6 , 8 , and 10 .
  • the sensor data transformation module continuously (or intermittently) converts received sensor data into estimated analyte values, also referred to as calibrated data, such as described in more detail with reference to FIGS. 6 , 8 , and 10 .
  • a quality evaluation module evaluates the quality of the calibration.
  • the quality of the calibration is based on the association of the calibration set data using statistical analysis.
  • Statistical analysis may comprise any known cost function such as linear regression, non-linear mapping/regression, rank (e.g., non-parametric) correlation, least mean square fit, mean absolute deviation (MAD), mean absolute relative difference, and the like.
  • the result of the statistical analysis provides a measure of the association of data used in calibrating the system.
  • a threshold of data association may be set to determine if sufficient quality is exhibited in a calibration set.
  • the quality of the calibration is determined by evaluating the calibration set for clinical acceptability, such as described with reference to blocks 82 and 83 (e.g., Clarke Error Grid, Consensus Grid, or clinical acceptability test).
  • the matched data pairs that form the calibration set may be plotted on a Clarke Error Grid, such that when all matched data pairs fall within the A and B regions of the Clarke Error Grid, then the calibration is determined to be clinically acceptable.
  • the quality of the calibration is determined based initially on the association of the calibration set data using statistical analysis, and then by evaluating the calibration set for clinical acceptability. If the calibration set fails the statistical and/or the clinical test, the processing returns to block 115 to recalculate the conversion function with a new (e.g., optimized) set of matched data pairs.
  • the processing loop (block 115 to block 117 ) iterates until the quality evaluation module 1 ) determines clinical acceptability, 2) determines sufficient statistical data association, 3) determines both clinical acceptability and sufficient statistical data association, or 4) surpasses a threshold of iterations; after which the processing continues to block 118 .
  • FIGS. 12A and 12B illustrate one exemplary embodiment wherein the accuracy of the conversion function is determined by evaluating the correlation coefficient from linear regression of the calibration set that formed the conversion function.
  • a threshold e.g., 0.79 is set for the R-value obtained from the correlation coefficient.
  • FIGS. 12A and 12B are graphs that illustrate an evaluation of the quality of calibration based on data association in one exemplary embodiment using a correlation coefficient. Particularly, FIGS. 12A and 12B pictorially illustrate the results of the linear least squares regression performed on a first and a second calibration set ( FIGS. 12A and 12B , respectively).
  • the x-axis represents reference analyte data; the y-axis represents sensor data.
  • the graph pictorially illustrates regression that determines the conversion function.
  • the regression line (and thus the conversion function) formed by the regression of the first calibration set of FIG. 12A is the same as the regression line (and thus the conversion function) formed by the regression of the second calibration set of FIG. 12B .
  • the correlation of the data in the calibration set to the regression line in FIG. 12A is significantly different than the correlation of the data in the calibration set to the regression line in FIG. 12A .
  • an R-value may be used to summarize the residuals (e.g., root mean square deviations) of the data when fitted to a straight line via least squares method, in this exemplary embodiment.
  • R-value may be calculated according to the following equation:
  • i is an index (1 to n)
  • x is a reference analyte value
  • y is a sensor analyte value
  • x is an average of 1/n reference analyte values
  • y is an average of 1/n sensor analyte values.
  • the calculated R-value is about 0.99, which may also be expressed as the correlation coefficient of regression. Accordingly, the calibration exhibits sufficient data association (and thus insufficient quality) because it falls above the 0.79 threshold set in this exemplary embodiment.
  • the calculated R-value is about 0.77, which may also be expressed as the correlation coefficient of regression. Accordingly, the calibration exhibits insufficient data association (and thus insufficient quality) because it falls below the 0.79 threshold set in this exemplary embodiment.
  • the interface control module also referred to as the fail-safe module, controls the user interface based upon the quality of the calibration. If the calibration is exhibits sufficient quality, then the user interface may function as normal; that is providing output for the user such as described in more detail with reference to FIG. 6 .
  • fail-safe module 118 begins the initial stages of fail-safe mode, which are described in more detail with reference to FIG. 8 .
  • the initial stages of fail-safe mode include altering the user interface so that estimated sensor data is not displayed to the user.
  • the initial stages of fail-safe mode also include prompting the user to provide an updated reference analyte value. The updated analyte value is then processed as described above and the updated conversion function that results from the repeated reference analyte test, if any, is evaluated for statistical accuracy.
  • the fail-safe module alters user interface to reflect full fail-safe mode, which is described in more detail with reference to FIG. 8 . If however the results of the updated evaluation exhibit sufficient quality, then the first reference analyte value is discarded, and the repeated reference analyte value is accepted and the process continues as described herein.
  • the initial stages of fail-safe mode and full fail safe mode may be similar to that described with reference to FIG. 8 , including user interface control for example. Additionally, it is contemplated herein that a variety of difference modes between initial and full fail-safe mode may be provided depending on the relative quality of the calibration. In other words, the confidence level of the calibration quality may control a plurality of different user interface screens providing error bars, ⁇ values, and the like. Similar screens may be implements in the clinical acceptability embodiments described with reference to FIG. 8 .

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Optics & Photonics (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Emergency Medicine (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)

Abstract

Systems and methods for processing sensor analyte data, including initiating calibration, updating calibration, evaluating clinical acceptability of reference and sensor analyte data, and evaluating the quality of sensor calibration. During initial calibration, the analyte sensor data is evaluated over a period of time to determine stability of the sensor. The sensor may be calibrated using a calibration set of one or more matched sensor and reference analyte data pairs. The calibration may be updated after evaluating the calibration set for best calibration based on inclusion criteria with newly received reference analyte data. Fail-safe mechanisms are provided based on clinical acceptability of reference and analyte data and quality of sensor calibration. Algorithms provide for optimized prospective and retrospective analysis of estimated blood analyte data from an analyte sensor.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a continuation of U.S. application Ser. No. 10/633,367 filed Aug. 1, 2003, which is incorporated by reference herein in its entirety, and is hereby made a part of this specification.
FIELD OF THE INVENTION
The present invention relates generally to systems and methods for analyte sensor data processing. Particularly, the present invention relates to retrospectively and/or prospectively initiating a calibration, converting sensor data, updating the calibration, evaluating received reference and sensor data, and evaluating the calibration for the analyte sensor.
BACKGROUND OF THE INVENTION
Diabetes mellitus is a disorder in which the pancreas cannot create sufficient insulin (Type I or insulin dependent) and/or in which insulin is not effective (Type 2 or noninsulin dependent). In the diabetic state, the victim suffers from high blood sugar, which may cause an array of physiological derangements (e.g., kidney failure, skin ulcers, or bleeding into the vitreous of the eye) associated with the deterioration of small blood vessels. A hypoglycemic reaction (low blood sugar) may be induced by an inadvertent overdose of insulin, or after a normal dose of insulin or glucose-lowering agent accompanied by extraordinary exercise or insufficient food intake.
Conventionally, a diabetic person carries a self-monitoring blood glucose (SMBG) monitor, which typically comprises uncomfortable finger pricking methods. Due to the lack of comfort and convenience, a diabetic will normally only measure his or her glucose level two to four times per day. Unfortunately, these time intervals are so far spread apart that the diabetic will likely find out too late, sometimes incurring dangerous side effects, of a hyper- or hypo-glycemic condition. In fact, it is not only unlikely that a diabetic will take a timely SMBG value, but the diabetic will not know if their blood glucose value is going up (higher) or down (lower) based on conventional methods, inhibiting their ability to make educated insulin therapy decisions.
SUMMARY OF THE INVENTION
Systems and methods are needed that accurately provide estimated glucose measurements to a diabetic patient continuously and/or in real time so that they may proactively care for their condition to safely avoid hyper- and hypo-glycemic conditions. Real time and retrospective estimated glucose measurements require reliable data processing in order to provide accurate and useful output to a patient and/or doctor.
Similarly, systems and methods are needed that accurately provide substantially continuous estimated analyte measurements for a variety of known analytes (e.g., oxygen, salts, protein, and vitamins) to provide prospective and/or retrospective data analysis and output to a user.
Accordingly, systems and methods are provided for retrospectively and/or prospectively calibrating a sensor, initializing a sensor, converting sensor data into calibrated data, updating and maintaining a calibration over time, evaluating received reference and sensor data for clinical acceptability, and evaluating the calibration statistical acceptability, to ensure accurate and safe data output to a patient and/or doctor.
In a first embodiment a method is provided for initializing a substantially continuous analyte sensor, the method including: receiving a data stream from an analyte sensor, including one or more sensor data points; receiving reference data from a reference analyte monitor, including two or more reference data points; providing at least two matched data pairs by matching reference analyte data to substantially time corresponding sensor data; forming a calibration set including the at least two matching data pairs; and determining a stability of the continuous analyte sensor.
In an aspect of the first embodiment, the step of determining the stability of the substantially continuous analyte sensor includes waiting a predetermined time period between about one minute and about six weeks.
In an aspect of the first embodiment, the step of determining the stability of the substantially continuous analyte sensor includes evaluating at least two matched data pairs.
In an aspect of the first embodiment, the step of determining the stability of the substantially continuous analyte sensor includes evaluating one of pH, oxygen, hypochlorite, interfering species, correlation of matched pairs, R-value, baseline drift, baseline offset, and amplitude.
In an aspect of the first embodiment, the method further includes providing one of an audible, visual, or tactile output to a user based on the stability of the sensor.
In an aspect of the first embodiment, the step of providing output based on the stability of the sensor includes indicating at least one of a numeric estimated analyte value, a directional trend of analyte concentration, and a graphical representation of an estimated analyte value.
In an aspect of the first embodiment, the step of receiving sensor data includes receiving sensor data from a substantially continuous glucose sensor.
In an aspect of the first embodiment, the step of receiving sensor data includes receiving sensor data from an implantable glucose sensor.
In an aspect of the first embodiment, the step of receiving sensor data includes receiving sensor data from subcutaneously implantable glucose sensor.
In an aspect of the first embodiment, the step of receiving reference data includes receiving reference data from a self-monitoring blood glucose test.
In an aspect of the first embodiment, the step of receiving reference data includes downloading reference data via a cabled connection.
In an aspect of the first embodiment, the step of receiving reference data includes downloading reference data via a wireless connection.
In an aspect of the first embodiment, the step of receiving reference data from a reference analyte monitor includes receiving within a receiver internal communication from a reference analyte monitor integral with the receiver.
In an aspect of the first embodiment, the step of forming a calibration set includes evaluating at least one matched data pair using inclusion criteria.
In an aspect of the first embodiment, the step of receiving sensor data includes receiving sensor data that has been algorithmically smoothed.
In an aspect of the first embodiment, the step of receiving sensor data includes algorithmically smoothing the received sensor data.
In an aspect of the first embodiment, the step of forming a calibration set includes including in the calibration set between one and six matched data pairs.
In an aspect of the first embodiment, the step of forming a calibration set includes including six matched data pairs.
In an aspect of the first embodiment, the step of forming a calibration set further includes determining a value for n, where n is greater than one and represents the number of matched data pairs in the calibration set.
In an aspect of the first embodiment, the step of determining a value for n is determined as a function of the frequency of the received reference data points and signal strength over time.
In a second embodiment, a system is provided for initializing a continuous analyte sensor, including: a sensor data module operatively connected to a continuous analyte sensor that receives a data stream including a plurality of time spaced sensor data points from the analyte sensor; a reference input module adapted to obtain reference data from a reference analyte monitor, including one or more reference data points; a processor module that forms one or more matched data pairs by matching reference data to substantially time corresponding sensor data and subsequently forms a calibration set including the one or more matched data pairs; and a start-up module associated with the processor module programmed to determine the stability of the continuous analyte sensor.
In an aspect of the second embodiment, the sensor data module is adapted to wirelessly receive sensor data points from the sensor.
In an aspect of the second embodiment, the start-up module is programmed to wait a predetermined time period between six hours and six weeks.
In an aspect of the second embodiment, the start-up module is programmed to evaluate at least two matched data pairs.
In an aspect of the second embodiment, the start-up module is programmed to evaluate one of pH, oxygen, hypochlorite, interfering species, correlation of matched pairs, R-value, baseline drift, baseline offset, and amplitude.
In an aspect of the second embodiment, the system further includes an output control module associated with the processor module and programmed to control output of sensor data.
In an aspect of the second embodiment, the output control module indicates at least one of a numeric estimated analyte value, a directional trend of analyte concentration, and a graphical representation of an estimated analyte value.
In an aspect of the second embodiment, the sensor data module is configured to receive sensor data from substantially the continuous glucose sensor.
In an aspect of the second embodiment, the sensor data module is configured to receive sensor data from an implantable glucose sensor.
In an aspect of the second embodiment, the sensor data module is configured to receive sensor data from subcutaneously implantable glucose sensor.
In an aspect of the second embodiment, the reference input module is configured to receive reference data from a self-monitoring blood glucose test.
In an aspect of the second embodiment, the reference input module is configured to download reference data via a cabled connection.
In an aspect of the second embodiment, the reference input module is configured to download reference data via a wireless connection.
In an aspect of the second embodiment, the system further includes a reference analyte monitor integral with the system and wherein the reference input module is configured to receive an internal communication from the reference analyte monitor.
In an aspect of the second embodiment, the processor module includes programming to evaluate at least one matched data pair using inclusion criteria.
In an aspect of the second embodiment, the reference input module is configured to receive sensor data that has been algorithmically smoothed.
In an aspect of the second embodiment, the reference input module is configured to algorithmically smooth the received sensor data.
In an aspect of the second embodiment, the calibration set includes between one and six matched data pairs.
In an aspect of the second embodiment, the calibration set includes six matched data pairs.
In an aspect of the second embodiment, the calibration set includes n matched data pairs, where n is greater than one.
In an aspect of the second embodiment, n is a function of the frequency of the received reference data points and signal strength over time.
In a third embodiment, a computer system is provided for initializing a continuous analyte sensor, the computer system including: a sensor data receiving module that receives sensor data from the substantially continuous analyte sensor via a receiver, including one or more sensor data points; a reference data receiving module that receives reference data from a reference analyte monitor, including one or more reference data points; a data matching module that forms one or more matched data pairs by matching reference data to substantially time corresponding sensor data; a calibration set module that forms a calibration set including at least one matched data pair; and a stability determination module that determines the stability of the continuous analyte sensor.
In an aspect of the third embodiment, the stability determination module includes a system for waiting a predetermined time period.
In an aspect of the third embodiment, the stability determination module evaluates at least two matched data pairs.
In an aspect of the third embodiment, the stability determination module evaluates one of pH, oxygen, hypochlorite, interfering species, correlation of matched pairs, R-value, baseline drift, baseline offset, and amplitude.
In an aspect of the third embodiment, the computer system further includes an interface control module that provides output to the user based on the stability of the sensor.
In an aspect of the third embodiment, the output from the interface control module includes at least one of a numeric estimated analyte value, an indication of directional trend of analyte concentration, and a graphical representation of an estimated analyte value.
In an aspect of the third embodiment, the reference data receiving module is adapted to receive sensor data from a substantially continuous glucose sensor.
In an aspect of the third embodiment, the reference data receiving module is adapted to receive sensor data from an implantable glucose sensor.
In an aspect of the third embodiment, the reference data receiving module is adapted to receive sensor data from a subcutaneously implantable glucose sensor.
In an aspect of the third embodiment, the reference data receiving module is adapted to receive sensor data from a self-monitoring blood glucose test.
In an aspect of the third embodiment, the reference data receiving module is adapted to receive sensor data from a cabled connection.
In an aspect of the third embodiment, the reference data receiving module is adapted to download reference data via a wireless connection.
In an aspect of the third embodiment, the reference data receiving module is adapted to receive reference data from an internal reference analyte monitor that is housed integrally the computer system.
In an aspect of the third embodiment, the calibration set module evaluates at least one matched data pair using inclusion criteria.
In an aspect of the third embodiment, the sensor data receiving module is adapted to receive sensor data that has been algorithmically smoothed.
In an aspect of the third embodiment, the computer system further includes a data smoothing module that smoothes the received sensor data.
In an aspect of the third embodiment, the calibration set module includes between one and six matched data pairs.
In an aspect of the third embodiment, the calibration set module includes six matched data pairs.
In an aspect of the third embodiment, the calibration set includes n number of matched data pairs, where n is greater than one.
In an aspect of the third embodiment, n is a function of the frequency of the received reference data points and signal strength over time.
In a fourth embodiment, method is provided for initializing a substantially continuous analyte sensor, the method including: receiving sensor data from a substantially continuous analyte sensor, including one or more sensor data points; receiving reference data from a reference analyte monitor, including one or more reference data points; forming one or more matched data pairs by matching reference data to substantially time corresponding sensor data; forming a calibration set including at least one matched data pair; determining stability of continuous analyte sensor; and outputting information reflective of the sensor data once a predetermined level of stability has been determined.
In a fifth embodiment, a system is provided for initializing a continuous analyte sensor, including: a sensor data module operatively linked to a continuous analyte sensor and configured to receive one or more sensor data points from the sensor; a reference input module adapted to obtain one or more reference data points; and a processor module associated with the sensor data module and the input module and programmed to match reference data points with time-matched sensor data points to form a calibration set including at least one matched data pair; and a start-up module associated with the processor module programmed to determine the stability of the continuous analyte sensor and output information reflective of the sensor data once a predetermined level of stability has been determined.
In a sixth embodiment, a computer system is provided for initializing a continuous analyte sensor, the system including: a sensor data receiving module that receives sensor data including one or more sensor data points from the substantially continuous analyte sensor via a receiver; a reference data receiving module for receiving reference data from a reference analyte monitor, including one or more reference data points; a data matching module for forming one or more matched data pairs by matching reference data to substantially time corresponding sensor data; a calibration set module for forming a calibration set including at least one matched data pair; a stability determination module for evaluating the stability of the continuous analyte sensor; and an interface control module that outputs information reflective of the sensor data once a predetermined level of stability has been determined.
In a seventh embodiment, a method for initializing a glucose sensor, the method including: receiving sensor data from the glucose sensor, including one or more sensor data points; receiving reference data from a reference glucose monitor, including one or more reference data points; forming one or more matched data pairs by matching reference data to substantially time corresponding sensor data; determining whether the glucose sensor has reached a predetermined level of stability.
In an eighth embodiment, a system is provided for initializing a continuous analyte sensor, including: a sensor data module operatively linked to a continuous analyte sensor and configured to receive one or more sensor data points from the sensor; a reference input module adapted to obtain one or more reference data points; and a processor module associated with the sensor data module and the input module and programmed to match reference data points with time-matched sensor data points to form a calibration set including at least one matched data pair; and a stability module associated with the processor module programmed to determine the stability of the continuous analyte sensor.
In a ninth embodiment, a method is provided for evaluating clinical acceptability of at least one of reference and sensor analyte data, the method including: receiving a data stream from an analyte sensor, including one or more sensor data points; receiving reference data from a reference analyte monitor, including one or more reference data points; and evaluating the clinical acceptability at least one of the reference and sensor analyte data using substantially time corresponding reference or sensor data, wherein the at least one of the reference and sensor analyte data is evaluated for deviation from its substantially time corresponding reference or sensor data and clinical risk associated with that deviation based on the glucose value indicated by at least one of the sensor and reference data.
In an aspect of the ninth embodiment, the method further includes providing an output through a user interface responsive to the clinical acceptability evaluation.
In an aspect of the ninth embodiment, the step of providing an output includes alerting the user based on the clinical acceptability evaluation.
In an aspect of the ninth embodiment, the step of providing an output includes altering the user interface based on the clinical acceptability evaluation.
In an aspect of the ninth embodiment, the step of altering the user interface includes at least one of providing color-coded information, trend information, directional information (e.g., arrows or angled lines), and/or fail-safe information.
In an aspect of the ninth embodiment, the step of evaluating the clinical acceptability includes using one of a Clarke Error Grid, a mean absolute difference calculation, a rate of change calculation, a consensus grid, and a standard clinical acceptance test.
In an aspect of the ninth embodiment, the method further includes requesting additional reference data if the clinical acceptability evaluation determines clinical unacceptability.
In an aspect of the ninth embodiment, the method further includes repeating the clinical acceptability evaluation step for the additional reference data.
In an aspect of the ninth embodiment, the method further includes a step of matching reference data to substantially time corresponding sensor data to form a matched pair after the clinical acceptability evaluation step.
In a tenth embodiment, a system is provided for evaluating clinical acceptability of at least one of reference and sensor analyte data, the method including: means for receiving a data stream from an analyte sensor, a plurality of time-spaced sensor data points; means for receiving reference data from a reference analyte monitor, including one or more reference data points; and means for evaluating the clinical acceptability of at least one of the reference and sensor analyte data using substantially time corresponding reference and sensor data, wherein the at least one of the reference and sensor analyte data is evaluated for deviation from its substantially time corresponding reference or sensor data and clinical risk associated with that deviation based on the glucose value indicated by at least one of the sensor and reference data.
In an aspect of the tenth embodiment, the system further includes means for providing an output based through a user interface responsive to the clinical acceptability evaluation.
In an aspect of the tenth embodiment, the means for providing an output includes means for alerting the user based on the clinical acceptability evaluation.
In an aspect of the tenth embodiment, the means for providing an output includes means for altering the user interface based on the clinical acceptability evaluation.
In an aspect of the tenth embodiment, the means for altering the user interface includes at least one of providing color-coded information, trend information, directional information (e.g., arrows or angled lines), and/or fail-safe information.
In an aspect of the tenth embodiment, the means for evaluating the clinical acceptability includes using one of a Clarke Error Grid, a mean absolute difference calculation, a rate of change calculation, a consensus grid, and a standard clinical acceptance test.
In an aspect of the tenth embodiment, the system further includes means for requesting additional reference data if the clinical acceptability evaluation determines clinical unacceptability.
In an aspect of the tenth embodiment, the system further includes means for repeated the clinical acceptability evaluation for the additional reference data.
In an aspect of the tenth embodiment, the system further includes means for matching reference data to substantially time corresponding sensor data to form a matched data pair after the clinical acceptability evaluation.
In an eleventh embodiment, a computer system is provided for evaluating clinical acceptability of at least one of reference and sensor analyte data, the computer system including: a sensor data receiving module that receives a data stream including a plurality of time spaced sensor data points from a substantially continuous analyte sensor; a reference data receiving module that receives reference data from a reference analyte monitor, including one or more reference data points; and a clinical acceptability evaluation module that evaluates at least one of the reference and sensor analyte data using substantially time corresponding reference and sensor data, wherein the at least one of the reference and sensor analyte data is evaluated for deviation from its substantially time corresponding reference or sensor data and clinical risk associated with that deviation based on the glucose value indicated by at least one of the sensor and reference data.
In an aspect of the eleventh embodiment, the computer system further includes an interface control module that controls the user interface based on the clinical acceptability evaluation.
In an aspect of the eleventh embodiment, the interface control module alerts the user based on the clinical acceptability evaluation.
In an aspect of the eleventh embodiment, the interface control module alters the user interface based on the clinical acceptability evaluation.
In an aspect of the eleventh embodiment, the interface control module alters the user interface by providing at least one of providing color-coded information, trend information, directional information (e.g., arrows or angled lines), and/or fail-safe information.
In an aspect of the eleventh embodiment, the clinical acceptability evaluation module uses one of a Clarke Error Grid, a mean absolute difference calculation, a rate of change calculation, a consensus grid, and a standard clinical acceptance test to evaluate clinical acceptability.
In an aspect of the eleventh embodiment, the interface control module that requests additional reference data if the clinical acceptability evaluation determines clinical unacceptability.
In an aspect of the eleventh embodiment, the interface control module evaluates the additional reference data using clinical acceptability evaluation module.
In an aspect of the eleventh embodiment, the computer system further includes a data matching module that matches clinically acceptable reference data to substantially time corresponding clinically acceptable sensor data to form a matched pair.
In a twelfth embodiment, a method is provided for evaluating clinical acceptability of at least one of reference and sensor analyte data, the method including: receiving a data stream from an analyte sensor, including one or more sensor data points; receiving reference data from a reference analyte monitor, including one or more reference data points; evaluating the clinical acceptability at least one of the reference and sensor analyte data using substantially time corresponding reference and sensor data, wherein the at least one of the reference and sensor analyte data is evaluated for deviation from its substantially time corresponding reference or sensor data and clinical risk associated with that deviation based on the glucose value indicated by at least one of the sensor and reference data; and providing an output through a user interface responsive to the clinical acceptability evaluation.
In an thirteenth embodiment, a method is provided for evaluating clinical acceptability of at least one of reference and sensor analyte data, the method including: receiving a data stream from an analyte sensor, including one or more sensor data points; receiving reference data from a reference analyte monitor, including one or more reference data points; and evaluating the clinical acceptability at least one of the reference and sensor analyte data using substantially time corresponding reference and sensor data, including using one of a Clarke Error Grid, a mean absolute difference calculation, a rate of change calculation, and a consensus grid.
In an fourteenth embodiment, a computer system is provided for evaluating clinical acceptability of at least one of reference and sensor analyte data, the computer system including: a sensor data module that receives a data stream including a plurality of time spaced sensor data points from a substantially continuous analyte sensor; a reference input module that receives reference data from a reference analyte monitor, including one or more reference data points; a clinical module that evaluates at least one of the reference and sensor analyte data using substantially time corresponding reference and sensor data, wherein the at least one of the reference and sensor analyte data is evaluated for deviation from its substantially time corresponding reference or sensor data and clinical risk associated with that deviation based on the glucose value indicated by at least one of the sensor and reference data; and an interface control module that controls the user interface based on the clinical acceptability evaluation.
In an fifteenth embodiment, a computer system is provided for evaluating clinical acceptability of at least one of reference and sensor analyte data, the computer system including: a sensor data module that receives a data stream including a plurality of time spaced sensor data points from a substantially continuous analyte sensor; a reference input module that receives reference data from a reference analyte monitor, including one or more reference data points; and a clinical module that evaluates at least one of the reference and sensor analyte data with substantially time corresponding reference and sensor data, wherein the clinical module uses one of a Clarke Error Grid, a mean absolute difference calculation, a rate of change calculation, a consensus grid, and a standard clinical acceptance test to evaluate clinical acceptability.
In an sixteenth embodiment, a computer system is provided for evaluating clinical acceptability of at least one of reference and sensor analyte data, the computer system including: a sensor data module that receives a data stream including a plurality of time spaced sensor data points from a substantially continuous analyte sensor via a receiver; a reference input module that receives reference data from a reference analyte monitor, including one or more reference data points; and a clinical module that uses a Clarke Error Grid to evaluate the clinical acceptability at least one of the reference and sensor analyte data using substantially time corresponding reference and sensor data; and a fail-safe module that controls the user interface responsive to the clinical module evaluating clinical unacceptability.
In an seventeenth embodiment, a method is provided for evaluating clinical acceptability of at least one of reference and sensor glucose data, the method including: receiving a data stream from an analyte sensor, including one or more sensor data points; receiving reference data from a reference glucose monitor, including one or more reference data points; evaluating the clinical acceptability at least one of the reference and sensor glucose data using substantially time corresponding reference and sensor data, wherein the at least one of the reference and sensor analyte data is evaluated for deviation from its substantially time corresponding reference or sensor data and clinical risk associated with that deviation based on the glucose value indicated by at least one of the sensor and reference data; and a fail-safe module that controls the user interface responsive to the clinical module evaluating clinical unacceptability.
In an eighteenth embodiment, a method is provided for maintaining calibration of a substantially continuous analyte sensor, the method including: receiving a data stream from an analyte sensor, including one or more sensor data points; receiving reference data from a reference analyte monitor, including two or more reference data points; providing at least two matched data pairs by matching reference analyte data to substantially time corresponding sensor data; forming a calibration set including the at least two matching data pairs; creating a conversion function based on the calibration set; converting sensor data into calibrated data using the conversion function; subsequently obtaining one or more additional reference data points and creating one or more new matched data pairs; evaluating the calibration set when the new matched data pair is created, wherein evaluating the calibration set includes at least one of 1) ensuring matched data pairs in the calibration set span a predetermined time range, 2) ensuring matched data pairs in the calibration set are no older than a predetermined value, 3) ensuring the calibration set has substantially distributed high and low matched data pairs over the predetermined time range, and 4) allowing matched data pairs only within a predetermined range of analyte values; and subsequently modifying the calibration set if such modification is required by the evaluation.
In an aspect of the eighteenth embodiment, the step of evaluating the calibration set further includes at least one of evaluating a rate of change of the analyte concentration, evaluating a congruence of respective sensor and reference data in the matched data pairs, and evaluating physiological changes.
In an aspect of the eighteenth embodiment, the step of evaluating the calibration set includes evaluating only the new matched data pair.
In an aspect of the eighteenth embodiment, the step of evaluating the calibration set includes evaluating all of the matched data pairs in the calibration set and the new matched data pair.
In an aspect of the eighteenth embodiment, the step of evaluating the calibration set includes evaluating combinations of matched data pairs from the calibration set and the new matched data pair.
In an aspect of the eighteenth embodiment, the step of receiving sensor data includes receiving a data stream from a long-term implantable analyte sensor.
In an aspect of the eighteenth embodiment, the step of receiving sensor data includes receiving a data stream that has been algorithmically smoothed.
In an aspect of the eighteenth embodiment, the step of receiving sensor data stream includes algorithmically smoothing the data stream.
In an aspect of the eighteenth embodiment, the step of receiving reference data includes downloading reference data via a cabled connection.
In an aspect of the eighteenth embodiment, the step of receiving reference data includes downloading reference data via a wireless connection.
In an aspect of the eighteenth embodiment, the step of receiving reference data from a reference analyte monitor includes receiving within a receiver internal communication from a reference analyte monitor integral with the receiver.
In an aspect of the eighteenth embodiment, the reference analyte monitor includes self-monitoring of blood analyte.
In an aspect of the eighteenth embodiment, the step of creating a conversion function includes linear regression.
In an aspect of the eighteenth embodiment, the step of creating a conversion function includes non-linear regression.
In an aspect of the eighteenth embodiment, the step of forming a calibration set includes including in the calibration set between one and six matched data pairs.
In an aspect of the eighteenth embodiment, the step of forming a calibration set includes including six matched data pairs.
In an aspect of the eighteenth embodiment, the step of forming a calibration set further includes determining a value for n, where n is greater than one and represents the number of matched data pairs in the calibration set.
In an aspect of the eighteenth embodiment, the step of determining a value for n is determined as a function of the frequency of the received reference data points and signal strength over time.
In an aspect of the eighteenth embodiment, the method further includes determining a set of matching data pairs from the evaluation of the calibration set and re-forming a calibration set.
In an aspect of the eighteenth embodiment, the method further includes repeating the step of re-creating the conversion function using the re-formed calibration set.
In an aspect of the eighteenth embodiment, the method further includes converting sensor data into calibrated data using the re-created conversion function.
In a nineteenth embodiment, a system is provided for maintaining calibration of a substantially continuous analyte sensor, the system including: means for receiving a data stream from an analyte sensor, a plurality of time-spaced sensor data points; means for receiving reference data from a reference analyte monitor, including two or more reference data points; means for providing two or more matched data pairs by matching reference analyte data to substantially time corresponding sensor data; means for forming a calibration set including at least two matched data pair; means for creating a conversion function based on the calibration set; means for converting sensor data into calibrated data using the conversion function; subsequently obtaining one or more additional reference data points and creating one or more new matched data pairs; means for evaluating the calibration set when the new matched data pair is created, wherein evaluating the calibration set includes at least one of 1) ensuring matched data pairs in the calibration set span a predetermined time range, 2) ensuring matched data pairs in the calibration set are no older than a predetermined value, 3) ensuring the calibration set has substantially distributed high and low matched data pairs over the predetermined time range, and 4) allowing matched data pairs only within a predetermined range of analyte values; and means for modifying the calibration set if such modification is required by the evaluation.
In an aspect of the nineteenth embodiment, the means for evaluating the calibration set further includes at least one of means for evaluating a rate of change of the analyte concentration, means for evaluating a congruence of respective sensor and reference data in matched data pairs; and means for evaluating physiological changes.
In an aspect of the nineteenth embodiment, the means for evaluating the calibration set includes means for evaluating only the one or more new matched data pairs.
In an aspect of the nineteenth embodiment, the means for evaluating the calibration set includes means for evaluating all of the matched data pairs in the calibration set and the one or more new matched data pairs.
In an aspect of the nineteenth embodiment, the means for evaluating the calibration set includes means for evaluating combinations of matched data pairs from the calibration set and the one or more new matched data pair.
In an aspect of the nineteenth embodiment, the means for receiving sensor data includes means for receiving sensor data from a long-term implantable analyte sensor.
In an aspect of the nineteenth embodiment, the means for receiving sensor data includes means for receiving sensor data that has been algorithmically smoothed.
In an aspect of the nineteenth embodiment, the means for receiving sensor data includes means for algorithmically smoothing the receiving sensor data.
In an aspect of the nineteenth embodiment, the means for receiving reference data includes means for downloading reference data via a cabled connection.
In an aspect of the nineteenth embodiment, the means for receiving reference data includes means for downloading reference data via a wireless connection.
In an aspect of the nineteenth embodiment, the means for receiving reference data from a reference analyte monitor includes means for receiving within a receiver internal communication from a reference analyte monitor integral with the receiver.
In an aspect of the nineteenth embodiment, the means for receiving reference data includes means for receiving from a self-monitoring of blood analyte.
In an aspect of the nineteenth embodiment, the means for creating a conversion function includes means for performing linear regression.
In an aspect of the nineteenth embodiment, the means for creating a conversion function includes means for performing non-linear regression.
In an aspect of the nineteenth embodiment, the means for forming a calibration set includes including in the calibration set between one and six matched data pairs.
In an aspect of the nineteenth embodiment, the means for forming a calibration set includes including in the calibration set six matched data pairs.
In an aspect of the nineteenth embodiment, the means for forming a calibration set further includes determining a value for n, where n is greater than one and represents the number of matched data pairs in the calibration set.
In an aspect of the nineteenth embodiment, the means for determining a value for n is determined as a function of the frequency of the received reference data points and signal strength over time.
In an aspect of the nineteenth embodiment, the system further includes means for determining a set of matching data pairs from the evaluation of the calibration set and re-forming a calibration set.
In an aspect of the nineteenth embodiment, the system further includes the means for repeating the set of creating the conversion function using the re-formed calibration set.
In an aspect of the nineteenth embodiment, the system further includes means for converting sensor data into calibrated data using the re-created conversion function.
In a twentieth embodiment, a computer system is provided for maintaining calibration of a substantially continuous analyte sensor, the computer system including: a sensor data receiving module that receives a data stream including a plurality of time spaced sensor data points from a substantially continuous analyte sensor; a reference data receiving module that receives reference data from a reference analyte monitor, including two or more reference data points; a data matching module that forms two or more matched data pairs by matching reference data to substantially time corresponding sensor data; a calibration set module that forms a calibration set including at least two matched data pairs; a conversion function module that creates a conversion function using the calibration set; a sensor data transformation module that converts sensor data into calibrated data using the conversion function; and a calibration evaluation module that evaluates the calibration set when the new matched data pair is provided, wherein evaluating the calibration set includes at least one of 1) ensuring matched data pairs in the calibration set span a predetermined time period, 2) ensuring matched data pairs in the calibration set are no older than a predetermined value, 3) ensuring the calibration set has substantially distributed high and low matched data pairs over a predetermined time range, and 4) allowing matched data pairs only within a predetermined range of analyte values, wherein the conversion function module is programmed to re-create the conversion function of such modification is required by the calibration evaluation module.
In an aspect of the twentieth embodiment, the evaluation calibration module further evaluates at least one of a rate of change of the analyte concentration, a congruence of respective sensor and reference data in matched data pairs; and physiological changes.
In an aspect of the twentieth embodiment, the evaluation calibration module evaluates only the new matched data pair.
In an aspect of the twentieth embodiment, the evaluation calibration module evaluates all of the matched data pairs in the calibration set and the new matched data pair.
In an aspect of the twentieth embodiment, the evaluation calibration module evaluates combinations of matched data pairs from the calibration set and the new matched data pair.
In an aspect of the twentieth embodiment, the sensor data receiving module receives the data stream from a long-term implantable analyte sensor.
In an aspect of the twentieth embodiment, the sensor data receiving module receives an algorithmically smoothed data stream.
In an aspect of the twentieth embodiment, the sensor data receiving module includes programming to smooth the data stream.
In an aspect of the twentieth embodiment, the reference data receiving module downloads reference data via a cabled connection.
In an aspect of the twentieth embodiment, the reference data receiving module downloads reference data via a wireless connection.
In an aspect of the twentieth embodiment, the reference data receiving module receives within a receiver internal communication from a reference analyte monitor integral with the receiver.
In an aspect of the twentieth embodiment, the reference data receiving module receives reference data from a self-monitoring of blood analyte.
In an aspect of the twentieth embodiment, the conversion function module includes programming that performs linear regression.
In an aspect of the twentieth embodiment, the conversion function module includes programming that performs non-linear regression.
In an aspect of the twentieth embodiment, the calibration set module includes in the calibration set between one and six matched data pairs.
In an aspect of the twentieth embodiment, the calibration set module includes in the calibration set six matched data pairs.
In an aspect of the twentieth embodiment, the calibration set module further includes programming for determining a value for n, where n is greater than one and represents the number of matched data pairs in the calibration set.
In an aspect of the twentieth embodiment, the programming for determining a value for n determines n as a function of the frequency of the received reference data points and signal strength over time.
In an aspect of the twentieth embodiment, data matching module further includes programming to re-form the calibration set based on the calibration evaluation.
In an aspect of the twentieth embodiment, the conversion function module further includes programming to re-create the conversion function based on the re-formed calibration set.
In an aspect of the twentieth embodiment, the sensor data transformation module further including programming for converting sensor data into calibrated using the re-created conversion function.
In a twenty-first embodiment, a method is provided for maintaining calibration of a glucose sensor, the method including: receiving a data stream from an analyte sensor, including one or more sensor data points; receiving reference data from a reference analyte monitor, including two or more reference data points; providing at least two matched data pairs by matching reference analyte data to substantially time corresponding sensor data; forming a calibration set including the at least two matching data pairs; creating a conversion function based on the calibration set; subsequently obtaining one or more additional reference data points and creating one or more new matched data pairs; and evaluating the calibration set when the new matched data pair is created, wherein evaluating the calibration set includes at least one of 1) ensuring matched data pairs in the calibration set span a predetermined time range, 2) ensuring matched data pairs in the calibration set are no older than a predetermined value, 3) ensuring the calibration set has substantially distributed high and low matched data pairs over the predetermined time range, and 4) allowing matched data pairs only within a predetermined range of analyte values.
In a twenty-second embodiment, a computer system is provided for maintaining calibration of a glucose sensor, the computer system including: a sensor data module that receives a data stream including a plurality of time spaced sensor data points from a substantially continuous analyte sensor; a reference input module that receives reference data from a reference analyte monitor, including two or more reference data points; a processor module that forms two or more matched data pairs by matching reference data to substantially time corresponding sensor data and subsequently forms a calibration set including the two or more matched data pairs; and a calibration evaluation module that evaluates the calibration set when the new matched data pair is provided, wherein evaluating the calibration set includes at least one of 1) ensuring matched data pairs in the calibration set span a predetermined time period, 2) ensuring matched data pairs in the calibration set are no older than a predetermined value, 3) ensuring the calibration set has substantially distributed high and low matched data pairs over a predetermined time range, and 4) allowing matched data pairs only within a predetermined range of analyte values, wherein the conversion function module is programmed to re-create the conversion function of such modification is required by the calibration evaluation module.
In a twenty-third embodiment, a method is provided for evaluating the quality of a calibration of an analyte sensor, the method including: receiving a data stream from an analyte sensor, including one or more sensor data points; receiving reference data from a reference analyte monitor, including two or more reference data points; providing at least two matched data pairs by matching reference analyte data to substantially time corresponding sensor data; forming a calibration set including the at least two matching data pairs; creating a conversion function based on the calibration set; receiving additional sensor data from the analyte sensor; converting sensor data into calibrated data using the conversion function; and evaluating the quality of the calibration set using a data association function.
In an aspect of the twenty-third embodiment, the step of receiving sensor data includes receiving a data stream that has been algorithmically smoothed.
In an aspect of the twenty-third embodiment, the step of receiving sensor data includes algorithmically smoothing the data stream.
In an aspect of the twenty-third embodiment, the step of receiving sensor data includes receiving sensor data from a substantially continuous glucose sensor.
In an aspect of the twenty-third embodiment, the step of receiving sensor data includes receiving sensor data from an implantable glucose sensor.
In an aspect of the twenty-third embodiment, the step of receiving sensor data includes receiving sensor data from a subcutaneously implantable glucose sensor.
In an aspect of the twenty-third embodiment, the step of receiving reference data includes receiving reference data from a self-monitoring blood glucose test.
In an aspect of the twenty-third embodiment, the step of receiving reference data includes downloading reference data via a cabled connection.
In an aspect of the twenty-third embodiment, the step of receiving reference data includes downloading reference data via a wireless connection.
In an aspect of the twenty-third embodiment, the step of receiving reference data from a reference analyte monitor includes receiving within a receiver internal communication from a reference analyte monitor integral with the receiver.
In an aspect of the twenty-third embodiment, the step of evaluating the quality of the calibration set based on a data association function includes performing one of linear regression, non-linear regression, rank correlation, least mean square fit, mean absolute deviation, and mean absolute relative difference.
In an aspect of the twenty-third embodiment, the step of evaluating the quality of the calibration set based on a data association function includes performing linear least squares regression.
In an aspect of the twenty-third embodiment, the step of evaluating the quality of the calibration set based on a data association function includes setting a threshold of data association.
In an aspect of the twenty-third embodiment, the step of evaluating the quality of the calibration set based on data association includes performing linear least squares regression and wherein the step of setting a threshold hold includes an R-value threshold of 0.79.
In an aspect of the twenty-third embodiment, the method further includes providing an output to a user interface responsive to the quality of the calibration set.
In an aspect of the twenty-third embodiment, the step of providing an output includes displaying analyte values to a user dependent upon the quality of the calibration.
In an aspect of the twenty-third embodiment, the step of providing an output includes alerting the dependent upon the quality of the calibration.
In an aspect of the twenty-third embodiment, the step of providing an output includes altering the user interface dependent upon the quality of the calibration.
In an aspect of the twenty-third embodiment, the step of providing an output includes at least one of providing color-coded information, trend information, directional information (e.g., arrows or angled lines), and/or fail-safe information.
In a twenty-fourth embodiment, a system is provided for evaluating the quality of a calibration of an analyte sensor, the system including: means for receiving a data stream from an analyte sensor, a plurality of time-spaced sensor data points; means for receiving reference data from a reference analyte monitor, including two or more reference data points; means for providing two or more matched data pairs by matching reference analyte data to substantially time corresponding sensor data; means for forming a calibration set including at least two matched data pair; means for creating a conversion function based on the calibration set; means for converting sensor data into calibrated data using the conversion function; means for evaluating the quality of the calibration set based on a data association function.
In an aspect of the twenty-fourth embodiment, the means for receiving sensor data includes means for receiving sensor data that has been algorithmically smoothed.
In an aspect of the twenty-fourth embodiment, the means for receiving sensor data includes means for algorithmically smoothing the receiving sensor data.
In an aspect of the twenty-fourth embodiment, the means for receiving sensor data includes means for receiving sensor data from substantially continuous glucose sensor.
In an aspect of the twenty-fourth embodiment, the means for receiving sensor data includes means for receiving sensor data from an implantable glucose sensor.
In an aspect of the twenty-fourth embodiment, the means for receiving sensor data includes means for receiving sensor data from subcutaneously implantable glucose sensor.
In an aspect of the twenty-fourth embodiment, the means for receiving reference data includes means for receiving reference data from a self-monitoring blood glucose test.
In an aspect of the twenty-fourth embodiment, the means for receiving reference data includes means for downloading reference data via a cabled connection.
In an aspect of the twenty-fourth embodiment, the means for receiving reference data includes means for downloading reference data via a wireless connection.
In an aspect of the twenty-fourth embodiment, the means for receiving reference data from a reference analyte monitor includes means for receiving within a receiver internal communication from a reference analyte monitor integral with the receiver.
In an aspect of the twenty-fourth embodiment, the means for evaluating the quality of the calibration set includes means for performing one of linear regression, non-linear regression, rank correlation, least mean square fit, mean absolute deviation, and mean absolute relative difference.
In an aspect of the twenty-fourth embodiment, the means for evaluating the quality of the calibration set includes means for performing linear least squares regression.
In an aspect of the twenty-fourth embodiment, the means for evaluating the quality of the calibration set includes means for setting a threshold of data association.
In an aspect of the twenty-fourth embodiment, the means for evaluating the quality of the calibration set includes means for performing linear least squares regression and wherein the means for setting a threshold hold includes an R-value threshold of 0.71.
In an aspect of the twenty-fourth embodiment, the system further includes means for providing an output to a user interface responsive to the quality of the calibration set.
In an aspect of the twenty-fourth embodiment, the means for providing an output includes means for displaying analyte values to a user dependent upon the quality of the calibration.
In an aspect of the twenty-fourth embodiment, the means for providing an output includes means for alerting the dependent upon the quality of the calibration.
In an aspect of the twenty-fourth embodiment, the means for providing an output includes means for altering the user interface dependent upon the quality of the calibration.
In an aspect of the twenty-fourth embodiment, the means for providing an output includes at least one of providing color-coded information, trend information, directional information (e.g., arrows or angled lines), and/or fail-safe information.
In a twenty-fifth embodiment, a computer system is provided for evaluating the quality of a calibration of an analyte sensor, the computer system including: a sensor data receiving module that receives a data stream including a plurality of time spaced sensor data points from a substantially continuous analyte sensor; a reference data receiving module that receives reference data from a reference analyte monitor, including two or more reference data points; a data matching module that forms two or more matched data pairs by matching reference data to substantially time corresponding sensor data; a calibration set module that forms a calibration set including at least two matched data pairs; a conversion function module that creates a conversion function using the calibration set; a sensor data transformation module that converts sensor data into calibrated data using the conversion function; and a quality evaluation module that evaluates the quality of the calibration set based on a data association function.
In an aspect of the twenty-fifth embodiment, the sensor data receiving module receives sensor data that has been algorithmically smoothed.
In an aspect of the twenty-fifth embodiment, the computer system further includes a data smoothing module that algorithmically smoothes sensor data received from the sensor data receiving module.
In an aspect of the twenty-fifth embodiment, the sensor data receiving module is adapted to receive sensor data from substantially continuous glucose sensor.
In an aspect of the twenty-fifth embodiment, the sensor data receiving module is adapted to receive sensor data from an implantable glucose sensor.
In an aspect of the twenty-fifth embodiment, the sensor data receiving module is adapted to receive sensor data from subcutaneously implantable glucose sensor.
In an aspect of the twenty-fifth embodiment, the reference data receiving module is adapted to receive reference data from a self-monitoring blood glucose test.
In an aspect of the twenty-fifth embodiment, the reference data receiving module is adapted to download reference data via a cabled connection.
In an aspect of the twenty-fifth embodiment, the reference data receiving module is adapted to download reference data via a wireless connection.
In an aspect of the twenty-fifth embodiment, the reference data receiving module is adapted to receive reference data from a reference analyte monitor integral with the receiver.
In an aspect of the twenty-fifth embodiment, the quality evaluation module performs one of linear regression, non-linear regression, rank correlation, least mean square fit, mean absolute deviation, and mean absolute relative difference to evaluate calibration set quality.
In an aspect of the twenty-fifth embodiment, the quality evaluation module performs linear least squares regression.
In an aspect of the twenty-fifth embodiment, the quality evaluation module sets a threshold for the data association function.
In an aspect of the twenty-fifth embodiment, the quality evaluation module performs linear least squares regression and wherein the threshold of the data association function includes an R-value threshold of at least 0.79.
In an aspect of the twenty-fifth embodiment, the computer system further includes an interface control module that controls the user interface based on the quality of the calibration set.
In an aspect of the twenty-fifth embodiment, the interface control module displays analyte values to a user dependent upon the quality of the calibration set.
In an aspect of the twenty-fifth embodiment, the interface control module alerts the user based upon the quality of the calibration set.
In an aspect of the twenty-fifth embodiment, the interface control module alters the user interface based upon the quality of the calibration set.
In an aspect of the twenty-fifth embodiment, the interface control module provides at least one of color-coded information, trend information, directional information (e.g., arrows or angled lines), and/or fail-safe information.
In a twenty-sixth embodiment, a method is provided for evaluating the quality of a calibration of an analyte sensor, the method including: receiving a data stream from an analyte sensor, including one or more sensor data points; receiving reference data from a reference analyte monitor, including two or more reference data points; providing at least two matched data pairs by matching reference analyte data to substantially time corresponding sensor data; forming a calibration set including the at least two matching data pairs; creating a conversion function based on the calibration set; receiving additional sensor data from the analyte sensor; converting sensor data into calibrated data using the conversion function; and evaluating the quality of the calibration set based on a data association function selected from the group consisting of linear regression, non-linear regression, rank correlation, least mean square fit, mean absolute deviation, and mean absolute relative difference.
In a twenty-seventh embodiment, a method is provided for evaluating the quality of a calibration of an analyte sensor, the method including: receiving a data stream from an analyte sensor, including one or more sensor data points; receiving reference data from a reference analyte monitor, including two or more reference data points; providing at least two matched data pairs by matching reference analyte data to substantially time corresponding sensor data; forming a calibration set including the at least two matching data pairs; creating a conversion function based on the calibration set; receiving additional sensor data from the analyte sensor; converting sensor data into calibrated data using the conversion function; evaluating the quality of the calibration set using a data association function; and providing an output to a user interface responsive to the quality of the calibration set.
In a twenty-eighth embodiment, a computer system is provided for evaluating the quality of a calibration of an analyte sensor, the computer system including: a sensor data module that receives a data stream including a plurality of time spaced sensor data points from a substantially continuous analyte sensor; a reference input module that receives reference data from a reference analyte monitor, including two or more reference data points; a processor module that forms two or more matched data pairs by matching reference data to substantially time corresponding sensor data and subsequently forms a calibration set including the two or more matched data pairs; and a conversion function module that creates a conversion function using the calibration set; a sensor data transformation module that converts sensor data into calibrated data using the conversion function; a quality evaluation module that evaluates the quality of the calibration set based on a data association selected from the group consisting of linear regression, non-linear regression, rank correlation, least mean square fit, mean absolute deviation, and mean absolute relative difference.
In a twenty-ninth embodiment, a computer system is provided for evaluating the quality of a calibration of an analyte sensor, the computer system including: a sensor data module that receives a data stream including a plurality of time spaced sensor data points from a substantially continuous analyte sensor; a reference input module that receives reference data from a reference analyte monitor, including two or more reference data points; a processor module that forms two or more matched data pairs by matching reference data to substantially time corresponding sensor data and subsequently forms a calibration set including the two or more matched data pairs; and a conversion function module that creates a conversion function using the calibration set; a sensor data transformation module that converts sensor data into calibrated data using the conversion function; a quality evaluation module that evaluates the quality of the calibration set based on data association; and a fail-safe module that controls the user interface based on the quality of the calibration set.
In a thirtieth embodiment, a method is provided for evaluating the quality of a calibration of a glucose sensor, the method including: receiving sensor data from a glucose sensor, including one or more sensor data points; receiving reference data from a reference glucose monitor, including one or more reference data points; providing one or more matched data pairs by matched reference glucose data to substantially time corresponding sensor data; forming a calibration set including at least one matched data pair; and evaluating the quality of the calibration set based on data association.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 is an exploded perspective view of a glucose sensor in one embodiment.
FIG. 2 is a block diagram that illustrates the sensor electronics in one embodiment.
FIG. 3 is a graph that illustrates data smoothing of a raw data signal in one embodiment.
FIGS. 4A to 4D are schematic views of a receiver in first, second, third, and fourth embodiments, respectively.
FIG. 5 is a block diagram of the receiver electronics in one embodiment.
FIG. 6 is a flow chart that illustrates the initial calibration and data output of the sensor data in one embodiment.
FIG. 7 is a graph that illustrates a regression performed on a calibration set to obtain a conversion function in one exemplary embodiment.
FIG. 8 is a flow chart that illustrates the process of evaluating the clinical acceptability of reference and sensor data in one embodiment.
FIG. 9 is a graph of two data pairs on a Clarke Error Grid to illustrate the evaluation of clinical acceptability in one exemplary embodiment.
FIG. 10 is a flow chart that illustrates the process of evaluation of calibration data for best calibration based on inclusion criteria of matched data pairs in one embodiment.
FIG. 11 is a flow chart that illustrates the process of evaluating the quality of the calibration in one embodiment.
FIGS. 12A and 12B are graphs that illustrate an evaluation of the quality of calibration based on data association in one exemplary embodiment using a correlation coefficient.
DETAILED DESCRIPTION OF PREFERRED EMBODIMENT
The following description and examples illustrate some exemplary embodiments of the disclosed invention in detail. Those of skill in the art will recognize that there are numerous variations and modifications of this invention that are encompassed by its scope. Accordingly, the description of a certain exemplary embodiment should not be deemed to limit the scope of the present invention.
Definitions
In order to facilitate an understanding of the disclosed invention, a number of terms are defined below.
The term “analyte,” as used herein, is a broad term and is used in its ordinary sense, including, without limitation, to refer to a substance or chemical constituent in a biological fluid (for example, blood, interstitial fluid, cerebral spinal fluid, lymph fluid or urine) that can be analyzed. Analytes may include naturally occurring substances, artificial substances, metabolites, and/or reaction products. In some embodiments, the analyte for measurement by the sensor heads, devices, and methods is analyte. However, other analytes are contemplated as well, including but not limited to acarboxyprothrombin; acylcarnitine; adenine phosphoribosyl transferase; adenosine deaminase; albumin; alpha-fetoprotein; amino acid profiles (arginine (Krebs cycle), histidine/urocanic acid, homocysteine, phenylalanine/tyrosine, tryptophan); andrenostenedione; antipyrine; arabinitol enantiomers; arginase; benzoylecgonine (cocaine); biotinidase; biopterin; c-reactive protein; carnitine; carnosinase; CD4; ceruloplasmin; chenodeoxycholic acid; chloroquine; cholesterol; cholinesterase; conjugated 1-β hydroxy-cholic acid; cortisol; creatine kinase; creatine kinase MM isoenzyme; cyclosporin A; d-penicillamine; de-ethylchloroquine; dehydroepiandrosterone sulfate; DNA (acetylator polymorphism, alcohol dehydrogenase, alpha 1-antitrypsin, cystic fibrosis, Duchenne/Becker muscular dystrophy, analyte-6-phosphate dehydrogenase, hemoglobinopathies, A,S,C,E, D-Punjab, beta-thalassemia, hepatitis B virus, HCMV, HIV-1, HTLV-1, Leber hereditary optic neuropathy, MCAD, RNA, PKU, Plasmodium vivax, sexual differentiation, 21-deoxycortisol); desbutylhalofantrine; dihydropteridine reductase; diptheria/tetanus antitoxin; erythrocyte arginase; erythrocyte protoporphyrin; esterase D; fatty acids/acylglycines; free β-human chorionic gonadotropin; free erythrocyte porphyrin; free thyroxine (FT4); free tri-iodothyronine (FT3); fumarylacetoacetase; galactose/gal-1-phosphate; galactose-1-phosphate uridyltransferase; gentamicin; analyte-6-phosphate dehydrogenase; glutathione; glutathione perioxidase; glycocholic acid; glycosylated hemoglobin; halofantrine; hemoglobin variants; hexosaminidase A; human erythrocyte carbonic anhydrase I; 17 alpha-hydroxyprogesterone; hypoxanthine phosphoribosyl transferase; immunoreactive trypsin; lactate; lead; lipoproteins ((a), B/A−1, B); lysozyme; mefloquine; netilmicin; phenobarbitone; phenytoin; phytanic/pristanic acid; progesterone; prolactin; prolidase; purine nucleoside phosphorylase; quinine; reverse tri-iodothyronine (rT3); selenium; serum pancreatic lipase; sissomicin; somatomedin C; specific antibodies (adenovirus, anti-nuclear antibody, anti-zeta antibody, arbovirus, Aujeszky's disease virus, dengue virus, Dracunculus medinensis, Echinococcus granulosus, Entamoeba histolytica, enterovirus, Giardia duodenalisa, Helicobacter pylori, hepatitis B virus, herpes virus, HIV-1, IgE (atopic disease), influenza virus, Leishmania donovani, leptospira, measles/mumps/rubella, Mycobacterium leprae, Mycoplasma pneumoniae, Myoglobin, Onchocerca volvulus, parainfluenza virus, Plasmodium falciparum, poliovirus, Pseudomonas aeruginosa, respiratory syncytial virus, rickettsia (scrub typhus), Schistosoma mansoni, Toxoplasma gondii, Trepenoma pallidium, Trypanosoma cruzi/rangeli, vesicular stomatis virus, Wuchereria bancrofti, yellow fever virus); specific antigens (hepatitis B virus, HIV-1); succinylacetone; sulfadoxine; theophylline; thyrotropin (TSH); thyroxine (T4); thyroxine-binding globulin; trace elements; transferrin; UDP-galactose-4-epimerase; urea; uroporphyrinogen I synthase; vitamin A; white blood cells; and zinc protoporphyrin. Salts, sugar, protein, fat, vitamins and hormones naturally occurring in blood or interstitial fluids may also constitute analytes in certain embodiments. The analyte may be naturally present in the biological fluid, for example, a metabolic product, a hormone, an antigen, an antibody, and the like. Alternatively, the analyte may be introduced into the body, for example, a contrast agent for imaging, a radioisotope, a chemical agent, a fluorocarbon-based synthetic blood, or a drug or pharmaceutical composition, including but not limited to insulin; ethanol; cannabis (marijuana, tetrahydrocannabinol, hashish); inhalants (nitrous oxide, amyl nitrite, butyl nitrite, chlorohydrocarbons, hydrocarbons); cocaine (crack cocaine); stimulants (amphetamines, methamphetamines, Ritalin, Cylert, Preludin, Didrex, PreState, Voranil, Sandrex, Plegine); depressants (barbituates, methaqualone, tranquilizers such as Valium, Librium, Miltown, Serax, Equanil, Tranxene); hallucinogens (phencyclidine, lysergic acid, mescaline, peyote, psilocybin); narcotics (heroin, codeine, morphine, opium, meperidine, Percocet, Percodan, Tussionex, Fentanyl, Darvon, Talwin, Lomotil); designer drugs (analogs of fentanyl, meperidine, amphetamines, methamphetamines, and phencyclidine, for example, Ecstasy); anabolic steroids; and nicotine. The metabolic products of drugs and pharmaceutical compositions are also contemplated analytes. Analytes such as neurochemicals and other chemicals generated within the body may also be analyzed, such as, for example, ascorbic acid, uric acid, dopamine, noradrenaline, 3-methoxytyramine (a3MT), 3,4-Dihydroxyphenylacetic acid (DOPAC), Homovanillic acid (HVA), 5-Hydroxytryptamine (5HT), and 5-Hydroxyindoleacetic acid (FHIAA).
The terms “operably connected” and “operably linked,” as used herein, are broad terms and are used in their ordinary sense, including, without limitation, one or more components being linked to another component(s) in a manner that allows transmission of signals between the components, e.g., wired or wirelessly. For example, one or more electrodes may be used to detect the amount of analyte in a sample and convert that information into a signal; the signal may then be transmitted to an electronic circuit means. In this case, the electrode is “operably linked” to the electronic circuitry.
The term “EEPROM,” as used herein, is a broad term and is used in its ordinary sense, including, without limitation, electrically erasable programmable read-only memory, which is user-modifiable read-only memory (ROM) that can be erased and reprogrammed (e.g., written to) repeatedly through the application of higher than normal electrical voltage.
The term “SRAM,” as used herein, is a broad term and is used in its ordinary sense, including, without limitation, static random access memory (RAM) that retains data bits in its memory as long as power is being supplied.
The term “A/D Converter,” as used herein, is a broad term and is used in its ordinary sense, including, without limitation, hardware that converts analog signals into digital signals.
The term “microprocessor,” as used herein, is a broad term and is used in its ordinary sense, including, without limitation a computer system or processor designed to perform arithmetic and logic operations using logic circuitry that responds to and processes the basic instructions that drive a computer.
The term “RF transceiver,” as used herein, is a broad term and is used in its ordinary sense, including, without limitation, a radio frequency transmitter and/or receiver for transmitting and/or receiving signals.
The term “jitter” as used herein, is a broad term and is used in its ordinary sense, including, without limitation, uncertainty or variability of waveform timing, which may be cause by ubiquitous noise caused by a circuit and/or environmental effects; jitter can be seen in amplitude, phase timing, or the width of the signal pulse.
The term “raw data signal,” as used herein, is a broad term and is used in its ordinary sense, including, without limitation, an analog or digital signal directly related to the measured analyte from the analyte sensor. In one example, the raw data signal is digital data in “counts” converted by an A/D converter from an analog signal (e.g., voltage or amps) representative of an analyte concentration.
The term “counts,” as used herein, is a broad term and is used in its ordinary sense, including, without limitation, a unit of measurement of a digital signal. In one example, a raw data signal measured in counts is directly related to a voltage (converted by an A/D converter), which is directly related to current.
The term “analyte sensor,” as used herein, is a broad term and is used in its ordinary sense, including, without limitation, any mechanism (e.g., enzymatic or non-enzymatic) by which analyte can be quantified. For example, some embodiments utilize a membrane that contains glucose oxidase that catalyzes the conversion of oxygen and glucose to hydrogen peroxide and gluconate:
Glucose+O2→Gluconate+H2O2
Because for each glucose molecule metabolized, there is a proportional change in the co-reactant O2 and the product H2O2, one can use an electrode to monitor the current change in either the co-reactant or the product to determine glucose concentration.
The term “host,” as used herein, is a broad term and is used in its ordinary sense, including, without limitation, mammals, particularly humans.
The term “matched data pairs”, as used herein, is a broad term and is used in its ordinary sense, including, without limitation, reference data (e.g., one or more reference analyte data points) matched with substantially time corresponding sensor data (e.g., one or more sensor data points).
The term “Clarke Error Grid”, as used herein, is a broad term and is used in its ordinary sense, including, without limitation, an error grid analysis, which evaluates the clinical significance of the difference between a reference glucose value and a sensor generated glucose value, taking into account 1) the value of the reference glucose measurement, 2) the value of the sensor glucose measurement, 3) the relative difference between the two values, and 4) the clinical significance of this difference. See Clarke et al., “Evaluating Clinical Accuracy of Systems for Self-Monitoring of Blood Glucose”, Diabetes Care, Volume 10, Number 5, September-October 1987, which is incorporated by reference herein in its entirety.
The term “Consensus Error Grid”, as used herein, is a broad term and is used in its ordinary sense, including, without limitation, an error grid analysis that assigns a specific level of clinical risk to any possible error between two time corresponding glucose measurements. The Consensus Error Grid is divided into zones signifying the degree of risk posed by the deviation. See Parkes et al., “A New Consensus Error Grid to Evaluate the Clinical Significance of Inaccuracies in the Measurement of Blood Glucose”, Diabetes Care, Volume 23, Number 8, August 2000, which is incorporated by reference herein in its entirety.
The term “clinical acceptability”, as used herein, is a broad term and is used in its ordinary sense, including, without limitation, determination of the risk of inaccuracies to a patient. Clinical acceptability considers a deviation between time corresponding glucose measurements (e.g., data from a glucose sensor and data from a reference glucose monitor) and the risk (e.g., to the decision making of a diabetic patient) associated with that deviation based on the glucose value indicated by the sensor and/or reference data. One example of clinical acceptability may be 85% of a given set of measured analyte values within the “A” and “B” region of a standard Clarke Error Grid when the sensor measurements are compared to a standard reference measurement.
The term “R-value,” as used herein, is a broad term and is used in its ordinary sense, including, without limitation, one conventional way of summarizing the correlation of data; that is, a statement of what residuals (e.g., root mean square deviations) are to be expected if the data are fitted to a straight line by the a regression.
The term “data association” and “data association function,” as used herein, are a broad terms and are used in their ordinary sense, including, without limitation, a statistical analysis of data and particularly its correlation to, or deviation from, from a particular curve. A data association function is used to show data association. For example, the data that forms that calibration set as described herein may be analyzed mathematically to determine its correlation to, or deviation from, a curve (e.g., line or set of lines) that defines the conversion function; this correlation or deviation is the data association. A data association function is used to determine data association. Examples of data association functions include, but are not limited to, linear regression, non-linear mapping/regression, rank (e.g., non-parametric) correlation, least mean square fit, mean absolute deviation (MAD), mean absolute relative difference. In one such example, the correlation coefficient of linear regression is indicative of the amount of data association of the calibration set that forms the conversion function, and thus the quality of the calibration.
The term “quality of calibration” as used herein, is a broad term and is used in its ordinary sense, including, without limitation, the statistical association of matched data pairs in the calibration set used to create the conversion function. For example, an R-value may be calculated for a calibration set to determine its statistical data association, wherein an R-value greater than 0.79 determines a statistically acceptable calibration quality, while an R-value less than 0.79 determines statistically unacceptable calibration quality.
The term “substantially” as used herein, is a broad term and is used in its ordinary sense, including, without limitation, being largely but not necessarily wholly that which is specified.
The term “congruence” as used herein, is a broad term and is used in its ordinary sense, including, without limitation, the quality or state of agreeing, coinciding, or being concordant. In one example, congruence may be determined using rank correlation.
The term “concordant” as used herein, is a broad term and is used in its ordinary sense, including, without limitation, being in agreement or harmony, and/or free from discord.
The phrase “continuous (or continual) analyte sensing,” as used herein, is a broad term and is used in its ordinary sense, including, without limitation, the period in which monitoring of analyte concentration is continuously, continually, and or intermittently (but regularly) performed, for example, about every 5 to 10 minutes.
The term “sensor head,” as used herein, is a broad term and is used in its ordinary sense, including, without limitation, the region of a monitoring device responsible for the detection of a particular analyte. In one example, a sensor head comprises a non-conductive body, a working electrode (anode), a reference electrode and a counter electrode (cathode) passing through and secured within the body forming an electrochemically reactive surface at one location on the body and an electronic connective means at another location on the body, and a sensing membrane affixed to the body and covering the electrochemically reactive surface. The counter electrode has a greater electrochemically reactive surface area than the working electrode. During general operation of the sensor a biological sample (e.g., blood or interstitial fluid) or a portion thereof contacts (directly or after passage through one or more membranes or domains) an enzyme (e.g., glucose oxidase); the reaction of the biological sample (or portion thereof) results in the formation of reaction products that allow a determination of the analyte (e.g., glucose) level in the biological sample. In some embodiments, the sensing membrane further comprises an enzyme domain (e.g., and enzyme layer), and an electrolyte phase (e.g., a free-flowing liquid phase comprising an electrolyte-containing fluid described further below).
The term “electrochemically reactive surface,” as used herein, is a broad term and is used in its ordinary sense, including, without limitation, the surface of an electrode where an electrochemical reaction takes place. In the case of the working electrode, the hydrogen peroxide produced by the enzyme catalyzed reaction of the analyte being detected creates a measurable electronic current (e.g., detection of analyte utilizing analyte oxidase produces H2O2 peroxide as a by product, H2O2 reacts with the surface of the working electrode producing two protons (2H+), two electrons (2e) and one molecule of oxygen (O2) which produces the electronic current being detected). In the case of the counter electrode, a reducible species, e.g., O2 is reduced at the electrode surface in order to balance the current being generated by the working electrode.
The term “electronic connection,” as used herein, is a broad term and is used in its ordinary sense, including, without limitation, any electronic connection known to those in the art that may be utilized to interface the sensor head electrodes with the electronic circuitry of a device such as mechanical (e.g., pin and socket) or soldered.
The term “sensing membrane,” as used herein, is a broad term and is used in its ordinary sense, including, without limitation, a permeable or semi-permeable membrane that may be comprised of two or more domains and constructed of materials of a few microns thickness or more, which are permeable to oxygen and may or may not be permeable to an analyte of interest. In one example, the sensing membrane comprises an immobilized glucose oxidase enzyme, which enables an electrochemical reaction to occur to measure a concentration of glucose.
The term “biointerface membrane,” as used herein, is a broad term and is used in its ordinary sense, including, without limitation, a permeable membrane that may be comprised of two or more domains and constructed of materials of a few microns thickness or more, which may be placed over the sensor body to keep host cells (e.g., macrophages) from gaining proximity to, and thereby damaging, the sensing membrane or forming a barrier cell layer and interfering with the transport of analyte across the tissue-device interface.
In the disclosure which follows, the following abbreviations apply: Eq and Eqs (equivalents); mEq (milliequivalents); M (molar); mM (millimolar) μM (micromolar); N (Normal); mol (moles); mmol (millimoles); μmol (micromoles); nmol (nanomoles); g (grams); mg (milligrams); μg (micrograms); Kg (kilograms); L (liters); mL (milliliters); dL (deciliters); μL (microliters); cm (centimeters); mm (millimeters); μm (micrometers); nm (nanometers); h and hr (hours); min. (minutes); s and sec. (seconds); ° C. (degrees Centigrade).
Overview
The preferred embodiments relate to the use of an analyte sensor that measures a concentration of analyte of interest or a substance indicative of the concentration or presence of the analyte. In some embodiments, the sensor is a continuous device, for example a subcutaneous, transdermal, or intravascular device. In some embodiments, the device may analyze a plurality of intermittent blood samples. The analyte sensor may use any method of analyte-sensing, including enzymatic, chemical, physical, electrochemical, spectrophotometric, polarimetric, calorimetric, radiometric, or the like.
The analyte sensor uses any known method, including invasive, minimally invasive, and non-invasive sensing techniques, to provide an output signal indicative of the concentration of the analyte of interest. The output signal is typically a raw signal that is used to provide a useful value of the analyte of interest to a user, such as a patient or physician, who may be using the device. Accordingly, appropriate smoothing, calibration, and evaluation methods may be applied to the raw signal and/or system as a whole to provide relevant and acceptable estimated analyte data to the user.
Sensor
The analyte sensor useful with the preferred embodiments may be any device capable of measuring the concentration of an analyte of interest. One exemplary embodiment is described below, which utilizes an implantable glucose sensor. However, it should be understood that the devices and methods described herein may be applied to any device capable of detecting a concentration of analyte of and providing an output signal that represents the concentration of the analyte.
FIG. 1 is an exploded perspective view of a glucose sensor in one embodiment. The implantable glucose sensor 10 utilizes amperometric electrochemical sensor technology to measure glucose. In this exemplary embodiment, a body 12 and a head 14 house electrodes 16 and sensor electronics, which are described in more detail with reference to FIG. 2. Three electrodes 16 are operably connected to the sensor electronics (FIG. 2) and are covered by a sensing membrane 17 and a biointerface membrane 18, which are attached by a clip 19. In alternative embodiments, the number of electrodes may be less than or greater than three.
The three electrodes 16, which protrude through the head 14, including a platinum working electrode, a platinum counter electrode, and a silver/silver chloride reference electrode. The top ends of the electrodes are in contact with an electrolyte phase (not shown), which is a free-flowing fluid phase disposed between the sensing membrane and the electrodes. The sensing membrane 17 includes an enzyme, e.g., glucose oxidase, which covers the electrolyte phase. In turn, the biointerface membrane 18 covers the sensing membrane 17 and serves, at least in part, to protect the sensor from external forces that may result in environmental stress cracking of the sensing membrane 17.
In the illustrated embodiment, the counter electrode is provided to balance the current generated by the species being measured at the working electrode. In the case of a glucose oxidase based glucose sensor, the species being measured at the working electrode is H2O2. Glucose oxidase catalyzes the conversion of oxygen and glucose to hydrogen peroxide and gluconate according to the following reaction:
Glucose+O2→Gluconate+H2O2
The change in H2O2 can be monitored to determine glucose concentration because for each glucose molecule metabolized, there is a proportional change in the product H2O2. Oxidation of H2O2 by the working electrode is balanced by reduction of ambient oxygen, enzyme generated H2O2, or other reducible species at the counter electrode. The H2O2 produced from the glucose oxidase reaction further reacts at the surface of working electrode and produces two protons (2H+), two electrons (2e)and one oxygen molecule (O2) (See, e.g., Fraser, D. M. “An Introduction to In vivo Biosensing: Progress and problems.” In “Biosensors and the Body,” D. M. Fraser, ed., 1997, pp. 1-56 John Wiley and Sons, New York.)
In one embodiment, a potentiostat is used to measure the electrochemical reaction(s) at the electrode(s) (see FIG. 2). The potentiostat applies a constant potential between the working and reference electrodes to produce a current value. The current that is produced at the working electrode (and flows through the circuitry to the counter electrode) is proportional to the diffusional flux of H2O2. Accordingly, a raw signal may be produced that is representative of the concentration of glucose in the users body, and therefore may be utilized to estimate a meaningful glucose value, such as described elsewhere herein.
One problem of enzymatic glucose sensors such as described above is the non-glucose reaction rate-limiting phenomenon. For example, if oxygen is deficient, relative to the amount of glucose, then the enzymatic reaction will be limited by oxygen rather than glucose. Consequently, the output signal will be indicative of the oxygen concentration rather than the glucose concentration.
FIG. 2 is a block diagram that illustrates the sensor electronics in one embodiment. In this embodiment, the potentiostat 20 is shown, which is operatively connected to electrodes 16 (FIG. 1) to obtain a current value, and includes a resistor (not shown) that translates the current into voltage. An A/D converter 21 digitizes the analog signal into counts for processing. Accordingly, the resulting raw data signal in counts is directly related to the current measured by the potentiostat 20.
A microprocessor 22 is the central control unit that houses EEPROM 23 and SRAM 24, and controls the processing of the sensor electronics. It may be noted that alternative embodiments utilize a computer system other than a microprocessor to process data as described herein. In some alternative embodiments, an application-specific integrated circuit (ASIC) may be used for some or all the sensor's central processing. The EEPROM 23 provides semi-permanent storage of data, storing data such as sensor ID and necessary programming to process data signals (e.g., programming for data smoothing such as described below). The SRAM 24 is used for the system's cache memory, for example for temporarily storing recent sensor data.
A battery 25 is operatively connected to the microprocessor 22 and provides the necessary power for the sensor. In one embodiment, the battery is a Lithium Manganese Dioxide battery, however any appropriately sized and powered battery may be used (e.g., AAA, Nickel-cadmium, Zinc-carbon, Alkaline, Lithium, Nickel-metal hydride, Lithium-ion, Zinc-air, Zinc-mercury oxide, Silver-zinc, or hermetically-sealed). In some embodiments, a plurality of batteries may be used to power the system. A Quartz Crystal 26 is operatively connected to the microprocessor 22 and maintains system time for the computer system as a whole.
An RF Transceiver 27 is operably connected to the microprocessor 22 and transmits the sensor data from the sensor to a receiver (see FIGS. 4 and 5). Although an RF transceiver is shown here, other embodiments include a wired rather than wireless connection to the receiver. In yet other embodiments, the receiver is transcutaneously powered via an inductive coupling, for example. A quartz crystal 28 provides the system time for synchronizing the data transmissions from the RF transceiver. It may be noted that the transceiver 27 may be substituted for a transmitter in one embodiment.
Data Smoothing
Typically, an analyte sensor produces a raw data signal that is indicative of the analyte concentration of a user, such as described in more detail with reference to FIGS. 1 and 2, above. However, it is well known that the above described glucose sensor is only one example of an abundance of analyte sensors that are able to provide a raw data signal output indicative of the concentration of the analyte of interest. Thus, it should be understood that the devices and methods of the preferred embodiments, including data smoothing, calibration, evaluation, and other data processing, may be applied to raw data obtained from any analyte sensor capable of producing a output signal.
It has been found that raw data signals received from an analyte sensor include signal noise, which degrades the quality of the data. Thus, it has been known to use smoothing algorithms help improve the signal-to-noise ratio in the sensor by reducing signal jitter, for example. One example of a conventional data smoothing algorithms include finite impulse response filter (FIR), which is particularly suited for reducing high-frequency noise (see Steil et al. U.S. Pat. No. 6,558,351). Other analyte sensors have utilized heuristic and moving average type algorithms to accomplish data smoothing of signal jitter in data signals, for example.
It is advantageous to also reduce signal noise by attenuating transient, low frequency, non-analyte related signal fluctuations (e.g., transient ischemia and/or long transient periods of postural effects that interfere with sensor function due to lack of oxygen and/or other physiological effects).
In one embodiment, this attenuation of transient low frequency non-analyte related signal noise is accomplished using a recursive filter. In contrast to conventional non-recursive (e.g., FIR) filters in which each computation uses new input data sets, a recursive filter is an equation that uses moving averages as inputs; that is, a recursive filter includes previous averages as part of the next filtered output. Recursive filters are advantageous at least in part due to their computational efficiency.
FIG. 3 is a graph that illustrates data smoothing of a raw data signal in one embodiment. In this embodiment, the recursive filter is implemented as a digital infinite impulse response filter (IIR) filter, wherein the output is computed using 6 additions and 7 multiplies as shown in the following equation:
y ( n ) = a 0 * x ( n ) + a 1 * x ( n - 1 ) + a 2 * x ( n - 2 ) + a 3 * x ( n - 3 ) - b 1 * y ( n - 1 ) - b 2 * y ( n - 2 ) - b 3 * y ( n - 3 ) b 0
This polynomial equation includes coefficients that are dependent on sample rate and frequency behavior of the filter. In this exemplary embodiment, frequency behavior passes low frequencies up to cycle lengths of 40 minutes, and is based on a 30 second sample rate.
In some embodiments, data smoothing may be implemented in the sensor and the smoothed data transmitted to a receiver for additional processing. In other embodiments, raw data may be sent from the sensor to a receiver for data smoothing and additional processing therein. In yet other embodiments, the sensor is integral with the receiver and therefore no transmission of data is required.
In one exemplary embodiment, wherein the sensor is an implantable glucose sensor, data smoothing is performed in the sensor to ensure a continuous stream of data. In alternative embodiments, data smoothing may be transmitted from the sensor to the receiver, and the data smoothing performed at the receiver; it may be noted however that there may be a risk of transmit-loss in the radio transmission from the sensor to the receiver when the transmission is wireless. For example, in embodiments wherein a sensor is implemented in vivo, the raw sensor signal may be more consistent within the sensor (in vivo) than the raw signal transmitted to a source (e.g., receiver) outside the body (e.g., if a patient were to take the receiver off to shower, communication between the sensor and receiver may be lost and data smoothing in the receiver would halt accordingly.) Consequently, it may be noted that a multiple point data loss in the filter may take, for example, anywhere from 25 to 40 minutes for the smoothed data to recover to where it would have been had there been no data loss.
Receiver
FIGS. 4A to 4D are schematic views of a receiver in first, second, third, and fourth embodiments, respectively. A receiver 40 comprises systems necessary to receive, process, and display sensor data from an analyte sensor, such as described elsewhere herein. Particularly, the receiver 40 may be a pager-sized device, for example, and comprise a user interface that has a plurality of buttons 42 and a liquid crystal display (LCD) screen 44, and which may include a backlight. In some embodiments the user interface may also include a keyboard, a speaker, and a vibrator such as described with reference to FIG. 5.
FIG. 4A illustrates a first embodiment wherein the receiver shows a numeric representation of the estimated analyte value on its user interface, which is described in more detail elsewhere herein.
FIG. 4B illustrates a second embodiment wherein the receiver shows an estimated glucose value and one hour of historical trend data on its user interface, which is described in more detail elsewhere herein.
FIG. 4C illustrates a third embodiment wherein the receiver shows an estimated glucose value and three hours of historical trend data on its user interface, which is described in more detail elsewhere herein.
FIG. 4D illustrates a fourth embodiment wherein the receiver shows an estimated glucose value and nine hours of historical trend data on its user interface, which is described in more detail elsewhere herein.
In some embodiments a user is able to toggle through some or all of the screens shown in FIGS. 4A to 4D using a toggle button on the receiver. In some embodiments, the user is able to interactively select the type of output displayed on their user interface. In some embodiments, the sensor output may have alternative configurations, such as is described with reference to FIG. 6, block 69, for example.
FIG. 5 is a block diagram of the receiver electronics in one embodiment. It may be noted that the receiver may comprise a configuration such as described with reference to FIGS. 4A to 4D, above. Alternatively, the receiver may comprise any configuration, including a desktop computer, laptop computer, a personal digital assistant (PDA), a server (local or remote to the receiver), or the like. In some embodiments, a receiver may be adapted to connect (via wired or wireless connection) to a desktop computer, laptop computer, a PDA, a server (local or remote to the receiver), or the like in order to download data from the receiver. In some alternative embodiments, the receiver is housed within or directly connected to the sensor in a manner that allows sensor and receiver electronics to work directly together and/or share data processing resources. Accordingly, the receiver, including its electronics, may be generally described as a “computer system.”
A quartz crystal 50 is operatively connected to an RF transceiver 51 that together function to receive and synchronize data signals (e.g., raw data signals transmitted from the RF transceiver). Once received, the microprocessor 52 processes the signals, such as described below.
The microprocessor 52 is the central control unit that provides the necessary processing, such as calibration algorithms stored within an EEPROM 53. The EEPROM 53 is operatively connected to the microprocessor 52 and provides semi-permanent storage of data, storing data such as receiver ID and necessary programming to process data signals (e.g., programming for performing calibration and other algorithms described elsewhere herein). In some embodiments, an application-specific integrated circuit (ASIC) may be used for some or all the receiver's central processing. An SRAM 54 is used for the system's cache memory and is helpful in data processing.
The microprocessor 52, which is operatively connected to EEPROM 53 and SRAM 54, controls the processing of the receiver electronics including, but not limited to, a sensor data receiving module, a reference data receiving module, a data matching module, a calibration set module, a conversion function module, a sensor data transformation module, a quality evaluation module, a interface control module, and a stability determination module, which are described in more detail below. It may be noted that any of the above processing may be programmed into and performed in the sensor electronics (FIG. 2) in place of, or in complement with, the receiver electronics (FIG. 5).
A battery 55 is operatively connected to the microprocessor 52 and provides the necessary power for the receiver. In one embodiment, the battery is a AAA battery, however any appropriately sized and powered battery may be used. In some embodiments, a plurality of batteries may be used to power the system. A quartz crystal 56 is operatively connected to the microprocessor 52 and maintains system time for the computer system as a whole.
A user interface 57 comprises a keyboard, speaker, vibrator, backlight, LCD, and a plurality of buttons. The components that comprise the user interface 57 provide the necessary controls to interact with the user. A keyboard may allow, for example, input of user information about himself/herself, such as mealtime, exercise, insulin administration, and reference analyte values. A speaker may provide, for example, audible signals or alerts for conditions such as present and/or predicted hyper- and hypoglycemic conditions. A vibrator may provide, for example, tactile signals or alerts for reasons such as described with reference to the speaker, above. A backlight may be provided, for example, to aid the user in reading the LCD in low light conditions. An LCD may be provided, for example, to provide the user with visual data output such as described in more detail with reference to FIGS. 4A to 4D and FIG. 6. Buttons may provide toggle, menu selection, option selection, mode selection, and reset, for example.
Communication ports, including a personal computer (PC) com port 58 and a reference analyte monitor com port 59 may be provided to enable communication with systems that are separate from, or integral with, the receiver. The PC com port 58 comprises means for communicating with another computer system (e.g., PC, PDA, server, or the like). In one exemplary embodiment, the receiver is able to download historic data to a physician's PC for retrospective analysis by the physician. The reference analyte monitor com port 59 comprises means for communicating with a reference analyte monitor so that reference analyte values may be automatically downloaded into the receiver. In one embodiment, the reference analyte monitor is integral with the receiver, and the reference analyte com port 59 allows internal communication between the two integral systems. In another embodiment, the reference analyte monitor com port 59 allows a wireless or wired connection to the reference analyte monitor such as a self-monitoring blood glucose monitor (e.g., for measuring finger stick blood samples).
Algorithms
Reference is now made to FIG. 6, which is a flow chart that illustrates the initial calibration and data output of the sensor data in one embodiment.
Calibration of an analyte sensor comprises data processing that converts sensor data signal into an estimated analyte measurement that is meaningful to a user. Accordingly, a reference analyte value is used to calibrate the data signal from the analyte sensor.
At block 61, a sensor data receiving module, also referred to as the sensor data module, receives sensor data (e.g., a data stream), including one or more time-spaced sensor data points, from a sensor via the receiver, which may be in wired or wireless communication with the sensor. The sensor data point(s) may be smoothed, such as described with reference to FIG. 3, above. It may be noted that during the initialization of the sensor, prior to initial calibration, the receiver (e.g., computer system) receives and stores the sensor data, however may not display any data to the user until initial calibration and possibly stabilization of the sensor has been determined.
At block 62, a reference data receiving module, also referred to as the reference input module, receives reference data from a reference analyte monitor, including one or more reference data points. In one embodiment, the reference analyte points may comprise results from a self-monitored blood analyte test (e.g., from a finger stick test). In one such embodiment, the user may administer a self-monitored blood analyte test to obtain an analyte value (e.g., point) using any known analyte sensor, and then enter the numeric analyte value into the computer system. In another such embodiment, a self-monitored blood analyte test comprises a wired or wireless connection to the receiver (e.g. computer system) so that the user simply initiates a connection between the two devices, and the reference analyte data is passed or downloaded between the self-monitored blood analyte test and the receiver. In yet another such embodiment, the self-monitored analyte test is integral with the receiver so that the user simply provides a blood sample to the receiver, and the receiver runs the analyte test to determine a reference analyte value.
It may be noted that certain acceptability parameters may be set for reference values received from the user. For example, in one embodiment, the receiver may only accept reference analyte values between about 40 and about 400 mg/dL. Other examples of determining valid reference analyte values are described in more detail with reference to FIG. 8.
At block 63, a data matching module, also referred to as the processor module, matches reference data (e.g., one or more reference analyte data points) with substantially time corresponding sensor data (e.g., one or more sensor data points) to provide one or more matched data pairs. In one embodiment, one reference data point is matched to one time corresponding sensor data point to form a matched data pair. In another embodiment, a plurality of reference data points are averaged (e.g., equally or non-equally weighted average, mean-value, median, or the like) and matched to one time corresponding sensor data point to form a matched data pair. In another embodiment, one reference data point is matched to a plurality of time corresponding sensor data points averaged to form a matched data pair. In yet another embodiment, a plurality of reference data points are averaged and matched to a plurality of time corresponding sensor data points averaged to form a matched data pair.
In one embodiment, a time corresponding sensor data comprises one or more sensor data points that occur 15±5 min after the reference analyte data timestamp (e.g., the time that the reference analyte data is obtained). In this embodiment, the 15 minute time delay has been chosen to account for an approximately 10 minute delay introduced by the filter used in data smoothing and an approximately 5 minute physiological time-lag (e.g., the time necessary for the analyte to diffusion through a membrane(s) of an analyte sensor). In alternative embodiments, the time corresponding sensor value may be more or less than the above-described embodiment, for example ±60 minutes. Variability in time correspondence of sensor and reference data may be attributed to, for example a longer or shorter time delay introduced by the data smoothing filter, or if the configuration of the analyte sensor incurs a greater or lesser physiological time lag.
It may be noted that in some practical implementations of the sensor, the reference analyte data may be obtained at a time that is different from the time that the data is input into the receiver. Accordingly, it should be noted that the “time stamp” of the reference analyte (e.g., the time at which the reference analyte value was obtained) is not the same as the time at which the reference analyte data was obtained by receiver. Therefore, some embodiments include a time stamp requirement that ensures that the receiver stores the accurate time stamp for each reference analyte value, that is, the time at which the reference value was actually obtained from the user.
In some embodiments, tests are used to evaluate the best matched pair using a reference data point against individual sensor values over a predetermined time period (e.g., about 30 minutes). In one such exemplary embodiment, the reference data point is matched with sensor data points at 5-minute intervals and each matched pair is evaluated. The matched pair with the best correlation may be selected as the matched pair for data processing. In some alternative embodiments, matching a reference data point with an average of a plurality of sensor data points over a predetermined time period may be used to form a matched pair.
At block 64, a calibration set module, also referred to as the processor module, forms an initial calibration set from a set of one or more matched data pairs, which are used to determine the relationship between the reference analyte data and the sensor analyte data, such as will be described in more detail with reference to block 67, below.
The matched data pairs, which make up the initial calibration set, may be selected according to predetermined criteria. It may be noted that the criteria for the initial calibration set may be the same as, or different from, the criteria for the update calibration set, which is described in more detail with reference to FIG. 10. In some embodiments, the number (n) of data pair(s) selected for the initial calibration set is one. In other embodiments, n data pairs are selected for the initial calibration set wherein n is a function of the frequency of the received reference data points. In one exemplary embodiment, six data pairs make up the initial calibration set.
In some embodiments, the data pairs are selected only within a certain analyte value threshold, for example wherein the reference analyte value is between about 40 and about 400 mg/dL. In some embodiments, the data pairs that form the initial calibration set are selected according to their time stamp. In some embodiments, the calibration set is selected such as described with reference to FIG. 10
At block 65, a stability determination module, also referred to as the start-up module, determines the stability of the analyte sensor over a period of time. It may be noted that some analyte sensors may have an initial instability time period during which the analyte sensor is unstable for environmental, physiological, or other reasons. One example of initial sensor instability is an embodiment wherein the analyte sensor is implanted subcutaneously; in this example embodiment, stabilization of the analyte sensor may be dependent upon the maturity of the tissue ingrowth around and within the sensor. Another example of initial sensor instability is in an embodiment wherein the analyte sensor is implemented transdermally; in this example embodiment, stabilization of the analyte sensor may be dependent upon electrode stabilization and/or sweat, for example.
Accordingly, in some embodiments, determination of sensor stability may include waiting a predetermined time period (e.g., an implantable sensor is known to require a time period for tissue, and a transdermal sensor is known to require time to equilibrate the sensor with the user's skin); in some embodiments, this predetermined waiting period is between about one minute and about six weeks. In some embodiments, the sensitivity (e.g., sensor signal strength with respect to analyte concentration) may be used to determine the stability of the sensor; for example, amplitude and/or variability of sensor sensitivity may be evaluated to determine the stability of the sensor. In alternative embodiments, detection of pH levels, oxygen, hypochlorite, interfering species (e.g., ascorbate, urea, and acetaminophen), correlation between sensor and reference values (e.g., R-value), baseline drift and/or offset, and the like may be used to determine the stability of the sensor. In one exemplary embodiment, wherein the sensor is a glucose sensor, it is known to provide a signal that is associated with interfering species (e.g., ascorbate, urea, acetaminophen), which may be used to evaluate sensor stability. In another exemplary embodiment, wherein the sensor is a glucose sensor such as described with reference to FIGS. 1 and 2, the counter electrode can be monitored for oxygen deprivation, which may be used to evaluate sensor stability or functionality.
At decision block 66, the system (e.g., microprocessor) determines whether the analyte sensor is sufficiently stable according to certain criteria, such as described above. In one embodiment wherein the sensor is an implantable glucose sensor, the system waits a predetermined time period believed necessary for sufficient tissue ingrowth and evaluates the sensor sensitivity (e.g., between about one minute and six weeks). In another embodiment, the receiver determines sufficient stability based on oxygen concentration near the sensor head. In yet another embodiment, the sensor determines sufficient stability based on a reassessment of baseline drift and/or offset. In yet another alternative embodiment, the system evaluates stability by monitoring the frequency content of the sensor data stream over a predetermined amount of time (e.g., 24 hours); in this alternative embodiment, a template (or templates) are provided that reflect acceptable levels of glucose physiology and are compared with the actual sensor data, wherein a predetermined amount of agreement between the template and the actual sensor data is indicative of sensor stability. It may be noted that a few examples of determining sufficient stability are given here, however a variety of known tests and parameters may be used to determine sensor stability without departing from the spirit and scope of the preferred embodiments.
If the receiver does not assess that the stability of the sensor is sufficient, then the processing returns to block 61, wherein the receiver receives sensor data such as described in more detail above. The above-described steps are repeated until sufficient stability is determined.
If the receiver does assess that the stability of the sensor is sufficient, then processing continues to block 67 and the calibration set is used to calibrate the sensor.
At block 67, the conversion function module uses the calibration set to create a conversion function. The conversion function substantially defines the relationship between the reference analyte data and the analyte sensor data.
A variety of known methods may be used with the preferred embodiments to create the conversion function from the calibration set. In one embodiment, wherein a plurality of matched data points form the initial calibration set, a linear least squares regression is performed on the initial calibration set such as described with reference to FIG. 7.
FIG. 7 is a graph that illustrates a regression performed on a calibration set to create a conversion function in one exemplary embodiment. In this embodiment, a linear least squares regression is performed on the initial calibration set. The x-axis represents reference analyte data; the y-axis represents sensor data. The graph pictorially illustrates regression of the matched pairs 76 in the calibration set. Regression calculates a slope 72 and an offset 74 (y=m×+b), which defines the conversion function.
In alternative embodiments other algorithms could be used to determine the conversion function, for example forms of linear and non-linear regression, for example fuzzy logic, neural networks, piece-wise linear regression, polynomial fit, genetic algorithms, and other pattern recognition and signal estimation techniques.
In yet other alternative embodiments, the conversion function may comprise two or more different optimal conversions because an optimal conversion at any time is dependent on one or more parameters, such as time of day, calories consumed, exercise, or analyte concentration above or below a set threshold, for example. In one such exemplary embodiment, the conversion function is adapted for the estimated glucose concentration (e.g., high vs. low). For example in an implantable glucose sensor it has been observed that the cells surrounding the implant will consume at least a small amount of glucose as it diffuses toward the glucose sensor. Assuming the cells consume substantially the same amount of glucose whether the glucose concentration is low or high, this phenomenon will have a greater effect on the concentration of glucose during low blood sugar episodes than the effect on the concentration of glucose during relatively higher blood sugar episodes. Accordingly, the conversion function is adapted to compensate for the sensitivity differences in blood sugar level. In one implementation, the conversion function comprises two different regression lines wherein a first regression line is applied when the estimated blood glucose concentration is at or below a certain threshold (e.g., 150 mg/dL) and a second regression line is applied when the estimated blood glucose concentration is at or above a certain threshold (e.g., 150 mg/dL). In one alternative implementation, a predetermined pivot of the regression line that forms the conversion function may be applied when the estimated blood is above or below a set threshold (e.g., 150 mg/dL), wherein the pivot and threshold are determined from a retrospective analysis of the performance of a conversion function and its performance at a range of glucose concentrations. In another implementation, the regression line that forms the conversion function is pivoted about a point in order to comply with clinical acceptability standards (e.g., Clarke Error Grid, Consensus Grid, mean absolute relative difference, or other clinical cost function). Although only a few example implementations are described, the preferred embodiments contemplate numerous implementations wherein the conversion function is adaptively applied based on one or more parameters that may affect the sensitivity of the sensor data over time.
Referring again to FIG. 6, at block 68, a sensor data transformation module uses the conversion function to transform sensor data into substantially real-time analyte value estimates, also referred to as calibrated data, as sensor data is continuously (or intermittently) received from the sensor. For example, in the embodiment of FIG. 7, the sensor data, which may be provided to the receiver in “counts”, is translated in to estimate analyte value(s) in mg/dL. In other words, the offset value at any given point in time may be subtracted from the raw value (e.g., in counts) and divided by the slope to obtain the estimate analyte value:
mg / dL = ( raw value - offset ) slope
In some alternative embodiments, the sensor and/or reference analyte values are stored in a database for retrospective analysis.
At block 69, an output module provides output to the user via the user interface. The output is representative of the estimated analyte value, which is determined by converting the sensor data into a meaningful analyte value such as described in more detail with reference to block 68, above. User output may be in the form of a numeric estimated analyte value, an indication of directional trend of analyte concentration, and/or a graphical representation of the estimated analyte data over a period of time, for example. Other representations of the estimated analyte values are also possible, for example audio and tactile.
In one exemplary embodiment, such as shown in FIG. 4A, the estimated analyte value is represented by a numeric value. In other exemplary embodiments, such as shown in FIGS. 4B to 4D, the user interface graphically represents the estimated analyte data trend over predetermined a time period (e.g., one, three, and nine hours, respectively). In alternative embodiments, other time periods may be represented.
In some embodiments, the user interface begins displaying data to the user after the sensor's stability has been affirmed. In some alternative embodiments however, the user interface displays data that is somewhat unstable (e.g., does not have sufficient stability at block 66); in these embodiments, the receiver may also include an indication of instability of the sensor data (e.g., flashing, faded, or another indication of sensor instability displayed on the user interface). In some embodiments, the user interface informs the user of the status of the stability of the sensor data.
Accordingly, after initial calibration of the sensor, and possibly determination of stability of the sensor data, real-time continuous analyte information may be displayed on the user interface so that the user may regularly and proactively care for his/her diabetic condition within the bounds set by his/her physician.
In alternative embodiments, the conversion function is used to predict analyte values at future points in time. These predicted values may be used to alert the user of upcoming hypoglycemic or hyperglycemic events. Additionally, predicted values may be used to compensate for the time lag (e.g., 15 minute time lag such as described elsewhere herein), so that an estimate analyte value displayed to the user represents the instant time, rather than a time delayed estimated value.
In some embodiments, the substantially real time estimated analyte value, a predicted future estimate analyte value, a rate of change, and/or a directional trend of the analyte concentration is used to control the administration of a constituent to the user, including an appropriate amount and time, in order to control an aspect of the user's biological system. One such example is a closed loop glucose sensor and insulin pump, wherein the analyte data (e.g., estimated glucose value, rate of change, and/or directional trend) from the glucose sensor is used to determine the amount of insulin, and time of administration, that may be given to a diabetic user to evade hyper- and hypoglycemic conditions.
Reference is now made to FIG. 8, which is a flow chart that illustrates the process of evaluating the clinical acceptability of reference and sensor data in one embodiment. Although some clinical acceptability tests are disclosed here, any known clinical standards and methodologies may be applied to evaluate the clinical acceptability of reference and analyte data herein.
It may be noted that the conventional analyte meters (e.g., self-monitored blood analyte tests) are known to have a +−20% error in analyte values. For example, gross errors in analyte readings are known to occur due to patient error in self-administration of the blood analyte test. In one such example, if the user has traces of sugar on his/her finger while obtaining a blood sample for a glucose concentration test, then the measured glucose value will likely be much higher than the actual glucose value in the blood. Additionally, it is known that self-monitored analyte tests (e.g., test strips) are occasionally subject to manufacturing error.
Another cause for error includes infrequency and time delay that may occur if a user does not self-test regularly, or if a user self-tests regularly but does not enter the reference value at the appropriate time or with the appropriate time stamp. Therefore, it may be advantageous to validate the acceptability of reference analyte values prior to accepting them as valid entries. Accordingly, the receiver evaluates the clinical acceptability of received reference analyte data prior to their acceptance as a valid reference value.
In one embodiment, the reference analyte data (and/or sensor analyte data) is evaluated with respect to substantially time corresponding sensor data (and/or substantially time corresponding reference analyte data) to determine the clinical acceptability of the reference analyte and/or sensor analyte data. Clinical acceptability considers a deviation between time corresponding glucose measurements (e.g., data from a glucose sensor and data from a reference glucose monitor) and the risk (e.g., to the decision making of a diabetic patient) associated with that deviation based on the glucose value indicated by the sensor and/or reference data. Evaluating the clinical acceptability of reference and sensor analyte data, and controlling the user interface dependent thereon, may minimize clinical risk.
In one embodiment, the receiver evaluates clinical acceptability each time reference data is obtained. In another embodiment, the receiver evaluates clinical acceptability after the initial calibration and stabilization of the sensor, such as described with reference to FIG. 6, above. In some embodiments, the receiver evaluates clinical acceptability as an initial pre-screen of reference analyte data, for example after determining if the reference glucose measurement is between about 40 and 400 mg/dL. In other embodiments, other methods of pre-screening data may be used, for example by determining if a reference analyte data value is physiologically feasible based on previous reference analyte data values (e.g., below a maximum rate of change).
After initial calibration such as described in more detail with reference to FIG. 6, the sensor data receiving module 61 receives substantially continuous sensor data (e.g., a data stream) via a receiver and converts that data into estimated analyte values. As used herein, “substantially continuous” is broad enough to include a data stream of individual measurements taken at time intervals (e.g., time-spaced) ranging from fractions of a second up to, e.g., 1, 2, or 5 minutes. As sensor data is continuously converted, it may be occasionally recalibrated such as described in more detail with reference FIG. 10. Initial calibration and re-calibration of the sensor requires a reference analyte value. Accordingly, the receiver may receive reference analyte data at any time for appropriate processing. These reference analyte values may be evaluated for clinical acceptability such as described below as a fail-safe against reference analyte test errors.
At block 81, the reference data receiving module, also referred to as the reference input module, receives reference analyte data from a reference analyte monitor. In one embodiment, the reference data comprises one analyte value obtained from a reference monitor. In some alternative embodiments however, the reference data includes a set of analyte values entered by a user into the interface and averaged by known methods such as described elsewhere herein.
In some embodiments, the reference data is pre-screened according to environmental and physiological issues, such as time of day, oxygen concentration, postural effects, and patient-entered environmental data. In one example embodiment, wherein the sensor comprises an implantable glucose sensor, an oxygen sensor within the glucose sensor is used to determine if sufficient oxygen is being provided to successfully complete the necessary enzyme and electrochemical reactions for glucose sensing. In another example embodiment wherein the sensor comprises an implantable glucose sensor, the counter electrode could be monitored for a “rail-effect”, that is, when insufficient oxygen is provided at the counter electrode causing the counter electrode to reach operational (e.g., circuitry) limits. In yet another example embodiment, the patient is prompted to enter data into the user interface, such as meal times and/or amount of exercise, which could be used to determine likelihood of acceptable reference data.
It may be further noted that evaluation data, such as described in the paragraph above, may be used to evaluate an optimum time for reference analyte measurement. Correspondingly, the user interface may then prompt the user to provide a reference data point for calibration within a given time period. Consequently, because the receiver proactively prompts the user during optimum calibration times, the likelihood of error due to environmental and physiological limitations may decrease and consistency and acceptability of the calibration may increase.
At block 82, the clinical acceptability evaluation module, also referred to as clinical module, evaluates the clinical acceptability of newly received reference data and/or time corresponding sensor data. In some embodiments of evaluating clinical acceptability, the rate of change of the reference data as compared to previous data is assessed for clinical acceptability. That is, the rate of change and acceleration (or deceleration) of many analytes has certain physiological limits within the body. Accordingly, a limit may be set to determine if the new matched pair is within a physiologically feasible range, indicated by a rate of change from the previous data that is within known physiological and/or statistical limits. Similarly, in some embodiments any algorithm that predicts a future value of an analyte may be used to predict and then compare an actual value to a time corresponding predicted value to determine if the actual value falls within a clinically acceptable range based on the predictive algorithm, for example.
In one exemplary embodiment, the clinical acceptability evaluation module 82 matches the reference data with a substantially time corresponding converted sensor value such as described with reference to FIG. 6 above, and plots the matched data on a Clarke Error Grid such as described in more detail with reference to FIG. 9.
FIG. 9 is a graph of two data pairs on a Clarke Error Grid to illustrate the evaluation of clinical acceptability in one exemplary embodiment. The Clarke Error Grid may be used by the clinical acceptability evaluation module to evaluate the clinical acceptability of the disparity between a reference glucose value and a sensor glucose (e.g., estimated glucose) value, if any, in an embodiment wherein the sensor is a glucose sensor. The x-axis represents glucose reference glucose data and the y-axis represents estimated glucose sensor data. Matched data pairs are plotted accordingly to their reference and sensor values, respectively. In this embodiment, matched pairs that fall within the A and B regions of the Clarke Error Grid are considered clinically acceptable, while matched pairs that fall within the C, D, and E regions of the Clarke Error Grid are not considered clinically acceptable. Particularly, FIG. 9 shows a first matched pair 92 is shown which falls within the A region of the Clarke Error Grid, therefore is it considered clinically acceptable. A second matched pair 94 is shown which falls within the C region of the Clarke Error Grid, therefore it is not considered clinically acceptable.
It may be noted that a variety of other known methods of evaluation of clinical acceptability may be utilized. In one alternative embodiment, the Consensus Grid is used to evaluate the clinical acceptability of reference and sensor data. In another alternative embodiment, a mean absolute difference calculation may be used to evaluate the clinical acceptability of the reference data. In another alternative embodiment, the clinical acceptability may be evaluated using any relevant clinical acceptability test, such as a known grid (e.g., Clarke Error or Consensus), and including additional parameters such as time of day and/or the increase or decreasing trend of the analyte concentration. In another alternative embodiment, a rate of change calculation may be used to evaluate clinical acceptability. In yet another alternative embodiment, wherein the received reference data is in substantially real time, the conversion function could be used to predict an estimated glucose value at a time corresponding to the time stamp of the reference analyte value (this may be required due to a time lag of the sensor data such as described elsewhere herein). Accordingly, a threshold may be set for the predicted estimated glucose value and the reference analyte value disparity, if any.
Referring again to FIG. 8, the results of the clinical acceptability evaluation are assessed. If clinical acceptability is determined with the received reference data, then processing continues to block 84 to optionally recalculate the conversion function using the received reference data in the calibration set. If, however, clinical acceptability is not determined, then the processing progresses to block 86 to control the user interface, such as will be described with reference to block 86 below.
At block 84, the conversion function module optionally recreates the conversion function using the received reference data. In one embodiment, the conversion function module adds the newly received reference data (e.g., including the matched sensor data) into the calibration set, displaces the oldest, and/or least concordant matched data pair from the calibration set, and recalculates the conversion function accordingly. In another embodiment, the conversion function module evaluates the calibration set for best calibration based on inclusion criteria, such as described in more detail with reference to FIG. 10.
At 85, the sensor data transformation module uses the conversion function to continually (or intermittently) convert sensor data into estimated analyte values, also referred to as calibrated data, such as described in more detail with reference to FIG. 6, block 68.
At block 86, the interface control module, also referred to as the fail-safe module, controls the user interface based upon the clinical acceptability of the reference data received. If the evaluation (block 82) deems clinical acceptability, then the user interface may function as normal; that is, providing output for the user such as described in more detail with reference to FIG. 6, block 69.
If however the reference data is not considered clinically acceptable, then the fail-safe module begins the initial stages of fail-safe mode. In some embodiments, the initial stages of fail-safe mode include altering the user interface so that estimated sensor data is not displayed to the user. In some embodiments, the initial stages of fail-safe mode include prompting the user to repeat the reference analyte test and provide another reference analyte value. The repeated analyte value is then evaluated for clinical acceptability such as described with reference to blocks 81 to 83, above.
If the results of the repeated analyte test are determined to be clinically unacceptable, then fail-safe module may alter the user interface to reflect full fail-safe mode. In one embodiment, full fail-safe mode includes discontinuing sensor analyte display output on the user interface. In other embodiments, color-coded information, trend information, directional information (e.g., arrows or angled lines), gauges, and/or fail-safe information may be displayed, for example.
If the results of the repeated analyte test are determined to be clinically acceptable, then the first analyte value is discarded, and the repeated analyte value is accepted. The process returns to block 84 to optionally recalculate the conversion function, such as described in more detail with reference to block 84, above.
Reference is now made to FIG. 10, which is a flow chart that illustrates the process of evaluation of calibration data for best calibration based on inclusion criteria of matched data pairs in one embodiment.
It may be noted that calibration of analyte sensors may be variable over time; that is, the conversion function suitable for one point in time may not be suitable for another point in time (e.g., hours, days, weeks, or months later). For example, in an embodiment wherein the analyte sensor is subcutaneously implantable, the maturation of tissue ingrowth over time may cause variability in the calibration of the analyte sensor. As another example, physiological changes in the user (e.g., metabolism, interfering blood constituents, lifestyle changes) may cause variability in the calibration of the sensor. Accordingly, a continuously updating calibration algorithm is disclosed that includes reforming the calibration set, and thus recalculating the conversion function, over time according to a set of inclusion criteria.
At block 101, the reference data receiving module, also referred to as the reference input module, receives a new reference analyte value (e.g., data point) from the reference analyte monitor. In some embodiments, the reference analyte value may be pre-screened according to criteria such as described in more detail with reference to FIG. 6, block 62. In some embodiments, the reference analyte value may be evaluated for clinical acceptability such as described in more detail with reference to FIG. 8.
At block 102, the data matching module, also referred to as the processor module, forms one or more updated matched data pairs by matching new reference data to substantially time corresponding sensor data, such as described in more detail with reference to FIG. 6, block 63.
At block 103, a calibration evaluation module evaluates the new matched pair(s) inclusion into the calibration set. In some embodiments, the receiver simply adds the updated matched data pair into the calibration set, displaces the oldest and/or least concordant matched pair from the calibration set, and proceeds to recalculate the conversion function accordingly (block 105).
In some embodiments, the calibration evaluation includes evaluating only the new matched data pair. In some embodiments, the calibration evaluation includes evaluating all of the matched data pairs in the existing calibration set and including the new matched data pair; in such embodiments not only is the new matched data pair evaluated for inclusion (or exclusion), but additionally each of the data pairs in the calibration set are individually evaluated for inclusion (or exclusion). In some alternative embodiments, the calibration evaluation includes evaluating all possible combinations of matched data pairs from the existing calibration set and including the new matched data pair to determine which combination best meets the inclusion criteria. In some additional alternative embodiments, the calibration evaluation includes a combination of at least two of the above-described embodiments.
Inclusion criteria comprise one or more criteria that define a set of matched data pairs that form a substantially optimal calibration set. One inclusion criterion comprises ensuring the time stamp of the matched data pairs (that make up the calibration set) span at least a set time period (e.g., three hours). Another inclusion criterion comprises ensuring that the time stamps of the matched data pairs are not more than a set age (e.g., one week old). Another inclusion criterion ensures that the matched pairs of the calibration set have a substantially distributed amount of high and low raw sensor data, estimated sensor analyte values, and/or reference analyte values. Another criterion comprises ensuring all raw sensor data, estimated sensor analyte values, and/or reference analyte values are within a predetermined range (e.g., 40 to 400 mg/dL for glucose values). Another criterion comprises evaluating the rate of change of the analyte concentration (e.g., from sensor data) during the time stamp of the matched pair(s). For example, sensor and reference data obtained during the time when the analyte concentration is undergoing a slow rate of change may be less susceptible inaccuracies caused by time lag and other physiological and non-physiological effects. Another criterion comprises evaluating the congruence of respective sensor and reference data in each matched data pair; the matched pairs with the most congruence may be chosen. Another criterion comprises evaluating physiological changes (e.g., low oxygen due to a user's posture that may effect the function of a subcutaneously implantable analyte sensor, or other effects such as described with reference to FIG. 6) to ascertain a likelihood of error in the sensor value. It may be noted that evaluation of calibration set criteria may comprise evaluating one, some, or all of the above described inclusion criteria. It is contemplated that additional embodiments may comprise additional inclusion criteria not explicitly described herein.
At block 104, the evaluation of the calibration set determines whether to maintain the previously established calibration set, or if the calibration set should be updated (e.g., modified) with the new matched data pair. In some embodiments, the oldest matched data pair is simply displaced when a new matched data pair is included. It may be noted however that a new calibration set may include not only the determination to include the new matched data pair, but in some embodiments, may also determine which of the previously matched data pairs should be displaced from the calibration set.
At block 105, the conversion function module recreates the conversion function using the modified calibration set. The calculation of the conversion function is described in more detail with reference to FIG. 6.
At block 106, the sensor data transformation module converts sensor data to calibrated data using the updated conversion function. Conversion of raw sensor data into estimated analyte values is described in more detail with reference to FIG. 6.
Reference is now made to FIG. 11, which is a flow chart that illustrates the process of evaluating the quality of the calibration in one embodiment. The calibration quality may be evaluated by determining the statistical association of data that forms the calibration set, which determines the confidence associated with the conversion function used in calibration and conversion of raw sensor data into estimated analyte values.
In one embodiment calibration quality may be evaluated after initial or updated calculation of the conversion function such as described elsewhere herein. However it may be noted that calibration quality may be performed at any time during the data processing.
At block 111, a sensor data receiving module, also referred to as the sensor data module, receives the sensor data from the sensor such as described in more detail with reference to FIG. 6.
At block 112, a reference data receiving module, also referred to as the reference input module, receives reference data from a reference analyte monitor, such as described in more detail with reference to FIG. 6.
At block 113, the data matching module, also referred to as the processor module, matches received reference data with substantially time corresponding sensor data to provide one or more matched data pairs, such as described in more detail with reference to FIG. 6.
At block 114, the calibration set module, also referred to as the processor module, forms a calibration set from one or more matched data pairs such as described in more detail with reference to FIGS. 6, 8, and 10.
At block 115, the conversion function module calculates a conversion function using the calibration set, such as described in more detail with reference to FIGS. 6, 8, and 10.
At block 116, the sensor data transformation module continuously (or intermittently) converts received sensor data into estimated analyte values, also referred to as calibrated data, such as described in more detail with reference to FIGS. 6, 8, and 10.
At block 117, a quality evaluation module evaluates the quality of the calibration. In one embodiment, the quality of the calibration is based on the association of the calibration set data using statistical analysis. Statistical analysis may comprise any known cost function such as linear regression, non-linear mapping/regression, rank (e.g., non-parametric) correlation, least mean square fit, mean absolute deviation (MAD), mean absolute relative difference, and the like. The result of the statistical analysis provides a measure of the association of data used in calibrating the system. A threshold of data association may be set to determine if sufficient quality is exhibited in a calibration set.
In another embodiment, the quality of the calibration is determined by evaluating the calibration set for clinical acceptability, such as described with reference to blocks 82 and 83 (e.g., Clarke Error Grid, Consensus Grid, or clinical acceptability test). As an example, the matched data pairs that form the calibration set may be plotted on a Clarke Error Grid, such that when all matched data pairs fall within the A and B regions of the Clarke Error Grid, then the calibration is determined to be clinically acceptable.
In yet another alternative embodiment, the quality of the calibration is determined based initially on the association of the calibration set data using statistical analysis, and then by evaluating the calibration set for clinical acceptability. If the calibration set fails the statistical and/or the clinical test, the processing returns to block 115 to recalculate the conversion function with a new (e.g., optimized) set of matched data pairs. In this embodiment, the processing loop (block 115 to block 117) iterates until the quality evaluation module 1) determines clinical acceptability, 2) determines sufficient statistical data association, 3) determines both clinical acceptability and sufficient statistical data association, or 4) surpasses a threshold of iterations; after which the processing continues to block 118.
FIGS. 12A and 12B illustrate one exemplary embodiment wherein the accuracy of the conversion function is determined by evaluating the correlation coefficient from linear regression of the calibration set that formed the conversion function. In this exemplary embodiment, a threshold (e.g., 0.79) is set for the R-value obtained from the correlation coefficient.
FIGS. 12A and 12B are graphs that illustrate an evaluation of the quality of calibration based on data association in one exemplary embodiment using a correlation coefficient. Particularly, FIGS. 12A and 12B pictorially illustrate the results of the linear least squares regression performed on a first and a second calibration set (FIGS. 12A and 12B, respectively). The x-axis represents reference analyte data; the y-axis represents sensor data. The graph pictorially illustrates regression that determines the conversion function.
It may be noted that the regression line (and thus the conversion function) formed by the regression of the first calibration set of FIG. 12A is the same as the regression line (and thus the conversion function) formed by the regression of the second calibration set of FIG. 12B. However, the correlation of the data in the calibration set to the regression line in FIG. 12A is significantly different than the correlation of the data in the calibration set to the regression line in FIG. 12A. In other words, there is a noticeably greater deviation of the data from the regression line in FIG. 12B than the deviation of the data from the regression line in FIG. 12A.
In order to quantify this difference in correlation, an R-value may be used to summarize the residuals (e.g., root mean square deviations) of the data when fitted to a straight line via least squares method, in this exemplary embodiment. R-value may be calculated according to the following equation:
R = i ( x i - x _ ) ( y i - y _ ) i ( x i - x ) 2 i ( y i - y ) 2
In the above equation: i is an index (1 to n), x is a reference analyte value, y is a sensor analyte value, x is an average of 1/n reference analyte values, and y is an average of 1/n sensor analyte values.
In the exemplary calibration set shown in FIG. 12A, the calculated R-value is about 0.99, which may also be expressed as the correlation coefficient of regression. Accordingly, the calibration exhibits sufficient data association (and thus insufficient quality) because it falls above the 0.79 threshold set in this exemplary embodiment.
In the exemplary calibration set shown in FIG. 12B, the calculated R-value is about 0.77, which may also be expressed as the correlation coefficient of regression. Accordingly, the calibration exhibits insufficient data association (and thus insufficient quality) because it falls below the 0.79 threshold set in this exemplary embodiment.
Reference is again made to FIG. 11, at block 118, the interface control module, also referred to as the fail-safe module, controls the user interface based upon the quality of the calibration. If the calibration is exhibits sufficient quality, then the user interface may function as normal; that is providing output for the user such as described in more detail with reference to FIG. 6.
If however the calibration is not deemed sufficient in quality, then fail-safe module 118 begins the initial stages of fail-safe mode, which are described in more detail with reference to FIG. 8. In some embodiments, the initial stages of fail-safe mode include altering the user interface so that estimated sensor data is not displayed to the user. In some embodiments, the initial stages of fail-safe mode also include prompting the user to provide an updated reference analyte value. The updated analyte value is then processed as described above and the updated conversion function that results from the repeated reference analyte test, if any, is evaluated for statistical accuracy.
If the results of the updated evaluation again exhibit insufficient quality, then the fail-safe module alters user interface to reflect full fail-safe mode, which is described in more detail with reference to FIG. 8. If however the results of the updated evaluation exhibit sufficient quality, then the first reference analyte value is discarded, and the repeated reference analyte value is accepted and the process continues as described herein.
It may be noted that the initial stages of fail-safe mode and full fail safe mode may be similar to that described with reference to FIG. 8, including user interface control for example. Additionally, it is contemplated herein that a variety of difference modes between initial and full fail-safe mode may be provided depending on the relative quality of the calibration. In other words, the confidence level of the calibration quality may control a plurality of different user interface screens providing error bars, ±values, and the like. Similar screens may be implements in the clinical acceptability embodiments described with reference to FIG. 8.
The above description discloses several methods and materials of the disclosed invention. This invention is susceptible to modifications in the methods and materials, as well as alterations in the fabrication methods and equipment. Such modifications will become apparent to those skilled in the art from a consideration of this disclosure or practice of the invention disclosed herein. Consequently, it is not intended that this invention be limited to the specific embodiments disclosed herein, but that it cover all modifications and alternatives coming within the true scope and spirit of the invention as embodied in the attached claims. All patents, applications, and other references cited herein are hereby incorporated by reference in their entirety.

Claims (49)

1. A system for displaying data from a substantially continuous glucose sensor, the system comprising:
a sensor data receiving module configured to receive sensor data including one or more sensor data points from the substantially continuous glucose sensor; and
an interface control module configured to display sensor data on a user interface responsive to a level of stability of the sensor data, wherein the level of stability is based at least in part on an evaluation of sensor data to check at least for an indication of a sensitivity change associated with the substantially continuous glucose sensor.
2. The system of claim 1, wherein the interface control module is configured to display sensor data after a predetermined level of stability has been determined.
3. The system of claim 2, wherein the interface control module is configured to display sensor data only after the predetermined level of stability has been determined.
4. The system of claim 1, wherein the interface control module is configured to alter the user interface based on the stability of the sensor data.
5. The system of claim 4,wherein the interface control module is configured to alter the user interface based on the level of stability of the sensor data.
6. The system of claim 1,wherein the interface control module is configured to provide an indication of the stability of the sensor data.
7. The system of claim 6,wherein the interface control module is configured to provide an indication of the level of stability of the sensor data.
8. The system of claim 6, wherein the indication comprises visual information on the user interface.
9. The system of claim 1, wherein the interface control module is configured to display sensor data in a display format comprising a numeric glucose value, a directional trend of glucose data, and/or a graphical representation of glucose data.
10. The system of claim 9, wherein the interface control module is configured to alter the display format based on the stability of the sensor data.
11. The system of claim 10, wherein the interface control module is configured to selectively alter the display format based on the stability of the sensor data.
12. The system of claim 10, wherein the interface control module is configured to selectively alter the display format based on the level of stability of the sensor data.
13. The system of claim 1, wherein the interface control module is configured to request a fingerstick after a predetermined level of stability is determined.
14. The system of claim 1, wherein the evaluation of sensor data to check at least for the indication of the sensitivity change is based at least in part on an amplitude of a sensitivity associated with the substantially continuous glucose sensor.
15. The system of claim 1, wherein the evaluation of sensor data to check at least for the indication of the sensitivity change is based at least in part on a variability of a sensitivity associated with the substantially continuous glucose sensor.
16. The system of claim 1, wherein the level of stability is determined during initialization of the substantially continuous glucose sensor.
17. The system of claim 1, wherein the level of stability is further based at least in part on a baseline associated with the sensor data.
18. The system of claim 1, wherein the interface control module is configured to display a request for reference glucose value after a predetermined level of stability is determined.
19. A method for displaying data from a substantially continuous glucose sensor, the method comprising:
receiving sensor data including one or more sensor data points from the substantially continuous glucose sensor; and
displaying sensor data on a user interface responsive to a level of stability of the sensor data, wherein the level of stability is determined at least in part by evaluating, using a processor module, sensor data to check at least for an indication of a sensitivity change associated with the substantially continuous glucose sensor.
20. The method of claim 19, wherein displaying sensor data on a user interface responsive to a level of stability of the sensor data comprises displaying sensor data after a predetermined level of stability has been determined.
21. The method of claim 20, wherein displaying sensor data on a user interface responsive to a level of stability of the sensor data comprises displaying sensor data only after the predetermined level of stability has been determined.
22. The method of claim 19, further comprising altering the user interface based on the level of stability of the sensor data.
23. The method of claim 19, further comprising providing an indication of the stability of the sensor data.
24. The method of claim 23, further comprising providing an indication of the level of stability of the sensor data.
25. The method of claim 23, wherein the indication comprises visual information on the user interface.
26. The method of claim 19, wherein displaying sensor data on a user interface responsive to a level of stability of the sensor data comprises displaying the sensor data in a display format comprising a numeric glucose value, a directional trend of glucose data, and/or a graphical representation of glucose data.
27. The method of claim 26, further comprising selectively altering the display format based on the stability of the sensor data.
28. The method of claim 27, further comprising selectively altering the display format based on the level of stability of the sensor data.
29. The method of claim 19, further comprising requesting a fingerstick after a predetermined level of stability is determined.
30. The method of claim 19, wherein evaluating sensor data to check at least for the indication of the a sensitivity change is based at least in part on evaluating an amplitude of a sensitivity associated with the substantially continuous glucose sensor.
31. The method of claim 19, wherein evaluating sensor data to check at least for the indication of the a sensitivity change is based at least in part on evaluating a variability of a sensitivity associated with the substantially continuous glucose sensor.
32. The method of claim 19, wherein the level of stability is determined during initialization of the substantially continuous glucose sensor.
33. The method of claim 19, wherein the level of stability is further based at least in part on a baseline associated with the sensor data.
34. The method of claim 19, further comprising displaying a request for a reference glucose value after a predetermined level of stability is determined.
35. A substantially continuous glucose sensor system, comprising:
a substantially continuous glucose sensor configured to substantially continuously measure a concentration of glucose in a host; and
a computer system configured to receive sensor data associated with the concentration of glucose in the host and configured to process the sensor data to provide displayable sensor data, wherein the computer system is configured to display sensor data on a user interface responsive to a level of stability of the sensor data, wherein the level of stability is based at least in part on an evaluation of sensor data to check at least for an indication of a sensitivity change associated with the substantially continuous glucose sensor.
36. The system of claim 35, wherein the computer system is configured display the sensor data on the user interface when a predetermined level of stability of the substantially continuous glucose sensor is determined.
37. The system of claim 36, wherein the computer system is configured display the sensor data on the user interface only when the predetermined level of stability of the substantially continuous glucose sensor is determined.
38. The system of claim 35, wherein the computer system is configured to alter the user interface based on the level of stability of the sensor data.
39. The system of claim 35, wherein the computer system is configured to provide an indication of the level of stability of the sensor data.
40. The system of claim 39, wherein the indication comprises visual information on the user interface.
41. The system of claim 35, wherein the computer system is configured to display sensor data in a display format comprising a numeric glucose value, a directional trend of glucose data, and/or a graphical representation of glucose data.
42. The system of claim 41, wherein the computer system is configured to alter the display format based on the level of stability of the sensor data.
43. The system of claim 42, wherein the computer system is configured to selectively alter the display format based on the level of stability of the sensor data.
44. The system of claim 35, wherein the computer system is configured to request a fingerstick after a predetermined level of stability is determined.
45. The system of claim 35, wherein the evaluation of sensor data to check at least for the indication of the sensitivity change is based at least in part on an amplitude of a sensitivity associated with the substantially continuous glucose sensor.
46. The system of claim 35, wherein the evaluation of sensor data to check at least for the indication of the sensitivity change is based at least in part on a variability of a sensitivity associated with the substantially continuous glucose sensor.
47. The system of claim 35, wherein the level of stability is determined during initialization of the substantially continuous glucose sensor.
48. The system of claim 35, wherein the level of stability is further based at least in part on a baseline associated with the sensor data.
49. The system of claim 35, wherein the computer system is configured to display a request for reference glucose value after a predetermined level of stability is determined.
US12/730,077 2003-08-01 2010-03-23 System and methods for processing analyte sensor data Expired - Lifetime US8285354B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/730,077 US8285354B2 (en) 2003-08-01 2010-03-23 System and methods for processing analyte sensor data

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/633,367 US7778680B2 (en) 2003-08-01 2003-08-01 System and methods for processing analyte sensor data
US12/730,077 US8285354B2 (en) 2003-08-01 2010-03-23 System and methods for processing analyte sensor data

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/633,367 Continuation US7778680B2 (en) 2003-08-01 2003-08-01 System and methods for processing analyte sensor data

Publications (2)

Publication Number Publication Date
US20100174168A1 US20100174168A1 (en) 2010-07-08
US8285354B2 true US8285354B2 (en) 2012-10-09

Family

ID=42312145

Family Applications (12)

Application Number Title Priority Date Filing Date
US12/730,108 Expired - Lifetime US7986986B2 (en) 2003-08-01 2010-03-23 System and methods for processing analyte sensor data
US12/730,152 Expired - Lifetime US7955261B2 (en) 2003-08-01 2010-03-23 System and methods for processing analyte sensor data
US12/730,077 Expired - Lifetime US8285354B2 (en) 2003-08-01 2010-03-23 System and methods for processing analyte sensor data
US12/730,123 Expired - Lifetime US7925321B2 (en) 2003-08-01 2010-03-23 System and methods for processing analyte sensor data
US12/730,058 Expired - Lifetime US7933639B2 (en) 2003-08-01 2010-03-23 System and methods for processing analyte sensor data
US12/730,144 Expired - Lifetime US7959569B2 (en) 2003-08-01 2010-03-23 System and methods for processing analyte sensor data
US12/730,132 Expired - Lifetime US8332008B2 (en) 2003-08-01 2010-03-23 System and methods for processing analyte sensor data
US12/748,144 Expired - Lifetime US8428679B2 (en) 2003-08-01 2010-03-26 System and methods for processing analyte sensor data
US12/772,849 Expired - Lifetime US7914450B2 (en) 2003-08-01 2010-05-03 System and methods for processing analyte sensor data
US12/772,842 Expired - Lifetime US8290562B2 (en) 2003-08-01 2010-05-03 System and methods for processing analyte sensor data
US12/788,125 Expired - Lifetime US7979104B2 (en) 2003-08-01 2010-05-26 System and methods for processing analyte sensor data
US13/868,766 Abandoned US20130237786A1 (en) 2003-08-01 2013-04-23 System and methods for processing analyte sensor data

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US12/730,108 Expired - Lifetime US7986986B2 (en) 2003-08-01 2010-03-23 System and methods for processing analyte sensor data
US12/730,152 Expired - Lifetime US7955261B2 (en) 2003-08-01 2010-03-23 System and methods for processing analyte sensor data

Family Applications After (9)

Application Number Title Priority Date Filing Date
US12/730,123 Expired - Lifetime US7925321B2 (en) 2003-08-01 2010-03-23 System and methods for processing analyte sensor data
US12/730,058 Expired - Lifetime US7933639B2 (en) 2003-08-01 2010-03-23 System and methods for processing analyte sensor data
US12/730,144 Expired - Lifetime US7959569B2 (en) 2003-08-01 2010-03-23 System and methods for processing analyte sensor data
US12/730,132 Expired - Lifetime US8332008B2 (en) 2003-08-01 2010-03-23 System and methods for processing analyte sensor data
US12/748,144 Expired - Lifetime US8428679B2 (en) 2003-08-01 2010-03-26 System and methods for processing analyte sensor data
US12/772,849 Expired - Lifetime US7914450B2 (en) 2003-08-01 2010-05-03 System and methods for processing analyte sensor data
US12/772,842 Expired - Lifetime US8290562B2 (en) 2003-08-01 2010-05-03 System and methods for processing analyte sensor data
US12/788,125 Expired - Lifetime US7979104B2 (en) 2003-08-01 2010-05-26 System and methods for processing analyte sensor data
US13/868,766 Abandoned US20130237786A1 (en) 2003-08-01 2013-04-23 System and methods for processing analyte sensor data

Country Status (1)

Country Link
US (12) US7986986B2 (en)

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013152090A2 (en) 2012-04-04 2013-10-10 Dexcom, Inc. Transcutaneous analyte sensors, applicators therefor, and associated methods
WO2013184566A2 (en) 2012-06-05 2013-12-12 Dexcom, Inc. Systems and methods for processing analyte data and generating reports
WO2014004460A1 (en) 2012-06-29 2014-01-03 Dexcom, Inc. Use of sensor redundancy to detect sensor failures
WO2014011488A2 (en) 2012-07-09 2014-01-16 Dexcom, Inc. Systems and methods for leveraging smartphone features in continuous glucose monitoring
WO2014052080A1 (en) 2012-09-28 2014-04-03 Dexcom, Inc. Zwitterion surface modifications for continuous sensors
WO2014158327A2 (en) 2013-03-14 2014-10-02 Dexcom, Inc. Advanced calibration for analyte sensors
WO2014158405A2 (en) 2013-03-14 2014-10-02 Dexcom, Inc. Systems and methods for processing and transmitting sensor data
WO2015156966A1 (en) 2014-04-10 2015-10-15 Dexcom, Inc. Sensors for continuous analyte monitoring, and related methods
US10561349B2 (en) 2016-03-31 2020-02-18 Dexcom, Inc. Systems and methods for display device and sensor electronics unit communication
EP3654348A1 (en) 2012-11-07 2020-05-20 Dexcom, Inc. Systems and methods for managing glycemic variability
US10856736B2 (en) 2012-12-31 2020-12-08 Dexcom, Inc. Remote monitoring of analyte measurements
US10860687B2 (en) 2012-12-31 2020-12-08 Dexcom, Inc. Remote monitoring of analyte measurements
US10932672B2 (en) 2015-12-28 2021-03-02 Dexcom, Inc. Systems and methods for remote and host monitoring communications
US10985804B2 (en) 2013-03-14 2021-04-20 Dexcom, Inc. Systems and methods for processing and transmitting sensor data
US11112377B2 (en) 2015-12-30 2021-09-07 Dexcom, Inc. Enzyme immobilized adhesive layer for analyte sensors
EP3925522A1 (en) 2017-06-23 2021-12-22 Dexcom, Inc. Transcutaneous analyte sensors, applicators therefor, and associated methods
US11331022B2 (en) 2017-10-24 2022-05-17 Dexcom, Inc. Pre-connected analyte sensors
US11350862B2 (en) 2017-10-24 2022-06-07 Dexcom, Inc. Pre-connected analyte sensors
EP4046571A1 (en) 2015-10-21 2022-08-24 Dexcom, Inc. Transcutaneous analyte sensors, applicators therefor, and associated methods
US11892426B2 (en) 2012-06-29 2024-02-06 Dexcom, Inc. Devices, systems, and methods to compensate for effects of temperature on implantable sensors
US11998329B2 (en) 2013-03-15 2024-06-04 Dexcom, Inc. Membrane for continuous analyte sensors
USD1036676S1 (en) 2018-06-22 2024-07-23 Dexcom, Inc. Wearable medical monitoring device

Families Citing this family (218)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5593852A (en) 1993-12-02 1997-01-14 Heller; Adam Subcutaneous glucose electrode
US6134461A (en) 1998-03-04 2000-10-17 E. Heller & Company Electrochemical analyte
US8346337B2 (en) 1998-04-30 2013-01-01 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8480580B2 (en) 1998-04-30 2013-07-09 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US6949816B2 (en) 2003-04-21 2005-09-27 Motorola, Inc. Semiconductor component having first surface area for electrically coupling to a semiconductor chip and second surface area for electrically coupling to a substrate, and method of manufacturing same
US8465425B2 (en) * 1998-04-30 2013-06-18 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8688188B2 (en) * 1998-04-30 2014-04-01 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US9066695B2 (en) 1998-04-30 2015-06-30 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8974386B2 (en) 1998-04-30 2015-03-10 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US6175752B1 (en) * 1998-04-30 2001-01-16 Therasense, Inc. Analyte monitoring device and methods of use
US20100288632A1 (en) * 1998-04-30 2010-11-18 Abbott Diabetes Care Inc. Analyte Monitoring Device and Methods of Use
US6560471B1 (en) 2001-01-02 2003-05-06 Therasense, Inc. Analyte monitoring device and methods of use
US8260393B2 (en) 2003-07-25 2012-09-04 Dexcom, Inc. Systems and methods for replacing signal data artifacts in a glucose sensor data stream
US8010174B2 (en) 2003-08-22 2011-08-30 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US7381184B2 (en) 2002-11-05 2008-06-03 Abbott Diabetes Care Inc. Sensor inserter assembly
US8771183B2 (en) * 2004-02-17 2014-07-08 Abbott Diabetes Care Inc. Method and system for providing data communication in continuous glucose monitoring and management system
US7811231B2 (en) 2002-12-31 2010-10-12 Abbott Diabetes Care Inc. Continuous glucose monitoring system and methods of use
US7587287B2 (en) 2003-04-04 2009-09-08 Abbott Diabetes Care Inc. Method and system for transferring analyte test data
US7679407B2 (en) * 2003-04-28 2010-03-16 Abbott Diabetes Care Inc. Method and apparatus for providing peak detection circuitry for data communication systems
US7722536B2 (en) * 2003-07-15 2010-05-25 Abbott Diabetes Care Inc. Glucose measuring device integrated into a holster for a personal area network device
US8060173B2 (en) * 2003-08-01 2011-11-15 Dexcom, Inc. System and methods for processing analyte sensor data
US20190357827A1 (en) 2003-08-01 2019-11-28 Dexcom, Inc. Analyte sensor
US7986986B2 (en) 2003-08-01 2011-07-26 Dexcom, Inc. System and methods for processing analyte sensor data
US20080119703A1 (en) 2006-10-04 2008-05-22 Mark Brister Analyte sensor
US8676287B2 (en) 2003-08-01 2014-03-18 Dexcom, Inc. System and methods for processing analyte sensor data
US7774145B2 (en) 2003-08-01 2010-08-10 Dexcom, Inc. Transcutaneous analyte sensor
US7519408B2 (en) 2003-11-19 2009-04-14 Dexcom, Inc. Integrated receiver for continuous analyte sensor
US8761856B2 (en) 2003-08-01 2014-06-24 Dexcom, Inc. System and methods for processing analyte sensor data
US8626257B2 (en) 2003-08-01 2014-01-07 Dexcom, Inc. Analyte sensor
US8369919B2 (en) 2003-08-01 2013-02-05 Dexcom, Inc. Systems and methods for processing sensor data
US8886273B2 (en) 2003-08-01 2014-11-11 Dexcom, Inc. Analyte sensor
US7920906B2 (en) 2005-03-10 2011-04-05 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US20140121989A1 (en) 2003-08-22 2014-05-01 Dexcom, Inc. Systems and methods for processing analyte sensor data
US7299082B2 (en) 2003-10-31 2007-11-20 Abbott Diabetes Care, Inc. Method of calibrating an analyte-measurement device, and associated methods, devices and systems
USD902408S1 (en) 2003-11-05 2020-11-17 Abbott Diabetes Care Inc. Analyte sensor control unit
US9247900B2 (en) 2004-07-13 2016-02-02 Dexcom, Inc. Analyte sensor
US8423114B2 (en) 2006-10-04 2013-04-16 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
ATE480761T1 (en) 2003-12-05 2010-09-15 Dexcom Inc CALIBRATION METHODS FOR A CONTINUOUSLY WORKING ANALYTICAL SENSOR
US11633133B2 (en) 2003-12-05 2023-04-25 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
EP2301428B1 (en) 2003-12-09 2016-11-30 Dexcom, Inc. Signal processing for continuous analyte sensor
CA3110101A1 (en) 2004-06-04 2005-12-15 Abbott Diabetes Care Inc. Systems and methods for managing diabetes care data
US9044199B2 (en) 2004-07-13 2015-06-02 Dexcom, Inc. Transcutaneous analyte sensor
US7640048B2 (en) 2004-07-13 2009-12-29 Dexcom, Inc. Analyte sensor
US10226207B2 (en) 2004-12-29 2019-03-12 Abbott Diabetes Care Inc. Sensor inserter having introducer
US9398882B2 (en) 2005-09-30 2016-07-26 Abbott Diabetes Care Inc. Method and apparatus for providing analyte sensor and data processing device
US7697967B2 (en) 2005-12-28 2010-04-13 Abbott Diabetes Care Inc. Method and apparatus for providing analyte sensor insertion
US20090105569A1 (en) 2006-04-28 2009-04-23 Abbott Diabetes Care, Inc. Introducer Assembly and Methods of Use
US9351669B2 (en) 2009-09-30 2016-05-31 Abbott Diabetes Care Inc. Interconnect for on-body analyte monitoring device
US7731657B2 (en) 2005-08-30 2010-06-08 Abbott Diabetes Care Inc. Analyte sensor introducer and methods of use
US7883464B2 (en) 2005-09-30 2011-02-08 Abbott Diabetes Care Inc. Integrated transmitter unit and sensor introducer mechanism and methods of use
US9259175B2 (en) 2006-10-23 2016-02-16 Abbott Diabetes Care, Inc. Flexible patch for fluid delivery and monitoring body analytes
US9743862B2 (en) 2011-03-31 2017-08-29 Abbott Diabetes Care Inc. Systems and methods for transcutaneously implanting medical devices
US9788771B2 (en) 2006-10-23 2017-10-17 Abbott Diabetes Care Inc. Variable speed sensor insertion devices and methods of use
US9636450B2 (en) 2007-02-19 2017-05-02 Udo Hoss Pump system modular components for delivering medication and analyte sensing at seperate insertion sites
US8333714B2 (en) 2006-09-10 2012-12-18 Abbott Diabetes Care Inc. Method and system for providing an integrated analyte sensor insertion device and data processing unit
US8512243B2 (en) 2005-09-30 2013-08-20 Abbott Diabetes Care Inc. Integrated introducer and transmitter assembly and methods of use
US8029441B2 (en) 2006-02-28 2011-10-04 Abbott Diabetes Care Inc. Analyte sensor transmitter unit configuration for a data monitoring and management system
US9572534B2 (en) 2010-06-29 2017-02-21 Abbott Diabetes Care Inc. Devices, systems and methods for on-skin or on-body mounting of medical devices
US20100331646A1 (en) * 2009-06-30 2010-12-30 Abbott Diabetes Care Inc. Health Management Devices and Methods
US7545272B2 (en) 2005-02-08 2009-06-09 Therasense, Inc. RF tag on test strips, test strip vials and boxes
US8133178B2 (en) 2006-02-22 2012-03-13 Dexcom, Inc. Analyte sensor
US7768408B2 (en) 2005-05-17 2010-08-03 Abbott Diabetes Care Inc. Method and system for providing data management in data monitoring system
EP1921980A4 (en) 2005-08-31 2010-03-10 Univ Virginia Improving the accuracy of continuous glucose sensors
US8880138B2 (en) 2005-09-30 2014-11-04 Abbott Diabetes Care Inc. Device for channeling fluid and methods of use
US9521968B2 (en) 2005-09-30 2016-12-20 Abbott Diabetes Care Inc. Analyte sensor retention mechanism and methods of use
US7756561B2 (en) * 2005-09-30 2010-07-13 Abbott Diabetes Care Inc. Method and apparatus for providing rechargeable power in data monitoring and management systems
US7583190B2 (en) * 2005-10-31 2009-09-01 Abbott Diabetes Care Inc. Method and apparatus for providing data communication in data monitoring and management systems
CA2636034A1 (en) 2005-12-28 2007-10-25 Abbott Diabetes Care Inc. Medical device insertion
US11298058B2 (en) 2005-12-28 2022-04-12 Abbott Diabetes Care Inc. Method and apparatus for providing analyte sensor insertion
US7736310B2 (en) 2006-01-30 2010-06-15 Abbott Diabetes Care Inc. On-body medical device securement
US7826879B2 (en) 2006-02-28 2010-11-02 Abbott Diabetes Care Inc. Analyte sensors and methods of use
US7885698B2 (en) 2006-02-28 2011-02-08 Abbott Diabetes Care Inc. Method and system for providing continuous calibration of implantable analyte sensors
US7981034B2 (en) 2006-02-28 2011-07-19 Abbott Diabetes Care Inc. Smart messages and alerts for an infusion delivery and management system
US20070260577A1 (en) * 2006-03-30 2007-11-08 Microsoft Corporation Providing COM access to an isolated system
US8224415B2 (en) 2009-01-29 2012-07-17 Abbott Diabetes Care Inc. Method and device for providing offset model based calibration for analyte sensor
US7630748B2 (en) 2006-10-25 2009-12-08 Abbott Diabetes Care Inc. Method and system for providing analyte monitoring
US9326709B2 (en) 2010-03-10 2016-05-03 Abbott Diabetes Care Inc. Systems, devices and methods for managing glucose levels
US8219173B2 (en) 2008-09-30 2012-07-10 Abbott Diabetes Care Inc. Optimizing analyte sensor calibration
US8346335B2 (en) 2008-03-28 2013-01-01 Abbott Diabetes Care Inc. Analyte sensor calibration management
US8473022B2 (en) 2008-01-31 2013-06-25 Abbott Diabetes Care Inc. Analyte sensor with time lag compensation
US7620438B2 (en) 2006-03-31 2009-11-17 Abbott Diabetes Care Inc. Method and system for powering an electronic device
US8140312B2 (en) 2007-05-14 2012-03-20 Abbott Diabetes Care Inc. Method and system for determining analyte levels
US9675290B2 (en) 2012-10-30 2017-06-13 Abbott Diabetes Care Inc. Sensitivity calibration of in vivo sensors used to measure analyte concentration
US8374668B1 (en) 2007-10-23 2013-02-12 Abbott Diabetes Care Inc. Analyte sensor with lag compensation
US8478557B2 (en) 2009-07-31 2013-07-02 Abbott Diabetes Care Inc. Method and apparatus for providing analyte monitoring system calibration accuracy
US9392969B2 (en) 2008-08-31 2016-07-19 Abbott Diabetes Care Inc. Closed loop control and signal attenuation detection
US7618369B2 (en) 2006-10-02 2009-11-17 Abbott Diabetes Care Inc. Method and system for dynamically updating calibration parameters for an analyte sensor
US7653425B2 (en) 2006-08-09 2010-01-26 Abbott Diabetes Care Inc. Method and system for providing calibration of an analyte sensor in an analyte monitoring system
US8583205B2 (en) 2008-03-28 2013-11-12 Abbott Diabetes Care Inc. Analyte sensor calibration management
US7801582B2 (en) 2006-03-31 2010-09-21 Abbott Diabetes Care Inc. Analyte monitoring and management system and methods therefor
US8206296B2 (en) 2006-08-07 2012-06-26 Abbott Diabetes Care Inc. Method and system for providing integrated analyte monitoring and infusion system therapy management
US8932216B2 (en) 2006-08-07 2015-01-13 Abbott Diabetes Care Inc. Method and system for providing data management in integrated analyte monitoring and infusion system
JP2010508091A (en) 2006-10-26 2010-03-18 アボット ダイアベティス ケア インコーポレイテッド Method, system, and computer program product for detecting in real time a decrease in sensitivity of an analyte sensor
US20080199894A1 (en) 2007-02-15 2008-08-21 Abbott Diabetes Care, Inc. Device and method for automatic data acquisition and/or detection
US8732188B2 (en) 2007-02-18 2014-05-20 Abbott Diabetes Care Inc. Method and system for providing contextual based medication dosage determination
US8930203B2 (en) * 2007-02-18 2015-01-06 Abbott Diabetes Care Inc. Multi-function analyte test device and methods therefor
US8123686B2 (en) 2007-03-01 2012-02-28 Abbott Diabetes Care Inc. Method and apparatus for providing rolling data in communication systems
US20080228056A1 (en) 2007-03-13 2008-09-18 Michael Blomquist Basal rate testing using frequent blood glucose input
EP2146624B1 (en) 2007-04-14 2020-03-25 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in medical communication system
WO2008130898A1 (en) 2007-04-14 2008-10-30 Abbott Diabetes Care, Inc. Method and apparatus for providing data processing and control in medical communication system
US8140142B2 (en) * 2007-04-14 2012-03-20 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in medical communication system
WO2008130896A1 (en) 2007-04-14 2008-10-30 Abbott Diabetes Care, Inc. Method and apparatus for providing data processing and control in medical communication system
WO2009096992A1 (en) 2007-04-14 2009-08-06 Abbott Diabetes Care, Inc. Method and apparatus for providing data processing and control in medical communication system
US8461985B2 (en) 2007-05-08 2013-06-11 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US7928850B2 (en) 2007-05-08 2011-04-19 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US20080281179A1 (en) * 2007-05-08 2008-11-13 Abbott Diabetes Care, Inc. Analyte monitoring system and methods
US20080278332A1 (en) * 2007-05-08 2008-11-13 Abbott Diabetes Care, Inc. Analyte monitoring system and methods
US8456301B2 (en) 2007-05-08 2013-06-04 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US8665091B2 (en) 2007-05-08 2014-03-04 Abbott Diabetes Care Inc. Method and device for determining elapsed sensor life
US8103471B2 (en) 2007-05-14 2012-01-24 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8444560B2 (en) 2007-05-14 2013-05-21 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8600681B2 (en) * 2007-05-14 2013-12-03 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US10002233B2 (en) 2007-05-14 2018-06-19 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8560038B2 (en) 2007-05-14 2013-10-15 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8260558B2 (en) 2007-05-14 2012-09-04 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US9125548B2 (en) 2007-05-14 2015-09-08 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8239166B2 (en) 2007-05-14 2012-08-07 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US7751907B2 (en) 2007-05-24 2010-07-06 Smiths Medical Asd, Inc. Expert system for insulin pump therapy
US8221345B2 (en) 2007-05-30 2012-07-17 Smiths Medical Asd, Inc. Insulin pump based expert system
WO2008150917A1 (en) 2007-05-31 2008-12-11 Abbott Diabetes Care, Inc. Insertion devices and methods
US8197650B2 (en) 2007-06-07 2012-06-12 Sensor Innovations, Inc. Silicon electrochemical sensors
WO2008157821A1 (en) * 2007-06-21 2008-12-24 Abbott Diabetes Care, Inc. Health monitor
WO2008157820A1 (en) 2007-06-21 2008-12-24 Abbott Diabetes Care, Inc. Health management devices and methods
US8160900B2 (en) 2007-06-29 2012-04-17 Abbott Diabetes Care Inc. Analyte monitoring and management device and method to analyze the frequency of user interaction with the device
US8834366B2 (en) 2007-07-31 2014-09-16 Abbott Diabetes Care Inc. Method and apparatus for providing analyte sensor calibration
US20090036760A1 (en) * 2007-07-31 2009-02-05 Abbott Diabetes Care, Inc. Method and apparatus for providing data processing and control in a medical communication system
US8409093B2 (en) 2007-10-23 2013-04-02 Abbott Diabetes Care Inc. Assessing measures of glycemic variability
US8216138B1 (en) 2007-10-23 2012-07-10 Abbott Diabetes Care Inc. Correlation of alternative site blood and interstitial fluid glucose concentrations to venous glucose concentration
US8377031B2 (en) 2007-10-23 2013-02-19 Abbott Diabetes Care Inc. Closed loop control system with safety parameters and methods
US8417312B2 (en) 2007-10-25 2013-04-09 Dexcom, Inc. Systems and methods for processing sensor data
US20090164239A1 (en) 2007-12-19 2009-06-25 Abbott Diabetes Care, Inc. Dynamic Display Of Glucose Information
US8986253B2 (en) 2008-01-25 2015-03-24 Tandem Diabetes Care, Inc. Two chamber pumps and related methods
US8591410B2 (en) 2008-05-30 2013-11-26 Abbott Diabetes Care Inc. Method and apparatus for providing glycemic control
US8924159B2 (en) 2008-05-30 2014-12-30 Abbott Diabetes Care Inc. Method and apparatus for providing glycemic control
US7826382B2 (en) 2008-05-30 2010-11-02 Abbott Diabetes Care Inc. Close proximity communication device and methods
WO2010009172A1 (en) 2008-07-14 2010-01-21 Abbott Diabetes Care Inc. Closed loop control system interface and methods
US8734422B2 (en) 2008-08-31 2014-05-27 Abbott Diabetes Care Inc. Closed loop control with improved alarm functions
US20100057040A1 (en) 2008-08-31 2010-03-04 Abbott Diabetes Care, Inc. Robust Closed Loop Control And Methods
US9943644B2 (en) 2008-08-31 2018-04-17 Abbott Diabetes Care Inc. Closed loop control with reference measurement and methods thereof
US8622988B2 (en) * 2008-08-31 2014-01-07 Abbott Diabetes Care Inc. Variable rate closed loop control and methods
WO2010033878A2 (en) 2008-09-19 2010-03-25 David Brown Solute concentration measurement device and related methods
US8986208B2 (en) * 2008-09-30 2015-03-24 Abbott Diabetes Care Inc. Analyte sensor sensitivity attenuation mitigation
US9801575B2 (en) 2011-04-15 2017-10-31 Dexcom, Inc. Advanced analyte sensor calibration and error detection
US9326707B2 (en) 2008-11-10 2016-05-03 Abbott Diabetes Care Inc. Alarm characterization for analyte monitoring devices and systems
US8103456B2 (en) 2009-01-29 2012-01-24 Abbott Diabetes Care Inc. Method and device for early signal attenuation detection using blood glucose measurements
US20100198034A1 (en) 2009-02-03 2010-08-05 Abbott Diabetes Care Inc. Compact On-Body Physiological Monitoring Devices and Methods Thereof
US8497777B2 (en) 2009-04-15 2013-07-30 Abbott Diabetes Care Inc. Analyte monitoring system having an alert
WO2010127050A1 (en) 2009-04-28 2010-11-04 Abbott Diabetes Care Inc. Error detection in critical repeating data in a wireless sensor system
EP2424426B1 (en) 2009-04-29 2020-01-08 Abbott Diabetes Care, Inc. Method and system for providing data communication in continuous glucose monitoring and management system
WO2010127051A1 (en) 2009-04-29 2010-11-04 Abbott Diabetes Care Inc. Method and system for providing real time analyte sensor calibration with retrospective backfill
US9184490B2 (en) 2009-05-29 2015-11-10 Abbott Diabetes Care Inc. Medical device antenna systems having external antenna configurations
EP3932309A1 (en) 2009-07-23 2022-01-05 Abbott Diabetes Care, Inc. Continuous analyte measurement system
EP3936032B1 (en) 2009-07-23 2024-05-29 Abbott Diabetes Care, Inc. Real time management of data relating to physiological control of glucose levels
US8641671B2 (en) 2009-07-30 2014-02-04 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
WO2011026148A1 (en) 2009-08-31 2011-03-03 Abbott Diabetes Care Inc. Analyte monitoring system and methods for managing power and noise
ES2952361T3 (en) 2009-08-31 2023-10-31 Abbott Diabetes Care Inc Displays for a medical device
JP5795584B2 (en) 2009-08-31 2015-10-14 アボット ダイアベティス ケア インコーポレイテッドAbbott Diabetes Care Inc. Medical device
WO2011041469A1 (en) 2009-09-29 2011-04-07 Abbott Diabetes Care Inc. Method and apparatus for providing notification function in analyte monitoring systems
US8185181B2 (en) 2009-10-30 2012-05-22 Abbott Diabetes Care Inc. Method and apparatus for detecting false hypoglycemic conditions
US8882701B2 (en) 2009-12-04 2014-11-11 Smiths Medical Asd, Inc. Advanced step therapy delivery for an ambulatory infusion pump and system
WO2011091336A1 (en) * 2010-01-22 2011-07-28 Abbott Diabetes Care Inc. Method and apparatus for providing notification in analyte monitoring systems
USD924406S1 (en) 2010-02-01 2021-07-06 Abbott Diabetes Care Inc. Analyte sensor inserter
DK3622883T3 (en) 2010-03-24 2021-07-19 Abbott Diabetes Care Inc Introduces medical devices and methods for introducing and using medical devices
US8635046B2 (en) 2010-06-23 2014-01-21 Abbott Diabetes Care Inc. Method and system for evaluating analyte sensor response characteristics
US11064921B2 (en) 2010-06-29 2021-07-20 Abbott Diabetes Care Inc. Devices, systems and methods for on-skin or on-body mounting of medical devices
US10092229B2 (en) 2010-06-29 2018-10-09 Abbott Diabetes Care Inc. Calibration of analyte measurement system
WO2012048168A2 (en) 2010-10-07 2012-04-12 Abbott Diabetes Care Inc. Analyte monitoring devices and methods
WO2012083258A2 (en) 2010-12-16 2012-06-21 Sensor Innovations, Inc. Electrochemical sensors
US20130226603A1 (en) * 2010-12-31 2013-08-29 Stephen Suffin Delivery of Medical Services Based on Observed Parametric Variation in Analyte Values
WO2012154286A1 (en) 2011-02-28 2012-11-15 Abbott Diabetes Care Inc. Devices, systems, and methods associated with analyte monitoring devices and devices incorporating the same
US10136845B2 (en) 2011-02-28 2018-11-27 Abbott Diabetes Care Inc. Devices, systems, and methods associated with analyte monitoring devices and devices incorporating the same
CN102820867A (en) * 2011-06-10 2012-12-12 中国科学院微电子研究所 Method for manufacturing titanium dioxide doped copper phthalocyanine sensitive film of surface acoustic wave sensor
WO2013066873A1 (en) 2011-10-31 2013-05-10 Abbott Diabetes Care Inc. Electronic devices having integrated reset systems and methods thereof
WO2013066849A1 (en) 2011-10-31 2013-05-10 Abbott Diabetes Care Inc. Model based variable risk false glucose threshold alarm prevention mechanism
US9980669B2 (en) 2011-11-07 2018-05-29 Abbott Diabetes Care Inc. Analyte monitoring device and methods
US8710993B2 (en) 2011-11-23 2014-04-29 Abbott Diabetes Care Inc. Mitigating single point failure of devices in an analyte monitoring system and methods thereof
US9317656B2 (en) 2011-11-23 2016-04-19 Abbott Diabetes Care Inc. Compatibility mechanisms for devices in a continuous analyte monitoring system and methods thereof
WO2013078426A2 (en) 2011-11-25 2013-05-30 Abbott Diabetes Care Inc. Analyte monitoring system and methods of use
ES2967952T3 (en) 2011-12-11 2024-05-06 Abbott Diabetes Care Inc Analyte Sensor Devices
US9335910B2 (en) 2012-04-23 2016-05-10 Tandem Diabetes Care, Inc. System and method for reduction of inadvertent activation of medical device during manipulation
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
US9555186B2 (en) 2012-06-05 2017-01-31 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
US9715327B2 (en) 2012-06-07 2017-07-25 Tandem Diabetes Care, Inc. Preventing inadvertent changes in ambulatory medical devices
EP2890297B1 (en) 2012-08-30 2018-04-11 Abbott Diabetes Care, Inc. Dropout detection in continuous analyte monitoring data during data excursions
US9968306B2 (en) 2012-09-17 2018-05-15 Abbott Diabetes Care Inc. Methods and apparatuses for providing adverse condition notification with enhanced wireless communication range in analyte monitoring systems
EP2901153A4 (en) 2012-09-26 2016-04-27 Abbott Diabetes Care Inc Method and apparatus for improving lag correction during in vivo measurement of analyte concentration with analyte concentration variability and range data
US9211092B2 (en) 2013-01-03 2015-12-15 Dexcom, Inc. End of life detection for analyte sensors
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump
US10076285B2 (en) 2013-03-15 2018-09-18 Abbott Diabetes Care Inc. Sensor fault detection using analyte sensor data pattern comparison
US9474475B1 (en) 2013-03-15 2016-10-25 Abbott Diabetes Care Inc. Multi-rate analyte sensor data collection with sample rate configurable signal processing
US10433773B1 (en) 2013-03-15 2019-10-08 Abbott Diabetes Care Inc. Noise rejection methods and apparatus for sparsely sampled analyte sensor data
US9486171B2 (en) 2013-03-15 2016-11-08 Tandem Diabetes Care, Inc. Predictive calibration
WO2015035304A1 (en) 2013-09-06 2015-03-12 Tandem Diabetes Care, Inc. System and method for mitigating risk in automated medicament dosing
CN105899132B (en) 2013-12-31 2020-02-18 雅培糖尿病护理公司 Self-powered analyte sensor and devices using same
EP4151150A1 (en) 2014-03-30 2023-03-22 Abbott Diabetes Care, Inc. Method and apparatus for determining meal start and peak events in analyte monitoring systems
US10238323B2 (en) * 2014-06-06 2019-03-26 Dexcom, Inc. Fault discrimination and responsive processing based on data and context
AU2015320803B2 (en) 2014-09-22 2019-01-03 Dexcom, Inc. System and method for mode switching
WO2016183493A1 (en) 2015-05-14 2016-11-17 Abbott Diabetes Care Inc. Compact medical device inserters and related systems and methods
US10213139B2 (en) 2015-05-14 2019-02-26 Abbott Diabetes Care Inc. Systems, devices, and methods for assembling an applicator and sensor control device
SI3101571T1 (en) * 2015-06-03 2018-06-29 F. Hoffmann-La Roche Ag Measurement system for measuring the concentration of an analyte with a subcutaneous analyte sensor
CN113349766A (en) 2015-07-10 2021-09-07 雅培糖尿病护理公司 System, device and method for dynamic glucose curve response to physiological parameters
US10569016B2 (en) 2015-12-29 2020-02-25 Tandem Diabetes Care, Inc. System and method for switching between closed loop and open loop control of an ambulatory infusion pump
CA3017255C (en) * 2016-05-02 2023-10-24 Dexcom, Inc. System and method for providing alerts optimized for a user
US11071478B2 (en) 2017-01-23 2021-07-27 Abbott Diabetes Care Inc. Systems, devices and methods for analyte sensor insertion
US12109032B1 (en) 2017-03-11 2024-10-08 Biolinq Incorporated Methods for achieving an isolated electrical interface between an anterior surface of a microneedle structure and a posterior surface of a support structure
WO2018175489A1 (en) 2017-03-21 2018-09-27 Abbott Diabetes Care Inc. Methods, devices and system for providing diabetic condition diagnosis and therapy
US11045142B1 (en) 2017-04-29 2021-06-29 Biolinq, Inc. Heterogeneous integration of silicon-fabricated solid microneedle sensors and CMOS circuitry
WO2018204568A1 (en) 2017-05-05 2018-11-08 Eli Lilly And Company Closed loop control of physiological glucose
US11246512B2 (en) * 2017-07-04 2022-02-15 Arkray, Inc. Measuring apparatus, computer readable medium storing measuring program and measuring method
EP4292533A3 (en) * 2017-09-26 2024-05-01 Senseonics, Incorporated Methods and systems for updating lag parameters
CA3085930A1 (en) 2017-12-21 2019-06-27 Eli Lilly And Company Closed loop control of physiological glucose
WO2019157102A1 (en) 2018-02-09 2019-08-15 Dexcom, Inc. System and method for decision support
CA3103479A1 (en) 2018-06-22 2019-12-26 Eli Lilly And Company Insulin and pramlintide delivery systems, methods, and devices
US11464908B2 (en) 2019-02-18 2022-10-11 Tandem Diabetes Care, Inc. Methods and apparatus for monitoring infusion sites for ambulatory infusion pumps
USD1002852S1 (en) 2019-06-06 2023-10-24 Abbott Diabetes Care Inc. Analyte sensor device
KR20230043779A (en) 2020-07-29 2023-03-31 바이오링크 인코포레이티드 Continuous Analyte Monitoring System with Microneedle Array
USD999913S1 (en) 2020-12-21 2023-09-26 Abbott Diabetes Care Inc Analyte sensor inserter
KR20240005085A (en) 2021-05-08 2024-01-11 바이오링크 인코포레이티드 Failure detection in a microneedle array-based continuous analyte monitoring device.

Citations (391)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3210578A (en) 1962-01-12 1965-10-05 Westinghouse Electric Corp Multispeed motor connector
US3219533A (en) 1962-11-29 1965-11-23 Merck & Co Inc Aerosol solid medicament in propellant and low-level ethanol avoiding higher-level ethanol dispersed-solid reflocculation
US3780727A (en) 1972-02-25 1973-12-25 Hoffmann La Roche Cardiac pacer monitoring means with rate and pulse discrimination
US3898984A (en) 1974-02-04 1975-08-12 Us Navy Ambulatory patient monitoring system
US3929971A (en) 1973-03-30 1975-12-30 Research Corp Porous biomaterials and method of making same
US3943918A (en) 1971-12-02 1976-03-16 Tel-Pac, Inc. Disposable physiological telemetric device
US3964974A (en) 1972-09-28 1976-06-22 Merck Patent Gesellschaft Mit Beschrankter Haftung Enzymatic determination of glucose
GB1442303A (en) 1972-09-08 1976-07-14 Radiometer As Cell for electro-chemical analysis
US3979274A (en) 1975-09-24 1976-09-07 The Yellow Springs Instrument Company, Inc. Membrane for enzyme electrodes
US4024312A (en) 1976-06-23 1977-05-17 Johnson & Johnson Pressure-sensitive adhesive tape having extensible and elastic backing composed of a block copolymer
US4076656A (en) 1971-11-30 1978-02-28 Debell & Richardson, Inc. Method of producing porous plastic materials
US4215703A (en) 1978-08-29 1980-08-05 Willson James K V Variable stiffness guide wire
US4240889A (en) 1978-01-28 1980-12-23 Toyo Boseki Kabushiki Kaisha Enzyme electrode provided with immobilized enzyme membrane
US4253469A (en) 1979-04-20 1981-03-03 The Narda Microwave Corporation Implantable temperature probe
US4259540A (en) 1978-05-30 1981-03-31 Bell Telephone Laboratories, Incorporated Filled cables
US4403984A (en) 1979-12-28 1983-09-13 Biotek, Inc. System for demand-based adminstration of insulin
US4415666A (en) 1981-11-05 1983-11-15 Miles Laboratories, Inc. Enzyme electrode membrane
EP0098592A2 (en) 1982-07-06 1984-01-18 Fujisawa Pharmaceutical Co., Ltd. Portable artificial pancreas
US4431004A (en) 1981-10-27 1984-02-14 Bessman Samuel P Implantable glucose sensor
US4436094A (en) 1981-03-09 1984-03-13 Evreka, Inc. Monitor for continuous in vivo measurement of glucose concentration
US4494950A (en) 1982-01-19 1985-01-22 The Johns Hopkins University Plural module medication delivery system
US4506680A (en) 1983-03-17 1985-03-26 Medtronic, Inc. Drug dispensing body implantable lead
USRE31916E (en) 1970-11-10 1985-06-18 Becton Dickinson & Company Electrochemical detection cell
GB2149918A (en) 1983-11-03 1985-06-19 John Anderson Sudden infant death syndrome monitor
US4554927A (en) 1983-08-30 1985-11-26 Thermometrics Inc. Pressure and temperature sensor
US4577642A (en) 1985-02-27 1986-03-25 Medtronic, Inc. Drug dispensing body implantable lead employing molecular sieves and methods of fabrication
USRE32361E (en) 1979-05-14 1987-02-24 Medtronic, Inc. Implantable telemetry transmission system for analog and digital data
US4655880A (en) 1983-08-01 1987-04-07 Case Western Reserve University Apparatus and method for sensing species, substances and substrates using oxidase
US4663824A (en) 1983-07-05 1987-05-12 Matsushita Electric Industrial Co., Ltd. Aluminum electrolytic capacitor and a manufacturing method therefor
US4671288A (en) 1985-06-13 1987-06-09 The Regents Of The University Of California Electrochemical cell sensor for continuous short-term use in tissues and blood
US4680268A (en) 1985-09-18 1987-07-14 Children's Hospital Medical Center Implantable gas-containing biosensor and method for measuring an analyte such as glucose
US4703756A (en) 1986-05-06 1987-11-03 The Regents Of The University Of California Complete glucose monitoring system with an implantable, telemetered sensor module
US4711251A (en) 1980-09-02 1987-12-08 Medtronic, Inc. Body implantable lead
US4731726A (en) 1986-05-19 1988-03-15 Healthware Corporation Patient-operated glucose monitor and diabetes management system
US4757022A (en) 1986-04-15 1988-07-12 Markwell Medical Institute, Inc. Biological fluid measuring device
US4759828A (en) 1987-04-09 1988-07-26 Nova Biomedical Corporation Glucose electrode and method of determining glucose
US4781798A (en) 1985-04-19 1988-11-01 The Regents Of The University Of California Transparent multi-oxygen sensor array and method of using same
US4805625A (en) 1987-07-08 1989-02-21 Ad-Tech Medical Instrument Corporation Sphenoidal electrode and insertion method
EP0107634B1 (en) 1982-10-25 1989-04-12 Lars Gustav Inge Hellgren Enzyme composition for cleaning, the use thereof and preparation of the composition
EP0320109A1 (en) 1987-11-05 1989-06-14 MediSense, Inc. Improved sensing system
US4852573A (en) 1987-12-04 1989-08-01 Kennedy Philip R Implantable neural electrode
US4858615A (en) 1981-11-10 1989-08-22 Sentron V.O.F. Catheter sensor and memory unit
US4871440A (en) 1987-07-06 1989-10-03 Daiken Industries, Ltd. Biosensor
US4890621A (en) 1988-01-19 1990-01-02 Northstar Research Institute, Ltd. Continuous glucose monitoring and a system utilized therefor
US4890620A (en) 1985-09-20 1990-01-02 The Regents Of The University Of California Two-dimensional diffusion glucose substrate sensing electrode
EP0353328A1 (en) 1988-08-03 1990-02-07 Dräger Nederland B.V. A polarographic-amperometric three-electrode sensor
US4907857A (en) 1988-07-25 1990-03-13 Abbott Laboratories Optical fiber distribution system for an optical fiber sensor
US4919141A (en) 1987-01-03 1990-04-24 Institute fur Diabetestechnologie Gemeinnutzige Forschungs- und Entwicklungsgesellschaft mbH Implantable electrochemical sensor
EP0288793A3 (en) 1987-04-22 1990-04-25 Abbott Laboratories Cartridge and methods for performing a solid-phase immunoassay
US4927516A (en) 1986-06-27 1990-05-22 Terumo Kabushiki Kaisha Enzyme sensor
US4944299A (en) 1989-08-08 1990-07-31 Siemens-Pacesetter, Inc. High speed digital telemetry system for implantable device
US4953552A (en) 1989-04-21 1990-09-04 Demarzo Arthur P Blood glucose monitoring system
EP0390390A1 (en) 1989-03-20 1990-10-03 Associated Universities, Inc. Electrochemical biosensor based on immobilized enzymes and redox polymers
EP0352610A3 (en) 1988-07-25 1990-11-28 Abbott Laboratories Fiber-optic physiological probes
US4975636A (en) 1989-05-01 1990-12-04 Hewlett-Packard Company Method and apparatus for selecting and displaying a high resolution window from a main display
US4986671A (en) 1989-04-12 1991-01-22 Luxtron Corporation Three-parameter optical fiber sensor and system
US4988341A (en) 1989-06-05 1991-01-29 Eastman Kodak Company Sterilizing dressing device and method for skin puncture
US4994167A (en) 1986-04-15 1991-02-19 Markwell Medical Institute, Inc. Biological fluid measuring device
US5002572A (en) 1986-09-11 1991-03-26 Picha George J Biological implant with textured surface
FR2656423A1 (en) 1989-12-22 1991-06-28 Rhone Poulenc Chimie Electrochemical biosensor
US5030333A (en) 1984-09-13 1991-07-09 Children's Hospital Medical Center Polarographic method for measuring both analyte and oxygen with the same detecting electrode of an electroenzymatic sensor
EP0352631A3 (en) 1988-07-25 1991-07-10 Abbott Laboratories Optical fiber distribution system for an optical fiber sensor
EP0440044A1 (en) 1990-01-31 1991-08-07 Abbott Laboratories Avoidance of human anti-mouse antibody interference in in vitro diagnostic testing
US5050612A (en) 1989-09-12 1991-09-24 Matsumura Kenneth N Device for computer-assisted monitoring of the body
US5068536A (en) 1989-01-19 1991-11-26 Futrex, Inc. Method for providing custom calibration for near infrared instruments for measurement of blood glucose
US5067491A (en) 1989-12-08 1991-11-26 Becton, Dickinson And Company Barrier coating on blood contacting devices
US5077476A (en) 1990-06-27 1991-12-31 Futrex, Inc. Instrument for non-invasive measurement of blood glucose
US5097834A (en) 1987-02-02 1992-03-24 Avl Ag Process for determining parameters of interest in living organisms
US5101814A (en) 1989-08-11 1992-04-07 Palti Yoram Prof System for monitoring and controlling blood glucose
US5108819A (en) 1990-02-14 1992-04-28 Eli Lilly And Company Thin film electrical component
US5137028A (en) 1989-10-18 1992-08-11 Nishimoto, Co., Ltd. Clinical thermometer for women
US5140985A (en) 1989-12-11 1992-08-25 Schroeder Jon M Noninvasive blood glucose measuring device
US5160418A (en) 1988-07-28 1992-11-03 Cambridge Life Sciences Plc Enzyme electrodes and improvements in the manufacture thereof
US5165407A (en) 1990-04-19 1992-11-24 The University Of Kansas Implantable glucose sensor
US5190041A (en) 1989-08-11 1993-03-02 Palti Yoram Prof System for monitoring and controlling blood glucose
US5198771A (en) 1991-09-03 1993-03-30 Transducer Research, Inc. Potentiostatic apparatus and methods
US5208147A (en) 1988-07-21 1993-05-04 Radiometer A/S Means for measuring a characteristic in a sample fluid
US5243983A (en) 1990-12-14 1993-09-14 Georgia Tech Research Corporation Non-invasive blood glucose measurement system and method using stimulated raman spectroscopy
US5264104A (en) 1989-08-02 1993-11-23 Gregg Brian A Enzyme electrodes
US5266179A (en) 1990-07-20 1993-11-30 Matsushita Electric Industrial Co., Ltd. Quantitative analysis method and its system using a disposable sensor
US5269891A (en) 1989-03-09 1993-12-14 Novo Nordisk A/S Method and apparatus for determination of a constituent in a fluid
EP0323605B1 (en) 1987-12-21 1994-01-26 Abbott Laboratories Chromatographic binding assay devices and methods
US5282848A (en) 1990-08-28 1994-02-01 Meadox Medicals, Inc. Self-supporting woven vascular graft
US5285513A (en) 1992-11-30 1994-02-08 At&T Bell Laboratories Optical fiber cable provided with stabilized waterblocking material
US5287753A (en) 1992-05-02 1994-02-22 Advanced Technology Laboratories, Inc. Continuous display of peak and mean blood flow velocities
US5299571A (en) 1993-01-22 1994-04-05 Eli Lilly And Company Apparatus and method for implantation of sensors
US5304468A (en) 1986-08-13 1994-04-19 Lifescan, Inc. Reagent test strip and apparatus for determination of blood glucose
US5307263A (en) 1992-11-17 1994-04-26 Raya Systems, Inc. Modular microprocessor-based health monitoring system
US5310469A (en) 1991-12-31 1994-05-10 Abbott Laboratories Biosensor with a membrane containing biologically active material
US5316008A (en) 1990-04-06 1994-05-31 Casio Computer Co., Ltd. Measurement of electrocardiographic wave and sphygmus
US5324322A (en) 1992-04-20 1994-06-28 Case Western Reserve University Thin film implantable electrode and method of manufacture
US5331555A (en) 1990-05-11 1994-07-19 Sharp Kabushiki Kaisha Electronic apparatus
US5330521A (en) 1992-06-29 1994-07-19 Cohen Donald M Low resistance implantable electrical leads
US5330634A (en) 1992-08-28 1994-07-19 Via Medical Corporation Calibration solutions useful for analyses of biological fluids and methods employing same
US5337747A (en) 1989-10-06 1994-08-16 Frederic Neftel Implantable device for estimating glucose levels
US5342409A (en) 1990-03-07 1994-08-30 Medtronic, Inc. Position-responsive neuro stimulator
US5343869A (en) 1992-01-29 1994-09-06 Hewlett Packard Company Method and system for monitoring vital signs
US5368224A (en) 1992-10-23 1994-11-29 Nellcor Incorporated Method for reducing ambient noise effects in electronic monitoring instruments
US5372133A (en) 1992-02-05 1994-12-13 N.V. Nederlandsche Apparatenfabriek Nedap Implantable biomedical sensor device, suitable in particular for measuring the concentration of glucose
US5376070A (en) 1992-09-29 1994-12-27 Minimed Inc. Data transfer system for an infusion pump
US5391250A (en) 1994-03-15 1995-02-21 Minimed Inc. Method of fabricating thin film sensors
US5390671A (en) 1994-03-15 1995-02-21 Minimed Inc. Transcutaneous sensor insertion set
US5411647A (en) 1992-11-23 1995-05-02 Eli Lilly And Company Techniques to improve the performance of electrochemical sensors
US5411866A (en) 1993-03-30 1995-05-02 National Research Council Of Canada Method and system for determining bioactive substances
US5429735A (en) 1994-06-27 1995-07-04 Miles Inc. Method of making and amperometric electrodes
US5431160A (en) 1989-07-19 1995-07-11 University Of New Mexico Miniature implantable refillable glucose sensor and material therefor
US5434412A (en) 1992-07-15 1995-07-18 Myron J. Block Non-spectrophotometric measurement of analyte concentrations and optical properties of objects
US5448992A (en) 1992-12-10 1995-09-12 Sunshine Medical Instruments, Inc. Method and apparatus for non-invasive phase sensitive measurement of blood glucose concentration
EP0406473B1 (en) 1989-07-07 1995-09-20 Abbott Laboratories Ion capture reagents and methods for performing binding assays
US5462051A (en) 1994-08-31 1995-10-31 Colin Corporation Medical communication system
US5462064A (en) 1993-12-22 1995-10-31 International Medical Associates, Inc. Integrated system for biological fluid constituent analysis
US5469846A (en) 1992-10-19 1995-11-28 Duquesne University Of The Holy Ghost Implantable non-enzymatic electrochemical glucose sensor
US5474552A (en) 1994-06-27 1995-12-12 Cb-Carmel Biotechnology Ltd. Implantable drug delivery pump
US5484404A (en) 1994-05-06 1996-01-16 Alfred E. Mann Foundation For Scientific Research Replaceable catheter system for physiological sensors, tissue stimulating electrodes and/or implantable fluid delivery systems
EP0424633B1 (en) 1989-10-23 1996-01-17 Abbott Laboratories Automated method and device for performing solid-phase diagnostic assay
US5491474A (en) 1991-05-22 1996-02-13 Polar Electro Oy Telemetric transmitter unit
US5494562A (en) 1994-06-27 1996-02-27 Ciba Corning Diagnostics Corp. Electrochemical sensors
US5496453A (en) 1991-05-17 1996-03-05 Kyoto Daiichi Kagaku Co., Ltd. Biosensor and method of quantitative analysis using the same
US5497772A (en) 1993-11-19 1996-03-12 Alfred E. Mann Foundation For Scientific Research Glucose monitoring system
US5502396A (en) 1993-09-21 1996-03-26 Asulab S.A. Measuring device with connection for a removable sensor
EP0127958B2 (en) 1983-05-05 1996-04-10 MediSense, Inc. Sensor electrode systems
US5507288A (en) 1994-05-05 1996-04-16 Boehringer Mannheim Gmbh Analytical system for monitoring a substance to be analyzed in patient-blood
US5513636A (en) 1994-08-12 1996-05-07 Cb-Carmel Biotechnology Ltd. Implantable sensor chip
EP0467078B1 (en) 1990-07-18 1996-05-08 Abbott Laboratories An analyte-subtitute reagent for use in specific binding assay methods, devices and kits
EP0647849A3 (en) 1986-04-30 1996-05-15 Igen Inc Detecting the presence of analytes in a sample.
US5518601A (en) 1993-04-09 1996-05-21 Ciba Corning Diagnostics Corp. Extended use planar sensors
US5531878A (en) 1992-05-29 1996-07-02 The Victoria University Of Manchester Sensor devices
US5540828A (en) 1987-06-08 1996-07-30 Yacynych; Alexander Method for making electrochemical sensors and biosensors having a polymer modified surface
US5553616A (en) 1993-11-30 1996-09-10 Florida Institute Of Technology Determination of concentrations of biological substances using raman spectroscopy and artificial neural network discriminator
US5569186A (en) 1994-04-25 1996-10-29 Minimed Inc. Closed loop infusion pump system with removable glucose sensor
US5568806A (en) 1995-02-16 1996-10-29 Minimed Inc. Transcutaneous sensor insertion set
US5582184A (en) 1993-10-13 1996-12-10 Integ Incorporated Interstitial fluid collection and constituent measurement
US5584813A (en) 1995-06-07 1996-12-17 Minimed Inc. Subcutaneous injection set
US5586553A (en) 1995-02-16 1996-12-24 Minimed Inc. Transcutaneous sensor insertion set
US5590651A (en) 1995-01-17 1997-01-07 Temple University - Of The Commonwealth System Of Higher Education Breathable liquid elimination analysis
US5624537A (en) 1994-09-20 1997-04-29 The University Of British Columbia - University-Industry Liaison Office Biosensor and interface membrane
US5640470A (en) 1995-03-27 1997-06-17 Abbott Laboratories Fiber-optic detectors with terpolymeric analyte-permeable matrix coating
US5653863A (en) 1995-05-05 1997-08-05 Bayer Corporation Method for reducing bias in amperometric sensors
EP0441252B1 (en) 1990-02-07 1997-09-03 Abbott Laboratories Alkaline phosphatase enzymes having improved specific activity for use in indicator reagents
US5695623A (en) 1989-07-07 1997-12-09 Disetronic Licensing Ag Glucose measuring device
US5711861A (en) 1995-11-22 1998-01-27 Ward; W. Kenneth Device for monitoring changes in analyte concentration
US5730654A (en) 1995-12-18 1998-03-24 Raya Systems, Inc. Multi-player video game for health education
US5743262A (en) 1995-06-07 1998-04-28 Masimo Corporation Blood glucose monitoring system
US5749907A (en) 1997-02-18 1998-05-12 Pacesetter, Inc. System and method for identifying and displaying medical data which violate programmable alarm conditions
US5779665A (en) 1997-05-08 1998-07-14 Minimed Inc. Transdermal introducer assembly
US5781455A (en) 1993-11-02 1998-07-14 Kyoto Daiichi Kagaku Co., Ltd. Article of manufacture comprising computer usable medium for a portable blood sugar value measuring apparatus
CA2127172C (en) 1993-08-05 1998-07-14 Amy H. Chu Analyte detection device and process
EP0563795B1 (en) 1992-03-31 1998-07-22 Dai Nippon Printing Co., Ltd. Enzyme-immobilized electrode, composition for preparation of the same and electrically conductive enzyme
US5791344A (en) 1993-11-19 1998-08-11 Alfred E. Mann Foundation For Scientific Research Patient monitoring system
US5795774A (en) 1996-07-10 1998-08-18 Nec Corporation Biosensor
US5800420A (en) 1994-11-04 1998-09-01 Elan Medical Technologies Limited Analyte-controlled liquid delivery device and analyte monitor
US5806517A (en) 1995-05-26 1998-09-15 The Regents Of The University Of Colorado In vivo electrochemistry computer system and method
US5814599A (en) 1995-08-04 1998-09-29 Massachusetts Insitiute Of Technology Transdermal delivery of encapsulated drugs
US5822715A (en) 1997-01-10 1998-10-13 Health Hero Network Diabetes management system and method for controlling blood glucose
US5836887A (en) 1996-09-19 1998-11-17 Colin Corporation Physical information monitor system having means for determining reference range for abnormality determination, based on moving average of previously obtained values
US5836989A (en) 1996-12-26 1998-11-17 Medtronic, Inc. Method and apparatus for controlling an implanted medical device in a time-dependent manner
US5851197A (en) 1997-02-05 1998-12-22 Minimed Inc. Injector for a subcutaneous infusion set
US5861019A (en) 1997-07-25 1999-01-19 Medtronic Inc. Implantable medical device microstrip telemetry antenna
US5871514A (en) 1997-08-01 1999-02-16 Medtronic, Inc. Attachment apparatus for an implantable medical device employing ultrasonic energy
US5882494A (en) 1995-03-27 1999-03-16 Minimed, Inc. Polyurethane/polyurea compositions containing silicone for biosensor membranes
EP0880936A3 (en) 1997-05-29 1999-03-24 Koji Akai Monitoring physical condition of a patient by telemetry
US5899855A (en) 1992-11-17 1999-05-04 Health Hero Network, Inc. Modular microprocessor-based health monitoring system
FR2760962B1 (en) 1997-03-20 1999-05-14 Sillonville Francis Klefstad REMOTE MEDICAL ASSISTANCE AND SURVEILLANCE SYSTEM
US5904708A (en) 1998-03-19 1999-05-18 Medtronic, Inc. System and method for deriving relative physiologic signals
US5913998A (en) 1995-06-07 1999-06-22 Gore Hybrid Technologies, Inc. Method of making an implantable containment apparatus for a therapeutical device
US5914026A (en) 1997-01-06 1999-06-22 Implanted Biosystems Inc. Implantable sensor employing an auxiliary electrode
US5917346A (en) 1997-09-12 1999-06-29 Alfred E. Mann Foundation Low power current to frequency converter circuit for use in implantable sensors
US5928155A (en) 1997-01-24 1999-07-27 Cardiox Corporation Cardiac output measurement with metabolizable analyte containing fluid
US5933136A (en) 1996-12-23 1999-08-03 Health Hero Network, Inc. Network media access control system for encouraging patient compliance with a treatment plan
US5931814A (en) 1994-10-28 1999-08-03 Hoffmann-La Roche Inc. Dermally affixed injection device
US5944661A (en) 1997-04-16 1999-08-31 Giner, Inc. Potential and diffusion controlled solid electrolyte sensor for continuous measurement of very low levels of transdermal alcohol
US5957903A (en) 1991-10-15 1999-09-28 Advanced Cardiovascular Systems, Inc. Variable stiffness guidewire
US5957854A (en) 1993-09-04 1999-09-28 Besson; Marcus Wireless medical diagnosis and monitoring equipment
US5961451A (en) 1997-04-07 1999-10-05 Motorola, Inc. Noninvasive apparatus having a retaining member to retain a removable biosensor
US5964993A (en) 1996-12-19 1999-10-12 Implanted Biosystems Inc. Glucose sensor
US5965380A (en) 1993-12-02 1999-10-12 E. Heller & Company Subcutaneous glucose electrode
US5971922A (en) 1998-04-07 1999-10-26 Meidensha Electric Mfg Co Ltd System and method for predicting blood glucose level
US5976085A (en) 1995-01-27 1999-11-02 Optical Sensors Incorporated In situ calibration system for sensors located in a physiologic line
US5995860A (en) 1995-07-06 1999-11-30 Thomas Jefferson University Implantable sensor and system for measurement and control of blood constituent levels
US5999848A (en) 1997-09-12 1999-12-07 Alfred E. Mann Foundation Daisy chainable sensors and stimulators for implantation in living tissue
US6001067A (en) 1997-03-04 1999-12-14 Shults; Mark C. Device and method for determining analyte levels
US6001471A (en) 1995-08-11 1999-12-14 3M Innovative Properties Company Removable adhesive tape with controlled sequential release
US6016448A (en) 1998-10-27 2000-01-18 Medtronic, Inc. Multilevel ERI for implantable medical devices
US6027445A (en) 1997-07-17 2000-02-22 Siemens Elema Ab Method for flushing and calibrating a sensor in a body fluid analysis system
JP2000060826A (en) 1998-08-19 2000-02-29 Omron Corp Noninvasive vital component measuring instrument
US6036924A (en) 1997-12-04 2000-03-14 Hewlett-Packard Company Cassette of lancet cartridges for sampling blood
US6049727A (en) 1996-07-08 2000-04-11 Animas Corporation Implantable sensor and system for in vivo measurement and control of fluid constituent levels
US6059946A (en) 1997-04-14 2000-05-09 Matsushita Electric Industrial Co., Ltd. Biosensor
US6063637A (en) 1995-12-13 2000-05-16 California Institute Of Technology Sensors for sugars and other metal binding analytes
US6081736A (en) 1997-10-20 2000-06-27 Alfred E. Mann Foundation Implantable enzyme-based monitoring systems adapted for long term use
US6081735A (en) 1991-03-07 2000-06-27 Masimo Corporation Signal processing apparatus
US6083523A (en) 1991-04-25 2000-07-04 Brown University Research Foundation Implantable biocompatable immunoisolatory vehicle for delivery of selected therapeutic products
US6088608A (en) 1997-10-20 2000-07-11 Alfred E. Mann Foundation Electrochemical sensor and integrity tests therefor
US6091975A (en) 1998-04-01 2000-07-18 Alza Corporation Minimally invasive detecting device
US6093172A (en) 1997-02-05 2000-07-25 Minimed Inc. Injector for a subcutaneous insertion set
US6103033A (en) 1998-03-04 2000-08-15 Therasense, Inc. Process for producing an electrochemical biosensor
US6107083A (en) 1998-08-21 2000-08-22 Bayer Corporation Optical oxidative enzyme-based sensors
US6115634A (en) 1997-04-30 2000-09-05 Medtronic, Inc. Implantable medical device and method of manufacture
US6123827A (en) 1997-01-17 2000-09-26 Via Medical Corporation Method for calibrating sensors used in diagnostic testing
US6134461A (en) 1998-03-04 2000-10-17 E. Heller & Company Electrochemical analyte
US6135978A (en) 1997-06-16 2000-10-24 Medtronic, Inc. System for pancreatic stimulation and glucose measurement
US6144869A (en) 1998-05-13 2000-11-07 Cygnus, Inc. Monitoring of physiological analytes
US6168568B1 (en) 1996-10-04 2001-01-02 Karmel Medical Acoustic Technologies Ltd. Phonopneumograph system
US6167614B1 (en) 1997-10-20 2001-01-02 Micron Technology, Inc. Method of manufacturing and testing an electronic device, and an electronic device
US6175752B1 (en) 1998-04-30 2001-01-16 Therasense, Inc. Analyte monitoring device and methods of use
US6180416B1 (en) 1998-09-30 2001-01-30 Cygnus, Inc. Method and device for predicting physiological values
US6189536B1 (en) 1999-04-15 2001-02-20 Medtronic Inc. Method for protecting implantable devices
US6201980B1 (en) 1998-10-05 2001-03-13 The Regents Of The University Of California Implantable medical sensor system
US6201993B1 (en) 1998-12-09 2001-03-13 Medtronic, Inc. Medical device telemetry receiver having improved noise discrimination
US6206856B1 (en) 1998-11-04 2001-03-27 Sakharam D. Mahurkar Safety syringe
US6208894B1 (en) 1997-02-26 2001-03-27 Alfred E. Mann Foundation For Scientific Research And Advanced Bionics System of implantable devices for monitoring and/or affecting body parameters
US6212424B1 (en) 1998-10-29 2001-04-03 Rio Grande Medical Technologies, Inc. Apparatus and method for determination of the adequacy of dialysis by non-invasive near-infrared spectroscopy
US6214185B1 (en) 1997-04-17 2001-04-10 Avl Medical Instruments Sensor with PVC cover membrane
US6223083B1 (en) 1999-04-16 2001-04-24 Medtronic, Inc. Receiver employing digital filtering for use with an implantable medical device
US6230059B1 (en) 1999-03-17 2001-05-08 Medtronic, Inc. Implantable monitor
US6233471B1 (en) 1998-05-13 2001-05-15 Cygnus, Inc. Signal processing for measurement of physiological analysis
US6233080B1 (en) 1998-08-26 2001-05-15 Ciena Corporation Crosstalk-free signal source for dense wavelength division multiplexed systems
US6241863B1 (en) 1998-04-27 2001-06-05 Harold G. Monbouquette Amperometric biosensors based on redox enzymes
US6248067B1 (en) 1999-02-05 2001-06-19 Minimed Inc. Analyte sensor and holter-type monitor system and method of using the same
US6256522B1 (en) 1992-11-23 2001-07-03 University Of Pittsburgh Of The Commonwealth System Of Higher Education Sensors for continuous monitoring of biochemicals and related method
US6259937B1 (en) 1997-09-12 2001-07-10 Alfred E. Mann Foundation Implantable substrate sensor
US6272364B1 (en) 1998-05-13 2001-08-07 Cygnus, Inc. Method and device for predicting physiological values
US6272480B1 (en) 1997-10-17 2001-08-07 Siemens Aktiengesellschaft Method and arrangement for the neural modelling of a dynamic system with non-linear stochastic behavior
US6275717B1 (en) 1997-06-16 2001-08-14 Elan Corporation, Plc Device and method of calibrating and testing a sensor for in vivo measurement of an analyte
US6293925B1 (en) 1997-12-31 2001-09-25 Minimed Inc. Insertion device for an insertion set and method of using the same
US6299578B1 (en) 1995-12-28 2001-10-09 Cygnus, Inc. Methods for monitoring a physiological analyte
US6302855B1 (en) 1998-05-20 2001-10-16 Novo Nordisk A/S Medical apparatus for use by a patient for medical self treatment of diabetes
US6309884B1 (en) 1997-02-26 2001-10-30 Diasense, Inc. Individual calibration of blood glucose for supporting noninvasive self-monitoring blood glucose
US6312388B1 (en) 1999-03-12 2001-11-06 Cardiac Pacemakers, Inc. Method and system for verifying the integrity of normal sinus rhythm templates
US20010041830A1 (en) 2000-05-08 2001-11-15 Varalli Maurizio Claudio Apparatus for measurment and control of the content of glucose, lactate or other metabolites in biological fluids
US6326160B1 (en) 1998-09-30 2001-12-04 Cygnus, Inc. Microprocessors for use in a device for predicting physiological values
US6325978B1 (en) 1998-08-04 2001-12-04 Ntc Technology Inc. Oxygen monitoring and apparatus
US6329929B1 (en) 1998-12-21 2001-12-11 Medtronic Inc. Telemetry system with phase-locking noise suppressing receiver
US6330464B1 (en) 1998-08-26 2001-12-11 Sensors For Medicine & Science Optical-based sensing devices
US20010051768A1 (en) 1997-10-20 2001-12-13 Joseph H Schulman Implantable enxzyme-based monitoring systems having improved longevity due to improved exterior surfaces
US6343225B1 (en) 1999-09-14 2002-01-29 Implanted Biosystems, Inc. Implantable glucose sensor
US20020026111A1 (en) 2000-08-28 2002-02-28 Neil Ackerman Methods of monitoring glucose levels in a subject and uses thereof
US6366794B1 (en) 1998-11-20 2002-04-02 The University Of Connecticut Generic integrated implantable potentiostat telemetry unit for electrochemical sensors
US6368274B1 (en) 1999-07-01 2002-04-09 Medtronic Minimed, Inc. Reusable analyte sensor site and method of using the same
US6370941B2 (en) 2000-02-03 2002-04-16 Nihon Kohden Corporation Gas sensor and gas sensor system
US20020045808A1 (en) 2000-08-18 2002-04-18 Russell Ford Formulation and manipulation of databases of analyte and associated values
US20020065453A1 (en) 2000-08-18 2002-05-30 Lesho Matthew J. Analyte monitoring device alarm augmentation system
US6405066B1 (en) 2000-03-17 2002-06-11 The Regents Of The University Of California Implantable analyte sensor
US6413393B1 (en) 1999-07-07 2002-07-02 Minimed, Inc. Sensor including UV-absorbing polymer and method of manufacture
US6416651B1 (en) 1999-02-26 2002-07-09 Honeywell Measurex Multi-electrode composition measuring device and method
US6424847B1 (en) * 1999-02-25 2002-07-23 Medtronic Minimed, Inc. Glucose monitor calibration methods
US20020099282A1 (en) 2000-09-22 2002-07-25 Knobbe Edward J. Method and apparatus for real-time estimation of physiological parameters
US20020119711A1 (en) 1997-06-09 2002-08-29 Minimed, Inc. Insertion set for a transcutaneous sensor
US6461496B1 (en) 1998-10-08 2002-10-08 Therasense, Inc. Small volume in vitro analyte sensor with diffusible or non-leachable redox mediator
US20020155615A1 (en) 2001-02-05 2002-10-24 Novikov Igor A. Method of determining concentration of glucose in blood
US6471689B1 (en) 1999-08-16 2002-10-29 Thomas Jefferson University Implantable drug delivery catheter system with capillary interface
US20020161288A1 (en) 2000-02-23 2002-10-31 Medtronic Minimed, Inc. Real time self-adjusting calibration algorithm
US6475750B1 (en) 1999-05-11 2002-11-05 M-Biotech, Inc. Glucose biosensor
US6477392B1 (en) 2000-07-14 2002-11-05 Futrex Inc. Calibration of near infrared quantitative measurement device using optical measurement cross-products
US6481440B2 (en) 1999-09-13 2002-11-19 Medtronic, Inc. Lamina prosthesis for delivery of medical treatment
US20020198513A1 (en) 2000-01-21 2002-12-26 Lebel Ronald J. Ambulatory medical apparatus and method using a robust communication protocol
US6510329B2 (en) 2001-01-24 2003-01-21 Datex-Ohmeda, Inc. Detection of sensor off conditions in a pulse oximeter
US20030023171A1 (en) 2000-02-03 2003-01-30 Katsuhiko Sato Noninvasion biological optical measuring instrument, measured portion holding device, and method for manufacturing the same
US20030028089A1 (en) 2001-07-31 2003-02-06 Galley Paul J. Diabetes management system
US20030032874A1 (en) 2001-07-27 2003-02-13 Dexcom, Inc. Sensor head for use with implantable devices
US6526298B1 (en) 1998-05-18 2003-02-25 Abbott Laboratories Method for the non-invasive determination of analytes in a selected volume of tissue
JP2003508746A (en) 1999-08-31 2003-03-04 シーエムイー テレメトリックス インク. How to calibrate a spectrometer
US6527729B1 (en) 1999-11-10 2003-03-04 Pacesetter, Inc. Method for monitoring patient using acoustic sensor
US20030050546A1 (en) 2001-06-22 2003-03-13 Desai Shashi P. Methods for improving the performance of an analyte monitoring system
US20030060765A1 (en) 2000-02-16 2003-03-27 Arthur Campbell Infusion device menu structure and method of using the same
US6546268B1 (en) 1999-06-02 2003-04-08 Ball Semiconductor, Inc. Glucose sensor
JP2003108679A (en) 2001-09-28 2003-04-11 Toshiba Corp Home treatment patient supporting system and method
US6553241B2 (en) 2000-08-31 2003-04-22 Mallinckrodt Inc. Oximeter sensor with digital memory encoding sensor expiration data
US6551496B1 (en) 2000-03-03 2003-04-22 Ysi Incorporated Microstructured bilateral sensor
US20030076082A1 (en) 2001-10-23 2003-04-24 Morgan Wayne A. Implantable sensor electrodes and electronic circuitry
US20030078560A1 (en) 2001-09-07 2003-04-24 Miller Michael E. Method and system for non-vascular sensor implantation
US20030078481A1 (en) 1999-02-25 2003-04-24 Minimed Inc. Glucose sensor package system
US6558321B1 (en) 1997-03-04 2003-05-06 Dexcom, Inc. Systems and methods for remote monitoring and modulation of medical devices
US6558351B1 (en) 1999-06-03 2003-05-06 Medtronic Minimed, Inc. Closed loop system for controlling insulin infusion
US6560471B1 (en) 2001-01-02 2003-05-06 Therasense, Inc. Analyte monitoring device and methods of use
US6558320B1 (en) 2000-01-20 2003-05-06 Medtronic Minimed, Inc. Handheld personal data assistant (PDA) with a medical device and method of using the same
US6561978B1 (en) 1999-02-12 2003-05-13 Cygnus, Inc. Devices and methods for frequent measurement of an analyte present in a biological system
US20030097082A1 (en) 2001-07-13 2003-05-22 Board Of Regents, The University Of Texas System Methods and apparatuses for navigating the subarachnoid space
US6569521B1 (en) 2000-07-06 2003-05-27 3M Innovative Properties Company Stretch releasing pressure sensitive adhesive tape and articles
US6574490B2 (en) 2001-04-11 2003-06-03 Rio Grande Medical Technologies, Inc. System for non-invasive measurement of glucose in humans
US6579498B1 (en) 1998-03-20 2003-06-17 David Eglise Implantable blood glucose sensor system
US6579690B1 (en) 1997-12-05 2003-06-17 Therasense, Inc. Blood analyte monitoring through subcutaneous measurement
US6585763B1 (en) 1997-10-14 2003-07-01 Vascusense, Inc. Implantable therapeutic device and method
US20030125612A1 (en) 2001-12-27 2003-07-03 Fox James Kelly System for monitoring physiological characteristics
US6589229B1 (en) 2000-07-31 2003-07-08 Becton, Dickinson And Company Wearable, self-contained drug infusion device
US20030130616A1 (en) 1999-06-03 2003-07-10 Medtronic Minimed, Inc. Closed loop system for controlling insulin infusion
US6605072B2 (en) 2000-05-03 2003-08-12 Aspect Medical Systems, Inc. System and method for adaptive drug delivery
US6607509B2 (en) 1997-12-31 2003-08-19 Medtronic Minimed, Inc. Insertion device for an insertion set and method of using the same
US6613379B2 (en) 2001-05-08 2003-09-02 Isense Corp. Implantable analyte sensor
US20030199744A1 (en) 1998-10-08 2003-10-23 Therasense, Inc. Small volume in vitro analyte sensor with diffusible or non-leachable redox mediator
US6642015B2 (en) 2000-12-29 2003-11-04 Minimed Inc. Hydrophilic polymeric material for coating biosensors
US6645181B1 (en) 1998-11-13 2003-11-11 Elan Pharma International Limited Drug delivery systems and methods
US20030212346A1 (en) 2002-05-09 2003-11-13 Vadim V. Yuzhakov Methods of fabricating physiological sample collection devices
US20030212347A1 (en) 2002-05-09 2003-11-13 Borzu Sohrab Devices and methods for accessing and analyzing physiological fluid
US20030211625A1 (en) 2002-04-05 2003-11-13 Cohan Bruce E. Method and apparatus for non-invasive monitoring of blood substances using self-sampled tears
US20030212317A1 (en) 2000-03-29 2003-11-13 Kovatchev Boris P. Method, system, and computer program product for the evaluation of glycemic control in diabetes from self-monitoring data
US6654625B1 (en) 1999-06-18 2003-11-25 Therasense, Inc. Mass transport limited in vivo analyte sensor
US20030217966A1 (en) 2002-05-22 2003-11-27 Dexcom, Inc. Techniques to improve polyurethane membranes for implantable glucose sensors
US20030235817A1 (en) 2002-03-22 2003-12-25 Miroslaw Bartkowiak Microprocessors, devices, and methods for use in analyte monitoring systems
US6673596B1 (en) 1997-11-25 2004-01-06 Ut-Battelle, Llc In vivo biosensor apparatus and method of use
US6673022B1 (en) 1999-08-20 2004-01-06 Innerspace Medical, Inc. Gas column pressure monitoring catheters
US20040010207A1 (en) 2002-07-15 2004-01-15 Flaherty J. Christopher Self-contained, automatic transcutaneous physiologic sensing system
US20040015063A1 (en) 2001-12-21 2004-01-22 Denuzzio John D. Minimally-invasive system and method for monitoring analyte levels
US6683535B1 (en) 2000-08-09 2004-01-27 Alderon Industries, Llc Water detection system and method
EP0995805B9 (en) 1998-10-23 2004-01-28 Pierre Beuret Heat treatment installation for a batch of metallic workpieces
US20040024327A1 (en) 2002-08-01 2004-02-05 Brodnick Donald Eugene Method and apparatus for real time display of filtered electrocardiogram data
US20040030294A1 (en) 2001-11-28 2004-02-12 Mahurkar Sakharam D. Retractable needle single use safety syringe
US6695860B1 (en) 2000-11-13 2004-02-24 Isense Corp. Transcutaneous sensor insertion device
US20040039298A1 (en) 1996-09-04 2004-02-26 Abreu Marcio Marc Noninvasive measurement of chemical substances
US20040039406A1 (en) 1998-06-01 2004-02-26 Jessen Jonh W. Method and apparatus for placing and maintaining a percutaneous tube into a body cavity
US6699188B2 (en) 2000-06-22 2004-03-02 Guidance Interactive Technologies Interactive reward devices and methods
US6699218B2 (en) 2000-11-09 2004-03-02 Insulet Corporation Transcutaneous delivery means
US6702857B2 (en) 2001-07-27 2004-03-09 Dexcom, Inc. Membrane for use with implantable devices
US20040045879A1 (en) 1997-03-04 2004-03-11 Dexcom, Inc. Device and method for determining analyte levels
US20040068230A1 (en) 2002-07-24 2004-04-08 Medtronic Minimed, Inc. System for providing blood glucose measurements to an infusion device
US6721587B2 (en) 2001-02-15 2004-04-13 Regents Of The University Of California Membrane and electrode structure for implantable sensor
EP0885932B1 (en) 1997-06-18 2004-04-14 Crompton Corporation Hydrophilic polysiloxane compositions
US20040078219A1 (en) 2001-12-04 2004-04-22 Kimberly-Clark Worldwide, Inc. Healthcare networks with biosensors
US6731976B2 (en) 1997-09-03 2004-05-04 Medtronic, Inc. Device and method to measure and communicate body parameters
US20040143173A1 (en) 1999-07-01 2004-07-22 Medtronic Minimed, Inc. Reusable analyte sensor site and method of using the same
US20040152187A1 (en) 2002-11-13 2004-08-05 Haight Levoy Golden System, apparatus and method for inferring glucose levels within the peritoneum with implantable sensors
US20040152622A1 (en) 2002-10-11 2004-08-05 Steven Keith System and method for initiating and maintaining continuous, long-term control of a concentration of a substance in a patient using a feedback or model-based controller coupled to a single-needle or multi-needle intradermal (ID) delivery device
US20040167801A1 (en) 1998-04-30 2004-08-26 James Say Analyte monitoring device and methods of use
EP0776628B1 (en) 1995-10-31 2004-09-15 Akitoshi Yoshida Intraocular substance measuring apparatus
US20040186365A1 (en) 2002-12-31 2004-09-23 Therasense, Inc. Continuous glucose monitoring system and methods of use
US20040199059A1 (en) 2003-04-04 2004-10-07 Dexcom, Inc. Optimized sensor geometry for an implantable glucose sensor
US20040219664A1 (en) 2000-05-12 2004-11-04 Therasense, Inc. Electrodes with multilayer membranes and methods of using and making the electrodes
US20050027181A1 (en) 2003-08-01 2005-02-03 Goode Paul V. System and methods for processing analyte sensor data
US20050027182A1 (en) 2001-12-27 2005-02-03 Uzair Siddiqui System for monitoring physiological characteristics
US20050031689A1 (en) 2003-05-21 2005-02-10 Dexcom, Inc. Biointerface membranes incorporating bioactive agents
US20050033132A1 (en) 1997-03-04 2005-02-10 Shults Mark C. Analyte measuring device
US20050038332A1 (en) 2001-12-27 2005-02-17 Frank Saidara System for monitoring physiological characteristics
US20050043598A1 (en) 2003-08-22 2005-02-24 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US20050054909A1 (en) 2003-07-25 2005-03-10 James Petisce Oxygen enhancing membrane systems for implantable devices
US20050051427A1 (en) 2003-07-23 2005-03-10 Brauker James H. Rolled electrode array and its method for manufacture
US20050056552A1 (en) 2003-07-25 2005-03-17 Simpson Peter C. Increasing bias for oxygen production in an electrode system
US6869413B2 (en) 2000-12-22 2005-03-22 Dca Design International Limited Pen-type injector having an electronic control unit
US20050143635A1 (en) 2003-12-05 2005-06-30 Kamath Apurv U. Calibration techniques for a continuous analyte sensor
US20050139489A1 (en) 2003-10-31 2005-06-30 Davies Oliver William H. Method of reducing the effect of direct and mediated interference current in an electrochemical test strip
US20050143675A1 (en) 2003-12-31 2005-06-30 Home Diagnostics, Inc. Integrated diagnostic test system
US20050154271A1 (en) 2003-11-19 2005-07-14 Andrew Rasdal Integrated receiver for continuous analyte sensor
US6925393B1 (en) 1999-11-18 2005-08-02 Roche Diagnostics Gmbh System for the extrapolation of glucose concentration
US20050192557A1 (en) 2004-02-26 2005-09-01 Dexcom Integrated delivery device for continuous glucose sensor
US20050203360A1 (en) 2003-12-09 2005-09-15 Brauker James H. Signal processing for continuous analyte sensor
US20050211571A1 (en) 2002-06-28 2005-09-29 Jurgen Schulein Electrochemical detection method and device
US20050239154A1 (en) 2003-10-31 2005-10-27 Feldman Benjamin J A method of calibrating an analyte-measurement device, and associated methods, devices and systems
US20050242479A1 (en) 2004-05-03 2005-11-03 Petisce James R Implantable analyte sensor
US20050245795A1 (en) 2004-05-03 2005-11-03 Dexcom, Inc. Implantable analyte sensor
US20050245799A1 (en) 2004-05-03 2005-11-03 Dexcom, Inc. Implantable analyte sensor
US20060015024A1 (en) 2004-07-13 2006-01-19 Mark Brister Transcutaneous medical device with variable stiffness
US20060015020A1 (en) 2004-07-06 2006-01-19 Dexcom, Inc. Systems and methods for manufacture of an analyte-measuring device including a membrane system
US20060020188A1 (en) 2004-07-13 2006-01-26 Dexcom, Inc. Transcutaneous analyte sensor
US6991643B2 (en) 2000-12-20 2006-01-31 Usgi Medical Inc. Multi-barbed device for retaining tissue in apposition and methods of use
US6998247B2 (en) 2002-03-08 2006-02-14 Sensys Medical, Inc. Method and apparatus using alternative site glucose determinations to calibrate and maintain noninvasive and implantable analyzers
US20060036144A1 (en) 2004-07-13 2006-02-16 Dexcom, Inc. Transcutaneous analyte sensor
US7025743B2 (en) 1998-08-18 2006-04-11 Medtronic Minimed, Inc. External infusion device with remote programming, bolus estimator and/or vibration alarm capabilities
US20060100588A1 (en) 2004-07-23 2006-05-11 Lennart Brunnberg Needle handling device
US7074307B2 (en) 2003-07-25 2006-07-11 Dexcom, Inc. Electrode systems for electrochemical sensors
US20060183985A1 (en) 2004-07-13 2006-08-17 Mark Brister Analyte sensor
US7098803B2 (en) 1998-10-08 2006-08-29 Medtronic Minimed, Inc. Telemetered characteristic monitor system and method of using the same
US7108778B2 (en) 2003-07-25 2006-09-19 Dexcom, Inc. Electrochemical sensors including electrode systems with increased oxygen generation
US20060222566A1 (en) 2003-08-01 2006-10-05 Brauker James H Transcutaneous analyte sensor
US20060258929A1 (en) 2005-03-10 2006-11-16 Goode Paul V Jr System and methods for processing analyte sensor data for sensor calibration
US20070016381A1 (en) 2003-08-22 2007-01-18 Apurv Kamath Systems and methods for processing analyte sensor data
US20070032706A1 (en) 2003-08-22 2007-02-08 Apurv Kamath Systems and methods for replacing signal artifacts in a glucose sensor data stream
US20070049873A1 (en) 2004-01-26 2007-03-01 Novo Nordisk A/S Impulse chamber for jet delivery device
US7192450B2 (en) 2003-05-21 2007-03-20 Dexcom, Inc. Porous membranes for use with implantable devices
US7248912B2 (en) 2002-10-31 2007-07-24 The Regents Of The University Of California Tissue implantable sensors for measurement of blood solutes
US20070203966A1 (en) 2003-08-01 2007-08-30 Dexcom, Inc. Transcutaneous analyte sensor
US20070208245A1 (en) 2003-08-01 2007-09-06 Brauker James H Transcutaneous analyte sensor
US20070208244A1 (en) 2003-08-01 2007-09-06 Brauker James H Transcutaneous analyte sensor
US20070208246A1 (en) 2003-08-01 2007-09-06 Brauker James H Transcutaneous analyte sensor
US20080033254A1 (en) 2003-07-25 2008-02-07 Dexcom, Inc. Systems and methods for replacing signal data artifacts in a glucose sensor data stream
US20080071158A1 (en) 2006-06-07 2008-03-20 Abbott Diabetes Care, Inc. Analyte monitoring system and method
US20080072663A1 (en) 2006-08-15 2008-03-27 Optiscan Biomedical Corporation Accurate and timely body fluid analysis
US20080193936A1 (en) 2005-03-22 2008-08-14 Enigma Diagnostics Ltd Polymorphism Detection Method
US20080306434A1 (en) 2007-06-08 2008-12-11 Dexcom, Inc. Integrated medicament delivery device for use with continuous analyte sensor
US20090156924A1 (en) 2007-12-17 2009-06-18 Dexcom, Inc. Systems and methods for processing sensor data
US20090182217A1 (en) 2003-12-05 2009-07-16 Dexcom, Inc. Analyte sensor
US20090192380A1 (en) 2003-07-25 2009-07-30 Dexcom, Inc. Systems and methods for processing sensor data
US20090192745A1 (en) 2003-08-01 2009-07-30 Dexcom, Inc. Systems and methods for processing sensor data
US20090192366A1 (en) 2007-12-17 2009-07-30 Dexcom, Inc Systems and methods for processing sensor data
US20090192751A1 (en) 2007-10-25 2009-07-30 Dexcom, Inc. Systems and methods for processing sensor data
US20090216103A1 (en) 2004-07-13 2009-08-27 Dexcom, Inc. Transcutaneous analyte sensor
US20090240193A1 (en) 2008-02-21 2009-09-24 Dexcom, Inc. Systems and methods for customizing delivery of sensor data
US20090247857A1 (en) 2008-03-28 2009-10-01 Abbott Diabetes Care, Inc. Analyte Sensor Calibration Management
US20090242399A1 (en) 2008-03-25 2009-10-01 Dexcom, Inc. Analyte sensor
US20090242425A1 (en) 2008-03-25 2009-10-01 Dexcom, Inc. Analyte sensor
US20090264856A1 (en) 2001-09-07 2009-10-22 Medronic MiniMed, Inc. Safety limits for closed-loop infusion pump control
US7647237B2 (en) 1998-04-29 2010-01-12 Minimed, Inc. Communication station and software for interfacing with an infusion pump, analyte monitor, analyte meter, or the like
US20100174168A1 (en) 2003-08-01 2010-07-08 Dexcom, Inc. System and methods for processing analyte sensor data

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6340532A (en) 1986-04-05 1988-02-20 日本光電工業株式会社 Apparatus for monitoring blood component
US5807247A (en) 1995-12-20 1998-09-15 Nellcor Puritan Bennett Incorporated Method and apparatus for facilitating compatibility between pulse oximeters and sensor probes
US6311175B1 (en) 1998-03-06 2001-10-30 Perot Systems Corp. System and method for generating performance models of complex information technology systems
US6684090B2 (en) 1999-01-07 2004-01-27 Masimo Corporation Pulse oximetry data confidence indicator
US20030208113A1 (en) * 2001-07-18 2003-11-06 Mault James R Closed loop glycemic index system
US6788965B2 (en) 2001-08-03 2004-09-07 Sensys Medical, Inc. Intelligent system for detecting errors and determining failure modes in noninvasive measurement of blood and tissue analytes
US8761856B2 (en) 2003-08-01 2014-06-24 Dexcom, Inc. System and methods for processing analyte sensor data
US6999848B2 (en) * 2003-12-19 2006-02-14 Intel Corporation Process control apparatus, systems, and methods
JP4866424B2 (en) 2005-10-25 2012-02-01 キャディ サイエンティフィック プライベート リミテッド System for measuring and tracking at least one physiological parameter and measuring device for doing so
CA2689459A1 (en) 2007-06-11 2009-01-08 Cesaroni Technology Incorporated Body temperature controlling system
US20090062645A1 (en) 2007-09-03 2009-03-05 Jens Fehre Method for diagnosis and treatment of prostate cancer

Patent Citations (535)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3210578A (en) 1962-01-12 1965-10-05 Westinghouse Electric Corp Multispeed motor connector
US3219533A (en) 1962-11-29 1965-11-23 Merck & Co Inc Aerosol solid medicament in propellant and low-level ethanol avoiding higher-level ethanol dispersed-solid reflocculation
USRE31916E (en) 1970-11-10 1985-06-18 Becton Dickinson & Company Electrochemical detection cell
US4076656A (en) 1971-11-30 1978-02-28 Debell & Richardson, Inc. Method of producing porous plastic materials
US3943918A (en) 1971-12-02 1976-03-16 Tel-Pac, Inc. Disposable physiological telemetric device
US3780727A (en) 1972-02-25 1973-12-25 Hoffmann La Roche Cardiac pacer monitoring means with rate and pulse discrimination
GB1442303A (en) 1972-09-08 1976-07-14 Radiometer As Cell for electro-chemical analysis
US3964974A (en) 1972-09-28 1976-06-22 Merck Patent Gesellschaft Mit Beschrankter Haftung Enzymatic determination of glucose
US3929971A (en) 1973-03-30 1975-12-30 Research Corp Porous biomaterials and method of making same
US3898984A (en) 1974-02-04 1975-08-12 Us Navy Ambulatory patient monitoring system
US3979274A (en) 1975-09-24 1976-09-07 The Yellow Springs Instrument Company, Inc. Membrane for enzyme electrodes
US4024312A (en) 1976-06-23 1977-05-17 Johnson & Johnson Pressure-sensitive adhesive tape having extensible and elastic backing composed of a block copolymer
US4240889A (en) 1978-01-28 1980-12-23 Toyo Boseki Kabushiki Kaisha Enzyme electrode provided with immobilized enzyme membrane
US4259540A (en) 1978-05-30 1981-03-31 Bell Telephone Laboratories, Incorporated Filled cables
US4215703A (en) 1978-08-29 1980-08-05 Willson James K V Variable stiffness guide wire
US4253469A (en) 1979-04-20 1981-03-03 The Narda Microwave Corporation Implantable temperature probe
USRE32361E (en) 1979-05-14 1987-02-24 Medtronic, Inc. Implantable telemetry transmission system for analog and digital data
US4403984A (en) 1979-12-28 1983-09-13 Biotek, Inc. System for demand-based adminstration of insulin
US4711251B1 (en) 1980-09-02 1994-06-28 Medtronic Inc Body implantable lead
US4711251A (en) 1980-09-02 1987-12-08 Medtronic, Inc. Body implantable lead
US4436094A (en) 1981-03-09 1984-03-13 Evreka, Inc. Monitor for continuous in vivo measurement of glucose concentration
US4431004A (en) 1981-10-27 1984-02-14 Bessman Samuel P Implantable glucose sensor
US4415666A (en) 1981-11-05 1983-11-15 Miles Laboratories, Inc. Enzyme electrode membrane
US4858615A (en) 1981-11-10 1989-08-22 Sentron V.O.F. Catheter sensor and memory unit
US4494950A (en) 1982-01-19 1985-01-22 The Johns Hopkins University Plural module medication delivery system
EP0098592A2 (en) 1982-07-06 1984-01-18 Fujisawa Pharmaceutical Co., Ltd. Portable artificial pancreas
EP0107634B1 (en) 1982-10-25 1989-04-12 Lars Gustav Inge Hellgren Enzyme composition for cleaning, the use thereof and preparation of the composition
US4506680A (en) 1983-03-17 1985-03-26 Medtronic, Inc. Drug dispensing body implantable lead
EP0127958B2 (en) 1983-05-05 1996-04-10 MediSense, Inc. Sensor electrode systems
US4663824A (en) 1983-07-05 1987-05-12 Matsushita Electric Industrial Co., Ltd. Aluminum electrolytic capacitor and a manufacturing method therefor
US4655880A (en) 1983-08-01 1987-04-07 Case Western Reserve University Apparatus and method for sensing species, substances and substrates using oxidase
US4554927A (en) 1983-08-30 1985-11-26 Thermometrics Inc. Pressure and temperature sensor
GB2149918A (en) 1983-11-03 1985-06-19 John Anderson Sudden infant death syndrome monitor
US5030333A (en) 1984-09-13 1991-07-09 Children's Hospital Medical Center Polarographic method for measuring both analyte and oxygen with the same detecting electrode of an electroenzymatic sensor
US4577642A (en) 1985-02-27 1986-03-25 Medtronic, Inc. Drug dispensing body implantable lead employing molecular sieves and methods of fabrication
US4781798A (en) 1985-04-19 1988-11-01 The Regents Of The University Of California Transparent multi-oxygen sensor array and method of using same
US4671288A (en) 1985-06-13 1987-06-09 The Regents Of The University Of California Electrochemical cell sensor for continuous short-term use in tissues and blood
US4721677A (en) 1985-09-18 1988-01-26 Children's Hospital Medical Center Implantable gas-containing biosensor and method for measuring an analyte such as glucose
US4680268A (en) 1985-09-18 1987-07-14 Children's Hospital Medical Center Implantable gas-containing biosensor and method for measuring an analyte such as glucose
US4890620A (en) 1985-09-20 1990-01-02 The Regents Of The University Of California Two-dimensional diffusion glucose substrate sensing electrode
US4994167A (en) 1986-04-15 1991-02-19 Markwell Medical Institute, Inc. Biological fluid measuring device
US4757022A (en) 1986-04-15 1988-07-12 Markwell Medical Institute, Inc. Biological fluid measuring device
EP0647849A3 (en) 1986-04-30 1996-05-15 Igen Inc Detecting the presence of analytes in a sample.
US4703756A (en) 1986-05-06 1987-11-03 The Regents Of The University Of California Complete glucose monitoring system with an implantable, telemetered sensor module
US4731726A (en) 1986-05-19 1988-03-15 Healthware Corporation Patient-operated glucose monitor and diabetes management system
US4927516A (en) 1986-06-27 1990-05-22 Terumo Kabushiki Kaisha Enzyme sensor
US5304468A (en) 1986-08-13 1994-04-19 Lifescan, Inc. Reagent test strip and apparatus for determination of blood glucose
US5002572A (en) 1986-09-11 1991-03-26 Picha George J Biological implant with textured surface
US4919141A (en) 1987-01-03 1990-04-24 Institute fur Diabetestechnologie Gemeinnutzige Forschungs- und Entwicklungsgesellschaft mbH Implantable electrochemical sensor
US5097834A (en) 1987-02-02 1992-03-24 Avl Ag Process for determining parameters of interest in living organisms
EP0286118B1 (en) 1987-04-09 1995-01-25 Nova Biomedical Corporation Glucose electrode and method of determining glucose
US4759828A (en) 1987-04-09 1988-07-26 Nova Biomedical Corporation Glucose electrode and method of determining glucose
EP0288793A3 (en) 1987-04-22 1990-04-25 Abbott Laboratories Cartridge and methods for performing a solid-phase immunoassay
US5540828A (en) 1987-06-08 1996-07-30 Yacynych; Alexander Method for making electrochemical sensors and biosensors having a polymer modified surface
US4871440A (en) 1987-07-06 1989-10-03 Daiken Industries, Ltd. Biosensor
US4805625A (en) 1987-07-08 1989-02-21 Ad-Tech Medical Instrument Corporation Sphenoidal electrode and insertion method
EP0320109A1 (en) 1987-11-05 1989-06-14 MediSense, Inc. Improved sensing system
US4852573A (en) 1987-12-04 1989-08-01 Kennedy Philip R Implantable neural electrode
EP0323605B1 (en) 1987-12-21 1994-01-26 Abbott Laboratories Chromatographic binding assay devices and methods
US4890621A (en) 1988-01-19 1990-01-02 Northstar Research Institute, Ltd. Continuous glucose monitoring and a system utilized therefor
US5208147A (en) 1988-07-21 1993-05-04 Radiometer A/S Means for measuring a characteristic in a sample fluid
EP0352610A3 (en) 1988-07-25 1990-11-28 Abbott Laboratories Fiber-optic physiological probes
US4907857A (en) 1988-07-25 1990-03-13 Abbott Laboratories Optical fiber distribution system for an optical fiber sensor
EP0352631A3 (en) 1988-07-25 1991-07-10 Abbott Laboratories Optical fiber distribution system for an optical fiber sensor
US5160418A (en) 1988-07-28 1992-11-03 Cambridge Life Sciences Plc Enzyme electrodes and improvements in the manufacture thereof
EP0353328A1 (en) 1988-08-03 1990-02-07 Dräger Nederland B.V. A polarographic-amperometric three-electrode sensor
US5068536A (en) 1989-01-19 1991-11-26 Futrex, Inc. Method for providing custom calibration for near infrared instruments for measurement of blood glucose
US5269891A (en) 1989-03-09 1993-12-14 Novo Nordisk A/S Method and apparatus for determination of a constituent in a fluid
EP0390390A1 (en) 1989-03-20 1990-10-03 Associated Universities, Inc. Electrochemical biosensor based on immobilized enzymes and redox polymers
US4986671A (en) 1989-04-12 1991-01-22 Luxtron Corporation Three-parameter optical fiber sensor and system
US4953552A (en) 1989-04-21 1990-09-04 Demarzo Arthur P Blood glucose monitoring system
US4975636A (en) 1989-05-01 1990-12-04 Hewlett-Packard Company Method and apparatus for selecting and displaying a high resolution window from a main display
US4988341A (en) 1989-06-05 1991-01-29 Eastman Kodak Company Sterilizing dressing device and method for skin puncture
EP0406473B1 (en) 1989-07-07 1995-09-20 Abbott Laboratories Ion capture reagents and methods for performing binding assays
US5695623A (en) 1989-07-07 1997-12-09 Disetronic Licensing Ag Glucose measuring device
US5431160A (en) 1989-07-19 1995-07-11 University Of New Mexico Miniature implantable refillable glucose sensor and material therefor
US5264104A (en) 1989-08-02 1993-11-23 Gregg Brian A Enzyme electrodes
US4944299A (en) 1989-08-08 1990-07-31 Siemens-Pacesetter, Inc. High speed digital telemetry system for implantable device
US5190041A (en) 1989-08-11 1993-03-02 Palti Yoram Prof System for monitoring and controlling blood glucose
US5101814A (en) 1989-08-11 1992-04-07 Palti Yoram Prof System for monitoring and controlling blood glucose
US5050612A (en) 1989-09-12 1991-09-24 Matsumura Kenneth N Device for computer-assisted monitoring of the body
US5337747A (en) 1989-10-06 1994-08-16 Frederic Neftel Implantable device for estimating glucose levels
US5137028A (en) 1989-10-18 1992-08-11 Nishimoto, Co., Ltd. Clinical thermometer for women
EP0424633B1 (en) 1989-10-23 1996-01-17 Abbott Laboratories Automated method and device for performing solid-phase diagnostic assay
US5067491A (en) 1989-12-08 1991-11-26 Becton, Dickinson And Company Barrier coating on blood contacting devices
US5140985A (en) 1989-12-11 1992-08-25 Schroeder Jon M Noninvasive blood glucose measuring device
FR2656423A1 (en) 1989-12-22 1991-06-28 Rhone Poulenc Chimie Electrochemical biosensor
EP0440044A1 (en) 1990-01-31 1991-08-07 Abbott Laboratories Avoidance of human anti-mouse antibody interference in in vitro diagnostic testing
EP0441252B1 (en) 1990-02-07 1997-09-03 Abbott Laboratories Alkaline phosphatase enzymes having improved specific activity for use in indicator reagents
US5108819A (en) 1990-02-14 1992-04-28 Eli Lilly And Company Thin film electrical component
US5342409A (en) 1990-03-07 1994-08-30 Medtronic, Inc. Position-responsive neuro stimulator
US5316008A (en) 1990-04-06 1994-05-31 Casio Computer Co., Ltd. Measurement of electrocardiographic wave and sphygmus
US5165407A (en) 1990-04-19 1992-11-24 The University Of Kansas Implantable glucose sensor
US5331555A (en) 1990-05-11 1994-07-19 Sharp Kabushiki Kaisha Electronic apparatus
US5077476A (en) 1990-06-27 1991-12-31 Futrex, Inc. Instrument for non-invasive measurement of blood glucose
EP0467078B1 (en) 1990-07-18 1996-05-08 Abbott Laboratories An analyte-subtitute reagent for use in specific binding assay methods, devices and kits
US5266179A (en) 1990-07-20 1993-11-30 Matsushita Electric Industrial Co., Ltd. Quantitative analysis method and its system using a disposable sensor
US5282848A (en) 1990-08-28 1994-02-01 Meadox Medicals, Inc. Self-supporting woven vascular graft
US5243983A (en) 1990-12-14 1993-09-14 Georgia Tech Research Corporation Non-invasive blood glucose measurement system and method using stimulated raman spectroscopy
US20030134347A1 (en) 1991-03-04 2003-07-17 Therasense, Inc. Subcutaneous glucose electrode
US20020042090A1 (en) 1991-03-04 2002-04-11 Therasense, Inc. Subcutaneous glucose electrode
US6081735A (en) 1991-03-07 2000-06-27 Masimo Corporation Signal processing apparatus
US6083523A (en) 1991-04-25 2000-07-04 Brown University Research Foundation Implantable biocompatable immunoisolatory vehicle for delivery of selected therapeutic products
US5496453A (en) 1991-05-17 1996-03-05 Kyoto Daiichi Kagaku Co., Ltd. Biosensor and method of quantitative analysis using the same
US5491474A (en) 1991-05-22 1996-02-13 Polar Electro Oy Telemetric transmitter unit
US5198771A (en) 1991-09-03 1993-03-30 Transducer Research, Inc. Potentiostatic apparatus and methods
US5957903A (en) 1991-10-15 1999-09-28 Advanced Cardiovascular Systems, Inc. Variable stiffness guidewire
US5310469A (en) 1991-12-31 1994-05-10 Abbott Laboratories Biosensor with a membrane containing biologically active material
US5343869A (en) 1992-01-29 1994-09-06 Hewlett Packard Company Method and system for monitoring vital signs
US5372133A (en) 1992-02-05 1994-12-13 N.V. Nederlandsche Apparatenfabriek Nedap Implantable biomedical sensor device, suitable in particular for measuring the concentration of glucose
EP0563795B1 (en) 1992-03-31 1998-07-22 Dai Nippon Printing Co., Ltd. Enzyme-immobilized electrode, composition for preparation of the same and electrically conductive enzyme
US5324322A (en) 1992-04-20 1994-06-28 Case Western Reserve University Thin film implantable electrode and method of manufacture
US5287753A (en) 1992-05-02 1994-02-22 Advanced Technology Laboratories, Inc. Continuous display of peak and mean blood flow velocities
US5531878A (en) 1992-05-29 1996-07-02 The Victoria University Of Manchester Sensor devices
US5330521A (en) 1992-06-29 1994-07-19 Cohen Donald M Low resistance implantable electrical leads
US5434412A (en) 1992-07-15 1995-07-18 Myron J. Block Non-spectrophotometric measurement of analyte concentrations and optical properties of objects
US5330634A (en) 1992-08-28 1994-07-19 Via Medical Corporation Calibration solutions useful for analyses of biological fluids and methods employing same
US5376070A (en) 1992-09-29 1994-12-27 Minimed Inc. Data transfer system for an infusion pump
US5469846A (en) 1992-10-19 1995-11-28 Duquesne University Of The Holy Ghost Implantable non-enzymatic electrochemical glucose sensor
US5368224A (en) 1992-10-23 1994-11-29 Nellcor Incorporated Method for reducing ambient noise effects in electronic monitoring instruments
US5899855A (en) 1992-11-17 1999-05-04 Health Hero Network, Inc. Modular microprocessor-based health monitoring system
US5307263A (en) 1992-11-17 1994-04-26 Raya Systems, Inc. Modular microprocessor-based health monitoring system
US6256522B1 (en) 1992-11-23 2001-07-03 University Of Pittsburgh Of The Commonwealth System Of Higher Education Sensors for continuous monitoring of biochemicals and related method
US5411647A (en) 1992-11-23 1995-05-02 Eli Lilly And Company Techniques to improve the performance of electrochemical sensors
US5285513A (en) 1992-11-30 1994-02-08 At&T Bell Laboratories Optical fiber cable provided with stabilized waterblocking material
US5448992A (en) 1992-12-10 1995-09-12 Sunshine Medical Instruments, Inc. Method and apparatus for non-invasive phase sensitive measurement of blood glucose concentration
US5299571A (en) 1993-01-22 1994-04-05 Eli Lilly And Company Apparatus and method for implantation of sensors
US5411866A (en) 1993-03-30 1995-05-02 National Research Council Of Canada Method and system for determining bioactive substances
US5518601A (en) 1993-04-09 1996-05-21 Ciba Corning Diagnostics Corp. Extended use planar sensors
CA2127172C (en) 1993-08-05 1998-07-14 Amy H. Chu Analyte detection device and process
US5957854A (en) 1993-09-04 1999-09-28 Besson; Marcus Wireless medical diagnosis and monitoring equipment
US5502396A (en) 1993-09-21 1996-03-26 Asulab S.A. Measuring device with connection for a removable sensor
US5582184A (en) 1993-10-13 1996-12-10 Integ Incorporated Interstitial fluid collection and constituent measurement
US5781455A (en) 1993-11-02 1998-07-14 Kyoto Daiichi Kagaku Co., Ltd. Article of manufacture comprising computer usable medium for a portable blood sugar value measuring apparatus
US5660163A (en) 1993-11-19 1997-08-26 Alfred E. Mann Foundation For Scientific Research Glucose sensor assembly
US5791344A (en) 1993-11-19 1998-08-11 Alfred E. Mann Foundation For Scientific Research Patient monitoring system
US5497772A (en) 1993-11-19 1996-03-12 Alfred E. Mann Foundation For Scientific Research Glucose monitoring system
US5553616A (en) 1993-11-30 1996-09-10 Florida Institute Of Technology Determination of concentrations of biological substances using raman spectroscopy and artificial neural network discriminator
US6284478B1 (en) 1993-12-02 2001-09-04 E. Heller & Company Subcutaneous glucose electrode
US6083710A (en) 1993-12-02 2000-07-04 E. Heller & Company Electrochemical analyte measurement system
US6329161B1 (en) 1993-12-02 2001-12-11 Therasense, Inc. Subcutaneous glucose electrode
US6121009A (en) 1993-12-02 2000-09-19 E. Heller & Company Electrochemical analyte measurement system
US6162611A (en) 1993-12-02 2000-12-19 E. Heller & Company Subcutaneous glucose electrode
US5965380A (en) 1993-12-02 1999-10-12 E. Heller & Company Subcutaneous glucose electrode
US5462064A (en) 1993-12-22 1995-10-31 International Medical Associates, Inc. Integrated system for biological fluid constituent analysis
US5390671A (en) 1994-03-15 1995-02-21 Minimed Inc. Transcutaneous sensor insertion set
US5391250A (en) 1994-03-15 1995-02-21 Minimed Inc. Method of fabricating thin film sensors
US5569186A (en) 1994-04-25 1996-10-29 Minimed Inc. Closed loop infusion pump system with removable glucose sensor
US5507288B1 (en) 1994-05-05 1997-07-08 Boehringer Mannheim Gmbh Analytical system for monitoring a substance to be analyzed in patient-blood
US5507288A (en) 1994-05-05 1996-04-16 Boehringer Mannheim Gmbh Analytical system for monitoring a substance to be analyzed in patient-blood
US5484404A (en) 1994-05-06 1996-01-16 Alfred E. Mann Foundation For Scientific Research Replaceable catheter system for physiological sensors, tissue stimulating electrodes and/or implantable fluid delivery systems
US5474552A (en) 1994-06-27 1995-12-12 Cb-Carmel Biotechnology Ltd. Implantable drug delivery pump
US5429735A (en) 1994-06-27 1995-07-04 Miles Inc. Method of making and amperometric electrodes
US5494562A (en) 1994-06-27 1996-02-27 Ciba Corning Diagnostics Corp. Electrochemical sensors
US5513636A (en) 1994-08-12 1996-05-07 Cb-Carmel Biotechnology Ltd. Implantable sensor chip
US5462051A (en) 1994-08-31 1995-10-31 Colin Corporation Medical communication system
US5624537A (en) 1994-09-20 1997-04-29 The University Of British Columbia - University-Industry Liaison Office Biosensor and interface membrane
US5931814A (en) 1994-10-28 1999-08-03 Hoffmann-La Roche Inc. Dermally affixed injection device
US5807375A (en) 1994-11-04 1998-09-15 Elan Medical Technologies Limited Analyte-controlled liquid delivery device and analyte monitor
US5800420A (en) 1994-11-04 1998-09-01 Elan Medical Technologies Limited Analyte-controlled liquid delivery device and analyte monitor
US5590651A (en) 1995-01-17 1997-01-07 Temple University - Of The Commonwealth System Of Higher Education Breathable liquid elimination analysis
US5976085A (en) 1995-01-27 1999-11-02 Optical Sensors Incorporated In situ calibration system for sensors located in a physiologic line
US5586553A (en) 1995-02-16 1996-12-24 Minimed Inc. Transcutaneous sensor insertion set
US5568806A (en) 1995-02-16 1996-10-29 Minimed Inc. Transcutaneous sensor insertion set
US5640470A (en) 1995-03-27 1997-06-17 Abbott Laboratories Fiber-optic detectors with terpolymeric analyte-permeable matrix coating
EP0817809B1 (en) 1995-03-27 2002-07-31 Medtronic MiniMed, Inc. Homogenous polymer compositions containing silicone for biosensor membranes
US5882494A (en) 1995-03-27 1999-03-16 Minimed, Inc. Polyurethane/polyurea compositions containing silicone for biosensor membranes
US5653863A (en) 1995-05-05 1997-08-05 Bayer Corporation Method for reducing bias in amperometric sensors
US5806517A (en) 1995-05-26 1998-09-15 The Regents Of The University Of Colorado In vivo electrochemistry computer system and method
US5584813A (en) 1995-06-07 1996-12-17 Minimed Inc. Subcutaneous injection set
US5743262A (en) 1995-06-07 1998-04-28 Masimo Corporation Blood glucose monitoring system
US5913998A (en) 1995-06-07 1999-06-22 Gore Hybrid Technologies, Inc. Method of making an implantable containment apparatus for a therapeutical device
US5995860A (en) 1995-07-06 1999-11-30 Thomas Jefferson University Implantable sensor and system for measurement and control of blood constituent levels
US6122536A (en) 1995-07-06 2000-09-19 Animas Corporation Implantable sensor and system for measurement and control of blood constituent levels
US5814599A (en) 1995-08-04 1998-09-29 Massachusetts Insitiute Of Technology Transdermal delivery of encapsulated drugs
US6001471A (en) 1995-08-11 1999-12-14 3M Innovative Properties Company Removable adhesive tape with controlled sequential release
EP0776628B1 (en) 1995-10-31 2004-09-15 Akitoshi Yoshida Intraocular substance measuring apparatus
US6466810B1 (en) 1995-11-22 2002-10-15 Legacy Good Samaritan Hospital And Medical Center Implantable device for monitoring changes in analyte concentration
US5711861A (en) 1995-11-22 1998-01-27 Ward; W. Kenneth Device for monitoring changes in analyte concentration
US6212416B1 (en) 1995-11-22 2001-04-03 Good Samaritan Hospital And Medical Center Device for monitoring changes in analyte concentration
US6063637A (en) 1995-12-13 2000-05-16 California Institute Of Technology Sensors for sugars and other metal binding analytes
US5730654A (en) 1995-12-18 1998-03-24 Raya Systems, Inc. Multi-player video game for health education
US6299578B1 (en) 1995-12-28 2001-10-09 Cygnus, Inc. Methods for monitoring a physiological analyte
US6309351B1 (en) 1995-12-28 2001-10-30 Cygnus, Inc. Methods for monitoring a physiological analyte
US6049727A (en) 1996-07-08 2000-04-11 Animas Corporation Implantable sensor and system for in vivo measurement and control of fluid constituent levels
US5795774A (en) 1996-07-10 1998-08-18 Nec Corporation Biosensor
US20040039298A1 (en) 1996-09-04 2004-02-26 Abreu Marcio Marc Noninvasive measurement of chemical substances
US5836887A (en) 1996-09-19 1998-11-17 Colin Corporation Physical information monitor system having means for determining reference range for abnormality determination, based on moving average of previously obtained values
US6168568B1 (en) 1996-10-04 2001-01-02 Karmel Medical Acoustic Technologies Ltd. Phonopneumograph system
US5964993A (en) 1996-12-19 1999-10-12 Implanted Biosystems Inc. Glucose sensor
US5933136A (en) 1996-12-23 1999-08-03 Health Hero Network, Inc. Network media access control system for encouraging patient compliance with a treatment plan
US5836989A (en) 1996-12-26 1998-11-17 Medtronic, Inc. Method and apparatus for controlling an implanted medical device in a time-dependent manner
US5914026A (en) 1997-01-06 1999-06-22 Implanted Biosystems Inc. Implantable sensor employing an auxiliary electrode
US6379301B1 (en) 1997-01-10 2002-04-30 Health Hero Network, Inc. Diabetes management system and method for controlling blood glucose
US5822715A (en) 1997-01-10 1998-10-13 Health Hero Network Diabetes management system and method for controlling blood glucose
US6123827A (en) 1997-01-17 2000-09-26 Via Medical Corporation Method for calibrating sensors used in diagnostic testing
US5928155A (en) 1997-01-24 1999-07-27 Cardiox Corporation Cardiac output measurement with metabolizable analyte containing fluid
US5851197A (en) 1997-02-05 1998-12-22 Minimed Inc. Injector for a subcutaneous infusion set
US6093172A (en) 1997-02-05 2000-07-25 Minimed Inc. Injector for a subcutaneous insertion set
US5749907A (en) 1997-02-18 1998-05-12 Pacesetter, Inc. System and method for identifying and displaying medical data which violate programmable alarm conditions
US6309884B1 (en) 1997-02-26 2001-10-30 Diasense, Inc. Individual calibration of blood glucose for supporting noninvasive self-monitoring blood glucose
US6208894B1 (en) 1997-02-26 2001-03-27 Alfred E. Mann Foundation For Scientific Research And Advanced Bionics System of implantable devices for monitoring and/or affecting body parameters
US6741877B1 (en) 1997-03-04 2004-05-25 Dexcom, Inc. Device and method for determining analyte levels
US7792562B2 (en) 1997-03-04 2010-09-07 Dexcom, Inc. Device and method for determining analyte levels
US6558321B1 (en) 1997-03-04 2003-05-06 Dexcom, Inc. Systems and methods for remote monitoring and modulation of medical devices
US20050033132A1 (en) 1997-03-04 2005-02-10 Shults Mark C. Analyte measuring device
US6001067A (en) 1997-03-04 1999-12-14 Shults; Mark C. Device and method for determining analyte levels
US20100204555A1 (en) 1997-03-04 2010-08-12 Dexcom, Inc. Device and method for determining analyte levels
US20100204559A1 (en) 1997-03-04 2010-08-12 Dexcom, Inc. Device and method for determining analyte levels
US20040045879A1 (en) 1997-03-04 2004-03-11 Dexcom, Inc. Device and method for determining analyte levels
FR2760962B1 (en) 1997-03-20 1999-05-14 Sillonville Francis Klefstad REMOTE MEDICAL ASSISTANCE AND SURVEILLANCE SYSTEM
US5961451A (en) 1997-04-07 1999-10-05 Motorola, Inc. Noninvasive apparatus having a retaining member to retain a removable biosensor
US6059946A (en) 1997-04-14 2000-05-09 Matsushita Electric Industrial Co., Ltd. Biosensor
US5944661A (en) 1997-04-16 1999-08-31 Giner, Inc. Potential and diffusion controlled solid electrolyte sensor for continuous measurement of very low levels of transdermal alcohol
US6214185B1 (en) 1997-04-17 2001-04-10 Avl Medical Instruments Sensor with PVC cover membrane
US6115634A (en) 1997-04-30 2000-09-05 Medtronic, Inc. Implantable medical device and method of manufacture
US5779665A (en) 1997-05-08 1998-07-14 Minimed Inc. Transdermal introducer assembly
EP0880936A3 (en) 1997-05-29 1999-03-24 Koji Akai Monitoring physical condition of a patient by telemetry
US20020119711A1 (en) 1997-06-09 2002-08-29 Minimed, Inc. Insertion set for a transcutaneous sensor
US6275717B1 (en) 1997-06-16 2001-08-14 Elan Corporation, Plc Device and method of calibrating and testing a sensor for in vivo measurement of an analyte
US6135978A (en) 1997-06-16 2000-10-24 Medtronic, Inc. System for pancreatic stimulation and glucose measurement
EP0885932B1 (en) 1997-06-18 2004-04-14 Crompton Corporation Hydrophilic polysiloxane compositions
US6027445A (en) 1997-07-17 2000-02-22 Siemens Elema Ab Method for flushing and calibrating a sensor in a body fluid analysis system
US5861019A (en) 1997-07-25 1999-01-19 Medtronic Inc. Implantable medical device microstrip telemetry antenna
US5919215A (en) 1997-08-01 1999-07-06 Medtronic, Inc. Attachment apparatus for an implantable medical device employing ultrasonic energy
US5871514A (en) 1997-08-01 1999-02-16 Medtronic, Inc. Attachment apparatus for an implantable medical device employing ultrasonic energy
US5897578A (en) 1997-08-01 1999-04-27 Medtronic, Inc. Attachment apparatus and method for an implantable medical device employing ultrasonic energy
US6731976B2 (en) 1997-09-03 2004-05-04 Medtronic, Inc. Device and method to measure and communicate body parameters
US5999848A (en) 1997-09-12 1999-12-07 Alfred E. Mann Foundation Daisy chainable sensors and stimulators for implantation in living tissue
US6498043B1 (en) 1997-09-12 2002-12-24 Alfred E. Mann Foundation For Scientific Research Substrate sensor
US6259937B1 (en) 1997-09-12 2001-07-10 Alfred E. Mann Foundation Implantable substrate sensor
US5917346A (en) 1997-09-12 1999-06-29 Alfred E. Mann Foundation Low power current to frequency converter circuit for use in implantable sensors
US6585763B1 (en) 1997-10-14 2003-07-01 Vascusense, Inc. Implantable therapeutic device and method
US6272480B1 (en) 1997-10-17 2001-08-07 Siemens Aktiengesellschaft Method and arrangement for the neural modelling of a dynamic system with non-linear stochastic behavior
US6167614B1 (en) 1997-10-20 2001-01-02 Micron Technology, Inc. Method of manufacturing and testing an electronic device, and an electronic device
US6088608A (en) 1997-10-20 2000-07-11 Alfred E. Mann Foundation Electrochemical sensor and integrity tests therefor
US6081736A (en) 1997-10-20 2000-06-27 Alfred E. Mann Foundation Implantable enzyme-based monitoring systems adapted for long term use
US20020042561A1 (en) 1997-10-20 2002-04-11 Schulman Joseph H. Implantable sensor and integrity tests therefor
US6512939B1 (en) 1997-10-20 2003-01-28 Medtronic Minimed, Inc. Implantable enzyme-based monitoring systems adapted for long term use
US20010051768A1 (en) 1997-10-20 2001-12-13 Joseph H Schulman Implantable enxzyme-based monitoring systems having improved longevity due to improved exterior surfaces
US6477395B2 (en) 1997-10-20 2002-11-05 Medtronic Minimed, Inc. Implantable enzyme-based monitoring systems having improved longevity due to improved exterior surfaces
US6673596B1 (en) 1997-11-25 2004-01-06 Ut-Battelle, Llc In vivo biosensor apparatus and method of use
US6036924A (en) 1997-12-04 2000-03-14 Hewlett-Packard Company Cassette of lancet cartridges for sampling blood
US6579690B1 (en) 1997-12-05 2003-06-17 Therasense, Inc. Blood analyte monitoring through subcutaneous measurement
US6607509B2 (en) 1997-12-31 2003-08-19 Medtronic Minimed, Inc. Insertion device for an insertion set and method of using the same
US6293925B1 (en) 1997-12-31 2001-09-25 Minimed Inc. Insertion device for an insertion set and method of using the same
US6103033A (en) 1998-03-04 2000-08-15 Therasense, Inc. Process for producing an electrochemical biosensor
US6484046B1 (en) 1998-03-04 2002-11-19 Therasense, Inc. Electrochemical analyte sensor
US6134461A (en) 1998-03-04 2000-10-17 E. Heller & Company Electrochemical analyte
US20030188427A1 (en) 1998-03-04 2003-10-09 Therasense, Inc. Process for producing an electrochemical biosensor
US5904708A (en) 1998-03-19 1999-05-18 Medtronic, Inc. System and method for deriving relative physiologic signals
US6579498B1 (en) 1998-03-20 2003-06-17 David Eglise Implantable blood glucose sensor system
US6091975A (en) 1998-04-01 2000-07-18 Alza Corporation Minimally invasive detecting device
US5971922A (en) 1998-04-07 1999-10-26 Meidensha Electric Mfg Co Ltd System and method for predicting blood glucose level
US6241863B1 (en) 1998-04-27 2001-06-05 Harold G. Monbouquette Amperometric biosensors based on redox enzymes
US7647237B2 (en) 1998-04-29 2010-01-12 Minimed, Inc. Communication station and software for interfacing with an infusion pump, analyte monitor, analyte meter, or the like
US20050121322A1 (en) 1998-04-30 2005-06-09 Therasense, Inc. Analyte monitoring device and methods of use
US20070203410A1 (en) 1998-04-30 2007-08-30 Abbott Diabetes Care, Inc. Analyte Monitoring Device and Methods of Use
US20040167801A1 (en) 1998-04-30 2004-08-26 James Say Analyte monitoring device and methods of use
US6565509B1 (en) 1998-04-30 2003-05-20 Therasense, Inc. Analyte monitoring device and methods of use
US20030187338A1 (en) 1998-04-30 2003-10-02 Therasense, Inc. Analyte monitoring device and methods of use
US20070213610A1 (en) 1998-04-30 2007-09-13 Abbott Diabetes Care, Inc. Analyte Monitoring Device and Methods of Use
US6175752B1 (en) 1998-04-30 2001-01-16 Therasense, Inc. Analyte monitoring device and methods of use
JP2002513602A (en) 1998-04-30 2002-05-14 セラセンス、インク. Analyte monitoring system and method of use
US6233471B1 (en) 1998-05-13 2001-05-15 Cygnus, Inc. Signal processing for measurement of physiological analysis
US6356776B1 (en) 1998-05-13 2002-03-12 Cygnus, Inc. Device for monitoring of physiological analytes
US6595919B2 (en) 1998-05-13 2003-07-22 Cygnus, Inc. Device for signal processing for measurement of physiological analytes
EP1078258B1 (en) 1998-05-13 2003-07-30 Cygnus, Inc. Device for predicting physiological values
US20010016682A1 (en) 1998-05-13 2001-08-23 Cygnus, Inc. Signal processing for measurement of physiological analytes
EP1077634B1 (en) 1998-05-13 2003-07-30 Cygnus, Inc. Monitoring of physiological analytes
US6272364B1 (en) 1998-05-13 2001-08-07 Cygnus, Inc. Method and device for predicting physiological values
US6144869A (en) 1998-05-13 2000-11-07 Cygnus, Inc. Monitoring of physiological analytes
US6546269B1 (en) 1998-05-13 2003-04-08 Cygnus, Inc. Method and device for predicting physiological values
US7295867B2 (en) 1998-05-13 2007-11-13 Animas Corporation Signal processing for measurement of physiological analytes
US20050215872A1 (en) 1998-05-13 2005-09-29 Cygnus, Inc. Monitoring of physiological analytes
US6526298B1 (en) 1998-05-18 2003-02-25 Abbott Laboratories Method for the non-invasive determination of analytes in a selected volume of tissue
US6302855B1 (en) 1998-05-20 2001-10-16 Novo Nordisk A/S Medical apparatus for use by a patient for medical self treatment of diabetes
US20040039406A1 (en) 1998-06-01 2004-02-26 Jessen Jonh W. Method and apparatus for placing and maintaining a percutaneous tube into a body cavity
US6325978B1 (en) 1998-08-04 2001-12-04 Ntc Technology Inc. Oxygen monitoring and apparatus
US7025743B2 (en) 1998-08-18 2006-04-11 Medtronic Minimed, Inc. External infusion device with remote programming, bolus estimator and/or vibration alarm capabilities
US6641533B2 (en) 1998-08-18 2003-11-04 Medtronic Minimed, Inc. Handheld personal data assistant (PDA) with a medical device and method of using the same
JP2000060826A (en) 1998-08-19 2000-02-29 Omron Corp Noninvasive vital component measuring instrument
US6107083A (en) 1998-08-21 2000-08-22 Bayer Corporation Optical oxidative enzyme-based sensors
US6330464B1 (en) 1998-08-26 2001-12-11 Sensors For Medicine & Science Optical-based sensing devices
US6233080B1 (en) 1998-08-26 2001-05-15 Ciena Corporation Crosstalk-free signal source for dense wavelength division multiplexed systems
US20020019022A1 (en) 1998-09-30 2002-02-14 Cygnus, Inc. Method and device for predicting physiological values
US6326160B1 (en) 1998-09-30 2001-12-04 Cygnus, Inc. Microprocessors for use in a device for predicting physiological values
US6180416B1 (en) 1998-09-30 2001-01-30 Cygnus, Inc. Method and device for predicting physiological values
US6201980B1 (en) 1998-10-05 2001-03-13 The Regents Of The University Of California Implantable medical sensor system
US6618934B1 (en) 1998-10-08 2003-09-16 Therasense, Inc. Method of manufacturing small volume in vitro analyte sensor
US6461496B1 (en) 1998-10-08 2002-10-08 Therasense, Inc. Small volume in vitro analyte sensor with diffusible or non-leachable redox mediator
US7098803B2 (en) 1998-10-08 2006-08-29 Medtronic Minimed, Inc. Telemetered characteristic monitor system and method of using the same
US20030199744A1 (en) 1998-10-08 2003-10-23 Therasense, Inc. Small volume in vitro analyte sensor with diffusible or non-leachable redox mediator
EP0995805B9 (en) 1998-10-23 2004-01-28 Pierre Beuret Heat treatment installation for a batch of metallic workpieces
US6016448A (en) 1998-10-27 2000-01-18 Medtronic, Inc. Multilevel ERI for implantable medical devices
US6212424B1 (en) 1998-10-29 2001-04-03 Rio Grande Medical Technologies, Inc. Apparatus and method for determination of the adequacy of dialysis by non-invasive near-infrared spectroscopy
US6206856B1 (en) 1998-11-04 2001-03-27 Sakharam D. Mahurkar Safety syringe
US20040030285A1 (en) 1998-11-13 2004-02-12 Gilad Lavi Drug delivery systems and methods
US20040015134A1 (en) 1998-11-13 2004-01-22 Elan Pharma International, Ltd. Drug delivery systems and methods
US6645181B1 (en) 1998-11-13 2003-11-11 Elan Pharma International Limited Drug delivery systems and methods
US6366794B1 (en) 1998-11-20 2002-04-02 The University Of Connecticut Generic integrated implantable potentiostat telemetry unit for electrochemical sensors
US6201993B1 (en) 1998-12-09 2001-03-13 Medtronic, Inc. Medical device telemetry receiver having improved noise discrimination
US6329929B1 (en) 1998-12-21 2001-12-11 Medtronic Inc. Telemetry system with phase-locking noise suppressing receiver
US6248067B1 (en) 1999-02-05 2001-06-19 Minimed Inc. Analyte sensor and holter-type monitor system and method of using the same
US6561978B1 (en) 1999-02-12 2003-05-13 Cygnus, Inc. Devices and methods for frequent measurement of an analyte present in a biological system
US6424847B1 (en) * 1999-02-25 2002-07-23 Medtronic Minimed, Inc. Glucose monitor calibration methods
US20030078481A1 (en) 1999-02-25 2003-04-24 Minimed Inc. Glucose sensor package system
US6416651B1 (en) 1999-02-26 2002-07-09 Honeywell Measurex Multi-electrode composition measuring device and method
US6312388B1 (en) 1999-03-12 2001-11-06 Cardiac Pacemakers, Inc. Method and system for verifying the integrity of normal sinus rhythm templates
US6230059B1 (en) 1999-03-17 2001-05-08 Medtronic, Inc. Implantable monitor
US6189536B1 (en) 1999-04-15 2001-02-20 Medtronic Inc. Method for protecting implantable devices
US6223083B1 (en) 1999-04-16 2001-04-24 Medtronic, Inc. Receiver employing digital filtering for use with an implantable medical device
US6475750B1 (en) 1999-05-11 2002-11-05 M-Biotech, Inc. Glucose biosensor
US6546268B1 (en) 1999-06-02 2003-04-08 Ball Semiconductor, Inc. Glucose sensor
US20030130616A1 (en) 1999-06-03 2003-07-10 Medtronic Minimed, Inc. Closed loop system for controlling insulin infusion
US6558351B1 (en) 1999-06-03 2003-05-06 Medtronic Minimed, Inc. Closed loop system for controlling insulin infusion
US7267665B2 (en) 1999-06-03 2007-09-11 Medtronic Minimed, Inc. Closed loop system for controlling insulin infusion
US6654625B1 (en) 1999-06-18 2003-11-25 Therasense, Inc. Mass transport limited in vivo analyte sensor
US20040143173A1 (en) 1999-07-01 2004-07-22 Medtronic Minimed, Inc. Reusable analyte sensor site and method of using the same
US6368274B1 (en) 1999-07-01 2002-04-09 Medtronic Minimed, Inc. Reusable analyte sensor site and method of using the same
US6413393B1 (en) 1999-07-07 2002-07-02 Minimed, Inc. Sensor including UV-absorbing polymer and method of manufacture
US6471689B1 (en) 1999-08-16 2002-10-29 Thomas Jefferson University Implantable drug delivery catheter system with capillary interface
US6673022B1 (en) 1999-08-20 2004-01-06 Innerspace Medical, Inc. Gas column pressure monitoring catheters
JP2003508746A (en) 1999-08-31 2003-03-04 シーエムイー テレメトリックス インク. How to calibrate a spectrometer
US6481440B2 (en) 1999-09-13 2002-11-19 Medtronic, Inc. Lamina prosthesis for delivery of medical treatment
US20020068860A1 (en) 1999-09-14 2002-06-06 Implanted Biosystems, Inc. Implantable glucose sensor
US6343225B1 (en) 1999-09-14 2002-01-29 Implanted Biosystems, Inc. Implantable glucose sensor
US6527729B1 (en) 1999-11-10 2003-03-04 Pacesetter, Inc. Method for monitoring patient using acoustic sensor
US6925393B1 (en) 1999-11-18 2005-08-02 Roche Diagnostics Gmbh System for the extrapolation of glucose concentration
US6558320B1 (en) 2000-01-20 2003-05-06 Medtronic Minimed, Inc. Handheld personal data assistant (PDA) with a medical device and method of using the same
US6648821B2 (en) 2000-01-21 2003-11-18 Medtronic Minimed, Inc. Microprocessor controlled ambulatory medical apparatus with hand held communication device
US6694191B2 (en) 2000-01-21 2004-02-17 Medtronic Minimed, Inc. Ambulatory medical apparatus and method having telemetry modifiable control software
US6585644B2 (en) 2000-01-21 2003-07-01 Medtronic Minimed, Inc. Ambulatory medical apparatus and method using a telemetry system with predefined reception listening periods
US20020198513A1 (en) 2000-01-21 2002-12-26 Lebel Ronald J. Ambulatory medical apparatus and method using a robust communication protocol
US6740075B2 (en) 2000-01-21 2004-05-25 Medtronic Minimed, Inc. Ambulatory medical apparatus with hand held communication device
US6810290B2 (en) 2000-01-21 2004-10-26 Medtronic Minimed, Inc. Ambulatory medical apparatus with hand held communication device
US6370941B2 (en) 2000-02-03 2002-04-16 Nihon Kohden Corporation Gas sensor and gas sensor system
US20030023171A1 (en) 2000-02-03 2003-01-30 Katsuhiko Sato Noninvasion biological optical measuring instrument, measured portion holding device, and method for manufacturing the same
US20030060765A1 (en) 2000-02-16 2003-03-27 Arthur Campbell Infusion device menu structure and method of using the same
US20020161288A1 (en) 2000-02-23 2002-10-31 Medtronic Minimed, Inc. Real time self-adjusting calibration algorithm
US6895263B2 (en) 2000-02-23 2005-05-17 Medtronic Minimed, Inc. Real time self-adjusting calibration algorithm
US7029444B2 (en) 2000-02-23 2006-04-18 Medtronic Minimed, Inc. Real time self-adjusting calibration algorithm
US6551496B1 (en) 2000-03-03 2003-04-22 Ysi Incorporated Microstructured bilateral sensor
US6405066B1 (en) 2000-03-17 2002-06-11 The Regents Of The University Of California Implantable analyte sensor
US20030212317A1 (en) 2000-03-29 2003-11-13 Kovatchev Boris P. Method, system, and computer program product for the evaluation of glycemic control in diabetes from self-monitoring data
US6605072B2 (en) 2000-05-03 2003-08-12 Aspect Medical Systems, Inc. System and method for adaptive drug delivery
US20010041830A1 (en) 2000-05-08 2001-11-15 Varalli Maurizio Claudio Apparatus for measurment and control of the content of glucose, lactate or other metabolites in biological fluids
EP1153571B1 (en) 2000-05-08 2007-04-04 A. Menarini Industrie Farmaceutiche Riunite S.R.L. Apparatus for measurement and control of the content of glucose, lactate or other metabolites in biological fluids
US20040219664A1 (en) 2000-05-12 2004-11-04 Therasense, Inc. Electrodes with multilayer membranes and methods of using and making the electrodes
US6699188B2 (en) 2000-06-22 2004-03-02 Guidance Interactive Technologies Interactive reward devices and methods
US6569521B1 (en) 2000-07-06 2003-05-27 3M Innovative Properties Company Stretch releasing pressure sensitive adhesive tape and articles
US6477392B1 (en) 2000-07-14 2002-11-05 Futrex Inc. Calibration of near infrared quantitative measurement device using optical measurement cross-products
US6589229B1 (en) 2000-07-31 2003-07-08 Becton, Dickinson And Company Wearable, self-contained drug infusion device
US6683535B1 (en) 2000-08-09 2004-01-27 Alderon Industries, Llc Water detection system and method
US20020045808A1 (en) 2000-08-18 2002-04-18 Russell Ford Formulation and manipulation of databases of analyte and associated values
US6553244B2 (en) 2000-08-18 2003-04-22 Cygnus, Inc. Analyte monitoring device alarm augmentation system
US20020065453A1 (en) 2000-08-18 2002-05-30 Lesho Matthew J. Analyte monitoring device alarm augmentation system
US6633772B2 (en) 2000-08-18 2003-10-14 Cygnus, Inc. Formulation and manipulation of databases of analyte and associated values
US20020026111A1 (en) 2000-08-28 2002-02-28 Neil Ackerman Methods of monitoring glucose levels in a subject and uses thereof
US6553241B2 (en) 2000-08-31 2003-04-22 Mallinckrodt Inc. Oximeter sensor with digital memory encoding sensor expiration data
US20020099282A1 (en) 2000-09-22 2002-07-25 Knobbe Edward J. Method and apparatus for real-time estimation of physiological parameters
US20020111547A1 (en) 2000-09-22 2002-08-15 Knobbe Edward J. Method and apparatus for real-time control of physiological parameters
US6575905B2 (en) 2000-09-22 2003-06-10 Knobbe, Lim & Buckingham Method and apparatus for real-time estimation of physiological parameters
US6572545B2 (en) 2000-09-22 2003-06-03 Knobbe, Lim & Buckingham Method and apparatus for real-time control of physiological parameters
US6699218B2 (en) 2000-11-09 2004-03-02 Insulet Corporation Transcutaneous delivery means
US6695860B1 (en) 2000-11-13 2004-02-24 Isense Corp. Transcutaneous sensor insertion device
US6991643B2 (en) 2000-12-20 2006-01-31 Usgi Medical Inc. Multi-barbed device for retaining tissue in apposition and methods of use
US6869413B2 (en) 2000-12-22 2005-03-22 Dca Design International Limited Pen-type injector having an electronic control unit
US6642015B2 (en) 2000-12-29 2003-11-04 Minimed Inc. Hydrophilic polymeric material for coating biosensors
US20030100821A1 (en) 2001-01-02 2003-05-29 Therasense, Inc. Analyte monitoring device and methods of use
US6560471B1 (en) 2001-01-02 2003-05-06 Therasense, Inc. Analyte monitoring device and methods of use
US6510329B2 (en) 2001-01-24 2003-01-21 Datex-Ohmeda, Inc. Detection of sensor off conditions in a pulse oximeter
US20020155615A1 (en) 2001-02-05 2002-10-24 Novikov Igor A. Method of determining concentration of glucose in blood
US6721587B2 (en) 2001-02-15 2004-04-13 Regents Of The University Of California Membrane and electrode structure for implantable sensor
US6574490B2 (en) 2001-04-11 2003-06-03 Rio Grande Medical Technologies, Inc. System for non-invasive measurement of glucose in humans
US6613379B2 (en) 2001-05-08 2003-09-02 Isense Corp. Implantable analyte sensor
US20030050546A1 (en) 2001-06-22 2003-03-13 Desai Shashi P. Methods for improving the performance of an analyte monitoring system
US7011630B2 (en) 2001-06-22 2006-03-14 Animas Technologies, Llc Methods for computing rolling analyte measurement values, microprocessors comprising programming to control performance of the methods, and analyte monitoring devices employing the methods
US20030097082A1 (en) 2001-07-13 2003-05-22 Board Of Regents, The University Of Texas System Methods and apparatuses for navigating the subarachnoid space
US20030032874A1 (en) 2001-07-27 2003-02-13 Dexcom, Inc. Sensor head for use with implantable devices
US20040186362A1 (en) 2001-07-27 2004-09-23 Dexcom, Inc. Membrane for use with implantable devices
US6702857B2 (en) 2001-07-27 2004-03-09 Dexcom, Inc. Membrane for use with implantable devices
US20030028089A1 (en) 2001-07-31 2003-02-06 Galley Paul J. Diabetes management system
US6544212B2 (en) 2001-07-31 2003-04-08 Roche Diagnostics Corporation Diabetes management system
US20090264856A1 (en) 2001-09-07 2009-10-22 Medronic MiniMed, Inc. Safety limits for closed-loop infusion pump control
US20030078560A1 (en) 2001-09-07 2003-04-24 Miller Michael E. Method and system for non-vascular sensor implantation
JP2003108679A (en) 2001-09-28 2003-04-11 Toshiba Corp Home treatment patient supporting system and method
US20030076082A1 (en) 2001-10-23 2003-04-24 Morgan Wayne A. Implantable sensor electrodes and electronic circuitry
US20040030294A1 (en) 2001-11-28 2004-02-12 Mahurkar Sakharam D. Retractable needle single use safety syringe
US20040078219A1 (en) 2001-12-04 2004-04-22 Kimberly-Clark Worldwide, Inc. Healthcare networks with biosensors
US20050096519A1 (en) 2001-12-21 2005-05-05 Denuzzio John D. Minimally-invasive system and method for monitoring analyte levels
US6952604B2 (en) 2001-12-21 2005-10-04 Becton, Dickinson And Company Minimally-invasive system and method for monitoring analyte levels
US20040015063A1 (en) 2001-12-21 2004-01-22 Denuzzio John D. Minimally-invasive system and method for monitoring analyte levels
US7426408B2 (en) 2001-12-21 2008-09-16 Becton, Dickinson And Company Minimally-invasive system and method for monitoring analyte levels
US20050027182A1 (en) 2001-12-27 2005-02-03 Uzair Siddiqui System for monitoring physiological characteristics
US20050113653A1 (en) 2001-12-27 2005-05-26 Fox James K. System for monitoring physiological characteristics
US7022072B2 (en) 2001-12-27 2006-04-04 Medtronic Minimed, Inc. System for monitoring physiological characteristics
US20030125612A1 (en) 2001-12-27 2003-07-03 Fox James Kelly System for monitoring physiological characteristics
US20050038332A1 (en) 2001-12-27 2005-02-17 Frank Saidara System for monitoring physiological characteristics
US6998247B2 (en) 2002-03-08 2006-02-14 Sensys Medical, Inc. Method and apparatus using alternative site glucose determinations to calibrate and maintain noninvasive and implantable analyzers
US20030235817A1 (en) 2002-03-22 2003-12-25 Miroslaw Bartkowiak Microprocessors, devices, and methods for use in analyte monitoring systems
US20030211625A1 (en) 2002-04-05 2003-11-13 Cohan Bruce E. Method and apparatus for non-invasive monitoring of blood substances using self-sampled tears
US20030212346A1 (en) 2002-05-09 2003-11-13 Vadim V. Yuzhakov Methods of fabricating physiological sample collection devices
US20030212347A1 (en) 2002-05-09 2003-11-13 Borzu Sohrab Devices and methods for accessing and analyzing physiological fluid
US20030217966A1 (en) 2002-05-22 2003-11-27 Dexcom, Inc. Techniques to improve polyurethane membranes for implantable glucose sensors
US7169289B2 (en) 2002-06-28 2007-01-30 november Aktiengesellschaft Gesellschaft für Molekulare Medizin Electrochemical detection method and device
US20050211571A1 (en) 2002-06-28 2005-09-29 Jurgen Schulein Electrochemical detection method and device
US20040010207A1 (en) 2002-07-15 2004-01-15 Flaherty J. Christopher Self-contained, automatic transcutaneous physiologic sensing system
US20040068230A1 (en) 2002-07-24 2004-04-08 Medtronic Minimed, Inc. System for providing blood glucose measurements to an infusion device
US20040024327A1 (en) 2002-08-01 2004-02-05 Brodnick Donald Eugene Method and apparatus for real time display of filtered electrocardiogram data
US20040152622A1 (en) 2002-10-11 2004-08-05 Steven Keith System and method for initiating and maintaining continuous, long-term control of a concentration of a substance in a patient using a feedback or model-based controller coupled to a single-needle or multi-needle intradermal (ID) delivery device
US7060059B2 (en) 2002-10-11 2006-06-13 Becton, Dickinson And Company System and method for initiating and maintaining continuous, long-term control of a concentration of a substance in a patient using a feedback or model-based controller coupled to a single-needle or multi-needle intradermal (ID) delivery device
US7248912B2 (en) 2002-10-31 2007-07-24 The Regents Of The University Of California Tissue implantable sensors for measurement of blood solutes
US20040152187A1 (en) 2002-11-13 2004-08-05 Haight Levoy Golden System, apparatus and method for inferring glucose levels within the peritoneum with implantable sensors
US20040186365A1 (en) 2002-12-31 2004-09-23 Therasense, Inc. Continuous glucose monitoring system and methods of use
US7134999B2 (en) 2003-04-04 2006-11-14 Dexcom, Inc. Optimized sensor geometry for an implantable glucose sensor
US20040199059A1 (en) 2003-04-04 2004-10-07 Dexcom, Inc. Optimized sensor geometry for an implantable glucose sensor
US7192450B2 (en) 2003-05-21 2007-03-20 Dexcom, Inc. Porous membranes for use with implantable devices
US20050031689A1 (en) 2003-05-21 2005-02-10 Dexcom, Inc. Biointerface membranes incorporating bioactive agents
US20050051427A1 (en) 2003-07-23 2005-03-10 Brauker James H. Rolled electrode array and its method for manufacture
US7074307B2 (en) 2003-07-25 2006-07-11 Dexcom, Inc. Electrode systems for electrochemical sensors
US7108778B2 (en) 2003-07-25 2006-09-19 Dexcom, Inc. Electrochemical sensors including electrode systems with increased oxygen generation
US20050054909A1 (en) 2003-07-25 2005-03-10 James Petisce Oxygen enhancing membrane systems for implantable devices
US20090192380A1 (en) 2003-07-25 2009-07-30 Dexcom, Inc. Systems and methods for processing sensor data
US20050056552A1 (en) 2003-07-25 2005-03-17 Simpson Peter C. Increasing bias for oxygen production in an electrode system
US20080033254A1 (en) 2003-07-25 2008-02-07 Dexcom, Inc. Systems and methods for replacing signal data artifacts in a glucose sensor data stream
US7599726B2 (en) 2003-08-01 2009-10-06 Dexcom, Inc. System and methods for processing analyte sensor data
US20100174168A1 (en) 2003-08-01 2010-07-08 Dexcom, Inc. System and methods for processing analyte sensor data
US7986986B2 (en) 2003-08-01 2011-07-26 Dexcom, Inc. System and methods for processing analyte sensor data
US7979104B2 (en) 2003-08-01 2011-07-12 Dexcom, Inc. System and methods for processing analyte sensor data
US7959569B2 (en) 2003-08-01 2011-06-14 Dexcom, Inc. System and methods for processing analyte sensor data
US7955261B2 (en) 2003-08-01 2011-06-07 Dexcom, Inc. System and methods for processing analyte sensor data
US7933639B2 (en) 2003-08-01 2011-04-26 Dexcom, Inc. System and methods for processing analyte sensor data
US7914450B2 (en) 2003-08-01 2011-03-29 Dexcom, Inc. System and methods for processing analyte sensor data
US20100234796A1 (en) 2003-08-01 2010-09-16 Dexcom, Inc. System and methods for processing analyte sensor data
US20060222566A1 (en) 2003-08-01 2006-10-05 Brauker James H Transcutaneous analyte sensor
US7797028B2 (en) 2003-08-01 2010-09-14 Dexcom, Inc. System and methods for processing analyte sensor data
US20050027181A1 (en) 2003-08-01 2005-02-03 Goode Paul V. System and methods for processing analyte sensor data
US20100217106A1 (en) 2003-08-01 2010-08-26 Dexcom, Inc. System and methods for processing analyte sensor data
US20100214104A1 (en) 2003-08-01 2010-08-26 Dexcom, Inc. System and methods for processing analyte sensor data
US20050027463A1 (en) 2003-08-01 2005-02-03 Goode Paul V. System and methods for processing analyte sensor data
US20050027180A1 (en) 2003-08-01 2005-02-03 Goode Paul V. System and methods for processing analyte sensor data
US20100185074A1 (en) 2003-08-01 2010-07-22 Dexcom, Inc. System and methods for processing analyte sensor data
US20100185065A1 (en) 2003-08-01 2010-07-22 Dexcom, Inc. System and methods for processing analyte sensor data
US20050187720A1 (en) 2003-08-01 2005-08-25 Dexcom, Inc. System and method for processing analyte sensor data
US6931327B2 (en) 2003-08-01 2005-08-16 Dexcom, Inc. System and methods for processing analyte sensor data
US20070203966A1 (en) 2003-08-01 2007-08-30 Dexcom, Inc. Transcutaneous analyte sensor
US20100185073A1 (en) 2003-08-01 2010-07-22 Dexcom, Inc. System and methods for processing analyte sensor data
US20070208245A1 (en) 2003-08-01 2007-09-06 Brauker James H Transcutaneous analyte sensor
US20070208244A1 (en) 2003-08-01 2007-09-06 Brauker James H Transcutaneous analyte sensor
US20070208246A1 (en) 2003-08-01 2007-09-06 Brauker James H Transcutaneous analyte sensor
US20100185072A1 (en) 2003-08-01 2010-07-22 Dexcom, Inc. System and methods for processing analyte sensor data
US20100179406A1 (en) 2003-08-01 2010-07-15 DesCom, Inc. System and methods for processing analyte sensor data
US7276029B2 (en) 2003-08-01 2007-10-02 Dexcom, Inc. System and methods for processing analyte sensor data
US20100179405A1 (en) 2003-08-01 2010-07-15 Dexcom, Inc. System and methods for processing analyte sensor data
US20080021666A1 (en) 2003-08-01 2008-01-24 Dexcom, Inc. System and methods for processing analyte sensor data
US20100179399A1 (en) 2003-08-01 2010-07-15 Dexcom, Inc. System and methods for processing analyte sensor data
US20100174167A1 (en) 2003-08-01 2010-07-08 Dexcom, Inc. System and methods for processing analyte sensor data
US7583990B2 (en) 2003-08-01 2009-09-01 Dexcom, Inc. System and methods for processing analyte sensor data
US20090192745A1 (en) 2003-08-01 2009-07-30 Dexcom, Inc. Systems and methods for processing sensor data
US20080183399A1 (en) 2003-08-01 2008-07-31 Dexcom, Inc. System and methods for processing analyte sensor data
US20080183061A1 (en) 2003-08-01 2008-07-31 Dexcom, Inc. System and methods for processing analyte sensor data
US20080189051A1 (en) 2003-08-01 2008-08-07 Dexcom, Inc. System and methods for processing analyte sensor data
US20080194937A1 (en) 2003-08-01 2008-08-14 Dexcom, Inc. System and methods for processing analyte sensor data
US20080195967A1 (en) 2003-08-01 2008-08-14 Dexcom, Inc. System and methods for processing analyte sensor data
US20060040402A1 (en) 2003-08-01 2006-02-23 Brauker James H System and methods for processing analyte sensor data
US20090192724A1 (en) 2003-08-01 2009-07-30 Dexcom, Inc. Transcutaneous analyte sensor
US7925321B2 (en) 2003-08-01 2011-04-12 Dexcom, Inc. System and methods for processing analyte sensor data
US20090012379A1 (en) 2003-08-01 2009-01-08 Dexcom, Inc. System and methods for processing analyte sensor data
US20080306368A1 (en) 2003-08-01 2008-12-11 Dexcom, Inc. System and methods for processing analyte sensor data
US20070032706A1 (en) 2003-08-22 2007-02-08 Apurv Kamath Systems and methods for replacing signal artifacts in a glucose sensor data stream
US20070066873A1 (en) 2003-08-22 2007-03-22 Apurv Kamath Systems and methods for processing analyte sensor data
US20090124878A1 (en) 2003-08-22 2009-05-14 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US20090124877A1 (en) 2003-08-22 2009-05-14 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US20070016381A1 (en) 2003-08-22 2007-01-18 Apurv Kamath Systems and methods for processing analyte sensor data
US20050043598A1 (en) 2003-08-22 2005-02-24 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US20050239154A1 (en) 2003-10-31 2005-10-27 Feldman Benjamin J A method of calibrating an analyte-measurement device, and associated methods, devices and systems
US20050139489A1 (en) 2003-10-31 2005-06-30 Davies Oliver William H. Method of reducing the effect of direct and mediated interference current in an electrochemical test strip
US20080287764A1 (en) 2003-11-19 2008-11-20 Dexcom, Inc. Integrated receiver for continuous analyte sensor
US20050154271A1 (en) 2003-11-19 2005-07-14 Andrew Rasdal Integrated receiver for continuous analyte sensor
US20080287765A1 (en) 2003-11-19 2008-11-20 Dexcom, Inc. Integrated receiver for continuous analyte sensor
US20080287766A1 (en) 2003-11-19 2008-11-20 Dexcom, Inc. Integrated receiver for continuous analyte sensor
US7519408B2 (en) 2003-11-19 2009-04-14 Dexcom, Inc. Integrated receiver for continuous analyte sensor
US20050143635A1 (en) 2003-12-05 2005-06-30 Kamath Apurv U. Calibration techniques for a continuous analyte sensor
US20090182217A1 (en) 2003-12-05 2009-07-16 Dexcom, Inc. Analyte sensor
US20090043542A1 (en) 2003-12-09 2009-02-12 Dexcom, Inc. Signal processing for continuous analyte sensor
US20050203360A1 (en) 2003-12-09 2005-09-15 Brauker James H. Signal processing for continuous analyte sensor
US20090062635A1 (en) 2003-12-09 2009-03-05 Dexcom, Inc. Signal processing for continuous analyte sensor
US20090204341A1 (en) 2003-12-09 2009-08-13 Dexcom, Inc. Signal processing for continuous analyte sensor
US20090043182A1 (en) 2003-12-09 2009-02-12 Dexcom, Inc. Signal processing for continuous analyte sensor
US20090043541A1 (en) 2003-12-09 2009-02-12 Dexcom, Inc. Signal processing for continuous analyte sensor
US20090043181A1 (en) 2003-12-09 2009-02-12 Dexcom, Inc. Signal processing for continuous analyte sensor
US20090043525A1 (en) 2003-12-09 2009-02-12 Dexcom, Inc. Signal processing for continuous analyte sensor
US20090203981A1 (en) 2003-12-09 2009-08-13 Dexcom, Inc. Signal processing for continuous analyte sensor
US20090036758A1 (en) 2003-12-09 2009-02-05 Dexcom, Inc. Signal processing for continuous analyte sensor
US20050143675A1 (en) 2003-12-31 2005-06-30 Home Diagnostics, Inc. Integrated diagnostic test system
US20070049873A1 (en) 2004-01-26 2007-03-01 Novo Nordisk A/S Impulse chamber for jet delivery device
EP2223710A1 (en) 2004-02-26 2010-09-01 DexCom, Inc. Integrated delivery device for continuous glucose sensor
US7591801B2 (en) 2004-02-26 2009-09-22 Dexcom, Inc. Integrated delivery device for continuous glucose sensor
US20050192557A1 (en) 2004-02-26 2005-09-01 Dexcom Integrated delivery device for continuous glucose sensor
EP2226086A1 (en) 2004-02-26 2010-09-08 DexCom, Inc. Integrated delivery device for continuous glucose sensor
US20050245799A1 (en) 2004-05-03 2005-11-03 Dexcom, Inc. Implantable analyte sensor
US20050245795A1 (en) 2004-05-03 2005-11-03 Dexcom, Inc. Implantable analyte sensor
US20050242479A1 (en) 2004-05-03 2005-11-03 Petisce James R Implantable analyte sensor
US20060015020A1 (en) 2004-07-06 2006-01-19 Dexcom, Inc. Systems and methods for manufacture of an analyte-measuring device including a membrane system
US20060015024A1 (en) 2004-07-13 2006-01-19 Mark Brister Transcutaneous medical device with variable stiffness
US20060183985A1 (en) 2004-07-13 2006-08-17 Mark Brister Analyte sensor
US20090216103A1 (en) 2004-07-13 2009-08-27 Dexcom, Inc. Transcutaneous analyte sensor
US20060020190A1 (en) 2004-07-13 2006-01-26 Dexcom, Inc. Transcutaneous analyte sensor
US20060036141A1 (en) 2004-07-13 2006-02-16 Dexcom, Inc. Transcutaneous analyte sensor
US20100174158A1 (en) 2004-07-13 2010-07-08 Dexcom, Inc. Transcutaneous analyte sensor
US20060020188A1 (en) 2004-07-13 2006-01-26 Dexcom, Inc. Transcutaneous analyte sensor
US20060183984A1 (en) 2004-07-13 2006-08-17 Dobbles J M Analyte sensor
US20090076361A1 (en) 2004-07-13 2009-03-19 Dexcom, Inc. Transcutaneous analyte sensor
US20100179404A1 (en) 2004-07-13 2010-07-15 Dexcom, Inc. Transcutaneous analyte sensor
US20060036144A1 (en) 2004-07-13 2006-02-16 Dexcom, Inc. Transcutaneous analyte sensor
US20060100588A1 (en) 2004-07-23 2006-05-11 Lennart Brunnberg Needle handling device
US20060258929A1 (en) 2005-03-10 2006-11-16 Goode Paul V Jr System and methods for processing analyte sensor data for sensor calibration
US20080193936A1 (en) 2005-03-22 2008-08-14 Enigma Diagnostics Ltd Polymorphism Detection Method
US20080071157A1 (en) 2006-06-07 2008-03-20 Abbott Diabetes Care, Inc. Analyte monitoring system and method
US20080071158A1 (en) 2006-06-07 2008-03-20 Abbott Diabetes Care, Inc. Analyte monitoring system and method
US20080072663A1 (en) 2006-08-15 2008-03-27 Optiscan Biomedical Corporation Accurate and timely body fluid analysis
US20080306444A1 (en) 2007-06-08 2008-12-11 Dexcom, Inc. Integrated medicament delivery device for use with continuous analyte sensor
US20080306435A1 (en) 2007-06-08 2008-12-11 Dexcom, Inc. Integrated medicament delivery device for use with continuous analyte sensor
US20080306434A1 (en) 2007-06-08 2008-12-11 Dexcom, Inc. Integrated medicament delivery device for use with continuous analyte sensor
US20090192751A1 (en) 2007-10-25 2009-07-30 Dexcom, Inc. Systems and methods for processing sensor data
US20090192722A1 (en) 2007-12-17 2009-07-30 Dexcom, Inc. Systems and methods for processing sensor data
US20090192366A1 (en) 2007-12-17 2009-07-30 Dexcom, Inc Systems and methods for processing sensor data
US20090156924A1 (en) 2007-12-17 2009-06-18 Dexcom, Inc. Systems and methods for processing sensor data
US20090240128A1 (en) 2008-02-21 2009-09-24 Dexcom, Inc. Systems and methods for blood glucose monitoring and alert delivery
US20090240193A1 (en) 2008-02-21 2009-09-24 Dexcom, Inc. Systems and methods for customizing delivery of sensor data
US20090240120A1 (en) 2008-02-21 2009-09-24 Dexcom, Inc. Systems and methods for processing, transmitting and displaying sensor data
US20090242425A1 (en) 2008-03-25 2009-10-01 Dexcom, Inc. Analyte sensor
US20090242399A1 (en) 2008-03-25 2009-10-01 Dexcom, Inc. Analyte sensor
US20090247857A1 (en) 2008-03-28 2009-10-01 Abbott Diabetes Care, Inc. Analyte Sensor Calibration Management

Non-Patent Citations (313)

* Cited by examiner, † Cited by third party
Title
Abel et al. 2002. Biosensors for in vivo glucose measurement: can we cross the experimental stage. Biosens Bioelectron 17:1059-1070.
Alcock & Turner. 1994. Continuous Analyte Monitoring to Aid Clinical Practice. IEEE Engineering in Med. & Biol. Mag. 13:319-325.
American Heritage Dictionary, 4th Edition. 2000. Houghton Mifflin Company, p. 82.
Armour et al. Dec. 1990. Application of Chronic Intravascular Blood Glucose Sensor in Dogs. Diabetes 39:1519-1526.
Atanasov et al. 1994. Biosensor for continuous glucose monitoring. Biotechnology and Bioengineering 43:262-266.
Atanasov et al. 1997. Implantation of a refillable glucose monitoring-telemetry device. Biosens Bioelectron 12:669-680.
Aussedat et al. 1997. A user-friendly method for calibrating a subcutaneous glucose sensor-based hypoglycaemic alarm. Biosensors & Bioelectronics 12(11):1061-1071.
Baker et al. 1993. Dynamic concentration challenges for biosensor characterization. Biosensors & Bioelectronics 8:433-441.
Baker et al. 1996. Dynamic delay and maximal dynamic error in continuous biosensors. Anal Chem 68(8):1292-1297.
Bani Amer, M. M. 2002. An accurate amperometric glucose sensor based glucometer with eliminated cross-sensitivity. J Med Eng Technol 26(5):208-213.
Beach et al. 1999. Subminiature implantable potentiostat and modified commercial telemetry device for remote glucose monitoring. IEEE Transactions on Instrumentation and Measurement 48(6):1239-1245.
Bellucci et al. Jan. 1986. Electrochemical behaviour of graphite-epoxy composite materials (GECM) in aqueous salt solutions, Journal of Applied Electrochemistry, 16(1):15-22.
Biermann et al. 2008. How would patients behave if they were continually informed of their blood glucose levels? A simulation study using a "virtual" patient. Diab. Thechnol. & Therapeut., 10:178-187.
Bindra et al. 1989. Pulsed amperometric detection of glucose in biological fluids at a surface-modified gold electrode. Anal Chem 61:2566-2570.
Bindra et al. 1991. Design and In Vitro Studies of a Needle-Type Glucose Senso for Subcutaneous Monitoring. Anal. Chem 63:1692-96.
Bisenberger et al. 1995. A triple-step potential waveform at enzyme multisensors with thick-film gold electrodes for detection of glucose and sucrose. Sensors and Actuators, B 28:181-189.
Bland et al. 1986. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1:307-310.
Bland et al. 1990. A note on the use of the intraclass correlation coefficient in the evaluation of agreement between two methods of measurement. Comput. Biol. Med. 20(5):337-340.
Bobbioni-Harsch et al. 1993. Lifespan of subcutaneous glucose sensors and their performances during dynamic glycaemia changes in rats, J. Biomed. Eng. 15:457-463.
Bode et al. 1999. Continuous glucose monitoring used to adjust diabetes therapy improves glycosylated hemoglobin: A pilot study. Diabetes Research and Clinical Practice 46:183-190.
Bode et al. 2000. Using the continuous glucose monitoring system to improve the management of type 1 diabetes. Diabetes Technology & Therapeutics, 2(Suppl 1):S43-48.
Bode, B. W. 2000. Clinical utility of the continuous glucose monitoring system. Diabetes Technol Ther, 2(Suppl 1):S35-41.
Boedeker Plastics, Inc. 2009. Polyethylene Specifications Data Sheet, http://www.boedeker.com/polye-p.htm [Aug. 19, 2009 3:36:33 PM].
Bolinder et al. 1992. Microdialysis measurement of the absolute glucose concentration in subcutaneous adipose tissue allowing glucose monitoring in diabetic patients. Diabetologia 35:1177-1180.
Bolinder et al. 1997. Self-monitoring of blood glucose in type 1 diabetic patients: Comparison with continuous microdialysis measurements of glucose in subcutaneous adipose tissue during ordinary life conditions. Diabetes Care 20(1):64-70.
Bott, A. 1998. Electrochemical methods for the determination of glucose. Current Separations 17(1):25-31.
Bott, A. W. 1997. A Comparison of Cyclic Voltammetry and Cyclic Staircase Voltammetry Current Separations 16:1, 23-26.
Bowman, L.; Meindl, J. D. 1986. The packaging of implantable integrated sensors. IEEE Trans Biomed Eng BME33(2):248-255.
Bremer et al. 1999. Is blood glucose predictable from previous values? A solicitation for data. Diabetes 48:445-451.
Bremer et al. 2001. Benchmark data from the literature for evaluation of new glucose sensing technologies. Diabetes Technology & Therapeutics 3(3):409-418.
Brooks et al. "Development of an on-line glucose sensor for fermentation monitoring," Biosensors, 3:45-56 (1987/88).
Cai et al. 2004. A wireless, remote query glucose biosensor based on a pH-sensitive polymer. Anal Chem 76(4):4038-4043.
Candas et al (1994). "An adaptive plasma glucose controller basedon on a nonlinear insulin/glucose model." IEEE Transactions on Biomedical Engineering, 41(2): 116-124.
Cass et al. "Ferrocene-mediated enzyme electrodes for amperometric determination of glucose," Anal. Chem., 36:667-71 (1984).
Chen et al. 2002. Defining the period of recovery of the glucose concentration after its local perturbation by the implantation of a miniature sensor. Clin. Chem. Lab. Med. 40:786-789.
Chia et al. 2004. Glucose sensors: toward closed loop insulin delivery. Endocrinol Metab Clin North Am 33:175-95.
Choleau et al. 2002. Calibration of a subcutaneous amperometric glucose sensor implanted for 7 days in diabetic patients. Part 1. Effect of measurement uncertainties on the determination of sensor sensitivity and background current . Biosensors and Bioel.
Choleau et al. 2002. Calibration of a subcutaneous amperometric glucose sensor implanted for 7 days in diabetic patients. Part 2. Superiority of the one-point calibration method. Biosensors and Bioelectronics 17:647-654.
Cox et al. 1985. Accuracy of perceiving blood glucose in IDDM. Diabetes Care 8(6):529-536.
Csöregi et al. 1994. Amperometric microbiosensors for detection of hydrogen peroxide and glucose based on peroxidase-modified carbon fibers. Electroanalysis 6:925-933.
Davies, et al. 1992. Polymer membranes in clinical sensor applications. I. An overview of membrane function, Biomaterials, 13(14):971-978.
Dixon et al. 2002. Characterization in vitro and in vivo of the oxygen dependence of an enzyme/polymer biosensor for monitoring brain glucose. Journal of Neuroscience Methods 119:135-142.
Electronic File History of Inter Partes Reexamination Control No. 95/001,038, filed Apr. 17, 2008 containing Office Action(s) dated Apr. 25, 2008, Jun. 17, 2008, Feb. 14, 2009, Jun. 19, 2009, Mar. 18, 2010, May 28, 2010, Aug. 13, 2010, Sep. 3, 2010, Sep. 17, 2010 and May 4, 2011, and Applicant(s) Responses filed Aug. 18, 2008, Oct. 19, 2009, Apr. 16, 2010, Jul. 28, 2010 and Third Party/Appellant Submissions of Sep. 16, 2008, Jul. 17, 2009, Sep. 17, 2009, Jun. 28, 2010, Oct. 8, 2010 as of May 5, 2011.
Electronic File History of Inter Partes Reexamination Control No. 95/001,039, filed Apr. 17, 2008 containing Office Action(s) dated May 29, 2008, Aug. 14, 2009, and Dec. 24, 2009 and May 3, 2011, 3rd Party/Requester Submissions dated Aug. 27, 2008, Nov. 13, 2009, Feb. 4, 2010, and May 3, 2010 and Applicant Response(s) filed Jul. 29, 2008, Oct. 14, 2009, Jan. 21, 2010, Apr. 2, 2010 and May 5, 2010 as of May 3, 2011.
Electronic File History of Reexam Control No. 90/011,467, filed Jan. 31, 2011 containing Office Action(s) dated Feb. 14, 2011 and Apr. 22, 2011 and Applicant/Third Party submissions filed Jan. 31, 2011, Jun. 22, 2011 as of Aug. 11, 2011.
Electronic File History of Reexam Control No. 90/011,635, Apr. 8, 2011 containing Office Action(s) dated Apr. 8, 2011, Apr. 22, 2011, Apr. 25, 2011 and Jun. 29, 2011 and Applicant/Third Party submissions filed Apr. 8, 2011.
Electronic File History of U.S. Appl. No. 10/633,367, filed Aug. 1, 2003 (U.S. Patent 7,778,680, issued Aug. 17, 2010) containing Office Action(s) dated Apr. 8, 2008; Jul. 15, 2008; Jan. 2, 2009 and Feb. 2, 2009; Jun. 11, 2009 and Mar. 17, 2010 and May 18, 2010; and Applicant Response(s) filed Sep. 24, 2007; Dec. 3, 2007; Apr. 10, 2008; Sep. 19, 2008; Mar. 9, 2009, Aug. 17, 2009 and May 3, 2010.
Electronic File History of U.S. Appl. No. 12/730,058, filed Mar. 23, 2010 (now U.S. Patent 7/933,639, issued Apr. 26, 2011) containing Office Actions dated Jul. 29, 2010, Dec. 10, 2010 and Jan. 23, 2011 and Applicant Responses filed Oct. 28, 2010 and Dec. 14, 2010.
Electronic File History of U.S. Appl. No. 12/730,108, filed Mar. 23, 2010 (now U.S. Patent 7,986,986, issued Jul. 26, 2011) containing Office Action(s) dated Mar. 9, 2011 and May 13, 2011 Applicant(s) Response(s) filed Apr. 4, 2011 and May 23, 2011.
Electronic File History of U.S. Appl. No. 12/730,123, filed Mar. 23, 2010 (now U.S. Patent 7,925,321, issued Apr. 12, 2011) containing Office Action(s) dated Jul. 27, 2010, Jan. 25, 2011, Feb. 11, 2011 and Feb. 24, 2011 and Applicant Response(s) filed Nov. 24, 2010, Jan. 31, 2011 and Feb. 11, 2011.
Electronic File History of U.S. Appl. No. 12/730,144, filed Mar. 23, 2010 (now U.S. Patent 7,959,569, issued Jun. 14, 2011 containing Office Action(s) dated Aug. 6, 2010, Jan. 26, 2011 and Feb. 28, 2011 and Applicant Response(s) filed Nov. 8, 2010 and Feb. 9, 2011.
Electronic File History of U.S. Appl. No. 12/730,152, filed Mar. 23, 2010 (now U.S. Patent 7,955,261, issued Jun. 7, 2011) containing Office Action(s) dated Aug. 6, 2010 and Jan. 26, 2011 and Applicant Response(s) filed Nov. 8, 2010 and Feb. 10, 2011.
Electronic File History of U.S. Appl. No. 12/772,849, filed May 3, 2010 (now U.S. Patent 7,914,450, issued Mar. 29, 2011)containing Office Action(s) dated Aug. 6, 2010 and Jan. 26, 2011 and Applicant Response(s) filed Nov. 8, 2010 as of Dec. 22, 2010.
Electronic File History of U.S. Appl. No. 12/788,125, filed May 26, 2010 (now U.S. Patent 7,979,104, issued Jul. 12, 2011 containing Office Action(s) dated Sep. 15, 2010, Jan. 4, 2011 and Mar. 10, 2011 and Applicant Response(s) filed Jan. 8, 2010.
Electronic File History of U.S. Reexamination Control No. 90/010,988, filed May 10, 2010 containing Office Action(s) dated May 28, 2010, Sep. 9, 2010 and Dec. 21, 2010 and Applicant Response(s) filed Nov. 9, 2010 and Jan. 14, 2011.
Electronic File History of U.S. Reexamination Control No. 90/011,031, filed Jun. 14, 2010 containing Office Action(s) dated Jun. 30, 2010, Sep. 9, 2010 and Dec. 21, 2010 and Applicant Response(s) filed Nov. 9, 2010 and Jan. 14, 2011.
El-Khatib et al. 2007. Adaptive closed-loop control provides blood-glucose regulation using dual subcutaneous insulin and glucagon infusion in diabetic swine, Journal of Diabetes Science and Technology, 1(2):181-192.
El-Sa'ad et al. 1990. Moisture Absorption by Epoxy Resins: the Reverse Thermal Effect. Journal of Materials Science 25:3577-3582.
Ernst et al. 2002. Reliable glucose monitoring through the use of microsystem technology. Anal. Bioanal. Chem. 373:758-761.
European Office Action dated Jun. 2, 2010 for Application No. 04779357.5, filed Jul. 27, 2004.
European Office Action dated Nov. 9, 2010 for Application No. 04779357.5, filed Jul. 27, 2004.
European Search Report for App. No. 98908875.2 dated Apr. 29, 2004.
Fabietti et al. 2007. Clinical validation of a new control-oriented model of insulin and glucose dynamcs in subjects with type 1 diabetes, Diabetes Technology & Therapeutics, 9(4):327-338.
Fare et al. 1998. Functional characterization of a conducting polymer-based immunoassay system. Biosensors & Bioelectronics 13(3-4):459-470.
Feldman et al. 2003. A continuous glucose sensor based on wired enzyme technology-results from a 3-day trial in patients with type 1 diabetes. Diabetes Technol Ther 5(5):769-779.
Freedman et al. 1991. Statistics, Second Edition, W.W. Norton & Company, p. 74.
Frost et al. 2002. Implantable chemical sensors for real-time clinical monitoring: Progress and challenges. Current Opinion in Chemical Biology 6:633-641.
Garg et al. 1999. Correlation of fingerstick blood glucose measurements with GlucoWatch biographer glucose results in young subjects with type 1 diabetes. Diabetes Care 22(10):1708-1714.
Garg et al. 2004. Improved Glucose Excursions Using an Implantable Real-Time continuous Glucose Sensor in Adults with Type I Diabetes. Diabetes Care 27:734-738.
Gerritsen et al. 1999. Performance of subcutaneously implanted glucose sensors for continuous monitoring. The Netherlands Journal of Medicine 54:167-179.
Gerritsen, M. 2000. Problems associated with subcutaneously implanted glucose sensors. Diabetes Care 23(2):143-145.
Gilligan et al. 1994. Evaluation of a subcutaneous glucose sensor out to 3 months in a dog model. Diabetes Care 17(8):882-887.
Gilligan et al. 2004, Feasibility of continuous long-term glucose monitoring from a subcutaneous glucose sensor in humans. Diabetes Technol Ther 6:378-386.
Gough et al. 2000. Immobilized glucose oxidase in implantable glucose sensor technology. Diabetes Technology & Therapeutics 2(3):377-380.
Gough. (May 2001) The implantable glucose sensor: an example of bioengineering design. Introduction to Bioengineering, Chapter 3, pp. 57-66.
Gross et al. 2000. Efficacy and reliability of the continuous glucose monitoring system. Diabetes Technology & Therapeutics, 2(Suppl 1):S19-26.
Gross et al. 2000. Performance evaluation of the MiniMed® continuous glucose monitoring system during patient home use. Diabetes Technology & Therapeutics 2(1):49-56.
Guerci et al., Clinical performance of CGMS in type 1 diabetic patents treated by continuous subcutaneous insulin infusion using insulin analogs, Diabetes Care, 26:582-589, 2003.
Hall et al. 1998. Electrochemical oxidation of hydrogen peroxide at platinum electrodes. Part I: An adsorption-controlled mechanism. Electrochimica Acta, 43(5-6):579-588.
Hall et al. 1998. Electrochemical oxidation of hydrogen peroxide at platinum electrodes. Part II: Effect of potential. Electrochimica Acta 43(14-15):2015-2024.
Hall et al. 1999. Electrochemical oxidation of hydrogen peroxide at platinum electrodes. Part III: Effect of temperature. Electrochimica Acta, 44:2455-2462.
Hall et al. 1999. Electrochemical oxidation of hydrogen peroxide at platinum electrodes. Part IV: Phosphate buffer dependence. Electrochimica Acta, 44:4573-4582.
Hall et al. 2000. Electrochemical oxidation of hydrogen peroxide at platinum electrodes. Part V: Inhibition by chloride. Electrochimica Acta, 45:3573-3579.
Hamilton Syringe Selection Guide. 2006. Syringe Selection. www.hamiltoncompany.com.
Heise et al. 2003. Hypoglycemia warning signal and glucose sensors: Requirements and concepts. Diabetes Technology & Therapeutics 5:563-571.
Heller, "Electrical wiring of redox enzymes," Acc. Chem. Res., 23:128-134 (1990).
Heller, A. 1992. Electrical Connection of Enzyme Redox Centers to Electrodes. J. Phys. Chem. 96:3579-3587.
Heller, A. 1999. Implanted electrochemical glucose sensors for the management of diabetes. Annu Rev Biomed Eng 1:153-175.
Heller, A. 2003. Plugging metal connectors into enzymes. Nat Biotechnol 21:631-2.
Hicks, 1985. In Situ Monitoring, Clinical Chemistry, 31(12):1931-1935.
Hitchman, M. L. 1978. Measurement of Dissolved Oxygen. In Elving et al. (Eds.). Chemical Analysis, vol. 49, Chap. 3, pp. 34-49, 59-123. New York: John Wiley & Sons.
Hoel, Paul G. 1976. Elementary Statistics, Fourth Edition. John Wiley & Sons, Inc.. pp. 113-114.
Hrapovic et al. 2003. Picoamperometric detection of glucose at ultrasmall platinum-based biosensors: preparation and characterization. Anal Chem 75:3308-3315.
Hu, et al. 1993. A needle-type enzyme-based lactate sensor for in vivo monitoring, Analytica Chimica Acta, 281:503-511.
Huang et al. Aug. 1975. Electrochemical Generation of Oxygen. 1: The Effects of Anions and Cations on Hydrogen Chemisorption and Aniodic Oxide Film Formation on Platinum Electrode. 2: The Effects of Anions and Cations on Oxygen Generation on Platinum E.
Hunter et al. 2000. Minimally Invasive Glucose Sensor and Insulin Delivery System. MIT Home Automation and Healthcare Consortium. Progress Report No. 25.
IPRP for PCT/US04/24263 filed Jul. 27, 2004.
Ishikawa et al. 1998. Initial evaluation of a 290-mm diameter subcutaneous glucose sensor: Glucose monitoring with a biocompatible, flexible-wire, enzyme-based amperonnetric microsensor in diabetic and nondiabetic humans. Journal of Diabetes and Its Compl.
ISR and WO for PCT/US04/24263 filed Jul. 27, 2004.
Jablecki et al. 2000. Simulations of the frequency response of implantable glucose sensors. Analytical Chemistry 72:1853-1859.
Jaffari et al. 1995. Recent advances in amperometric glucose biosensors for in vivo monitoring, Physiol. Meas. 16: 1-15.
Japanese Office Action dated Apr. 19, 2011 for Application No. 2007-294586, filed Jul. 27, 2004.
Japanese Office Action dated Aug. 31, 2010 for Application No. 2006-522016, filed Jul. 27, 2004.
Japanese Office Action dated Nov. 24, 2010 for Application No. 2007-294586, filed Jul. 27, 2004.
Jaremko et al. 1998. Advances toward the implantable artificial pancreas for treatment of diabetes. Diabetes Care 21(3):444-450.
Jensen et al. 1997. Fast wave forms for pulsed electrochemical detection of glucose by incorporation of reductive desorption of oxidation products. Analytical Chemistry 69(9):1776-1781.
Jeutter, D. C. 1982. A transcutaneous implanted battery recharging and biotelemeter power switching system. IEEE Trans Biomed Eng 29:314-321.
Jobst et al., (1996) Thin-Film Microbiosensors for Glucose-Lactate Monitoring, Anal Chem. 8(18): 3173-3179.
Johnson et al. 1992. In vivo evaluation of an electroenzymatic glucose sensor implanted in subcutaneous tissue. Biosensors & Bioelectronics, 7:709-714.
Jovanovic, L. 2000. The role of continuous glucose monitoring in gestational diabetes mellitus. Diabetes Technology & Therapeutics, 2 Suppl 1, S67-71.
Kamath et al. Calibration of a continuous glucose monitor: effect of glucose rate of change, Eighth Annual Diabetes Technology Meeting, Nov. 13-15, 2008, p. A88.
Kang et al. 2003. In vitro and short-term in vivo characteristics of a Kel-F thin film modified glucose sensor. Anal Sci 19:1481-1486.
Kaufman. 2000. Role of the continuous glucose monitoring system in pediatric patients. Diabetes Technology & Therapeutics 2(1):S-49-S-52.
Kawagoe et al. 1991. Enzyme-modified organic conducting salt microelectrode, Anal. Chem. 63:2961-2965.
Kerner et al. "The function of a hydrogen peroxide-detecting electroenzymatic glucose electrode is markedly impaired in human sub-cutaneous tissue and plasma," Biosensors & Bioelectronics, 8:473-482 (1993).
Kerner, W. 2001. Implantable glucose sensors: Present status and future developments. Exp. Clin. Endocrinol. Diabetes 109(Suppl 2):S341-346.
Ko, Wen H. 1985. Implantable Sensors for Closed-Loop Prosthetic Systems, Futura Pub. Co., Inc., Mt. Kisco, NY, Chapter 15:197-210.
Koschinsky et al. 1988. New approach to technical and clinical evaluation of devices for self-monitoring of blood glucose. Diabetes Care 11(8): 619-619.
Koschinsky et al. 2001. Sensors for glucose monitoring: Technical and clinical aspects. Diabetes Metab. Res. Rev. 17:113-123.
Kraver et al. 2001. A mixed-signal sensor interface microinstrument. Sensors and Actuators A 91:266-277.
Krouwer, J. S. 2002. Setting performance goals and evaluating total analytical error for diagnostic assays. Clinical Chemistry 48(6):919-927.
Kruger et al. 2000. Psychological motivation and patient education: A role for continuous glucose monitoring. Diabetes Technology & Therapeutics, 2(Suppl 1):S93-97.
Kurnik et al. 1999. Application of the mixtures of experts algorithm for signal processing in a noninvasive glucose monitoring system. Sensors and Actuators B, 60:19-26.
LaCourse et al. 1993. Optimization of waveforms for pulsed amperometric detection of carbohydrates based on pulsed voltammetry. Analytical Chemistry 65:50-52.
Lerner et al. 1984. An implantable electrochemical glucose sensor. Ann. N. Y. Acad. Sci. 428:263-278.
Leypoldt et al. 1984. Model of a two-substrate enzyme electrode for glucose. Anal. Chem. 56:2896-2904.
Lohn et al., A knowledge-based system for real-time validation of calibrations and measurements, Chemometrics and Intelligent Laboratory Systems, 1999 46, 57-66.
Lynch et al. 2001. Estimation-based model predictive control of blood glucose in type I diabetics: A simulation study. Proceedings of the IEEE 27th Annual Northeast Bioengineering Conference, pp. 79-80.
Lynn, P. A. 1971. Recursive digital filters for biological signals. Med. & Biol. Engng. 9:37-43.
Maidan et al. 1992. Elimination of Electrooxidizable Interferent-Produced Currents in Amperometric Biosensors, Analytical Chemistry, 64:2889-2896.
Makale et al. 2003. Tissue window chamber system for validation of implanted oxygen sensors. Am. J. Physiol. Heart Circ. Physiol. 284:H2288-2294.
Malin et al. 1999. Noninvasive Prediction of Glucose by Near-Infrared Diffuse Reflectance Spectroscopy. Clinical Chemistry 45:9,1651-1658.
Mancy et al. 1962. A galvanic cell oxygen analyzer. Journal of Electroanalytical Chemistry 4:65-92.
Maran et al. 2002. Continuous subcutaneous glucose monitoring in diabetic patients: A multicenter analysis. Diabetes Care 25(2):347-352.
March, W. F. 2002. Dealing with the delay. Diabetes Technol Ther 4(1):49-50.
Martin, R. F. 2000. General Deming regression for estimating systematic bias and its confidence interval in method-comparison studies. Clinical Chemistry, 46(1):100-104.
Mastrototaro et al. "An electroenzymatic glucose sensor fabricated on a flexible substrate," Sensors and Actuators B, 5:139-44 (1991).
Mastrototaro et al. 2003. Reproducibility of the continuous glucose monitoring system matches previous reports and the intended use of the product. Diabetes Care 26:256; author reply p. 257.
Mastrototaro, J. J. 2000. The MiniMed continuous glucose monitoring system. Diabetes Technol Ther 2(Suppl 1):S13-8.
Mazze et al. 2008. Characterizing glucose exposure for individuals with normal glucose tolerance using continuous glucose monitoring and ambulatory glucose profile analysis. Diab. Thechnol. & Therapeut., 10:149-159.
McCartney et al. 2001. Near-infrared fluorescence lifetime assay for serum glucose based on allophycocyanin-labeled concanavalin A. Anal Biochem 292:216-221.
McGrath et al. 1995. The use of differential measurements with a glucose biosensor for interference compensation during glucose determinations by flow injection analysis. Biosens Bioelectron 10:937-943.
McKean, et al. Jul. 7, 1988. A Telemetry Instrumentation System for Chronically Implanted Glucose and Oxygen Sensors. Transactions on Biomedical Engineering 35:526-532.
Memoli et al. 2002. A comparison between different immobilised glucoseoxidase-based electrodes. J Pharm Biomed Anal 29:1045-1052.
Merriam-Webster Online Dictionary. Definition of "acceleration". http://www.merriam-webster.com/dictionary/Acceleration Jan. 11, 2010.
Merriam-Webster Online Dictionary. Definition of "system". http://www.merriam-webster.com/dictionary/System Jan. 11, 2010.
Metzger et al. Jul. 2002. Reproducibility of glucose measurements using the glucose sensor. Diabetes Care 25(6):1185-1191.
Moatti-Sirat et al. 1992. Towards continuous glucose monitoring: in vivo evaluation of a miniaturized glucose sensor implanted for several days in rat subcutaneous tissue. Diabetologia 35:224-230.
Monsod et al. 2002. Do sensor glucose levels accurately predict plasma glucose concentrations during hypoglycemia and hyperinsulinemia? Diabetes Care 25(5):889-893.
Moussy et al. 1993. Performance of subcutaneously implanted needle-type glucose sensors employing a novel trilayer coating, Anal Chem. 85: 2072-2077.
Moussy et al. 1994. A miniaturized Nafion-based glucose sensor: In vitro and in vivo evaluation in dogs. Int. J. Artif. Organs 17(2):88-94.
Moussy, Francis (Nov. 2002) Implantable Glucose Sensor: Progress and Problems, Sensors, 1:270-273.
Murphy, et al. 1992. Polymer membranes in clinical sensor applications. II. The design and fabrication of permselective hydrogels for electrochemical devices, Biomaterials, 13(14):979-990.
Neuburger et al. 1987. Pulsed amperometric detection of carbohydrates at gold electrodes with a two-step potential waveform. Anal. Chem. 59:150-154.
Office Action dated Apr. 28, 2009 in U.S. Appl. No. 11/077,740.
Office Action dated Aug. 11, 2008 in U.S. Appl. No. 11/360,819.
Office Action dated Aug. 25, 2009 in U.S. Appl. No. 11/334,876.
Office Action dated Aug. 26, 2008 in U.S. Appl. No. 11/334,876.
Office Action dated Dec. 18, 2008 in U.S. Appl. No. 10/633,329.
Office Action dated Dec. 21, 2004 in U.S. Appl. No. 10/632,537.
Office Action dated Dec. 23, 2008 in U.S. Appl. No. 12/102,745.
Office Action dated Dec. 26, 2008 in U.S. Appl. No. 11/360,819.
Office Action dated Dec. 31, 2007 in U.S. Appl. No. 11/077,765.
Office Action dated Feb. 12, 2007 in U.S. Appl. No. 10/633,404.
Office Action dated Feb. 4, 2008 in U.S. Appl. No. 10/633,329.
Office Action dated Feb. 7, 2008 in U.S. Appl. No. 11/077,740.
Office Action dated Jan. 23, 2009 in U.S. Appl. No. 11/077,765.
Office Action dated Jan. 29, 2009, in U.S. Appl. No. 11/360,252.
Office Action dated Jan. 5, 2009 in U.S. Appl. No. 11/038,340.
Office Action dated Jan. 7, 2009 in U.S. Appl. No. 11/157,365.
Office Action dated Jul. 10, 2008 in U.S. Appl. No. 11/077,759.
Office Action dated Jul. 21, 2009 in U.S. Appl. 11/077,739.
Office Action dated Jul. 21, 2009 in U.S. Appl. No. 11/157,365.
Office Action dated Jul. 22, 2008 in U.S. Appl. No. 10/991,966.
Office Action dated Jul. 23, 2009, in U.S. Appl. No. 11/360,252.
Office Action dated Jul. 25, 2008 in U.S. Appl. No. 11/077,740.
Office Action dated Jul. 30, 2007 in U.S. Appl. No. 10/633,329.
Office Action dated Jul. 30, 2009 in U.S. Appl. No. 12/102,654.
Office Action dated Jun. 1, 2007 in U.S. Appl. No. 11/077,740.
Office Action dated Jun. 11, 2009 in U.S. Appl. No. 10/633,329.
Office Action dated Jun. 12, 2008 in U.S. Appl. No. 10/633,329.
Office Action dated Jun. 17, 2008 in U.S. Appl. No. 11/038,340.
Office Action dated Jun. 17, 2008 in U.S. Reexam. No. 95/001,038.
Office Action dated Jun. 23, 2009 in U.S. Appl. No. 10/648,849.
Office Action dated Jun. 24, 2008 n. U.S. Appl. No. 11/007,920.
Office Action dated Jun. 26, 2008 in U.S. Appl. No. 11/157,365.
Office Action dated Jun. 30, 2008 in U.S. Appl. No. 11/360,252.
Office Action dated Mar. 20, 2008 in U.S. Appl. No. 10/789,359.
Office Action dated Mar. 26, 2007 in U.S. Appl. No. 10/633,329.
Office Action dated Mar. 31, 2008 in U.S. Appl. No. 11/077,759.
Office Action dated May 16, 2008 in U.S. Appl. No. 11/077,765.
Office Action dated May 19, 2009 in U.S. Appl. No. 11/038,340.
Office Action dated May 2, 2008 in U.S. Appl. No. 11/334,876.
Office Action dated May 26, 2009 in U.S. Appl. No. 11/077,759.
Office Action dated May 29, 2008 in U.S. Reexam. No. 95/001,039.
Office Action dated Nov. 1, 2007 in U.S. Appl. No. 11/077,740.
Office Action dated Nov. 27, 2006 in U.S. Appl. No. 10/789,359.
Office Action dated Nov. 28, 2007 in U.S. Appl. No. 10/991,966.
Office Action dated Nov. 9, 2009 in U.S. Appl. No. 11/038,340.
Office Action dated Oct. 20, 2004 in U.S. Appl. No. 10/632,537.
Office Action dated Oct. 29, 2009 in U.S. Appl. No. 11/360,819.
Office Action dated Oct. 3, 2008 in U.S. Appl. No. 10/789,359.
Office Action dated Oct. 4, 2006 in U.S. Appl. No. 11/334,876.
Office Action dated Oct. 5, 2006 in U.S. Appl. No. 10/633,329.
Office Action dated Sep. 19, 2008 in U.S. Appl. No. 11/077,765.
Office Action dated Sep. 25, 2007 in U.S. Appl. No. 11/334,876.
Office Action dated Sep. 30, 2002 in U.S. Appl. No. 09/636,369.
Ohara et al. 1994. "Wired" enzyme electrodes for amperometric determination of glucose or lactate in the presence of interfering substances. Anal Chem 66:2451-2457.
Ohara, et al. Dec. 1993. Glucose electrodes based on cross-linked bis(2,2′-bipyridine)chloroosmium(+/2+) complexed poly(1-vinylimidazole) films, Analytical Chemistry, 65:3512-3517.
Okuda et al. 1971. Mutarotase effect on micro determinations of D-glucose and its anomers with β-D-glucose oxidase. Anal Biochem 43:312-315.
Oxford English Dictionary Online. Definition of "impending". http://www.askoxford.com/results/?view=dev dict&field-12668446 Impending&branch= Jan. 11, 2010.
Palmisano et al. 2000. Simultaneous monitoring of glucose and lactate by an interference and cross-talk free dual electrode amperometric biosensor based on electropolymerized thin films. Biosensors & Bioelectronics 15:531-539.
Panteleon et al. 2003. The role of the independent variable to glucose sensor calibration. Diabetes Technology & Therapeutics 5(3):401-410.
Parker et al. 1999. A model-based algorithm for blood glucose control in type I diabetic patients. IEEE Trans. Biomed. Eng. 46(2):148-157.
Patel et al. 2003. Amperometric glucose sensors based on ferrocene containing polymeric electron transfer systems-a preliminary report. Biosens Bioelectron 18:1073-6.
Pichert et al. 2000. Issues for the coming age of continuous glucose monitoring Diabetes Educ 26(6):969-980.
Pickup et al. "Implantable glucose sensors: choosing the appropriate sensing strategy," Biosensors, 3:335-346 (1987/88).
Pickup et al. "In vivo molecular sensing in diabetes mellitus: an implantable glucose sensor with direct electron transfer," Diabetologia, 32:213-217 (1989).
Pickup et al. 1993. Developing glucose sensors for in vivo use. Elsevier Science Publishers Ltd (UK), TIBTECH vol. 11: 285-291.
Pishko et al. "Amperometric glucose microelectrodes prepared through immobilization of glucose oxidase in redox hydrogels," Anal. Chem., 63:2268-72 (1991).
Pitzer et al. 2001. Detection of hypoglycemia with the GlucoWatch biographer. Diabetes Care 24(5):881-885.
Poirier et al. 1998. Clinical and statistical evaluation of self-monitoring blood glucose meters. Diabetes Care 21(11):1919-1924.
Poitout et al. 1993. A glucose monitoring system for on line estimation in man of blood glucose concentration using a miniaturized glucose sensor implanted in the subcutaneous tissue and a wearable control unit. Diabetologia 36:658-663.
Poitout, et al. 1991. In Vitro and In Vivo Evaluation in Dogs of a Miniaturized Glucose Sensor, ASAIO Transactions, 37:M298-M300.
Postlethwaite et al. 1996. Interdigitated array electrode as an alternative to the rotated ring-disk electrode for determination of the reaction products of dioxygen reduction. Analytical Chemistry 68:2951-2958.
Prabhu et al. 1981. Electrochemical studies of hydrogen peroxide at a platinum disc electrode, Electrochimica Acta 26(6):725-729.
Preliminary Amendment filed Sep. 21, 2009 in U.S. Appl. No. 12/405,958 to James Say.
Quinn et al. 1997. Biocompatible, glucose-permeable hydrogel for in situ coating of implantable biosensors. Biomaterials 18:1665-1670.
Reach et al. 1986. A Method for Evaluating in vivo the Functional Characteristics of Glucose Sensors. Biosensors 2:211-220.
Reach et al. 1992. Can continuous glucose monitoring be used for the treatment of diabetes? Analytical Chemistry 64(5):381-386.
Reach, G. 2001. Which threshold to detect hypoglycemia? Value of receiver-operator curve analysis to find a compromise between sensitivity and specificity. Diabetes Care 24(5):803-804.
Reach, Gerard. 2001. Letters to the Editor Re: Diabetes Technology & Therapeutics, 2000;2:49-56. Diabetes Technology & Therapeutics 3(1):129-130.
Rebrin et al. "Automated feedback control of subcutaneous glucose concentration in diabetic dogs," Diabetologia, 32:573-76 (1989).
Rebrin et al. 1999. Subcutaneous glucose predicts plasma glucose independent of insulin: Implications for continuous monitoring. Am. J. Physiol. 277:E561-71.
Reusch. 2004. Chemical Reactivity. Organometallic Compounds. Virtual Textbook of Organic Chem. pp. 1-16, http://www.cem.msu.edu/˜reusch/VirtualText/orgmetal.htm.
Rhodes et al. 1994. Prediction of pocket-portable and implantable glucose enzyme electrode performance from combined species permeability and digital simulation analysis. Analytical Chemistry 66(9):1520-1529.
Rigla et al. 2008. Real-time continuous glucose monitoring together with telemedical assitance improves glycemic control and glucose stability in pump-treated patients. Diab. Thechnol. & Therapeut., 10:194-199.
Rinken et al. 1998. Calibration of glucose biosensors by using pre-steady state kinetic data. Biosensors & Bioelectronics, 13:801-807.
Sakakida et al. 1993. Ferrocene-Mediated Needle Type Glucose Sensor Covered with Newly Designed Biocompatible Membran, Sensors and Actuators B 13-14:319-322.
Samuels, M.P. 2004. The effects of flight and altitude. Arch Dis Child. 89: 448-455.
San Diego Plastics, Inc. 2009. Polyethylene Data Sheet, http://www.sdplastics.com/polyeth.html.
Sansen et al. 1985. "Glucose sensor with telemetry system." In Ko, W. H. (Ed.). Implantable Sensors for Closed Loop Prosthetic Systems. Chap. 12, pp. 167-175, Mount Kisco, NY: Futura Publishing Co.
Sansen et al. 1990. A smart sensor for the voltammetric measurement of oxygen or glucose concentrations. Sensors and Actuators B 1:298-302.
Schmidt et al. 1993. Glucose concentration in subcutaneous extracellular space. Diabetes Care 16(5):695-700.
Schmidtke et al. 1998. Accuracy of the one-point in vivo calibration of "wired" glucose oxidase electrodes implanted in jugular veins of rats in periods of rapid rise and decline of the glucose concentration. Anal Chem 70:2149-2155.
Schoemaker et al. 2003. The SCGM1 system: Subcutaneous continuous glucose monitoring based on microdialysis technique. Diabetes Technology & Therapeutics 5(4):599-608.
Service et al. 1970. Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes, 19: 644-655.
Service, R. F. 2002. Can sensors make a home in the body? Science 297:962-3.
Shaw et al. "In vitro testing of a simply constructed, highly stable glucose sensor suitable for implantation in diabetic patients," Biosensors & Bioelectronics, 6:401-406 (1991).
Shichiri et al. 1982. Wearable artificial endocrine pancrease with needle-type glucose sensor. Lancet 2:1129-1131.
Shichiri et al. 1985. Needle-type Glucose Sensor for Wearable Artificial Endocrine Pancreas in Implantable Sensors 197-210.
Shichiri et al. 1986. Telemetry Glucose Monitoring Device with Needle-Type Glucose Sensor: A Useful Tool for Blood Glucose Monitoring in Diabetic Individuals. Diabetes Care, Inc. 9(3):298-301.
Shichiri et al. 1989. Membrane Design for Extending the Long-Life of an Implantable Glucose Sensor. Diab. Nutr. Metab. 2:309-313.
Shults et al. 1994. A telemetry-instrumentation system for monitoring multiple subcutaneously implanted glucose sensors. IEEE Transactions on Biomedical Engineering 41(10):937-942.
Skyler, J. S. 2000. The economic burden of diabetes and the benefits of improved glycemic control: The potential role of a continuous glucose monitoring system. Diabetes Technology & Therapeutics 2 Suppl 1:S7-12.
Sokol et al. 1980, Immobilized-enzyme rate-determination method for glucose analysis, Clin. Chem. 26(1):89-92.
Sokolov et al. 1995. Metrological opportunities of the dynamic mode of operating an enzyme amperometric biosensor. Med. Eng. Phys. 17(6):471-476.
Sproule et al. 2002. Fuzzy pharmacology: Theory and applications. Trends in Pharmacological Sciences, 23(9):412-417.
Sriyudthsak et al. 1996. Enzyme-epoxy membrane based glucose analyzing system and medical applications. Biosens Bioelectron 11:735-742.
Steil et al. 2003. Determination of plasma glucose during rapid glucose excursions with a subcutaneous glucose sensor. Diabetes Technology & Therapeutics 5(1):27-31.
Sternberg et al. 1988. Study and Development of Multilayer Needle-type Enzyme-based Glucose Microsensors. Biosensors 4:27-40.
Sternberg et al. 1996. Does fall in tissue glucose precede fall in blood glucose? Diabetologia 39:609-612.
Street et al. 1988. A note on computing robust regression estimates via iteratively reweighted least squares. The American Statistician 42(2):152-154.
Tamura, T. et al. 2000. Preliminary study of continuous glucose monitoring with a microdialysis technique and a null method—a numerical analysis. Frontiers Med. Biol. Engng. 10(2):147-156.
Tanenberg et al. 2000. Continuous glucose monitoring system: A new approach to the diagnosis of diabetic gastroparesis. Diabetes Technology & Therapeutics, 2 Suppl 1:S73-80.
Thijssen et al. 1984. A Kalman Filter for Calibration, Evaluation of Unknown Samples and Quality Control in Drifting Systems, Part 1. Theory and Simulations, Anal Chim Acta 156: 87-101.
Thijssen et al. 1985. A Kalman Filter for Calibration, Evaluation of Unknown Samples and Quality Control in Drifting Systems, Part 3. Variance Reduction, Anal Chim Acta. 173: 265-272.
Thijssen et al. 1985. A Kalman Filter for Calibration, Evaluation of Unknown Samples and Quality Control in Drifting Systems, Part 4. Flow Injection Analysis, Anal Chim Acta. 174: 27-40.
Thijssen, P.C. 1984. A Kalman Filder for Calibration, Evaluation of Unknown Samples and Quality Control in Drifting Systems, Part 2. Optimal Designs, Anal Chim Acta. 162: 253-262.
Thome-Duret et al. 1996. Use of a subcutaneous glucose sensor to detect decreases in glucose concentration prior to observation in blood, Anal. Chem. 68:3822-3826.
Thomé-Duret et al. 1998. Continuous glucose monitoring in the free-moving rat. Metabolism, 47:799-803.
Thompson et al., In Vivo Probes: Problems and Perspectives, Department of Chemistry, University of Toronto, Canada, pp. 255-261, 1986.
Tierney et al. 2000. Effect of acetaminophen on the accuracy of glucose measurements obtained with the GlucoWatch biographer. Diabetes Technol Ther 2:199-207.
Tierney et al. 2000. The GlucoWatch® biographer: A frequent, automatic and noninvasive glucose monitor. Ann. Med. 32:632-641.
Tilbury et al. 2000. Receiver operating characteristic analysis for intelligent medical systems—A new approach for finding confidence intervals. IEEE Transactions on Biomedical Engineering 47(7):952-963.
Trajanoski et al. 1998. Neural predictive controller for insulin delivery using the subcutaneous route. IEEE Transactions on Biomedical Engineering 45(9):1122-1134.
Trecroci, D. 2002. A Glimpse into the Future—Continuous Monitoring of Glucose with a Microfiber. Diabetes Interview 42-43.
Turner and Pickup, "Diabetes mellitus: biosensors for research and management," Biosensors, 1:85-115 (1985).
U.S. Appl. No. 12/405,958, filed Mar. 17, 2009 to James Say.
Updike et al. 1967. The enzyme electrode. Nature, 214:986-988.
Updike et al. 1979. Continuous glucose monitor based on an immobilized enzyme electrode detector. J Lab Clin Med, 93(4):518-527.
Updike et al. 1982. Implanting the glucose enzyme electrode: Problems, progress, and alternative solutions. Diabetes Care, 5(3):207-212.
Updike et al. 1994. Enzymatic glucose sensor: Improved long-term performance in vitro and in vivo. ASAIO Journal, 40(2):157-163.
Updike et al. 1997. Principles of long-term fully implanted sensors with emphasis on radiotelemetric monitoring of blood glucose form inside a subcutaneous foreign body capsule (FBC). In Fraser, ed., Biosensors in the Body. New York. John Wiley & Sons.
Updike et al. 2000. A subcutaneous glucose sensor with improved longevity, dynamic range, and stability of calibration. Diabetes Care 23(2):208-214.
US 7,530,950, 5/12/2009, Brister et al. (withdrawn).
Vadgama. 1988. Diffusion limited enzyme electrodes. NATO ASI Series: Series C, Math and Phys. Sci. 226:359-377.
Valdes et al. 2000. In vitro and in vivo degradation of glucose oxidase enzyme used for an implantable glucose biosensor. Diabetes Technol. Ther. 2:367-376.
Velho et al. 1989. In vitro and in vivo stability of electrode potentials in needle-type glucose sensors. Influence of needle material. Diabetes 38:164-171.
Velho et al. 1989. Strategies for calibrating a subcutaneous glucose sensor. Biomed Biochim Acta 48(11/12):957-964.
von Woedtke et al. 1989. In situ calibration of implanted electrochemical glucose sensors. Biomed Biochim. Acta 48(11/12):943-952.
Wagner et al. 1998. Continuous amperometric monitoring of glucose in a brittle diabetic chimpanzee with a miniature subcutaneous electrode. Proc. Natl. Acad. Sci. A, 95:6379-6382.
Wang et al. 1994. Highly Selective Membrane-Free, Mediator-Free Glucose Biosensor. Anal. Chem. 66:3600-3603.
Wang et al. 1997. Improved ruggedness for membrane-based amperometric sensors using a pulsed amperometric method. Anal Chem 69:4482-4489.
Ward et al. 1999. Assessment of chronically implanted subcutaneous glucose sensors in dogs: The effect of surrounding fluid masses. ASAIO Journal, 45:555-561.
Ward et al. 2000. Rise in background current over time in a subcutaneous glucose sensor in the rabbit: Relevance to calibration and accuracy. Biosensors & Bioelectronics, 15:53-61.
Ward et al. 2000. Understanding Spontaneous Output Fluctuations of an Amperometric Glucose Sensor: Effect of Inhalation Anesthesia and e of a Nonenzyme Containing Electrode. ASAIO Journal 540-546.
Ward et al. 2002. A new amperometric glucose microsensor: In vitro and short-term in vivo evaluation. Biosensors & Bioelectronics, 17:181-189.
Ward et al. 2004. A wire-based dual-analyte sensor for Glucose and Lactate: In Vitro and In Vivo Evaluation, Diab Tech Therapeut. 6(3): 389-401.
Wientjes, K. J. C. 2000. Development of a glucose sensor for diabetic patients (Ph.D. Thesis).
Wiley Electrical and Electronics Engineering Dictionary. 2004. John Wiley & Sons, Inc. pp. 141, 142, 548, 549.
Wilkins et al. 1995. Glucose monitoring: state of the art and future possibilities. Med Eng Phys 18:273-288.
Wilkins et al. 1995. Integrated implantable device for long-term glucose monitoring. Biosens. Bioelectron 10:485-494.
Wilson et al. 1992. Progress toward the development of an implantable sensor for glucose. Clin. Chem. 38(9):1613-1617.
Wilson et al. 2000. Enzyme-based biosensors for in vivo measurements. Chem. Rev., 100:2693-2704.
Wood, W. et al. Mar. 1990. Hermetic Sealing with Epoxy. Mechanical Engineering 1-3.
Wu et al. 1999. In situ electrochemical oxygen generation with an immunoisolation device. Annals New York Academy of Sciences, pp. 105-125.
Yang et al (1996). "A glucose biosensor based on an oxygen electrode: In-vitro performances in a model buffer solution and in blood plasma," Biomedical Instrumentation & Technology, 30:55-61.
Yang et al. 1998. Development of needle-type glucose sensor with high selectivity. Science and Actuators B 46:249-256.
Ye et al. 1993. High Current Density ‘Wired’ Quinoprotein Glucose Dehydrogenase Electrode. Anal. Chem. 65:238-241.
Zavalkoff et al. 2002. Evaluation of conventional blood glucose monitoring as an indicator of integrated glucose values using a continuous subcutaneous sensor. Diabetes Care 25(9):1603-1606.
Zhang et al. 1994. Elimination of the acetaminophen interference in an implantable glucose sensor. Analytical Chemistry 66(7):1183-1188.
Zhu et al. 2002. Planar amperometric glucose sensor based on glucose oxidase immobilized by chitosan film on prussian blue layer. Sensors, 2:127-136.

Cited By (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4275598A2 (en) 2012-04-04 2023-11-15 DexCom, Inc. Applicator and method for applying a transcutaneous analyte sensor
WO2013152090A2 (en) 2012-04-04 2013-10-10 Dexcom, Inc. Transcutaneous analyte sensors, applicators therefor, and associated methods
WO2013184566A2 (en) 2012-06-05 2013-12-12 Dexcom, Inc. Systems and methods for processing analyte data and generating reports
US11145410B2 (en) 2012-06-05 2021-10-12 Dexcom, Inc. Dynamic report building
EP3975192A1 (en) 2012-06-05 2022-03-30 Dexcom, Inc. Systems and methods for processing analyte data and generating reports
US12080414B2 (en) 2012-06-05 2024-09-03 Dexcom, Inc. Dynamic report building
EP4018929A1 (en) 2012-06-29 2022-06-29 Dexcom, Inc. Method and system for processing data from a continuous glucose sensor
US11737692B2 (en) 2012-06-29 2023-08-29 Dexcom, Inc. Implantable sensor devices, systems, and methods
EP3915465A2 (en) 2012-06-29 2021-12-01 Dexcom, Inc. Use of sensor redundancy to detect sensor failures
US11892426B2 (en) 2012-06-29 2024-02-06 Dexcom, Inc. Devices, systems, and methods to compensate for effects of temperature on implantable sensors
WO2014004460A1 (en) 2012-06-29 2014-01-03 Dexcom, Inc. Use of sensor redundancy to detect sensor failures
WO2014011488A2 (en) 2012-07-09 2014-01-16 Dexcom, Inc. Systems and methods for leveraging smartphone features in continuous glucose monitoring
EP4075441A1 (en) 2012-07-09 2022-10-19 Dexcom, Inc. Systems and methods for leveraging smartphone features in continuous glucose monitoring
EP3767633A1 (en) 2012-07-09 2021-01-20 Dexcom, Inc. Systems and methods for leveraging smartphone features in continuous glucose monitoring
EP4080517A1 (en) 2012-07-09 2022-10-26 Dexcom, Inc. Systems and methods for leveraging smartphone features in continuous glucose monitoring
EP4344632A2 (en) 2012-09-28 2024-04-03 DexCom, Inc. Zwitterion surface modifications for continuous sensors
US11179079B2 (en) 2012-09-28 2021-11-23 Dexcom, Inc. Zwitterion surface modifications for continuous sensors
US11864891B2 (en) 2012-09-28 2024-01-09 Dexcom, Inc. Zwitterion surface modifications for continuous sensors
EP3782550A1 (en) 2012-09-28 2021-02-24 Dexcom, Inc. Zwitterion surface modifications for continuous sensors
WO2014052080A1 (en) 2012-09-28 2014-04-03 Dexcom, Inc. Zwitterion surface modifications for continuous sensors
EP3654348A1 (en) 2012-11-07 2020-05-20 Dexcom, Inc. Systems and methods for managing glycemic variability
EP4231309A2 (en) 2012-11-07 2023-08-23 DexCom, Inc. Systems and methods for managing glycemic variability
US10856736B2 (en) 2012-12-31 2020-12-08 Dexcom, Inc. Remote monitoring of analyte measurements
US11382508B2 (en) 2012-12-31 2022-07-12 Dexcom, Inc. Remote monitoring of analyte measurements
US10869599B2 (en) 2012-12-31 2020-12-22 Dexcom, Inc. Remote monitoring of analyte measurements
US10993617B2 (en) 2012-12-31 2021-05-04 Dexcom, Inc. Remote monitoring of analyte measurements
US10860687B2 (en) 2012-12-31 2020-12-08 Dexcom, Inc. Remote monitoring of analyte measurements
US11109757B2 (en) 2012-12-31 2021-09-07 Dexcom, Inc. Remote monitoring of analyte measurements
US11744463B2 (en) 2012-12-31 2023-09-05 Dexcom, Inc. Remote monitoring of analyte measurements
US11213204B2 (en) 2012-12-31 2022-01-04 Dexcom, Inc. Remote monitoring of analyte measurements
US11160452B2 (en) 2012-12-31 2021-11-02 Dexcom, Inc. Remote monitoring of analyte measurements
US11850020B2 (en) 2012-12-31 2023-12-26 Dexcom, Inc. Remote monitoring of analyte measurements
EP3806103A1 (en) 2013-03-14 2021-04-14 Dexcom, Inc. Advanced calibration for analyte sensors
WO2014158405A2 (en) 2013-03-14 2014-10-02 Dexcom, Inc. Systems and methods for processing and transmitting sensor data
US12125588B2 (en) 2013-03-14 2024-10-22 Dexcom Inc. Systems and methods for processing and transmitting sensor data
US12081287B2 (en) 2013-03-14 2024-09-03 Dexcom, Inc. Systems and methods for processing and transmitting sensor data
WO2014158327A2 (en) 2013-03-14 2014-10-02 Dexcom, Inc. Advanced calibration for analyte sensors
US12081288B2 (en) 2013-03-14 2024-09-03 Dexcom, Inc. Systems and methods for processing and transmitting sensor data
US12052067B2 (en) 2013-03-14 2024-07-30 Dexcom, Inc. Systems and methods for processing and transmitting sensor data
EP4220654A1 (en) 2013-03-14 2023-08-02 Dexcom, Inc. Systems and methods for processing and transmitting sensor data
EP4235684A1 (en) 2013-03-14 2023-08-30 Dexcom, Inc. Systems and methods for processing and transmitting sensor data
US11677443B1 (en) 2013-03-14 2023-06-13 Dexcom, Inc. Systems and methods for processing and transmitting sensor data
EP3401818A1 (en) 2013-03-14 2018-11-14 Dexcom, Inc. Systems and methods for processing and transmitting sensor data
US10985804B2 (en) 2013-03-14 2021-04-20 Dexcom, Inc. Systems and methods for processing and transmitting sensor data
US11998329B2 (en) 2013-03-15 2024-06-04 Dexcom, Inc. Membrane for continuous analyte sensors
WO2015156966A1 (en) 2014-04-10 2015-10-15 Dexcom, Inc. Sensors for continuous analyte monitoring, and related methods
EP4257044A2 (en) 2014-04-10 2023-10-11 DexCom, Inc. Sensor for continuous analyte monitoring
EP4046571A1 (en) 2015-10-21 2022-08-24 Dexcom, Inc. Transcutaneous analyte sensors, applicators therefor, and associated methods
EP4378390A2 (en) 2015-10-21 2024-06-05 Dexcom, Inc. Transcutaneous analyte sensors, applicators therefor, and associated methods
US11399721B2 (en) 2015-12-28 2022-08-02 Dexcom, Inc. Systems and methods for remote and host monitoring communications
US10932672B2 (en) 2015-12-28 2021-03-02 Dexcom, Inc. Systems and methods for remote and host monitoring communications
EP4324921A2 (en) 2015-12-30 2024-02-21 Dexcom, Inc. Biointerface layer for analyte sensors
EP3895614A1 (en) 2015-12-30 2021-10-20 Dexcom, Inc. Enzyme immobilized adhesive layer for analyte sensors
US11112377B2 (en) 2015-12-30 2021-09-07 Dexcom, Inc. Enzyme immobilized adhesive layer for analyte sensors
EP4253536A2 (en) 2015-12-30 2023-10-04 DexCom, Inc. Diffusion resistance layer for analyte sensors
EP4292528A1 (en) 2015-12-30 2023-12-20 Dexcom, Inc. Membrane layers for analyte sensors
US10561349B2 (en) 2016-03-31 2020-02-18 Dexcom, Inc. Systems and methods for display device and sensor electronics unit communication
US10980453B2 (en) 2016-03-31 2021-04-20 Dexcom, Inc. Systems and methods for display device and sensor electronics unit communication
US10881335B2 (en) 2016-03-31 2021-01-05 Dexcom, Inc. Systems and methods for display device and sensor electronics unit communication
US10980451B2 (en) 2016-03-31 2021-04-20 Dexcom, Inc. Systems and methods for display device and sensor electronics unit communication
US10799157B2 (en) 2016-03-31 2020-10-13 Dexcom, Inc. Systems and methods for display device and sensor electronics unit communication
US10980450B2 (en) 2016-03-31 2021-04-20 Dexcom, Inc. Systems and methods for display device and sensor electronics unit communication
US10568552B2 (en) 2016-03-31 2020-02-25 Dexcom, Inc. Systems and methods for display device and sensor electronics unit communication
US11395631B2 (en) 2017-06-23 2022-07-26 Dexcom, Inc. Transcutaneous analyte sensors, applicators therefor, and associated methods
US11311241B2 (en) 2017-06-23 2022-04-26 Dexcom, Inc. Transcutaneous analyte sensors, applicators therefor, and associated methods
EP3928688A1 (en) 2017-06-23 2021-12-29 Dexcom, Inc. Transcutaneous analyte sensors, applicators therefor, and associated methods
EP3925522A1 (en) 2017-06-23 2021-12-22 Dexcom, Inc. Transcutaneous analyte sensors, applicators therefor, and associated methods
EP4111949A1 (en) 2017-06-23 2023-01-04 Dexcom, Inc. Transcutaneous analyte sensors, applicators therefor, and needle hub comprising anti-rotation feature
US11504063B2 (en) 2017-06-23 2022-11-22 Dexcom, Inc. Transcutaneous analyte sensors, applicators therefor, and associated methods
EP4008240A1 (en) 2017-06-23 2022-06-08 Dexcom, Inc. Transcutaneous analyte sensors, applicators therefor, and associated methods
US11510625B2 (en) 2017-06-23 2022-11-29 Dexcom, Inc. Transcutaneous analyte sensors, applicators therefor, and associated methods
US11943876B2 (en) 2017-10-24 2024-03-26 Dexcom, Inc. Pre-connected analyte sensors
US11331022B2 (en) 2017-10-24 2022-05-17 Dexcom, Inc. Pre-connected analyte sensors
US11350862B2 (en) 2017-10-24 2022-06-07 Dexcom, Inc. Pre-connected analyte sensors
US11706876B2 (en) 2017-10-24 2023-07-18 Dexcom, Inc. Pre-connected analyte sensors
US11382540B2 (en) 2017-10-24 2022-07-12 Dexcom, Inc. Pre-connected analyte sensors
USD1036676S1 (en) 2018-06-22 2024-07-23 Dexcom, Inc. Wearable medical monitoring device

Also Published As

Publication number Publication date
US20100185072A1 (en) 2010-07-22
US8428679B2 (en) 2013-04-23
US20100174168A1 (en) 2010-07-08
US20100214104A1 (en) 2010-08-26
US20100185074A1 (en) 2010-07-22
US20100185073A1 (en) 2010-07-22
US20100179406A1 (en) 2010-07-15
US20100234796A1 (en) 2010-09-16
US8290562B2 (en) 2012-10-16
US20100179399A1 (en) 2010-07-15
US7959569B2 (en) 2011-06-14
US20100179405A1 (en) 2010-07-15
US8332008B2 (en) 2012-12-11
US7986986B2 (en) 2011-07-26
US7925321B2 (en) 2011-04-12
US20130237786A1 (en) 2013-09-12
US7955261B2 (en) 2011-06-07
US20100185065A1 (en) 2010-07-22
US20100217106A1 (en) 2010-08-26
US7979104B2 (en) 2011-07-12
US7914450B2 (en) 2011-03-29
US7933639B2 (en) 2011-04-26

Similar Documents

Publication Publication Date Title
US8761856B2 (en) System and methods for processing analyte sensor data
US8808182B2 (en) System and methods for processing analyte sensor data
US8285354B2 (en) System and methods for processing analyte sensor data
US8622905B2 (en) System and methods for processing analyte sensor data

Legal Events

Date Code Title Description
AS Assignment

Owner name: DEXCOM, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GOODE, PAUL V. JR.;BRAUKER, JAMES H.;KAMATH, APURV U.;AND OTHERS;REEL/FRAME:024133/0353

Effective date: 20040112

STCF Information on status: patent grant

Free format text: PATENTED CASE

CC Certificate of correction
FPAY Fee payment

Year of fee payment: 4

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 8

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 12TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1553); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 12